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Abstract 
 
Background 
The complex shape of the pleural cavity and the close proximity of normal 
radiosensitive structures render the delivery of radical radiotherapy in 
malignant pleural mesothelioma (MPM) challenging. However, the advent of 
conformal, intensity modulated radiotherapy (IMRT), where dose is 
selectively delivered to the tumour whilst sparing normal tissues, can 
facilitate safe dose escalation. SYSTEMS-2 is the only randomised controlled 
trial of radiotherapy dose escalation to be attempted in MPM and is 
comparing the palliative efficacy of two hypofractionated radiotherapy 
regimes to sites of pain using conformal techniques.   
 
Although traditionally associated with unacceptable late normal tissue 
toxicity, the success of stereotactic radiotherapy (SABR) and the discovery 
that two common malignancies exhibit low α/β ratios, has enhanced the 
popularity of hypofractionated regimes. While the radiobiology of MPM is 
not well understood, its slow growth and apparent radioresistance suggests 
that it may exhibit a low α/β ratio and therefore that it may respond more 
favourably to dose hypofractionation.  
 
 
Aims of thesis 
To investigate the possibility of further radiotherapy dose escalation in 
MPM, beyond that delivered in the SYSTEMS-2 study. 
 
 
Methods 
I. Novel radiotherapy dose constraints were generated for use in the 
SYSTEMS-2 study and tested on five patients from the SYSTEMS study. 
 
II. Multi criteria optimisation (MCO) software was used to assess 
whether the original dose escalated radiotherapy plans for the 
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Glasgow cohort of SYSTEMS-2 could be improved, without 
compromising target volume coverage. 
 
III. A clinically relevant 3D in vitro spheroid model was used to 
investigate the radiobiology of two independent MPM cell lines 
(H2052 and 211H). Spheroids were established and exposed to the 
same total dose of ionising radiation (IR) delivered in different doses 
per fraction. Data was used to investigate response to dose 
fractionation and to estimate the α/β ratio of this tumour. 
 
IV. The response of H2052 and 211H spheroids to two radiosensiting 
agents was investigated in combination with fractionated 
radiotherapy. Spheroids were incubated with increasing 
concentrations of either NU7441 (a DNA-PKcs inhibitor) or A1331852 
(a BH3 mimetic) before being exposed to fractionated IR. The 
immunohistochemical (IHC) expression of DNA-PKcs and Bcl-xL was 
explored in diagnostic biopsies obtained from MPM patients to 
investigate clinical validity of the targets. 
 
V. IHC expression of nine proteins, selected for their potential to 
impact on radioresponse, was analysed in diagnostic tumour tissue 
collected from SYSTEMS and SYSTEMS-2 patients. Expression data was 
correlated with baseline clinical trial data in all patients, and with 
clinical trial outcome data from SYSTEMS patients. 
 
Results 
I. Initial planning studies showed that none of the five SYSTEMS 
patients met all of the SYSTEMS-2 dose constraints, but the plans 
were deemed to be potentially clinically acceptable and the 
constraints were taken forward in the trial. The value of familiarity 
with a planning technique was evidenced by the fact that all 
constraints were achieved when the cases were re-planned by the 
same staff member in April 2019.  
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II. MCO re-planning of dose escalated SYSTEMS-2 plans achieved 
clinically significant dose reductions to organs at risk (OAR) without 
compromising target volume coverage in 13/20 cases. Plans which 
did not meet OAR constraints or conform to the prescribed target 
volume coverage may still have been clinically acceptable. 
 
III. In vitro studies confirmed that growth of MPM spheroids can be 
delayed by IR. Spheroids demonstrated sensitivity to changes in dose 
per fraction, with the greatest volume reductions observed in 
hypofractionated radiotherapy regimes. This data implies that these 
MPM cell lines may exhibit a low α/β ratio, a suggestion which was 
further supported by in vitro multi-fraction IR studies. 
 
IV. Data suggest that NU7441 and A1331852 are potent radiosensitisers 
of MPM spheroids and that both are valid clinical targets in MPM. The 
supposition that a BH3 mimetic may offer tumour specific 
radiosensitisation, combined with the observation that A1331852 
demonstrated greatest efficacy with hypofractionated IR, suggests 
that this agent may be clinically valuable in the radiosensitisation of 
MPM.  
 
V. No statistically significant correlations were found between baseline 
clinical characteristics and expression of the proteins of interest and 
no potential biomarkers of radiosensitisation were identified in the 
SYSTEMS cohort.  
 
 
Conclusions 
Novel dose constraints are being used to facilitate the delivery of 
hypofractionated, dose escalated palliative radiotherapy in the SYSTEMS-2 
study. Results from this trial may guide future dose escalation in this 
disease and data from MCO planning studies suggest that further dose 
escalation to the target volume may be feasible without breaching OAR 
limits. In vitro studies suggest that MPM is sensitive to IR, responds more 
effectively to dose hypofractionation and may have a low α/β ratio. This 
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data may be helpful in determining dose and fractionation regimes in future 
MPM radiotherapy trials. Combination of BH3 mimetics with IR may provide 
MPM specific radiosensitisation, achieving greatest efficacy with dose 
hypofractionation. Ongoing IHC analysis of tumour samples from the 
SYSTEMS-2 study may identify a biomarker of radiotherapy response which 
would be helpful in guiding radiotherapy treatment decisions for future 
patients.  
 
 
In summary, this thesis has investigated ways in which radiotherapy could 
be delivered with radical intent in MPM. Practical aspects of radiotherapy 
planning and delivery have been considered and are presented in 
conjunction with laboratory data to demonstrate how technical advances 
can be combined with an appreciation of disease radiobiology to facilitate 
radical treatment.  
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Chapter 1: Introduction 
 
1.1 Malignant Pleural Mesothelioma  
 1.1.1 Incidence and epidemiology 
Malignant pleural mesothelioma (MPM) is an aggressive malignancy which affects 
the lining of the lung. Therapeutic options are limited and the prognosis is 
dismal, with a median overall survival of 8 to 14 months (Wiggins, 2007) and 
survival rates at one and three years of just 41% and 12% respectively. (Beckett 
et al., 2015) 
 
The incidence of MPM in the UK is amongst the highest worldwide, with numbers 
of disease-related deaths rising dramatically since 1968, when the British 
Mesothelioma Register was established. (McElvenny et al., 2005) Asbestos 
exposure is widely documented as the common aetiological factor and studies 
suggest that up to 85% of cases in the UK are directly attributable to this 
material. (Yates et al., 1997, Howel et al., 1997) High-risk occupations for 
exposure include production of brake and clutch linings, construction/demolition 
work, electricians, plumbers and shipyard workers. (Aguilar-Madrid et al., 2010) 
The use of asbestos was banned in the UK in 1999, but the incidence of the 
disease is expected to increase for the remainder of this decade, reflecting the 
long latency period of 30 to 40 years (McElvenny et al., 2005) and the heavy 
industrial use of asbestos in the 1970’s and 80’s. The National Lung Cancer Audit 
report suggests that 8740 cases of MPM were seen in England and Wales between 
2008 and 2012. (Beckett et al., 2015) The vast majority (83%) of these patients 
were male and the median age at diagnosis was 73 years. The recently published 
British Thoracic Society guidelines into the investigation and management of 
MPM state that 2535 mesothelioma deaths were reported in the UK in 2015 
(Woolhouse and Maskell, 2018) and it is estimated that 1/170 of men born in 
Britain in the 1940s will die of MPM. (McElvenny et al., 2005)  
 
Asbestos continues to be mined and exported from several countries and is still 
used without adequate protection in much of the world. Therefore, it can be 
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expected that the MPM-epidemic which is currently affecting westernised 
countries may develop in more recently industrialised areas in the near future. 
(Rudd, 2010) This epidemiological trend will present both diagnostic and clinical 
challenges as more effective treatment options are sought for these patients. 
 
 1.1.2 Pathogenesis 
The link between MPM and asbestos was first made in an epidemiological study 
published in 1960, (Wagner et al., 1960) but the pathogenic mechanisms through 
which asbestos causes neoplastic transformation of mesothelial cells is not fully 
understood.  
 
The type of asbestos fibre to which exposure occurs appears to have a dramatic 
effect on the risk of developing MPM. Evidence suggests that amphiboles, of 
which the most commonly used types industrially, are crocidolite (blue asbestos) 
and amosite (brown asbestos), are much more potent inducers of MPM than 
chrysotile (white asbestos). Chrysotile appears to be cleared from the lungs 
more rapidly that amphiboles which may at least partly explain its lower 
carcinogenic capacity. (Rudd, 2010) Hodgson suggests that the potency of each 
type of fibre to induce carcinogenic changes is in the ratio of 1:100:500 for 
chrysotile, amosite and crocidolite respectively. (Hodgson and Darnton, 2000) By 
far the most commonly used type of asbestos in the UK was chrysotile, but 
amosite and crocidolite were both used to some degree and therefore  many 
exposures are likely to have involved a mixture of fibre types. (Shuker et al., 
1997) 
 
Data suggests that asbestos fibres interact with mesothelial cells through direct 
and indirect mechanisms. Direct effects occur after inhaled fibres, which are 
deposited in the lungs, translocate to the pleura and cause irritation. 
Morphological studies have confirmed that contact between the fibres and 
mesothelial cells results in phagocytosis of the fibre, (Jaurand et al., 1979) 
which in turn is associated with intracellular oxidation and free radical 
production. (Liu et al., 2000) The interaction between reactive oxygen species 
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and cellular molecules induces DNA damage and alters the expression of proteins 
important in the control of cell proliferation and apoptosis. (Jaurand and Fleury-
Feith, 2005) Asbestos fibres can also directly penetrate mesothelial cells where 
they disrupt the mitotic process, inducing structural chromosomal alterations 
and aneuploidy. (Wang et al., 1987, Yegles et al., 1993) 
 
Indirect effects of asbestos on mesothelial cells are mediated through the 
release of inflammatory and growth factors in the pleural cavity, creating an 
environment which favours tumour growth. (Sekido, 2013) Furthermore, asbestos 
has been linked with activation of the mitogen activated protein kinase 
pathway, inducing the phosphorylation of proteins which drive the transcription 
of inflammatory proteins which facilitate tumorigenesis. (Zanella et al., 1996) 
 
Although asbestos accounts for the majority of MPM, around 20% of cases have 
no history of asbestos exposure, suggesting that alternative aetiological factors 
may be important. DNA sequencing of MPM tissue has detected simian virus 40 
(SV40) in some cases of MPM, suggesting that this virus may trigger neoplastic 
transformation within the pleura. (Carbone et al., 1994) Nevertheless, reports of 
false positives associated with contaminants from common laboratory plasmids 
containing SV40 should be taken into consideration. (Lopez-Rios et al., 2004) A 
role for ionizing radiation (IR) has been suggested, (Cavazza et al., 1996) as has 
exposure to chemicals such as nitrosamine or nitrosurea derivatives. (Peterson et 
al., 1984, Katada et al., 1983) Furthermore, fibres other than asbestos have 
been linked with MPM. An epidemiological study investigating the high incidence 
of MPM amongst inhabitants from villages in Turkey has suggested that erionite 
fibres from the volcanic region of Cappadocia represent the local carcinogenic 
agent. (Baris et al., 1987) 
 
Clustering of MPM cases within families suggest that there may be a genetic 
component to the disease. Genetic profiling has identified a number of 
mutations which are commonly seen in MPM, although recently published studies 
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suggests that MPM has a relatively low mutational burden compared to many 
tumours. (Guo et al., 2015, Bueno et al., 2016) 
 
Whilst studies have failed to identify any persisting oncogenic mutations, (Papp 
et al., 2001, Ni et al., 2000, Kitamura et al., 2002) research into tumour 
suppressor gene activity has been more successful. While TP53 is relatively 
preserved, (Murthy and Testa, 1999, Vivo et al., 2003) common tumour 
suppressor gene mutations have been identified in p16/CDKN2A and the NF2 
gene, which appears to confer susceptibility to MPM in patients with a history of 
asbestos exposure. (Baser et al., 2002, Murthy and Testa, 1999, Deguen et al., 
1998, De Rienzo and Testa, 2000) More recently, the loss of the tumour 
suppressor gene BRCA1 Associated Protein-1 (BAP-1) has been identified as an 
important driver mutation in MPM. (Bott et al., 2011, Testa et al., 2011) 
Germline mutations in BAP-1 are known to be associated with an increased 
susceptibility to a number of malignancies, including MPM, uveal melanoma and 
cutaneous melanoma. (Cheung and Testa, 2017) 
 
 1.1.3 Diagnosis and staging 
The diagnosis of MPM can be challenging and relies on a combination of clinical 
history, physical examination, radiology and pathology. For this reason, it is 
recommended that all suspected cases of MPM should be discussed by a regional 
MPM multidisciplinary team. (Woolhouse et al., 2018)  
 
 1.1.3.1 Clinical presentation 
The clinical signs and symptoms of MPM are insidious and non-specific, leading to 
a high rate of misdiagnosis in the early stages. Chest pain and breathlessness are 
the most common presenting symptoms. (Macleod et al., 2014) Less frequently, 
patients may present with cough, weight loss, fatigue or fevers. (Wiggins, 2007) 
The pain of MPM is typically dull and diffuse and characteristically gets worse 
throughout the course of the disease. Its aetiology can be multifactorial: 
infiltration of the intercostal nerves or brachial plexus by the tumour can cause 
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a neuropathic component while invasion of ribs and vertebrae results in bone 
pain. (Saunders et al., 2019) Furthermore, in addition to tumour infiltration, 
pain can also result from the investigation and management of the disease. 
(Baas et al., 2015) MPM-associated pain is typically difficult to control, even 
with a combination of analgesics and patients often require non-pharmacological 
interventions to achieve symptom relief. (Saunders et al., 2019) The dyspnoea of 
early disease is typically caused by pleural effusions, but as the disease 
progresses, a restrictive effect is exerted on the chest wall due to pleural 
thickening.  
 
 1.1.3.2 Imaging 
Several imaging modalities are employed in the diagnosis and staging of MPM. A 
contrast-enhanced computed tomography (CT) is usually the first cross-sectional 
imaging to be undertaken. Pleural disease (malignant or inflammatory) enhances 
strongly and the contrast can help distinguish between the thickened pleura, 
effusion and underlying collapsed or aerated lung. (Wiggins, 2007) Features may 
be present which suggest malignancy rather than benign pleural disease, 
including circumferential pleural thickening, pleural nodularity, parietal pleural 
thickening >1cm, chest wall invasion and mediastinal pleural involvement. 
(Leung et al., 1990) While many of these features have a high specificity, their 
sensitivity is less accurate and their absence does not exclude MPM. There may 
be other radiological features of asbestos exposure to support a diagnosis of MPM 
(e.g. pleural plaques), but CT cannot definitively differentiate between benign 
pleural disease and MPM. Furthermore, CT is poor at assessing soft tissue 
involvement and in detecting nodal disease.  
 
Where a surgical approach is being considered, magnetic resonance imaging 
(MRI) can be used to highlight morphological and anatomical features of the 
disease and in particular, to clarify the tumour stage by delineating the extent 
of diaphragmatic involvement, as well as that of the chest wall and 
mediastinum. (Stewart et al., 2003) Studies suggest that gadolinium-based 
contrast MRI can distinguish between malignant pleural thickening and benign 
disease, with sensitivity of 100% and specificity of 95% reported by Boraschi et 
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al. (Boraschi et al., 1999) Furthermore, diffusion-weighted MRI has been 
reported to distinguish between epithelioid and non-epithelioid subtypes of 
MPM, (Gill et al., 2010) but these data are yet to be robustly validated in a 
prospective manner. (Woolhouse et al., 2018) 
 
Positron emission tomography-computer tomography (PET-CT) may have 
additional value in distinguishing benign pleural disease from MPM, through 
differentiating the maximal standardised uptake value (SUVmax) detected in 
pleural thickening. (Treglia et al., 2014) Furthermore, this imaging modality may 
aid in the choice of biopsy site and is helpful in the staging of nodal disease and 
distant metastases. (Wilcox et al., 2009) Despite having a high sensitivity and 
specificity for malignant disease, PET-CT can be associated with false positives, 
particularly following talc pleurodesis which is associated with a large 
inflammatory response. (Coolen et al., 2012) False negatives can also occur, 
especially in small volume disease and where the malignancy has a low 
proliferative index. (Woolhouse et al., 2018) 
 
 1.1.3.3 Staging 
MPM is staged using the tumour, nodes and metastases (TNM) system, as 
proposed by the International Mesothelioma Interest Group (IMIG) in 1995. 
(Aisner et al., 1995) This system was originally developed as an assessment tool 
for surgical intervention and can be difficult to reliably apply with CT or MRI 
imaging, both of which can under-stage the tumour. (Heelan et al., 1999) 
Information is often required from thoracoscopy with regard to the degree of 
visceral and parietal involvement. The diagnosis of mediastinal nodal disease is 
also difficult to accurately assess on imaging and mediastinoscopy may be 
required to determine nodal stage. In 2016, an update to the staging system was 
proposed by the International Association for the Study of Lung Cancer (IASLC), 
which allowed categories to be modified according to prognostic performance in 
surgically and non-surgically managed patients. (Rusch et al., 2016) This eighth 
edition of the TNM system is currently in clinical use, although data from the 
2016 National Mesothelioma Audit suggests that stage is not recorded in the 
majority of patients. (2016) 
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 1.1.3.4 Response assessment 
Tumour response to treatment is traditionally graded according to the response 
evaluation criteria in solid tumours (RECIST). These criteria are based on the 
assumption that tumours are spherical and that the maximal uni-dimension 
measurement is sufficient to determine the degree of response. (Therasse et al., 
2000) MPM does not conform to these assumptions because it grows 
circumferentially around the pleural cavity and response to treatment is 
therefore more accurately assessed by measuring the thickness of the pleural 
disease perpendicular to the chest wall. The RECIST criteria have now been 
amended to reflect this and validated with reference to MPM. (Byrne and Nowak, 
2004a) Caution needs to be applied when patients have undergone talc 
pleurodesis since this can make the pleural lining appear thicker. 
 
 1.1.3.5 Pathology 
Securing a pathological diagnosis of MPM can be difficult because MPM mimics a 
number of other malignancies of epithelioid or sarcomatoid origin. Pleural fluid 
can be obtained for analysis if an effusion is present, but making an accurate 
cytological diagnosis is challenging, as immunocytochemistry does not clearly 
distinguish highly reactive mesothelial cells from malignant ones. The British 
Thoracic Society guidelines advise against relying on cytology alone to make a 
diagnosis of MPM. (Woolhouse et al., 2018) 
 
A pleural biopsy provides a more robust diagnostic sample and can be obtained 
through an image guided procedure or thoracoscopy.  Studies have shown that a 
CT-guided percutaneous pleural biopsy is more effective for diagnosing the cause 
of pleural thickening than a blind Abram’s punch biopsy (Maskell et al., 2003) 
and therefore this is the preferred technique. In cases which are clearly 
malignant on initial imaging, thoracoscopy is a useful technique for evaluating 
the pleural space and draining pleural effusions prior to talc pleurodesis. (Waller 
et al., 1995) This procedure is associated with a diagnostic sensitivity of >90% 
and a 10% complication rate. (Pistolesi and Rusthoven, 2004) 
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There are three different histological subtypes of MPM: epithelioid, sarcomatoid 
and mixed/biphasic. Accurate histological subtyping is important for 
prognostication and guiding treatment, since non-epithelioid subtypes are 
associated with significantly shorter overall survival (2016) and tend to be more 
refractory to treatment. Morphologically, epithelioid mesothelioma is associated 
with several patterns which can look microscopically similar to adenocarcinoma. 
Sarcomatoid mesothelioma often displays a spindle-cell pattern, which can look 
very similar to benign pleural fibrosis and can also be difficult to distinguish 
from sarcomas. Mixed/biphasic tumours exhibit a combination of epithelioid and 
sarcomatoid patterns and are the easiest to distinguish from other malignancies 
morphologically. (Inai, 2008) 
 
Due to the non-specific morphological appearance of these subtypes, a range of 
immunohistochemical (IHC) markers are used to differentiate MPM from other 
pathologies. Commonly expressed mesothelial markers include calretinin, 
thrombomodulin, CK5/6, CAM5.2, EMA, vimentin, GLUT-1, HBME-1, WT-1 and 
p53. Negative markers include Ber-Ep4, CEA, Leu-1, CD15 and TTF-1. It is 
recommended that a combination of at least two positive mesothelial IHC 
markers and at least two negative adenocarcinoma IHC markers should be used 
to support a diagnosis of MPM. (Woolhouse et al., 2018) 
 
Unfortunately, it is not uncommon for the definitive pathology to remain 
uncertain, even after detailed immunohistochemical analysis. Furthermore, IHC 
profiling cannot reliably distinguish malignant disease from benign mesothelial 
proliferations; nevertheless, clinically useful information can be obtained from 
expression analysis of p16 and BAP1 genes. In a study by Wu et al, hemizygous or 
homozygous deletion of p16, assessed by fluorescent in situ hybridisation (FISH), 
was predictive of MPM over benign fibrous pleurisy, demonstrating 100% 
positivity in cases of sarcomatoid MPM. (Wu et al., 2013) This trend was 
repeated in a study by Hida et al, which also suggested a role for BAP1 deletion 
in differentiating MPM from benign mesothelial proliferation. (Hida et al., 2015) 
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 1.1.3.6 Biomarkers 
Extensive research efforts have been directed towards finding an MPM biomarker 
to aid screening, diagnosis, guide prognostication and assess response to 
treatment. Sources include serum, plasma or pleural fluid and amongst 
promising candidates are mesothelin, fibulin-3, megakaryocyte-potentiating 
factor (MPF), soluble mesothelin related peptide and osteopontin. 
Unfortunately, the sensitivity and specificity of these markers are too low to 
permit their use in clinical diagnosis, even when combined together. (Creaney et 
al., 2008) Fibulin-3 was proposed as a soluble diagnostic biomarker by Pass et al 
in 2012, who demonstrated encouraging results in retrospective analysis. (Pass, 
2012) More recent data has suggested that this marker may be useful in 
prognostication, but is of limited value in the diagnosis of MPM. (Kirschner et al., 
2015) Soluble mesothelin related peptide has demonstrated a positive 
correlation with tumour bulk and falls following surgical resection of disease, 
but cannot predict stage of disease at baseline. (Creaney et al., 2011) The 
current British Thoracic Society guidelines suggest that biomarkers should not be 
used to screen for MPM, nor should they be used to predict treatment response 
or survival. They may be helpful at diagnosis in patients with suspicious cytology 
who are not fit enough for more invasive tests. (Woolhouse et al., 2018) 
 
 1.1.4 Prognostication 
Whilst the overall outlook following an MPM diagnosis is poor, a number of 
independent factors have been studied in an attempt to identify outcome 
predictors. These include patient factors, disease variables and symptom 
burden. 
 
Three large retrospective studies identified an association between worse 
overall survival and the presence of increasing age, male sex, advanced stage 
and non-epithelioid histology. (Gemba et al., 2013, Milano and Zhang, 2010, 
Taioli et al., 2014) The presence of chest wall pain has also been identified as an 
independent predictor of poor outcome in three retrospective case series. 
(Meniawy et al., 2013, Herndon et al., 1998, Bottomley et al., 2007)  
- 36 - 
A number of validated MPM prognostication scores are available, including the 
European Organisation for Research and Treatment of Cancer (EORTC) prognostic 
score, the Cancer and leukaemia group B (CALGB) score and the modified 
Glasgow Prognostic Score. (Woolhouse et al., 2018) 
 
 1.1.5 Management of MPM 
 1.1.5.1 Surgery 
Surgical resection, in conjunction with chemotherapy and radiotherapy, is the 
most aggressive therapy offered to a highly selected cohort of patients with 
MPM, although its role is controversial. The traditional surgical approach of 
extrapleural pneumonectomy (EPP) is an extensive and technically challenging 
operation which aims to remove all macroscopic disease, including the 
underlying lung. This approach seemed encouraging in 1996, when Sugarbaker et 
al reported a 22% five year survival in 120 patients treated with multimodality 
therapy, (Sugarbaker et al., 1996) however, EPP has fallen out of favour in 
recent years due to safety concerns. Peri-operative mortality rates of 3-9% have 
been reported (Treasure and Sedrakyan, 2004) and significant post-operative 
complications have been observed in up to 60% of cases. (Sugarbaker et al., 
2004) A number of non-randomised studies suggest that combination treatment 
may be associated with better overall survival, (Weder et al., 2007, Federico et 
al., 2013, Van Schil et al., 2010, Krug et al., 2009) but the first and only 
randomised study to assess the role of EPP in multimodality treatment of MPM 
was the Mesothelioma and Radical Surgery (MARS) study. This feasibility study 
enrolled 50 patients and concluded that a larger study would not be possible due 
to the high mortality associated with EPP. (Treasure et al., 2011) This outcome 
was largely contested in the oncological and surgical communities because MARS 
had been neither designed nor powered to assess the outcome of surgery versus 
no surgery, but EPP has largely been abandoned since the publication of this 
data.  
 
The less aggressive surgical approach of pleurectomy decortication (PD) may be 
a more suitable option for patients with operable disease. This procedure, which 
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leaves the underlying lung intact has been shown to be effective in preventing 
the re-accumulation of fluid in MPM. (Soysal et al., 1997) It appears to be 
associated with lower rates of intraoperative mortality (Flores et al., 2008) and 
better quality of life post-operatively. (Mollberg et al., 2012) The MARS-2 trial is 
currently underway in the UK to assess the feasibility of recruiting to a large 
randomised controlled study of PD versus no surgery in association with 
neoadjuvant chemotherapy. (Lim, 2016) 
 
 1.1.5.2 Systemic anti-cancer treatment 
  1.1.5.2.1 First line treatment  
Chemotherapy is the only treatment modality for which there is randomised 
controlled evidence of survival benefit in MPM. The Vogelzang study, published 
in 2003, is the largest randomised controlled trial (RCT) of chemotherapy in 
MPM. (Vogelzang et al., 2003) The study recruited 456 patients and compared a 
combination of 3 weekly Pemetrexed and Cisplatin to Cisplatin alone. Results 
suggested that dual administration of Pemetrexed and Cisplatin was associated 
with a significant survival benefit compared to Cisplatin alone (12.1 months 
versus 9.3 months: p=0.02). Patients who received full vitamin supplementation 
had a further survival advantage (median survival of 13.2 months). Similar 
benefits were seen in a smaller randomised study of 250 patients, assessing 
Ralitrexed with Cisplatin, or Cisplatin alone. (van Meerbeeck et al., 2005) 
Median overall survival was 11.4 months in the combined arm and 8.8 months in 
the Cisplatin only arm, supporting the efficacy of antifolates in MPM.  
 
Guidelines suggest that all patients who are PS 0-1 should be considered for 
palliative chemotherapy. (Woolhouse et al., 2018) The optimal timing for this is 
uncertain, but studies suggest that early chemotherapy offers a better survival 
advantage than delayed. (O'Brien et al., 2006) 
 
The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) recently reported 
a significant survival advantage associated with the addition of Bevicizumab to 
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Cisplatin/Pemetrexed chemotherapy in MPM. This randomised phase III trial 
randomised 448 patients and delivered 3 weekly cycles of either 
Cisplatin/Pemetrexed alone or in combination with Bevacizumab. A median 
overall survival of 18.8 months was reported in the group treated with Cisplatin/ 
Pemetrexed/ Bevacizumab compared to 16.1 months in those treated with 
Cisplatin and Pemetrexed only (p=0.0167). The addition of Bevacizumab was 
associated with higher rates of hypertension and thromboses and more grade 3 
events. (Zalcman et al., 2015) Bevacizumab is not currently licenced in the UK 
for use in MPM and is not available on the NHS; current UK British Thoracic 
Society guidelines recommend the use of Cisplatin/Pemetrexed in the first line 
setting. (Woolhouse et al., 2018) 
 
  1.1.5.2.2 Second line treatment  
Studies investigating second line chemotherapy in MPM report no survival 
advantage of Pemetrexed (Jassem et al., 2008) or Vorinostat (Krug et al., 2015). 
Whilst single agent Vinorelbine is offered to patients of good performance status 
(PS) who relapse following first line platinum-containing chemotherapy, a 
systematic review of the literature concluded that fit patients should be 
referred for clinical trials, since the reported activity of second line 
chemotherapeutic agents is low. (Buikhuisen et al., 2015) The Vinorelbine in 
mesothelioma (VIM) study is a randomised controlled phase II trial of Vinorelbine 
versus best supportive care in the second line setting. This study, which has now 
completed recruitment in the UK, aims to establish whether Vinorelbine confers 
a survival advantage in MPM and whether underlying molecular changes may 
predict drug efficacy. 
 
1.1.5.2.3 Ongoing clinical trials of systemic therapy 
Despite a relative stagnation in the development of systemic treatment options 
for MPM in the years following publication of the Vogelzang study, the research 
climate in this disease has progressed dramatically in more recent years. Some 
of the most promising early phase data has been generated using molecularly 
targeted agents, such as Nintedanib (Grosso et al., 2017) and immunotherapy, 
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with drugs such as Pembrolizumab. (Alley et al., 2017) Anti-mesothelin agents 
have shown promise in the epithelioid subtype, (Hassan et al., 2014) whilst 
arginine deprivation has been shown to have activity alongside standard 
chemotherapy in patients with sarcomatoid and biphasic MPM. (Beddowes et al., 
2017) 
 
A large number of clinical trials of systemic therapies are ongoing in the first, 
second and third line MPM settings, using a variety of these systemic approaches. 
A comprehensive summary of these studies has been recently published in The 
Clinical Respiratory Journal. (Bibby and Maskell, 2018) 
 
1.2 The changing role of radiotherapy in MPM 
Radiotherapy delivery in MPM is challenging because of the complex shape of the 
pleural cavity and the close proximity of critical radiosensitive structures to the 
planning target volume (PTV). Attempts to deliver radical radiotherapy to the 
hemithorax using parallel opposed beams have been associated with severe 
radiation lung injuries (Maasilta, 1991, Linden et al., 1996, Ball and Cruickshank, 
1990, Mattson et al., 1992, Law et al., 1984) and changes in spirometry 
compatible with total loss of ipsilateral lung function. (Maasilta, 1991) For this 
reason, radiotherapy in MPM has traditionally been limited to modest doses 
delivered using standard 2-dimensional (2D) techniques, for prophylactic or 
palliative purposes. Nevertheless, recent developments in radiotherapy planning 
and delivery technologies have revolutionised our ability to dose escalate 
treatment to the pleura, whilst keeping doses to normal tissues at an acceptable 
level.  
 
 1.2.1 Palliative radiotherapy 
To date, the only robust evidence supporting the use of radiotherapy in MPM is 
in the palliation of pain. (MacLeod et al., 2015a) One of the first studies 
addressing this was performed in Glasgow by Bissett et al with a cohort of 19 
patients. (Bissett et al., 1991) A radiation dose of 30Gy in 10 fractions was 
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delivered over 2 weeks to the whole hemithorax using parallel opposed pairs, 
with pain assessments before and after the treatment. This regimen was 
reported to be well tolerated, with results suggesting an improvement in pain 
control for about 70% of patients, but the response was short lived, displaying a 
median duration of 2 months.  
 
A number of case reports and studies detailing the use of radiotherapy for pain 
control in MPM have subsequently been published (Ball and Cruickshank, 1990, 
Linden et al., 1996, Jenkins et al., 2011, de Graaf-Strukowska et al., 1999) and a 
systematic review of the available literature was carried out by MacLeod et al in 
2014. (Macleod et al., 2014) It was noted that there were large variations in the 
total radiotherapy doses and fractionation regimes employed and in response 
rates, which varied from 0% to 69%. Eight papers were identified which fulfilled 
the inclusion criteria but due to a combination of poor study design and small 
patient numbers, only Level 2 to 3 evidence was identified, rendering it 
impossible to draw firm conclusions regarding the use of radiotherapy for pain 
control in MPM. This review exposed the fact that radiotherapy was being 
utilised as the key analgesic modality in MPM, recommended by both the British 
Thoracic Society and the European Respiratory Society, (Scherpereel et al., 
2010) despite there being no consensus on dose, fractionation or optimal mode 
of delivery and with very little efficacy data. The need for a robust prospective 
study to address this practise was identified. (Macleod et al., 2014)  
 
The symptoms study of radiotherapy in mesothelioma (SYSTEMS) was the first 
prospective study to use validated outcome measures to assess pain response to 
radiotherapy in MPM. (MacLeod et al., 2015a) This multicentre, single arm phase 
II trial recruited forty patients from three centres over eighteen months and 
delivered a standard radiotherapy dose of 20 Gray (Gy) in 5 fractions to sites of 
pain using parallel opposed pairs. Analgesia was optimised prior to study entry 
and pain was assessed using the brief pain inventory, a validated assessment tool 
for cancer pain, (Cleeland and Ryan, 1994) at baseline and at five weeks after 
the radiotherapy. Radio-opaque wire markers were applied at the time of CT 
planning scan acquisition to demarcate painful areas and aid radiotherapy 
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planning. A clinically significant response was deemed as a ≥30% reduction in 
pain score from baseline to week 5. (Farrar et al., 2000) Complete case analysis 
revealed a clinically significant improvement in pain in 47% of the 30 patients 
assessable at week 5 (confidence intervals 28.3 to 65.7), with minimal toxicity. 
Although a variety of secondary endpoints were assessed, radiotherapy was not 
found to be useful in the palliation of any other symptoms. 
 
This study provided the first robust evidence for using radiotherapy for pain 
control in MPM. The value of dose-escalated radiotherapy for MPM-associated 
pain is now being assessed in the SYSTEMS-2 study. (Ashton et al., 2018) This 
prospective, multicentre, randomised, Phase II study is comparing standard 
palliative radiotherapy (20Gy in 5 fractions delivered over 1 week) with a dose-
escalated regime (36Gy in 6 fractions delivered over 2 weeks) and aims to 
recruit 112 patients from 20 UK centres. To facilitate safe dose escalation to the 
PTV without incurring unacceptable toxicities to organs at risk (OARs), 
radiotherapy is planned using either 3D conformal radiotherapy (3DCRT) or 
intensity modulated radiotherapy (IMRT). The primary outcome of this trial is 
pain control at week 5, assessed using the brief pain inventory. Secondary 
endpoints include acute toxicity, duration of pain response, radiological 
response and overall survival. The set up and progress of SYSTEMS-2 is discussed 
in more detail in Chapter 2. 
 
 1.2.2 Prophylactic radiotherapy 
The value of prophylactic radiotherapy in preventing subcutaneous MPM tumour 
deposits at intervention sites has been investigated in a number of studies. Low 
et al published retrospective data on 20 patients irradiated prophylactically at a 
single centre between 1990 and 1994 and concluded that prophylactic radiation 
is highly effective in preventing tumour seeding following chest wall intervention 
in MPM. (Low et al., 1995) Findings of a French study, using a dose of 21Gy in 3 
fractions, supported this conclusion, (Boutin et al., 1995) although subsequent 
studies using 21Gy in 3 fractions and a 10Gy single fraction failed to find any 
benefit of prophylactic radiotherapy and concluded that drain site radiotherapy 
in MPM is a wasted resource. (O'Rourke et al., 2007, Bydder et al., 2004) Practise 
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changing studies in this field were published in 2016 and 2019. (Clive et al., 
2016, Bayman et al., 2019) The SMART study, a multicentre, open-label, Phase 
III, randomised controlled trial recruited 203 patients, from 22 UK hospitals, who 
had undergone large-bore pleural intervention in the 35 days prior to 
recruitment. Patients were randomised to receive immediate radiotherapy (21Gy 
in 3 fractions) or the same dose only at diagnosis of tract site metastases. No 
significant difference was seen in the incidence of tract site metastases in the 
immediate and deferred radiotherapy groups and the authors concluded that 
routine use of prophylactic radiotherapy is not justified. (Clive et al., 2016) This 
conclusion was supported by the results of the prophylactic irradiation of tracts 
(PIT) study in 2019, which recruited 375 patients from 54 centres and delivered 
21Gy in 3 fractions to intervention sites. (Bayman et al., 2019) 
 
 1.2.3 Adjuvant radiotherapy  
Tri-modality treatment with chemotherapy, surgery and radiotherapy is the most 
aggressive and radical option available to patients with MPM, although a change 
in the surgical landscape means that this is not currently offered in the UK. The 
aim of surgery is to achieve a macroscopic complete resection (MCR), although 
the infiltrative growth pattern of MPM renders this objective very challenging. 
Neoadjuvant chemotherapy is given with the intent of down staging the tumour 
prior to surgery, but local recurrence remains a problem, even after complete 
MCR. (Baldini et al., 1997, Stewart et al., 2004, Yan et al., 2009) Hemithoracic 
adjuvant radiotherapy has been an integral component of this treatment 
approach for decades, (Vaeth and Purcell, 1964) aiming to prevent recurrent 
local disease. The practise is supported by prospective data collected from 59 
patients, suggesting that radiotherapy is associated with improved disease 
control: local recurrence occurred in 51% of the overall cohort compared to 29% 
of those who received adjuvant radiotherapy. (Yan et al., 2009) 
 
Despite the relative advantage conveyed by removal of the ipsilateral underlying 
lung during EPP, the post-operative volume is large and complex, with a number 
of dose-limiting structures remaining in close proximity to the PTV. The inability 
to dose escalate without selectively protecting radiosensitive OARs has rendered 
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traditional radiotherapy techniques largely obsolete in this setting, (Ashton et 
al., 2017) although a number of solutions have been described which facilitate 
dose escalation to target volumes using a 2D or 3D approach. (Baldini et al., 
1997, Rusch et al., 2001, Mychalezak et al., 1989) Nevertheless, high rates of 
local failure have been reported (Yajnik et al., 2003), substantiating concerns 
regarding target dose inhomogeneity with these techniques. (Gupta et al., 2009) 
 
Advanced radiotherapy planning techniques, such as IMRT, increase dose 
conformity, facilitating dose escalation to the target volume, while keeping 
doses delivered to OARs at a safe level. In MPM, IMRT has been demonstrated to 
achieve a more uniform pleural dose than could be accomplished with traditional 
techniques, (Tobler et al., 2002) although the popularity of this modality in the 
post-operative setting has fluctuated. Encouraging initial data from MD Anderson 
suggested that IMRT could deliver 45-50Gy to the post-operative volume, with 
boosts to 60Gy in areas of clinical concern, and reported 100% local control rates 
within treated volumes at 9 months. (Ahamad et al., 2003) Enthusiasm for IMRT 
declined however, following the publication of toxicity data from three centres 
of excellence between 2006 and 2008. (Allen et al., 2006, Miles et al., 2008, 
Rice et al., 2007a) High incidences of fatal pneumonitis were reported and were 
found to correlate with dosimetric parameters received by the contralateral 
(intact) lung. While the volume of lung receiving 5Gy (V5) and the mean lung 
dose (MLD) were both linked with pneumonitis, only the volume receiving 20Gy 
(V20) has been found to have a predictive association. (Rice et al., 2007a) 
Generation of dose constraints informed by these studies, combined with 
modifications to the delivery of IMRT (Allen et al., 2007) and significant 
advances in patient imaging which increases the accuracy of treatment delivery, 
has led to the re-emergence of IMRT in the post-EPP setting. Encouraging rates 
of local control associated with improved median survival have been reported 
(14.2 months in irradiated patients versus 10.2 months in non-irradiated cohort). 
This survival advantage was extended to 28 months in patients with favourable 
clinical features (node negative disease and epithelioid histology). (Rice et al., 
2007b)  
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The change in surgical management of MPM from EPP to PD has rendered the 
role of the clinical oncologist even more challenging, since radical doses now 
need to be delivered to the pleura in the context of two intact radiosensitive 
lungs. Furthermore, the incomplete resection associated with PD brings with it a 
stronger indication for adjuvant radiotherapy. (Ashton et al., 2017) A 
prospective phase II study by Rimner et al demonstrated the feasibility of 
delivering hemithoracic IMRT to the pleura to a dose of 50.4Gy in 28 fractions 
following PD. In conjunction with chemotherapy, this technique was not 
associated with any incidences of grade 3 or 4 pneumonitis. (Rimner et al., 
2016b) Nevertheless, increasingly sophisticated methods of radiotherapy 
delivery, such as volumetric arc radiotherapy (VMAT) and helical tomotherapy 
(HT) have been used in MPM to achieve greater dose conformity in the context of 
two intact lungs than can be achieved with IMRT. (Dumane et al., 2016, Minatel 
et al., 2012, Minatel et al., 2014, Giraud et al., 2011, Helou et al., 2013) 
Recently published retrospective data from Parisi et al has demonstrated that 
hypofractionated radiotherapy can be safely delivered to the hemithorax after 
PD or biopsy using HT. A dose of 25Gy was delivered in 5 fractions to 36 patients 
with MPM, with acceptable levels of toxicity. (Parisi et al., 2017) 
 
There are several difficulties in drawing robust conclusions regarding the 
efficacy of adjuvant radiotherapy from the available data, primarily due to the 
lack of control groups and randomisation. (Ashton et al., 2017) Many of the 
studies are retrospective and report results from small numbers of patients at 
single centres. Between studies there is variation in the radiotherapy technique 
employed, dose delivered to the PTV and in the reporting of achieved dosimetry. 
Furthermore, the inherent selection bias associated with studies in which 
patients have been selected for surgery (Hasani et al., 2009) makes the accurate 
interpretation of survival data even more challenging. 
 
The only RCT to specifically address the role of radiotherapy in the tri-modality 
treatment of MPM was published in 2015. (Stahel et al., 2015) Patients received 
neo-adjuvant chemotherapy and those who achieved MCR after EPP were 
randomised to receive hemithoracic radiotherapy or not. A dose of 45Gy to 46Gy 
- 45 - 
(in 1.75Gy, 1.8Gy or 2Gy fractions) was delivered to the post-operative volume 
with boosts of 55.9Gy to 57.6Gy to areas of clinical concern using either IMRT or 
3DCRT. A total of 54 patients were eligible for randomisation; 27 patients 
started radiotherapy and 25 patients completed the treatment. No statistically 
significant difference in relapse-free survival was found between those who 
received adjuvant radiotherapy and those who did not (9.4 months and 7.6 
months respectively) and the study concluded that there was inadequate support 
for the routine use of hemithoracic radiotherapy in the post-operative setting. 
(Stahel et al., 2015) This conclusion has been challenged by the oncological 
community, particularly given the lack of statistical power, the heterogenous 
nature of the radiotherapy planning, the absence of central review and the 
failure to publish any dosimetry data. (Rimner et al., 2016a) 
 
 1.2.4 Neo-adjuvant radiotherapy 
A novel approach using pre-operative radiotherapy has been reported from 
Princess Margaret Hospital, Toronto, with encouraging results. (de Perrot et al., 
2016, Cho et al., 2014) In this technique, the aim of which is to sterilise the 
tumour bed and prevent tumour seeding during surgery, 25Gy in 5 fractions is 
delivered to the pre-operative hemithorax using IMRT, with a concomitant boost 
of 5Gy to areas of gross tumour volume (GTV) and tract sites. Patients proceed 
to EPP within one week of the radiotherapy, the timing of which is crucial in 
preventing the development of fatal pneumonitis. Adjuvant chemotherapy is 
offered to any patient found to have mediastinal node involvement post 
operatively. Findings from a non-randomised, phase I/II feasibility study of 25 
patients with T1-T3 disease were encouraging, with a peri-operative mortality 
rate of zero and no grade 3-5 radiation toxicities. Post-operatively, 96% of the 
cohort was confirmed to have had stage III or IV disease and cumulative overall 
survival was reported as 58% at 3 years. Dichotomising these data by histological 
subtype revealed that patients with epithelioid disease survived significantly 
longer (84% at 3 years) than their biphasic counterparts. (Cho et al., 2014) 
Further phase II data from 62 patients, 94% of whom had stage III or IV disease, 
supported a prognostic advantage for the epithelioid subtype, reporting a 
median overall survival of 51 months and disease free survival of 47 months in 
this cohort. (de Perrot et al., 2016) 
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1.3 Advances in radiotherapy delivery 
Many of the changes seen in MPM-associated radiotherapy over recent years have 
been driven by accumulating data which suggest that delivery of an increased 
radiation dose to the tumour may be associated with better local control. (Rusch 
et al., 2001, Rosenzweig et al., 2012, Buduhan et al., 2009, Krayenbuehl et al., 
2014) Furthermore, encouraging data from the SYSTEMS study has prompted the 
question of whether dose escalated radiotherapy may be of additional benefit in 
palliation of MPM-associated pain. (MacLeod et al., 2015a)  
 
In order to safely dose escalate treatment to the PTV, increasingly sophisticated 
methods of radiotherapy delivery have been utilised which can better manage 
the compromise between adequate tumour irradiation and sparing of healthy 
tissue. These techniques vary from fixed-field IMRT, to increasingly complex 
rotational techniques (VMAT and HT). 
 
 1.3.1 Fixed-field IMRT 
In fixed-field IMRT, dose conformity is enhanced by dividing the radiation beam 
into multiple small beamlets, which are delivered from a number of angles. The 
intensity of the beams are modulated through the presence of a multileaf 
collimator (MLC), using either a segmental-based or dynamic-based approach. In 
the segmental (or step-and-shoot) approach, the MLC aperture is set to discrete 
shapes and the beam is only delivered when the leaves are stationary at each 
position. In the dynamic (or sliding-windows) approach, the leaves move 
continuously, modulating the beam as the radiotherapy is delivered. In addition 
to achieving a more uniform dose distribution and greater conformity to the 
target, IMRT allows boosts to be incorporated into the plan so areas at high risk 
of disease relapse can be further dose escalated throughout the course of the 
treatment, rather than at the end. Furthermore, challenges to dose delivery 
resulting from the large field sizes associated with MPM and the constraints of 
the MLC leaves have been addressed using a leaf-sequencing algorithm. (Xia et 
al., 2002) 
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A significant disadvantage of any technique that dose escalates through the use 
of multiple beams delivered from different angles is the ‘dose bathing effect’. 
This refers to the low radiation dose which is necessarily deposited in normal 
tissue by the increased number of beams to achieve dose escalation at the 
target. Planning studies comparing post-operative radiotherapy delivered with 
IMRT and conventional techniques have highlighted the potential impact of this 
issue in MPM. (Cho et al., 2010, Hill-Kayser et al., 2009, Krayenbuehl et al., 
2007) Although IMRT was associated with improved clinical target volume (CTV) 
coverage and the achieved dosimetry was more homogenous across the target, 
this technique consistently delivered larger doses to OARs than conventional 2D 
or 3D techniques. Worryingly, one study identified that IMRT was associated with 
a statistically significant increase of 7.2% in the contralateral lung V20. 
(Krayenbuehl et al., 2007) The clinical impact of this dose bathing effect in 
mesothelioma patients was highlighted in 2006-2008, when toxicity data from 
three large institutions was published. (Allen et al., 2006, Miles et al., 2008, 
Rice et al., 2007a) A correlation was noted between the dose delivered to the 
single remaining lung and poor patient outcomes. In particular, the volume of 
lung receiving 20Gy was demonstrated to have a statistically significant 
predictive association with pneumonitis. (Rice et al., 2007a) This data has been 
crucial in informing appropriate dose constraints to OARs in both the post-EPP 
and non-surgical setting. 
 
 1.3.2 VMAT/HT 
VMAT and HT are progressively more advanced methods of IMRT. They 
theoretically facilitate safer dose escalation by further enhancing dose 
conformity. Both are rotational techniques, in which the gantry rotates around 
the patient, delivering continuous radiotherapy beams, as opposed to the ‘fixed-
field’, static gantry technique associated with traditional IMRT. VMAT is able to 
achieve highly conformal radiation doses by allowing simultaneous variations in 
rotation of the gantry, dose rate and MLC position. This facilitates delivery of 
radiotherapy to the entire tumour in a 360o rotation using single or multiple 
arcs. (Rana, 2013) HT permits further conformity through continuous rotation of 
the gantry around the patient, delivering a fan-beam of radiotherapy which is 
modulated by a pneumatically powered multileaf collimator. Additional 
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manipulation of the treatment couch position as it moves through the gantry 
facilitates the delivery of a very precise radiotherapy shape and dose to the 
target. Treatment verification with on-board CT imaging also helps to ensure 
accurate treatment delivery and increases the feasibility of dose escalation. 
(Welsh et al., 2002) 
 
A planning study comparing Varian’s Rapid Arc VMAT with conventional dynamic-
based IMRT in 6 MPM patients reported equivalent target coverage and 
homogeneity but observed that VMAT was associated with improved OAR sparing 
and also required fewer monitor units (MU) and less time to deliver the 
treatment. (Scorsetti et al., 2010) A similar study comparing Philips’ Smart Arc 
VMAT with segmental-based IMRT found very little difference in the dose indices 
achieved, but reported consistently shorter delivery times and more efficient MU 
use with VMAT. (Kawashima et al., 2013) Such data imply that this technique 
may be more suited to the treatment of MPM patients, in whom target volumes 
may be large and where reduced intra-fraction patient motion and variability 
would help ensure that dose is delivered within the intended target margins. 
(Rana, 2013)  
 
Sterzing et al compared the dosimetry achieved with HT to segmental-based 
IMRT. They reported that HT significantly improved dose homogeneity and target 
coverage (average PTV receiving more than 95% of the prescribed dose: 96.42% 
for HT compared to 87.10% for IMRT) and that the contralateral MLD could be 
reduced to less than 5Gy with HT. (Sterzing et al., 2008) Clinical studies have 
confirmed this dosimetric superiority. (Sylvestre et al., 2010) In a pilot study, 
performed on a single patient post-pleurectomy, Rapid Arc VMAT was compared 
with HT. While homogenous PTV coverage and acceptable OAR doses were 
achieved with both techniques, HT was associated with improved dosimetry in 
the contralateral lung (V20, V10, V5: 0%, 2.3%, 17.1% for HT compared to 0%, 
14.8%, 65.8% for VMAT), while VMAT required fewer MUs and could deliver 
treatment significantly faster than HT. (Yip et al., 2011) 
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 1.3.3 RapidPlan 
In order to reduce planning time and streamline workflow, knowledge-based 
radiotherapy planning has been incorporated into clinical practise. Within 
Eclipse (v15.5), a database of previously created IMRT or VMAT plans are 
accumulated for a particular anatomical area to create a ‘training cohort’. The 
RapidPlan model learns from these plans by exploiting anatomical correlations of 
dose volume distributions, specifically the geometrical arrangement of OARs 
with respect to the PTV and the previously achieved doses to OARs and PTVs. 
The system is then able to automatically generate dose volume histogram (DVH) 
estimates for a new patient and translate these into suggested optimal IMRT or 
VMAT plan objectives. (Appenzoller et al., 2012, Chanyavanich et al., 2011, 
Zarepisheh et al., 2014) RapidPlan has been demonstrated to reduce planner 
interaction time and improve plan quality and consistency, (Tol et al., 2015, 
Fogliata et al., 2017) but the quality of the plans produced is heavily dependent 
on the quality and robustness of those in the training database. (Hussein et al., 
2016)  
 
 1.3.4 Multi-criteria optimisation 
Common to these advanced radiotherapy techniques is the inverse planning 
process, in which the desired dose to the PTV is prescribed and acceptable dose 
limits for the surrounding radiosensitive structures are set. An iterative 
optimisation process is then undertaken, whereby the cost-function associated 
with the stated objectives is minimised to create the ‘optimal’ plan. This 
approach is time consuming and is often associated with sub-optimal plans, in 
which, for example, the compromise made between the planning goals may not 
be clinically acceptable. (Miguel-Chumacero et al., 2018) Radiotherapy planning 
is therefore a multi-criteria problem, in which the risk of under dose in the PTV 
is balanced against the risk of overdose in the OARs. (Teichert et al., 2019) 
 
To address this, a multi-criteria optimisation (MCO) approach has been 
suggested. (Craft et al., 2006, Craft et al., 2012a, Craft et al., 2012b, Kierkels 
et al., 2015, Wala et al., 2013, Kamran et al., 2016, Thieke et al., 2007, Muller 
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et al., 2017) This system finds multiple solutions to the problem, all of which 
prioritise a specific optimisation objective over all others. By combining these 
solutions in a mathematical construct, trade-offs can be made between two or 
more conflicting objectives, allowing the ‘best-compromise’ solution to be 
found. This method brings the plan closer to the Pareto surface, which 
represents the optimal solution from which it is impossible to reallocate to make 
any one preference criterion better off, without making at least one preference 
criterion worse off. A comprehensive review of the mathematical modelling 
which underpins this technology is presented by Katrin et al. (Teichert et al., 
2019) 
 
In practise, MCO generates 3n+1 alternate plans for each objective. The first 
plan targets the selected objective and optimises it as much as possible along 
the Pareto surface, while letting some of the other objectives vary. The second 
plan allows the chosen objective to deteriorate in a controlled manner, while 
letting the others improve. The final plan is a combination of the first two plans. 
This process is repeated for each of the objectives and an ‘optimal’ plan is 
selected for trade-off taking into account all of the parameters. Possible 
solutions with the resulting trade-offs can be explored to find the plan that best 
fulfils the treatment goals. Choice of initial plan is critical, since this influences 
the subsequent approximation of the Pareto front. It is therefore advisable to 
begin trade-off exploration using a plan which is already clinically acceptable. 
(Teichert et al., 2019) 
 
The value of MCO has been explored in a number of tumour sites, including 
pancreatic cancer, glioblastoma, non-small cell lung cancer and prostate cancer. 
(Wala et al., 2013, Muller et al., 2017, Kamran et al., 2016) MCO has 
consistently demonstrated the ability to reduce planning time and increase plan 
quality compared to standard planning techniques. (Craft et al., 2012b, Wala et 
al., 2013, Kamran et al., 2016, Teichert et al., 2019) Paramount to the success 
of MCO is the ability to trade off small variations in PTV coverage, which do not 
compromise clinically stipulated requirements, while significantly sparing OAR 
doses. (Teichert et al., 2019) 
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Miguel-Chumacero et al explored the combination of MCO with RapidPlan in 
head and neck cancer and reported that combination of these techniques could 
improve the balance between OAR doses and PTV coverage. It was observed that 
plans generated through a RapidPlan model provide an optimal starting point for 
MCO; plan quality was maximally enhanced by the MCO optimisation of a plan 
generated via the RapidPlan model which had been trained using MCO-optimised 
plans. Compared to the original clinical plan, these plans were associated with a 
mean parotid dose of 15± 4.6Gy versus 22.9± 5.5Gy (left) and 17.1± 5Gy versus 
24.8± 5.8Gy (right). (Miguel-Chumacero et al., 2018) 
 
Despite the potential benefits associated with MCO, no studies have been 
published in which radiotherapy plans for MPM have been optimised using this 
technology.   
 
1.4 Radiobiological considerations impacting radiotherapy delivery 
 1.4.1 The lethality of ionising radiation  
The consequences of cell exposure to ionising radiation (IR) are mediated 
through its interaction with DNA and include cell death, carcinogenesis and 
genomic mutation. Both direct ionisations and free radical production can result 
in DNA-lesions including base damage, DNA-protein crosslinks, single strand 
breaks (SSB) and double strand breaks (DSB). A 2Gy dose of radiation will 
produce on average around 2000 SSB and 80 DSB. An intricate series of pathways 
exist through which the cell can sense and repair each type of lesion prior to 
undergoing mitosis. (Thacker and Zdzienicka, 2003) Checkpoints within the cell 
cycle block the progression of the cell into the subsequent stage until the 
damage has been repaired, or until cell death is triggered. (Sancar et al., 2004) 
SSB are generally repaired readily by the cell and do not directly contribute to 
the cytotoxicity of IR. DSB, by contrast, are difficult for the cell to repair and 
are the most toxic form of radiation-induced DNA damage. Failure to accurately 
repair DSB leads to the development of genomic aberrations. Where these 
involve two chromosome breaks, asymmetric exchange-type aberrations can 
occur, forming di-centrics and rings, culminating in the loss of reproductive 
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integrity and death, either by apoptosis, mitotic catastrophe or an alternative 
cell death pathway. Cells deficient in the DSB-DNA repair pathways have been 
demonstrated to have an increased number of chromosomal aberrations and are 
very sensitive to radiation-induced cell death, (Willers et al., 2009, Abbott et 
al., 1998) supporting the proposal that DSB is the principle cytotoxic lesion for 
IR. Mechanisms of DSB repair will be discussed further in section 1.7. 
 
 1.4.2 Normal tissue radiation toxicity 
The toxicity associated with radiotherapy can be explained by the radiation-
induced death of normal cells and are generally categorised into ‘acute’ and 
‘late’ effects. Although the DNA damage is inflicted at the time of radiotherapy, 
cell death and therefore side effects may not become apparent until cell division 
is attempted. (Fowler, 1992) Acute/early side effects typically occur in rapidly 
proliferating tissues which are actively renewing and tend to occur during or 
shortly after radiotherapy. Such effects tend to cause inflammatory reactions in 
exposed epithelial surfaces and mucosa. These are usually manageable with 
supportive treatment and tend to be temporary due to proliferation and 
repopulation by surviving stem cells. (Timmerman, 2008, Fowler, 1992)  
 
Late side effects, conversely, occur in slowly, or non-proliferating tissues and 
become apparent months to years after the completion of radiotherapy. Unlike 
acute reactions which can be reversed, the slow growing nature of these cells 
means that the effects tend to be permanent. Late effects can be destructive 
and are often associated with underlying vascular injury and chronic 
inflammation. This can lead to devascularisation and denervation of tissue and 
consequential fibrosis, stenosis and ulceration. These events can have 
devastating implications for patients, heavily impacting on quality of life with 
considerable morbidity and mortality. For this reason, late normal tissue effects 
are the dose limiting factor in radiotherapy delivery.  (Timmerman, 2008)  
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 1.4.3 The linear quadratic model of cell survival  
Depending on the situation, cell survival is defined in several ways. In 
differentiated tissues where cells do not proliferate, cell survival can be defined 
as the retention of function or viability, whereas in actively dividing tissues (e.g. 
intestinal epithelium), ‘survivors’ are those cells which have maintained their 
reproductive integrity. Cells able to proliferate indefinitely are said to have 
retained clonogenic capacity. The relationship between a delivered radiation 
dose and the proportion of cells that retain their ability to reproduce is 
described by a cell survival curve and can be demonstrated experimentally in an 
in vitro clonogenic assay. In clonogenic assays, the proportion of cells that have 
retained clonogenic capacity can be calculated and expressed as the surviving 
fraction of cells. The shape of the curve depends on the type of radiation 
delivered. For densely ionising radiation with a high linear energy transfer (LET), 
e.g. α particles, the response follows an approximately linear relationship (i.e. 
survival is approximated by an exponential function of dose). Conversely, for 
sparsely ionizing radiation (e.g. x- or γ-rays), the curve has an initial linear 
slope, but exhibits curvature at higher radiation doses, reflecting a quadratic 
relationship between dose and surviving fraction. This characteristic cell survival 
curve, shown in Figure 1.1, illustrates the linear quadratic (LQ) model, which 
has become the cornerstone of radiobiological modelling to predict cellular 
survival following exposure to a given dose of IR. (Hall, 1973) Whilst a number of 
models have been proposed to predict radiobiological response, the LQ model is 
the most robustly validated by both experimental and clinical data. (van 
Leeuwen et al., 2018) It is used clinically to account for missed treatments and 
to compare different dose/fractionation regimes, and several extensions to the 
basic model have been suggested, to compensate for factors of incomplete DNA 
repair (Dale, 1985) and tumour repopulation. (Dale, 1989) 
 
The linear quadratic model has been derived to describe experimental cell 
survival data, in which the coefficients α and β relate dose to surviving fraction. 
Although the parameters α and β have no mechanistic basis, attempts have been 
made to link them with biological processes, including DNA damage repair. 
(Goodhead, 1994, Chapman, 2003, Chapman et al., 1999) A lack of dose rate 
dependence for α inactivation suggests that this coefficient may represent 
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irreparable damage, leading to instant cell death. Conversely, β does seem to be 
affected by a change in dose-rate, suggesting time as a factor and leading to this 
parameter being linked to the accumulation of repairable damage eventually 
causing death.(Chapman, 2003) 
 
 
Figure 1.1 Cell survival curves for densely and sparsely ionising radiation, 
illustrating the linear quadratic model. Adapted from Joiner and van der Kogel. 
(Joiner and van der Kogel, 2009) 
 
The linear quadratic model of cell killing can be expressed as: 
 
𝑆𝐹 =
𝑁𝑠
𝑁0
= 𝑒𝑥𝑝{−𝛼𝑑 − 𝛽𝑑2} 
 
where N0 is the initial number of clonogens, Ns is the mean number of surviving 
clonogens after a radiation dose (d) and SF is the surviving fraction. (Nahum, 
2015) 
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The ratio of α to β provides a convenient way of expressing the shape of the 
survival curve in a single parameter and the shape of the survival curve, 
specifically, its shoulder or ‘bendiness’, determines the effect of dose 
fractionation.  
 
 1.4.4 The rationale of dose fractionation 
When given with curative intent, external beam radiotherapy is almost always 
delivered in a large number of small fractions, usually of the order of 2Gy. The 
rationale for this practice can initially seem confusing, since radiobiologically, a 
given dose of IR is almost always less effective at cell killing if given in divided 
doses compared to one single exposure. (Chapman, 2003) Nevertheless, 
radiotherapy dose fractionation is biologically advantageous to normal tissue 
over tumour, due to subtle differences between them, as defined by the 5R’s of 
radiobiology: repopulation, re-distribution, re-oxygenation, radiosensitivity and 
repair. (Withers, 1975, Steel and Peacock, 1989) In order to be effective, a 
radiotherapy regime should deliver a sufficient dose per fraction to ensure that 
more tumour cells are killed per day than are added in the process of 
repopulation. Cells which are undergoing mitosis (tumour cells and rapidly 
proliferating normal tissues) will be preferentially killed, allowing other cells 
time to redistribute into a radiosensitive part of the cell cycle prior to the next 
dose. Tumours are usually more hypoxic than normal tissue and cell killing in 
oxygenated parts of the tumour may, over time, result in improved perfusion of 
hypoxic areas, thereby increasing radiosensitivity by re-oxygenation. Repair of 
sublethal radiation damage between fractions occurs in both tumour and in 
normal tissue and although fractionation reduces the amount of tumour kill, it 
permits the restoration of late normal tissues. (Chapman, 2014)  
 
Of these radiobiological concepts, it is repair of sublethal DNA damage which is 
the most important factor in the success of dose fractionation. The biological 
advantage conveyed to late normal tissues over tumour can be explained by the 
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differences in the shape of their relative cell survival curves (and therefore α/β 
ratios). 
 
The α/β ratio varies between normal tissue effects and clonogen kill for most 
tumours. Classically, it has been taught that tumours and rapidly proliferating 
normal tissues (e.g. gastric mucosa) have ‘high’ α/β ratios, in the order of 8Gy-
10Gy (with a linear cell survival curve), whereas well differentiated normal 
tissue effects have ‘lower’ α/β ratios of between 1Gy and 3Gy (displaying a 
broad shoulder on the cell survival curve).  
 
When exposed to low doses of radiation, late normal tissues are more proficient 
at repairing DNA damage than cancer cells. Therefore, within this part of the 
cell survival curve exists a window of opportunity for selectively killing greater 
numbers of tumour cells than normal tissue. This therapeutic benefit is 
illustrated in Figure 1.2. 
 
 
 
 
Figure 1.2 Cell survival curves for late-responding normal tissue and tumour 
effects associated with low and high α/β ratios, respectively 
 
High α/β ratio (e.g. 
acutely responding 
tissues/ tumour cells) 
Low α/β ratio (e.g. late 
responding normal tissue) 
Therapeutic benefit from the 
delivery of low radiotherapy 
doses  
Dose per fraction (Gy) 
Surviving 
fraction 
2 8 
1 
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When radiotherapy is delivered in a large number of small fractions, the initial 
linear part of the cell survival curve is repeated as the total dose accumulates. 
This leads to a straightening of the curves for both tumour and late normal 
tissue effects, but the sparing effect is much greater in tissues with a high β 
value (low α/β ratio) than in those with a low β (high α/β ratio). If the time 
between dose delivery is sufficient, fractionation allows for almost complete 
repair to occur in late normal tissues, thereby negating the influence of β. In 
this manner, tissues with a greater shoulder on their survival curve are 
preferentially spared over tissues that typically have straighter curves. This 
important radiobiological phenomenon is illustrated in Figure 1.3 and is the 
fundamental basis for dose fractionation and the sparing of late normal tissue 
toxicity. 
 
 
Figure 1.3 Fractionation-associated straightening of the survival curves, 
illustrating the radiobiological basis of improved therapeutic ratio achieved 
with fractionated radiotherapy  
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Despite the firmly held concept that all tumours exhibit a generically high α/β 
ratio, recent data suggests that α/β ratios of two common tumour types (breast 
and prostate) may be significantly lower than originally assumed. (Yarnold et al., 
2011, Miralbell et al., 2012) Furthermore, work by Chapman et al which 
summarised the in vitro and in vivo radiosensitivity of a number of human 
tumour cell lines demonstrates that the α/β ratios are mostly lower than the 
generic value of 10Gy. (Chapman, 2014) Clinically, this is extremely relevant, 
since the α/β ratio is used to predict tissue sensitivity to a change in the 
delivered dose per fraction. Therefore, whilst fractionating the prescribed dose 
spares late normal tissue toxicity, if the tumour has a low α/β ratio then it is 
also spared to a similar extent, negating much of the advantage of fractionation. 
In this situation, the optimal therapeutic ratio is likely achieved from 
hypofractionated dose delivery since this would maximise tumour kill. There is 
currently a paucity of data on which to estimate the α/β ratio of MPM, although 
the slow growth and mesenchymal origin of this tumour suggests that the α/β 
ratio may be low therefore that hypofractionated radiotherapy may be more 
efficacious in this malignancy.  
 
 1.4.5 The application of hypofractionation 
The first radiotherapy regimes used soon after the discovery of x-rays in 1895 
were hypofractionated (i.e. delivered >2Gy/fraction). Although techniques were 
fairly crude and dose deposition in-homogenous, hypofractionated regimes were 
employed during surgical interventions and in the treatment of skin cancer. 
(Williams, 1901, Forssell, 1910) Treatment over a short timeframe was 
convenient for the patient and afforded the radiobiological advantage of a 
reduced overall treatment time, which could often produce dramatic tumour 
responses. Nevertheless, the appearance of late normal tissue toxicity meant 
that hypofractionation was abandoned for curative regimes and reserved for 
palliation. 
 
The successful and safe application of large doses of radiotherapy in a single 
fraction during neurosurgery was pioneered in the 1950s by Lars Leksell. His 
work, subsequently termed stereotactic radiosurgery, identified that damage to 
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normal tissue and therefore late toxicity, could be minimised if the areas 
receiving a large dose were of small volume or noneloquent. (Leksell, 1951) 
Likewise, the intraoperative delivery of 1 or 2 hypofractionated doses of 
radiotherapy safely continued during the 1960s under the same premise, i.e. 
that late effects could be avoided if radiosensitive structures could be physically 
moved out of the radiotherapy beam or that only very small volumes of nearby 
critical structures were irradiated. (Timmerman, 2008)  
 
As discussed in section 1.3, recent advances in radiotherapy planning and 
delivery have facilitated our ability to conform radiotherapy beams to the target 
lesion more precisely, permitting much steeper margins of dose fall-off than 
traditional techniques can offer. Not only has this facilitated dose escalation of 
conventionally fractionated regimes, but it has presented a mechanism through 
which hypofractionated treatments, such as stereotactic ablative radiotherapy 
(SABR) could be safely delivered. Initially used to treat lung cancer, this 
technique can deliver ablative, hypofractionated regimes (in the order of 11Gy 
per fraction) without incurring an unacceptable late toxicity profile because the 
volume of critical tissue treated is a very small proportion of the total tissue 
volume (usually <1cm3 for lung cancer with minimal margins). Patient set-up is 
very precise to avoid a geographical miss in the precarious moving lung and the 
application of sophisticated delivery regimes permit rapid dose fall-off beyond 
the target volume. The success of this approach in lung cancer has led to its use 
for other primary cancer sites and in oligometastatic disease.  
 
In addition to treating tumours with high α/β ratios, through careful 
management of normal tissue volume effects, hypofractionated radiotherapy has 
now become the standard of care in breast and prostate cancer. Radiobiological 
data estimate that prostate cancer has an α/β ratio of 1.4Gy to 1.9Gy, (Brenner 
et al., 2002, Fowler et al., 2001) which is lower than the estimated α/β ratio of 
3Gy for late normal bowel effects. (Thames et al., 1990) In this situation, 
hypofractionation of dose could potentially improve tumour control, without 
disproportionately increasing side effects. This hypothesis was tested in the 
conventional or hypofractionated high dose intensity modulated radiotherapy for 
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prostate cancer (CHHIP) trial. (Dearnaley et al., 2016) This randomised 
controlled phase III trial compared conventional radiotherapy (74Gy delivered in 
37 fractions over 7.4 weeks) with one of two hypofractionated schedules (60Gy 
in 20 fractions over 4 weeks or 57Gy in 19 fractions over 3.8 weeks). Data 
suggested that the hypofractionated regime utilising 3Gy per fraction to a total 
dose of 60Gy was equally effective as the conventional 2Gy per fraction regime, 
with no clinically apparent increase in toxicity. This suggests that in tumours 
with a low α/β ratio, where the rationale for dose fractionation is lost, 
hypofractionated radiotherapy can improve the therapeutic ratio, safely 
improving the probability of disease control with a lower total dose of radiation 
than is required for conventional fractionation. This study has now defined the 
standard of care in localised prostate cancer.  
 
 1.4.6 Radiobiological modelling  
Fundamental to the prediction of the likely clinical outcome of a given radiation 
regime is the accurate determination of the radiobiological parameters of the LQ 
model, α, β and so α/β ratio. These values are most commonly established 
through clonogenic survival assays using cancer cell lines, which will be 
discussed in sections 1.5 and 6.1.  
 
Following the generation of reliable radiobiological data, a number of 
approaches are used to predict radiotherapy response and to guide optimal dose 
and fractionation schedules. Classically, the concept of a biologically equivalent 
dose (BED) is used in the clinical setting to illustrate the dependence of the 
therapeutic ratio on the number of fractions. If delivered in an infinite number 
of tiny fractions, a total dose equivalent to the BED would be radiobiologically 
equal to the dose/fractionation regime in question. (Nahum, 2015) BED for late 
normal tissue effects is typically calculated assuming α/β ratio of 3Gy and for 
early responding normal tissue and tumour effects with an α/β of 10Gy. 
Conventionally fractionated radical schedules usually have a BED for late effects 
of between 100 Gy3 and 117Gy3 and between 72Gy10 and 84Gy10 for tumour 
effects. (Fowler, 1992) As the number of fractions increases, the BEDα/β=3 
decreases steadily, so the highest therapeutic ratio is obtained at the smallest 
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fraction sizes. (Nahum, 2015)  Our understanding of the likely effects of a 
change in dose/fractionation schedule can also be facilitated by the concept of 
relative effectiveness, which is used to express the radiobiological impact of any 
schedule in terms of a number of 2Gy fractions. (Yaes et al., 1991) Although BED 
continues to be a valid and useful tool, the analysis has to assume a single 
uniform dose per structure, which isn’t a realistic reflection of radiotherapy 
delivery in current practice. 
 
More recently, a greater appreciation of volume effects for late normal tissue 
complications have permitted the development of macroscopic models of 
radiobiological modelling, which are beginning to supersede traditional methods. 
Tumour control probability (TCP) and normal tissue complication probability 
(NTCP) models are advantageous in that they can account for heterogeneous 
dose distributions throughout the tumour and normal tissue as well as their 
volume effects. Using these methods, we can simulate the effect in both the 
tumour and normal tissue of changing the number of fractions in a given regime. 
(Nahum, 2015)  
 
These models eloquently demonstrate the influence of fractionation on 
therapeutic ratio. Plotting the TCP of target volumes exhibiting different α/β 
ratios over a range of fraction numbers illustrates how, for a fixed NTCP, the 
therapeutic ratio will depend on fraction number. This is shown in Figure 1.4, 
where the complication of rectal bleeding (α/β ratio = 3Gy) is modelled. For a 
tumour clonogen displaying an α/β ratio of 10Gy, treating with a high number of 
fractions clearly results in an enhanced therapeutic ratio. As the α/β ratio of the 
tumour is reduced however, the benefit of increased fraction number declines, 
and where the α/β ratio of the tumour clonogens is equivalent to the α/β ratio 
of the modelled complication (i.e. 3Gy), the dependence on fractionation is 
completely lost. When the tumour α/β ratio is reduced to below that of the 
critical tissue complication, the effect of fractionation is reversed, with the 
greatest therapeutic ratio being achieved with a single fraction. 
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Although the optimal dose and fraction size for hypofractionated regimes will 
eventually be established through the outcomes achieved in clinical trials 
employing hypofractionated radiotherapy regimes, such as SYSTEMS-2, 
TCP/NTCP models are advantageous in guiding the protocols for such studies. 
 
Figure 1.4 Tumour control probability (TCP) for target volumes exhibiting 
different α/β ratios, receiving a homogenous dose over 1-50 fractions 
All curves are isotoxic for the same normal tissue late complication of rectal 
bleeding (4.3%), for which α/β ratio of 3Gy has been applied. (No account has 
been taken of re-oxygenation between fractions and clonogen proliferation 
assumed to be negligible). Adapted from: Nahum AE. The radiobiology of 
hypofractionation. (Nahum, 2015) 
 
 
1.5 In vitro studies of MPM 
 1.5.1 In vitro tumour models 
The ability to study cancer using in vitro models has advanced our understanding 
of specific tumour biology, as well as aiding the selection and development of 
the most efficacious anticancer strategies to employ. A chronic lack of 
investment in mesothelioma research, however, has meant that this disease has 
not been studied as intensively as many other types of cancer. Although the link 
with asbestos exposure is well established (Yates et al., 1997, McElvenny et al., 
2005), there is an ongoing hiatus in our understanding of the basic biology of this 
disease and how it can be effectively treated. This is illustrated by the fact that 
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first line chemotherapy option carries with it a survival benefit of just 3 months 
(Vogelzang et al., 2003) and further reflected in the dismal prognosis of 9-12 
months. (Beckett et al., 2015) There is a desperate need for the development of 
relevant pre-clinical models of MPM, with which to explore basic tumour biology 
and facilitate the development of novel therapeutic interventions.  
 
 1.5.2 Cell lines 
Immortal cell lines are frequently used to study tumour characteristics in place 
of primary cells. The advantages of this approach include cost effectiveness, 
ease of attainment and the ability to bypass ethical considerations associated 
with use of human tissue. Furthermore, many cell lines exist as a relatively 
homogenous population, which can provide a consistent sample and reproducible 
behaviour. (Kaur and Dufour, 2012)  Primary cells are also difficult to maintain in 
culture or to store successfully, as has been the experience of our own 
laboratory with primary MPM cells and lends further weight to the case for 
utilising cell lines in the research of this disease. Despite the benefits of using 
established cell lines, the genetic manipulation often required for their creation, 
in addition to the genetic drift associated with sequential passaging has led to 
controversy surrounding the extent to which they reflect the phenotype and 
behavioural characteristics of the original tumour. (Kaur and Dufour, 2012) 
Furthermore, contamination with Mycoplasma or other cell lines has been 
demonstrated to be a substantial problem surrounding the integrity of cell lines 
in the past, (Nelson-Rees et al., 1981) necessitating regular monitoring with cell 
line authentication and Mycoplasma testing.  
 
 1.5.3 In vitro 3D Spheroid Models 
Traditional in vitro models consist of cell lines grown as 2D monolayers. (Zanoni 
et al., 2016) Although this approach has many advantages, the use of 3D in vitro 
models has recently become an attractive alternative to 2D systems for a 
number of reasons. Firstly, a 3D tumour model is able to mimic more closely the 
complexities of cellular organisation, architecture and cell to cell 
communication seen in clinical tumours. It is this structure and cell to cell 
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interaction that is thought to be in part responsible for the increased resistance 
of cancer cells cultured as spheroids to anticancer therapies compared to their 
2D counterparts. (Kobayashi et al., 1993) This property, which may contribute to 
the chemo and radioresistance of solid tumours, is known as ‘multicellular 
resistance’ (Desoize and Jardillier, 2000) and suggests that a 3D spheroid system 
would provide a more clinically-relevant model for studies of radioresistance or 
drug screening than a 2D system. (Thoma et al., 2014)  Mesothelioma cells have 
been demonstrated to display enhanced resistance to chemo and radiotherapy 
when they are grown as multi-cellular spheroids rather than in monolayer 
culture, which matches the resistance to therapies observed in the clinic. 
(Barbone et al., 2008) 
 
In addition to multicellular resistance, 3D spheroid models can adequately 
represent other inherent properties of solid tumours, which can affect 
treatment outcomes, such as hypoxia (Wartenberg et al., 2003), sub lethal 
damage (SLD) repair (Dubessy et al., 2000) and the presence of chemical 
gradients (oxygen, nutrients, catabolites). (Zanoni et al., 2016) Low penetration 
into solid tumours may limit drug efficacy, which can also be better modelled by 
spheroid systems (Minchinton and Tannock, 2006) and a dynamic response can be 
monitored in terms of spheroid growth or shrinkage. Furthermore, large 
spheroids (diameter exceeding 500µm) exhibit the spatial heterogeneity often 
seen in solid tumours, with peripheral proliferative cells, an internal quiescent 
zone with limited oxygen availability and a necrotic core.  (Mueller-Klieser, 
1987, Vinci et al., 2012) For studies of radiosensitivity, a hypoxic environment is 
particularly relevant, in light of the oxygen fixation hypothesis. This hypothesis 
states that DNA damage caused by radiation in the presence of oxygen is more 
difficult to repair, leading to increased cytotoxicity in oxygenated cells. (Gray et 
al., 1953) Oxygen therefore acts as a radiosensitiser, increasing the lethality of 
any given dose of radiation. Conversely, hypoxia renders IR less effective at cell 
killing and contributes to the radioresistance exhibited by many solid tumours. 
Cancer cells cultured in parallel in 2D and 3D conditions frequently exhibit 
different gene expression profiles, with 3D culture more closely aligning with the 
clinical specimens. (Kim et al., 2012, Sakai et al., 2010) Furthermore, analysis of 
the gene expression profile of spheroids has identified tumour-relevant genes 
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associated with survival.  (Ernst et al., 2009) The use of in vitro 3D tumour 
models is now commonplace and this valuable resource appears to be bridging 
the gap between conventional in vitro 2D systems and animal models. (Yamada 
and Cukierman, 2007) 
 
There are many general 3D culture systems, but two of the commonly used 3D in 
vitro tumour spheroid models are multicellular spheroids and tumour fragment 
spheroids. Multicellular spheroids are generated from cell lines that have been 
allowed to grow into 3D structures. (Mueller-Klieser, 1997) Whilst they are 
particularly useful for studying resistance to radiotherapy (Santini et al., 1999), 
they remain a highly artificial model, generated from selected clonal 
subpopulations, which lacks the complexity of the primary tumour and its 
associated microenvironment. (Kim et al., 2005) Tumour fragment spheroids by 
contrast, are small pieces of the original tumour, cultivated to form a 3D 
structure. This model is more representative of the original tumour, the 
heterogeneity of which is preserved with the expression of the actual (rather 
than selected) tumour cells, non-malignant tumour-associated cells and the 
tumour extracellular matrix. The interaction between these cell types is known 
to be important in determining the growth, migration and differentiation of 
tumour cells as well as survival and resistance to apoptosis. (Chrenek et al., 
2001, Fracasso and Colombatti, 2000) 
 
Within this thesis, 3D spheroid models will be used to study not only the 
radiosensitivity of MPM cell lines, but also to investigate the impact of various 
radiosensitisers on MPM response to single dose and fractionated IR. These 
radiosensitisers target important pathways that determine cell survival after 
exposure to IR, including apoptosis and DNA damage repair. 
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 1.5.4 Studies of radiosensitivity  
 1.5.4.1 2D techniques 
Radiosensitivity measures generated from a clonogenic survival assay include the 
survival fraction after delivery of 2Gy of IR (SF2Gy), in addition to the individual 
values of α and β. Mean inactivation dose (MID) is commonly quoted as a 
measure of radiosensitivity in human cell lines. This approach has several 
advantages over other parameters in that it is representative of the whole cell 
population and minimises variation in survival data of a given cell line quoted by 
different authors, (Fertil et al., 1984) a phenomenon which has been observed in 
a number of established cancer cell lines. (Brock et al., 1990, Kelland and 
Bingle, 1988, Rofstad et al., 1987) The concept of MID was first introduced by 
Kellerer and Hug (Kellerer and Hug, 1972) and its application is based on the 
assumption that the survival curve is regarded as a probability distribution of 
dose. More accurately: ‘the survival probability s(D) can be considered as an 
integral probability distribution; this is so because s(D) is the probability that a 
dose larger than D is necessary to inactivate a cell which has been randomly 
selected from the population’; where s=surviving fraction and D=dose. (Kellerer 
and Hug, 1972) The differential probability distribution s(D) can be characterised 
by its average dose, the ‘mean inactivation dose’. (Fertil et al., 1984)  
 
Despite the well-established role of the clonogenic assay in radiobiology, this 
technique is laborious and time consuming and the advance of automated cell 
survival assays has allowed the rapid assessment of cell viability in microtitre 
plates following exposure to drugs or IR. The MTT assay, for example, detects 
the enzymatic reduction of 3-(4,5-dimethylthiazole-2-yl) -2,5-
diphenyltetrazolium bromide (MTT) to MTT-formazan, in the presence of 
mitochondrial respiration. The reaction produces a colour change which can be 
easily detected from cell monolayers and used to produce dose response curves 
from which SF2Gy and other measures of radiosensitivity can be determined. A 
similar approach is taken with the fluorescence based assay, using the DNA 
specific dye Hoechst 33258 to determine the number of viable cells per well. 
(Begg and Mooren, 1989) Whilst these assays may be more rapid, they are less 
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robust than a clonogenic approach, since they cannot distinguish between viable 
but sterilized cells and true surviving cells. 
 
 1.5.4.2 3D techniques 
Common to both the clonogenic and cell viability assays is the requirement for 
cells to be grown as monolayers prior to irradiation. The advantages of 3D 
culture systems in representing tumour behaviour and complexity has been 
discussed in section 1.5.3, and several studies have shown that cells grown in 3D 
better model the clinical response to drugs and radiation. (Gomez-Roman et al., 
2017, Hehlgans et al., 2008, Zschenker et al., 2012)  A number of studies 
assessing the impact of IR alone have used 3D spheroid models. Culture of 
neuroblastoma (Wheldon et al., 1985, Deacon et al., 1985) and melanoma cells 
(Rofstad et al., 1986) as multicellular tumour spheroids demonstrated a good 
correlation of the behaviour of both cell types to the original clinical tumour 
following single doses of IR. Furthermore, Schwachofer et al demonstrated that 
following single doses of IR, parameters of growth delay and cell survival analysis 
could be used to determine the relative radiosensitivity of five different human 
tumour cell lines grown as multi-cellular tumour spheroids and that these 
sensitivities paralleled the behaviour of the original tumour. (Schwachofer et 
al., 1989) Spheroids have also been used to study brachytherapy regimes (Fritz 
et al., 1996) and dose fractionation, where they have been found to be superior 
to monolayers in assessing hypofractionated protocols in glioblastoma cells. 
(Kaaijk et al., 1997) Their role in assessing response to multi-fractionation 
radiation schedules has been reported by Sham et al (1988), where cellular 
growth kinetics and repopulation rates of irradiated spheroids were determined 
by flow cytometry. Results importantly highlighted that tumour repopulation 
began earlier during the fractionation regime than had been assumed from 
clinical data and the authors concluded that spheroid models are a valuable tool 
in the evaluation of fractionation regimes, yielding results which are closer to 
the clinical picture than observed with monolayers. (Sham and Durand, 1998) 
 
Despite the improved representation of clinical tumours, determining 
parameters of radiosensitivity from 3D systems may be more difficult than in 2D 
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experiments. Nevertheless, suggested techniques have been published (Stuschke 
et al., 1995) and approaches used to determine α/β ratio from in vivo models 
provide useful guidance. (Stewart et al., 1984, Douglas and Fowler, 1976)  
 
1.5.4.3 In vivo techniques 
Mouse models are essential tools in cancer research, advancing understanding of 
basic tumour biology and allowing the assessment of responses to anti cancer 
therapies. Furthermore, the study of radiobiology has greatly benefitted from 
the use of animal models, pioneered by work by Regaud and Nogier in 1911, in 
which the ability of fractionation to spare normal tissues was investigated in 
rams. (Regaud, 1911) The outcome from this work formed the biological basis of 
fractionation, which has subsequently guided radiotherapy delivery. Recent 
developments in small animal irradiators have significantly improved techniques 
for studying radioresponse, allowing more advanced radiotherapy delivery to be 
studied in the laboratory.  
 
While in vivo models are useful for studying objective cancer responses and 
normal tissue toxicity to radiotherapy, the ability to extrapolate accurate 
radiobiological parameters in this setting is more difficult than in the traditional 
clonogenic assay. Derivation of such data assumes that endpoints such as tumour 
control or normal tissue response are driven by cell death, and the magnitude of 
effect is directly related to the fraction of surviving target cells. (Butterworth, 
2019) Accurate application of the LQ model from in vivo endpoints is therefore 
challenging, since the proportion of surviving cells is difficult to determine.  
 
This issue was noted in a review of the literature conducted by van Leeuwen et 
al in 2018. This work provides a summary of α and β parameters derived from 
clinical radiotherapy studies of a number of different tumours, although no data 
were provided for MPM. (van Leeuwen et al., 2018) Investigated outcomes 
included local and local regional tumour control, patient survival and 
biochemical data. A combination of radiobiological approaches were used to 
generate measures of α and β, including the standard LQ model in addition to 
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versions modified to consider repair and repopulation. In studies not quoting 
individual values for α and β, α/β ratio was often estimated based on iso-
effective treatment schedules. (van Leeuwen et al., 2018) Considerable 
variation was noted in reported α/β ratios for the same tumour type, attributed 
to inter-study heterogeneity rather than expected statistical uncertainty. 
Discrepancies were attributed to differences in patient populations and 
radiotherapy techniques, in addition to the models used to predict response and 
calculate the α/β ratio. This work highlights the importance of considering 
underlying assumptions when applying radiobiological models as well as the 
inherent difficulties of quantifying radiation response in the clinical or in vivo 
setting. (McMahon, 2018) 
 
Despite these difficulties, a seminal paper investigating radioresponse in vivo 
was published by Stewart et al in 1984. In this study, a mouse model was used to 
determine the repair capacity of kidneys exposed to hyperfractionated 
radiotherapy and subsequently used to establish the α/β ratio of murine renal 
tissue. Radiation schedules employed 1 to 64 fractions, using 240kVp X-rays, 
delivering a dose of between 0.9Gy and 16Gy per fraction. The treatment time 
was limited to three weeks to ensure that there was limited cell proliferation 
during treatment, and a minimum of five hours was left between fractions, a 
delay which had previously been shown to provide adequate time for SLD repair 
in irradiated mouse skin. (Douglas and Fowler, 1976) Three non-destructive, 
functional endpoints (isotope clearance, urine output and haematocrit) were 
assessed 19 to 48 weeks post irradiation and used to generate steep dose effect 
curves. Isoeffective doses between the differing radiation schedules could be 
estimated by determining equivalent levels of damage inflicted by each regime. 
Using this information, ‘equivalent single dose’ response curves for an isoeffect 
could be constructed, in which the 100% effect is attributed to that achieved by 
a single dose, the 50% effect is the dose per fraction given in two equal fractions 
and the 25% effect is the dose per fraction given in four fractions. Plotting data 
in this manner generated a continuously bending curve, which fitted the LQ 
model. It has been suggested that data expressed in this fashion may be 
considered ‘quasi-survival’ if the assumption is made that the endpoint is the 
direct result of cell death and that each fraction contributes equally to total cell 
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kill. (Hornsey, 1970, Fowler, 1983) Nevertheless, Fowler et al state that it is 
more accurate to consider these curves as dose effect curves for function rather 
than cell survival, unless a direct link between clonogenic survival and function 
has been confirmed. (Fowler, 1983) 
 
While dose effect curves illustrate the effect of radiation dose fractionation and 
allow isoeffective dose levels to be established, they cannot be used to 
determine absolute radiosensitivity. This is because the surviving fraction of 
cells corresponding to the measured effect (e.g. spheroid volume) is unknown. 
(Stewart et al., 1984) Nevertheless, by using the ‘Fe’ technique, described by 
Douglas and Fowler, such data can be used to establish the dose at which α and 
β components of cell kill become equally effective. (Douglas and Fowler, 1976) 
For data which conform to the LQ equation, plotting the reciprocal of the total 
isoeffective dose (Fe) against the corresponding dose per fraction exhibits a 
linear relationship, with gradient proportional to the value of β and  y-intercept 
corresponding to the value of α. (Douglas and Fowler, 1976)  
 
1.6 Apoptosis 
 1.6.1 Background 
Cells that are experiencing extensive stress, for example, that following damage 
induced by IR, often activate pathways of cell death, including the apoptotic 
pathway. Apoptosis is the carefully controlled process of programmed cell 
death, characterised by distinct morphological cellular changes and energy 
dependent biochemical mechanisms. It is crucial in maintaining the homeostatic 
balance of cell populations in tissues and is responsible for the healthy 
functioning of a number of processes, including normal cell turnover, embryonic 
development and immune regulation and function. (Elmore, 2007) Disruption of 
the pathways that control apoptosis can lead to various disease states. Excessive 
activation can cause autoimmune and neurodegenerative conditions, whereas 
apoptotic resistance is considered to be a critical step in the development of 
cancer (Hanahan and Weinberg, 2000) and may underpin the mechanism by 
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which some tumours are resistant to chemo and radiotherapy. (Johnstone et al., 
2002) 
 
Initiation of apoptosis results in the activation of a complex and coordinated 
series of cysteine proteases, known as caspases, leading to the final demise of 
the cell. (Elmore, 2007) The stimuli that initiate apoptosis are varied, but there 
are two principal mechanisms through which apoptosis can be triggered: the 
extrinsic pathway and the intrinsic pathway. The extrinsic pathway involves 
interaction between extracellular ligands and their transmembrane receptors to 
produce an intracellular cascade of events leading to the activation of caspase 8 
and ultimately cell death. A full review of this pathway can be found in 
‘Apoptosis: a review of programmed cell death’ by Susan Elmore, (Elmore, 2007) 
but will not be considered further here. 
 
 1.6.2 The intrinsic pathway 
The intrinsic pathway is a non-receptor driven pathway of apoptosis in which 
mitochondria are of central importance. Intracellular signals are generated 
which act on targets to affect apoptosis. Signals such as DNA damage result from 
exposure to cellular stresses (toxins, IR, viruses and free radicals) and promote 
apoptosis. (Elmore, 2007)  Loss of cell survival proteins, such as hormones or 
growth factors, result in a lack of apoptotic suppression and tips the cell towards 
death. However the stimulus is generated, the intrinsic pathway is initiated as a 
result of mitochondrial outer membrane permeabilisation (MOMP). In this 
process, the formation of pores in the mitochondrial outer membrane release 
proapoptotic proteins from the mitochondrial intermembrane space into the 
cytosol. (Saelens et al., 2004) These include Cytochrome C, Smac/DIABLO and 
HtrA2/omi. Cytochrome C binds to the adaptor protein (APAF1) and procaspase 
9, forming an apoptosome which activates caspase 9 by proteolytic cleavage. 
(Hill et al., 2004, Chinnaiyan, 1999) Smac/DIABLO and HtrA2/omi antagonise the 
inhibitor of apoptosis family of proteins (IAP), which inhibit the function of 
activated caspases. Inhibition of IAPs liberates active caspases to drive the cell 
towards death. (van Loo et al., 2002) 
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 1.6.3 The Bcl-2 family 
Critical to the control and regulation of the mitochondrial pathway of apoptosis, 
is the B cell lymphoma protein 2 (Bcl-2) family of proteins. This family of 
structurally related proteins consists of both promoters and inhibitors of 
apoptosis, which interact to create a delicate intracellular equilibrium, the 
balance of which will ultimately determine whether a cell will undergo 
apoptosis. (Cory and Adams, 2002) More than 25 members of the Bcl-2 family 
have been identified to date, characterised by the presence of a conserved 
sequence, known as the Bcl-2 homology (BH) domain. Those proteins acting as 
apoptotic inhibitors share all 4 BH domains and include Bcl-2, Bcl-xL, Bcl-W, 
A1/BFL-1 and Mcl-1. Pro-apoptotic family members express either BH1-3 
domains or BH3 only and are classified as either ‘activator’, ‘effector’ or 
‘sensitiser’ proteins. Activator BH3-only proteins (Bid, Bim, Puma) bind to the 
effector proteins (Bax and Bak) which, once activated, oligomerise in the 
mitochondrial outer membrane to produce pores, leading to MOMP. Anti-
apoptotic proteins can bind directly to the BH3 motifs of activator proteins, 
inhibiting their function and promoting cell survival. The sensitiser BH3-only pro-
apoptotic subset (Bad, Bik, HRK) do not directly activate effector proteins, but 
compete with activators binding with anti-apoptotic proteins, thereby releasing 
the brake exerted on the pro-death signal. (Chipuk et al., 2010, Czabotar et al., 
2014, Letai, 2008) The role of Bcl-2 proteins in the regulation of apoptosis is 
illustrated in Figure 1.5. 
 
The expression of the Bcl-2 family of proteins is in turn carefully regulated by 
the tumour suppressor gene TP53. (Schuler and Green, 2001) The product of the 
TP53 gene, p53, is critical for regulating the cell cycle and maintaining the 
integrity of the genome. On the detection of DNA damage, genomic repair 
proteins are activated and cell cycle arrest is induced, allowing time for DNA 
repair to occur. If the damage is too extensive to be repaired, p53 induces 
apoptosis by a number of mechanisms, including interaction with the Bcl-2 
family. (Pietenpol and Stewart, 2002) Although the exact mechanism of this 
interaction is not fully understood, data suggest that p53 may promote Bcl-2 
phosphorylation and inactivation via Cdc42. (Thomas et al., 2000) Further data 
suggest that p53 related manipulation of the pro-apoptotic proteins PUMA and 
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Noxa may also contribute to release of Cytochrome C from the mitochondria, 
pushing the damaged cell into apoptosis. (Oda et al., 2000, Nakano and Vousden, 
2001) 
 
 1.6.4 The final common pathway of apoptosis 
Both the extrinsic and intrinsic pathway of apoptosis converge on a final 
common apoptotic pathway, involving the executioner caspases, caspase 3, 6 
and 7. Activation of these proteases leads to the degradation of nuclear and 
cytoskeletal proteins, resulting in the morphological and biochemical changes 
that are characteristic of apoptosis. (Slee et al., 2001) Of the effector caspases, 
caspase 3 is critical and can be activated by any of the initiator caspases (8, 9 or 
10). Active caspase 3 cleaves and inactivates the CAD (Caspase-Activated-DNase) 
inhibitor. CAD is an endonuclease which in its active form degrades chromosomal 
DNA and causes chromatin condensation. (Sakahira et al., 1998) Activated 
caspase 3 also causes the reorganisation of the cytoskeleton and promotes cell 
disintegration into apoptotic bodies. Expression of phosphatidylserine on 
apoptotic bodies leads to early phagocytic recognition and efficient uptake 
without the release of any intracellular material; thereby ensuring that 
apoptosis is a non-immunogenic process. (Fadok et al., 2001) An illustration of 
the mechanisms involved in the apoptotic pathway are shown in Figure 1.5. 
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Figure 1.5 A schematic outlining the apoptotic pathway  
The induction of MOMP is the pivotal event which drives the intrinsic apoptotic 
pathway. This process is carefully regulated by the interaction of the Bcl-2 
family of proteins following cellular stress. Following the induction of MOMP, 
pro-apoptotic proteins are released into the cytoplasm and drive a sequence of 
caspase activation which pushes the cell towards the final common pathway of 
apoptosis. This final common pathway critically utilises caspase 3 to induce the 
morphological and biochemical changes that are characteristic of apoptosis.  
 
  
1.6.5 Mesothelioma and apoptosis 
Mesothelioma is highly resistant to the activation of apoptosis, (Fennell and 
Rudd, 2004, Narasimhan et al., 1998) a property which is likely to confer much 
of the resistance to therapy that is seen in this aggressive tumour. Apoptosis is a 
highly complex process and disruption to any one of its integrative pathways can 
have an impact on its regulation and result in a treatment-resistant phenotype. 
Understanding the molecular mechanisms by which mesothelioma avoids 
apoptosis is advancing, bringing with it developments in therapeutic strategies 
to overcome resistance. (Villanova et al., 2008) Dysregulation of a number of 
pathways has been implicated in MPM, including TNF death receptor activation 
pathways (Liu et al., 2001, Broaddus et al., 2005) and the PI3/Akt mTOR survival 
pathway (Ramos-Nino et al., 2005, Mohiuddin et al., 2002). However, the central 
role played by the Bcl-2 family of proteins in controlling intrinsic apoptosis and 
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the potential consequences of protein misregulation, has generated great 
interest in this area and makes this family a very attractive target for the 
development of novel anti-cancer therapies.  
 
 1.6.6 Dysregulation of Bcl-2 family in MPM 
Over-expression of anti-apoptotic Bcl-2 proteins is a common strategy used by 
cancer cells to increase the threshold for activation of apoptosis. (Inoue-
Yamauchi et al., 2017, Cao et al., 2007) A number of studies have noted a 
characteristic Bcl-2 family expression profile in MPM, suggesting that there may 
be a reliance on a single anti-apoptotic Bcl-2 protein to maintain survival. 
(Narasimhan et al., 1998, Segers et al., 1994, Soini et al., 1999) Addiction to 
specific anti-apoptotic Bcl-2 proteins has been noted in other malignancies 
(Simoes-Wust et al., 2000, Kondo et al., 1998) and studies suggest that different 
cell lines from the same cancer demonstrate addiction to different anti-
apoptotic Bcl-2 proteins. (Inoue-Yamauchi et al., 2017) Predicting the addiction 
profile of a cancer cell creates a therapeutic opportunity for the anti-apoptotic 
protein of interest to be targeted, facilitating the effective induction of 
apoptosis. (Inoue-Yamauchi et al., 2017) 
 
Work in the Chalmers lab using chemical BH3 profiling (Butterworth et al., 2016) 
has explored a key role for Bcl-xL addiction in the pathogenesis of MPM. (Jackson 
et al., 2020) Bcl-xL is the longer splice product of the BCL2L1 gene which 
functions to inhibit Bak/Bax activation and so prevent MOMP. (Vander Heiden et 
al., 1997) Bcl-xL has been demonstrated to be at least as potent as Bcl-2 in 
preventing apoptosis in a number of human cancer cell lines following exposure 
to pro-apoptotic signals (Amundson et al., 2000) and numerous studies have 
alluded to a dominance of Bcl-xL in promoting tumour survival and treatment 
resistance in lung (Karczmarek-Borowska et al., 2006, Tan et al., 2011, Corcoran 
et al., 2013), colon (Colak et al., 2014)and ovarian (Wong et al., 2012) cancers. 
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 1.6.7 Single agent Bcl-xL inhibition  
Recognition that many tumours exist in a state in which they are ‘primed for 
death’ has come from an understanding that the intracellular balance between 
Bcl-2 proteins is such that cells are reliant on anti-apoptotic proteins to stay 
alive. Any increase in BH3-only protein expression would be anticipated to tip 
the cell into apoptosis due to the subsequent increased levels of free pro-
apoptotic proteins. (Hennessy, 2016) Given the potential therapeutic benefit of 
this approach, a number of strategies have been used to manipulate Bcl-xL 
expression in MPM.  
 
Early methods involved histone deacetylase inhibition (Cao et al., 2001) and 
antisense oligonucleotides. (Stein and Cheng, 1993) Although antisense 
oligonucleotide data were promising, (Smythe et al., 2002, Ozvaran et al., 2004) 
redundancy amongst the anti-apoptotic Bcl-2 proteins coupled with the ability of 
MPM cells to switch expression from one protein to another, resulted in 
sustained cell survival after a selective knockdown. (Ozvaran et al., 2004, Han et 
al., 1996) These challenges favoured an approach which could simultaneously 
suppress the function of numerous anti-apoptotic Bcl-2 proteins.  
 
Development of small molecules which mimic the ability of BH3-only proteins 
(BH-3 mimetics) to inactivate the anti-apoptotic Bcl-2 family has been the focus 
of considerable effort over recent years and has resulted in the identification of 
a number of compounds, some of which have been taken forward in clinical 
trials. Early compounds such as ABT-737 and the orally bioavailable variant 
navitoclax (ABT-263) bind to Bcl-2, Bcl-w and Bcl-xL with subnanomolar affinity 
and engender apoptosis in a number of cancer cell lines. (Park et al., 2008, 
Wendt, 2008) Preclinical studies using navitoclax in combination with standard 
chemotherapies demonstrated encouraging results, (Chen et al., 2011, Ackler et 
al., 2010) but the clinical application of multi-protein inhibition has been limited 
by a number of on-target toxicities (thrombocytopenia resulting from Bcl-xL 
inhibition and neutropenia associated with Bcl-2 inhibition). (Zhang et al., 2007, 
Mason et al., 2007) This has driven the development of BH3-mimetics which 
selectively target individual anti-apoptotic proteins. Venetoclax (ABT-199) is a 
- 77 - 
selective Bcl-2 inhibitor which has demonstrated encouraging clinical results 
especially in haematological malignancies, whilst largely avoiding 
thrombocytopenia. (Souers et al., 2013) Selective Bcl-xL inhibitors include A-
1155463 (Tao et al., 2014) and its orally bioavailable variant A-1331852. 
(Leverson et al., 2015) Availability of these single agent inhibitors has enabled 
the role of specific Bcl-2 proteins to be interrogated in vitro and in vivo to 
determine if their selective inhibition is sufficient for a given effect. (Leverson 
et al., 2015) In vivo studies using a range of solid tumours suggested that Bcl-xL 
inhibition in combination with docetaxel could produce effects as robust as that 
previously seen with navitoclax and chemotherapy, but without the dose limiting 
toxicities. (Leverson et al., 2015)  
 
The employment of combined Bcl-2 and Bcl-xL inhibition in MPM cell lines in 2D 
has demonstrated significant growth inhibition associated with the induction of 
apoptosis, via a pathway which is mitochondrial dependent and p53 
independent. (Cao et al., 2007) Furthermore, co-administration of cisplatin 
resulted in the synergistic induction of apoptosis in vivo and in vitro, suggesting 
that in MPM, BH-3 mimetics in combination with chemotherapy may have 
untapped therapeutic potential. (Cao et al., 2007) Studies investigating the 
multicellular resistance of mesothelioma spheroids suggest that the resistance to 
the proteasome inhibitor bortezomib, acquired when cells are grown in 3D 
rather than 2D, is mediated through an increased resistance to apoptosis 
conferred by a dependence on anti-apoptotic defences. This study also noted 
that despite being resistant to apoptosis, MPM spheroids overexpressed the pro-
apoptotic Bcl-2 protein Bim and that exposure to ABT-737 could release this 
protein from sequestration by Bcl-2 and Bcl-xL, re-sensitising the spheroids to 
the toxic effect of bortezomib and even producing a single agent effect. 
(Barbone et al., 2011) Together these findings demonstrate the reliance of MPM 
on Bcl-xL function, confirming this protein as an attractive therapeutic target. 
 
 1.6.8 Bcl-2 protein downregulation in combination with IR 
In addition to the single agent activity exhibited by Bcl-xL inhibitors, and 
considering the potential role of anti-apoptotic proteins in therapy resistance, 
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several studies have assessed the ability of these drugs to sensitize cells to other 
forms of therapy. The chemoresistance commonly seen in MPM, underpinned by 
the knowledge that most forms of chemotherapy induce apoptosis via the 
intrinsic pathway, which could be augmented by manipulation of Bcl-2 protein 
expression (Ozvaran et al., 2004) has led to a bias in the literature towards using 
pro-apoptotic strategies to overcome chemo-resistance in MPM, rather than 
radioresistance.  
 
Resistance to IR is also a pertinent clinical issue in MPM. Whilst technological 
improvements in radiotherapy delivery have started to overcome some of the 
challenges of dose escalation, the characteristics of disease distribution and 
resulting treatment volumes are likely continue to preclude the employment of 
this modality in any capacity beyond palliation. Furthermore, despite limited in 
vitro studies, which suggest that MPM may be more radiosensitive than originally 
assumed, (Carmichael et al., 1989, Hakkinen et al., 1996) any potentially radical 
treatment is still likely to require a combined modality approach. Strategies to 
increase the sensitivity of mesothelioma to IR could therefore have huge 
potential clinical benefit in this disease. 
 
The role of apoptosis in the radioresistance of mesothelioma cells has been 
explored in our own laboratory using three mesothelioma cell lines (MSTO-211H, 
NCI-H2052 and NCI-H226). (Jackson et al., 2020) Cells were cultured in 2D and 
3D systems, where their radioresistant nature was confirmed. Viability and 
clonogenic survival assays were used to determine the effect of a panel of BH3-
mimetics on cell survival following radiation. The BH3-mimetics A-1331852 and 
A-1155463 reduced cell survival as single agents and crucially, sensitised 
mesothelioma cells to IR. Following combination treatment, caspase 3/7 assays 
detected an increase in the activity of these caspases, suggesting that the 
reduced survival was due to the promotion of apoptosis. Inhibition of other Bcl-2 
proteins with alternative small molecule inhibitors showed little efficacy, 
highlighting the dependency of mesothelioma cells on Bcl-xL for survival and 
radioresistance. Furthermore, the relative expression of anti-apoptotic Bcl-2 
proteins in mesothelioma cells predicted the radiosensitising capacity of Bcl-xL 
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inhibition, revealing a potential biomarker of BH3 mimetic activity. This very 
important work has elucidated mechanisms of radioresistance in mesothelioma 
cells and identified clinically-relevant targets for radiosensitisation. (Jackson et 
al., 2020)   
 
1.7 DNA damage responses 
 1.7.1 DNA damage and cell cycle arrest  
The essential role played by DSB in conveying the lethal effects of IR were 
introduced in section 1.4.1. The ability to repair these lesions is critical for 
maintaining chromosomal integrity and ensuring cell survival. DSB are detected 
by DNA damage response (DDR) proteins, which are responsible for the tight 
regulation of cell cycle checkpoints in G1, S, early G2 and late G2. These 
checkpoints are biological pathways which block the cell from progressing 
through the cell cycle. This allows repair of the DNA damage before the cell 
attempts to replicate its DNA (G1/S checkpoint) or undergo mitosis (G2/M 
checkpoint), where the lethality of such damage is more likely to be manifested. 
The DDR protein ataxia-telangiectasia mutated (ATM) is pivotal in this process 
and can directly phosphorylate proteins, as well as activating several other 
protein kinases. Ataxia-telangiectasia and rad-3 related protein (ATR) is also 
critical in DDR, but it primarily focussed on protecting cells from replication 
stress. DDR protein driven kinase activation leads to the phosphorylation of p53, 
checkpoint effector kinases 1/2 (CHK1/2) and downstream proteins such as p21, 
cdc25, cyclin/CDK complexes and retinoblastoma proteins. Significant 
interaction occurs between the ATM and ATR pathways, which facilitates the 
mutual coordination of cell cycle arrest through the amplification of damage 
signals and subsequent activation of downstream DDR proteins. (Weber and 
Ryan, 2015, Bouwman and Jonkers, 2012, Curtin, 2012, Malumbres and Barbacid, 
2009)  
 
 1.7.2 Repair of DNA-DSB  
Repair of DNA DSB during cell cycle arrest is a potential mechanism through 
which tumours develop resistance to radiotherapy. An appreciation of this 
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process could therefore reveal potential targets for therapeutic manipulation. 
The majority of DNA DSB repair occurs by two different processes: homologous 
recombination repair (HRR) and non-homologous end joining (NHEJ). The 
principal determinant of which pathway is utilised is the cell cycle stage at the 
time of DNA damage. (Takata et al., 1998, Yoshida et al., 2002) HRR, which acts 
exclusively in the late S/G2 phase of the cell cycle, utilises the undamaged sister 
chromatid as a template for repair and is therefore a robustly accurate process. 
NHEJ, by contrast, is far more error-prone, re-joining broken ends of DNA 
without reference to a template. It is a simple and efficient process, but is 
inherently associated with the loss of genetic material, resulting from DNA end-
processing. NHEJ primarily occurs in the G0 or G1 phase of the cell cycle, when 
cells are in a diploid state and HRR is not possible, but can be employed in all 
phases of the cell cycle. This is primarily due to the cellular abundance of the 
NHEJ activator proteins Ku70/80, which bind robustly to terminal DNA residues 
within seconds of a DSB occurring. (Jackson, 2002, Mahaney et al., 2009, 
Rothkamm et al., 2003, Beucher et al., 2009)  
 
The method employed for DS DNA repair has been postulated to explain the 
fractionation sensitivity of cells at different stages of the cell cycle. (Somaiah et 
al., 2013, Somaiah et al., 2012) Sensitivity to fraction size in G0/G1 has been 
linked to the dominance of NHEJ within this phase of the cell cycle and has been 
suggested as an explanation for the fractionation sensitivity of late normal 
tissues with low proliferation indices. In contrast, the high fidelity of DS DNA 
repair conveyed by HRR in the S/G2 phase of the cell cycle is associated with a 
loss of fractionation sensitivity and increased radioresistance. (Somaiah et al., 
2015) This has been demonstrated in vitro using cell lines displaying differential 
mutations in DNA repair pathways. (Somaiah et al., 2013) Cells which were able 
to undergo HRR displayed reduced sensitivity to fraction size and increased 
radioresistance. In contrast, cells which were defective in HRR but displayed 
functional NHEJ, retained sensitivity to fraction size. Furthermore, cells 
defective in NHEJ also displayed acquired radioresistance to a fractionated 
regime, accumulating in the late S/G2 phase and lost sensitivity to fraction size. 
(Somaiah et al., 2013) 
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Upregulation of the HRR pathway has also been suggested as an explanation for 
the loss of fractionation sensitivity seen clinically in breast cancer. This has been 
supported in a study which demonstrated HRR upregulation and enhanced S/G2 
arrest in breast epidermal tissue following 5 weeks of irradiation. (Somaiah et 
al., 2012) 
 
 1.7.3 DNA-DSB Repair and MPM 
DNA DSB repair pathways are important in the pathogenesis of MPM. Exposure to 
asbestos fibres has been shown to induce DS DNA breaks in mesothelial cells 
(Upadhyay and Kamp, 2003, Jaurand, 1997) and chromosomal deletions are 
observed in MPM. (Taguchi et al., 1993, Neragi-Miandoab and Sugarbaker, 2009) 
A study analysing the germline mutations of cancer predisposing genes revealed 
that 9.7% of MPM patients carry pathogenic truncating variants in DNA repair 
genes. These genes were primarily involved in the HRR pathway and were 
associated with the development of tumourigenesis at a statistically significantly 
lower level of asbestos exposure. These findings suggested that the pathogenesis 
of MPM may be linked in certain patients to a genetic predisposition which 
prevented cells from adequately repairing asbestos-induced DS DNA breaks. 
(Betti et al., 2017) 
 
Although HRR is important in the development of MPM, a number of genes 
involved in the NHEJ pathway have also been implicated in this disease and its 
resistance to treatment. (Toumpanakis and Theocharis, 2011) Overexpression of 
the gene encoding the protein subunit Ku80 has been detected in MPM cell lines 
(Kettunen et al., 2001) and the XRCC4 gene, the product of which is responsible 
for the ligation step of NHEJ, has also been found to be upregulated in clinical 
mesothelioma samples. (Roe et al., 2010) Such an upregulation of key DDR 
proteins could facilitate the repair of excessive DS DNA breaks induced by anti-
cancer therapies such as IR or DNA-damaging chemotherapies and engender 
resistance to treatment. This makes the NHEJ an attractive pathway to target in 
the development of novel therapeutic strategies against MPM. (Toumpanakis and 
Theocharis, 2011) 
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 1.7.4 DNA-dependent protein kinase catalytic subunit  
A critical component of the NHEJ repair pathway is DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs), a serine/threonine protein belonging to the 
phosphatidylinositol 3-kinase (PI3K) family. In response to a DSB, two molecules 
of DNA-PKcs are recruited to the lesion by the Ku70/Ku80 heterodimer. Together 
these molecules form a DNA repair complex, which spans the two broken ends of 
DNA and allows them to be tethered together. (DeFazio et al., 2002) 
Phosphorylation of the threonine 2609 cluster appears to be initiated by ATM 
(Chen et al., 2007), while auto-phosphorylation by DNA-PKcs itself occurs at 
multiple sites including serine 2056, (Chen et al., 2007, Chen et al., 2005, Cui et 
al., 2005) threonine 3950 (Douglas et al., 2007) and threonine 2609. (Douglas et 
al., 2002) This auto-phosphorylation induces a critical conformational change in 
the protein which promotes disassociation from the Ku-DNA complex and 
facilitates the access of other repair proteins to the DSB. (Douglas et al., 2007) 
Studies using cells expressing DNA-PKcs which are unable to undergo auto-
phosphorylation report extreme radiosensitivity and problems with DSB-repair 
defects. (Ding et al., 2003) 
 
In addition to providing a structural support for repair, DNA-PKcs also recruits 
other DDR proteins to aid the ligation process and its kinase activity permits the 
phosphorylation of multiple substrates which are directly or indirectly involved 
in maintaining DNA integrity. (Collis et al., 2005) Relevant DDR proteins for DNA 
end processing include Artemis, an endonuclease which modifies the overhanging 
DNA ends, and mammalian polynucleotide kinase (PNK) which adds 5’ phosphate 
groups to facilitate ligation. The Ligase IV/XRCC4 complex is responsible for the 
final stage of NHEJ, which involves ligation of the juxtaposed DNA ends. (Collis 
et al., 2005, Lees-Miller and Meek, 2003, Weterings and van Gent, 2004) A 
schematic for the processes involved in NHEJ is shown in Figure 1.6. 
 
In addition to its role in DNA-DSB repair, DNA-PKcs has been shown to regulate 
cell cycle progression by regulation of cell cycle checkpoints. (Dong et al., 2017) 
In the absence of a proficient NHEJ pathway, irradiated cells undergo aberrant 
cell cycle progression, resulting in a prolonged G2/M phase arrest. (Shang et al., 
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2010, Wang et al., 2002) The G2/M checkpoint prevents cells from entering 
mitosis before DNA damage has been repaired and is the point of the cycle at 
which cells are most sensitive to IR. (Morgan and Lawrence, 2015) 
 
 
Figure 1.6 A schematic outlining the process of NHEJ 
Following a DNA-DSB, two molecules of DNA-PKcs are recruited to the lesion and 
form a DNA repair complex. A process of sequential DNA-PKcs phosphorylation 
facilitates a conformational change in the protein which permits the access of 
other DNA repair proteins to the lesion, allowing it to be repaired and ligated. 
 
 
The critical role of DNA-PKcs in NHEJ is illustrated by in vitro studies using 
mouse and human cancer cells which do not express DNA-PKcs or Ku70. These 
cells are compromised in their ability to repair DSB, have prolonged periods of 
cell cycle arrest and display enhanced radiosensitivity compared to their wild 
type counterparts. (Chitnis et al., 2014, Kurimasa et al., 1999, Dong et al., 2018, 
Dong et al., 2017, He et al., 2007). Furthermore, overexpression of DNA-PKcs 
has been linked with radioresistance and poor clinical outcome in several 
cancers. (Lee et al., 2005, Xing et al., 2008) The central role of DNA-PKcs in 
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repair-mediated therapeutic resistance makes it an attractive target for 
radiosensitisation strategies in cancer treatment. 
 
 1.7.5 Inhibition of DNA-PKcs 
Preclinical experimental models of cancer exposed to broad spectrum PI3K 
inhibitors, such as wortmannin and LY294002, have demonstrated an association 
of these agents with reduced DSB repair and enhanced cellular sensitivity to IR 
and topoisomerase inhibitors. (Price and Youmell, 1996, Boulton et al., 2000, 
Rosenzweig et al., 1997) However, the unstable nature of these compounds 
within cells and inherent toxicity makes them unsuitable for clinical application. 
(Wipf and Halter, 2005)   
 
Using the competitive PI3K inhibitor LY294002 as a template, the compound 
NU7026 (2-(morpholin-4-yl)-benzo-h-chromen-4-one) was developed. This is a 
more potent and specific inhibitor of DNA-PKcs than its predecessor and induces 
a greater degree of sensitivity to both IR and the DNA-damaging topoisomerase II 
inhibitors. (Veuger et al., 2003, Willmore et al., 2004) NU7441 (2-N-morpholino-
8-dibenzothiophenyl-chromen-4-one) is a synthetic small molecule, which was 
developed by optimisation of NU7026. (Leahy et al., 2004) This drug is a highly 
potent and selective inhibitor of DNA-PK phosphorylation, with a documented 
IC50 of 14nmol/L. (Leahy et al., 2004) Pre-clinical studies have demonstrated 
radiosensitisation with NU7441 in several human cancer cell lines, including 
NSCLC, colon, breast, prostate and nasopharyngeal cancer. (Dong et al., 2018, 
Yang et al., 2016, Yu et al., 2015, Shaheen et al., 2011, Ciszewski et al., 2014, 
Zhao et al., 2006) Enhanced radiosensitivity has been associated with increased 
DSB and G2-arrest. (Dong et al., 2018) In vivo studies have demonstrated 
NU7441-associated potentiation of etoposide (Zhao et al., 2006) and have shown 
that concentrations of NU7441 required for radiosensitisation in vitro could be 
achieved and maintained in tumour tissue for up to 4 hours. (Zhao et al., 2006) 
The limited aqueous solubility and poor bioavailability profile of NU7441 suggests 
that further clinical development of this compound may be difficult. 
Nevertheless, the encouraging in vitro and in vivo chemo and radiosensitisation 
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data provide excellent justification for the further development of this drug 
class for therapeutic use.  
 
A possible explanation for the potent chemo and radiosensitisation seen with 
DNA-PK inhibitors is the promotion of apoptosis resulting from disturbed cell 
cycle progression and persistent DNA damage. However, alternative non-
apoptotic pathways may exist. Mitotic catastrophe has been proposed as one 
such mechanism (Shang et al., 2010), mediated by an ineffective G2 checkpoint 
which permits the premature entry of cells into mitosis with unrepaired DNA. 
(Vitale et al., 2011) This progression disturbs the mitotic kinetochore-
microtubule structure, causing mitotic arrest due to spindle checkpoint 
activation, resulting in cell death. (Mikhailov et al., 2002) It has also been 
proposed that NU7441 may exert some of its radiosensitising properties through 
its impact on the HRR pathway. There have been reports of competition 
between the DNA damage repair pathways, with cells lacking the components of 
NHEJ demonstrating compensatory elevated levels of HRR. (Essers et al., 2000, 
Allen et al., 2002) Nevertheless, rather than stimulating HRR, DNA-PK inhibitors 
appear to block the pathway in a dominant negative fashion by inhibiting the 
dissociation of DNA-PKcs from the DNA, thereby preventing access of the HRR 
proteins to the lesion. (Allen et al., 2003) A similar effect has been reported 
during poly (ADP-ribose) polymerase-1 (PARP-1) trapping, limiting the amount of 
PARP-1 associated DNA repair which can occur. (Veuger et al., 2003)  
 
It is therefore possible that a number of ‘off target’ effects may contribute to 
the radiosensitising activity of DNA-PK inhibitors. 
 
1.8 Aims of thesis 
MPM is a cancer of huge unmet need, with no effective treatment options to 
extend survival beyond a short number of months. The role of radiotherapy in 
this disease has been limited to palliation, but recent advances in radiotherapy 
planning and delivery has facilitated safe dose escalation within this remit, 
currently being investigated in the SYSTEMS-2 study.  
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There exists a gap in our knowledge with regard to the optimal role of 
radiotherapy in MPM. A lack of research into the basic radiobiology of this 
cancer, including its mechanisms of radioresistance, makes the selection of 
appropriate dose and fractionation regimes difficult and hinders our ability to 
simultaneously deliver tumour-selective radiosensitising drugs. There are no 
clinical biomarkers available to suggest which patients may benefit from 
radiotherapy or to monitor response to treatment. Furthermore, although 
radiotherapy delivery techniques have improved, it is unclear whether current 
technology would safely facilitate delivery of dose escalated hypofractionated 
radiotherapy to the entire pleura.  
 
This thesis aims to bridge some of the gaps in our current knowledge, exploring 
the possibility of using radiotherapy with a more radical intent in MPM. The 
premise of the SYSTEMS-2 study will underpin much of this work, reflecting the 
importance of this randomised clinical trial of radiotherapy dose escalation as an 
initial step towards the employment of radical radiotherapy in this disease. A 
broad approach will be taken, encompassing clinical and laboratory work, in 
addition to radiotherapy planning and dose delivery considerations. 
 
Specifically, this thesis aims to: 
1. Facilitate the set up and delivery of SYSTEMS-2: a multicentre, phase II, 
randomised controlled trial of radiotherapy dose escalation for pain 
control in MPM. 
 
2. Develop dose constraints which will facilitate the safe delivery of dose 
escalated, hypofractionated radiotherapy within the SYSTEMS-2 study. 
 
3. Explore radiotherapy planning options which may enable further dose 
escalation in MPM, including MCO and isotoxic radiotherapy planning. 
 
4. Investigate the radiobiology of two distinct MPM cell lines, using a 
clinically relevant 3D in vitro model. In particular, the response to 
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fractionated radiotherapy regimes will be studied and this data 
interrogated to determine the α/β ratio of this tumour. 
 
5. Explore the potential for using radiosensitising drugs in MPM. The activity 
of NU7441 (a DNA-PKcs inhibitor) and A1331852 (a Bcl-xL inhibitor) will be 
studied in combination with fractionated radiotherapy using an in vitro 3D 
model of MPM. The clinical validity of these targets will be determined by 
IHC analysis of diagnostic biopsies taken from MPM patients. 
 
6. Determine the expression of nine proteins, selected for their potential to 
influence radioresponse, in tumour biopsies taken from patients who 
participated in the SYSTEMS and SYSTEMS-2 studies. Expression data from 
the SYSTEMS cohort will be correlated with clinical trial outcomes to 
identify any potential biomarker of radioresponse. Baseline clinical trial 
data will be correlated with protein expression data from both cohorts, in 
an exploratory analysis. 
 
It is hoped that this body of work will advance our understanding of the 
radiobiology of MPM and therefore of how radiotherapy may be best utilised to 
treat it. 
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Chapter 2: Materials and Methods 
 
2.1 Methods used to determine dose constraints for SYSTEMS-2 
 2.1.1 Dose constraints 
In order to generate dose constraints for the 36Gy in 6 fraction arm of SYSTEMS-
2, constraints for the local thoracic SABR regimen (55Gy in 5 fractions) were 
used as a guide. Given the radiobiological variance between these two regimes, 
BED and EQD2 were calculated to allow a more useful comparison between 
them. The following equations were used: 
𝐵𝐸𝐷 = 𝐷 [1 + 𝑑/(𝛼/𝛽)] 
 
𝐸𝑄𝐷2 = 𝐷 
(𝑑 + 𝛼/𝛽)
(2 +
𝛼
𝛽)
 
Where: 
D= total dose 
d= dose per fraction 
α/β= 2, 3 or 10 
 
Calculation of BED and EQD2 for the 36Gy in 6 fraction regime allowed an 
appreciation of the relative dose which would be delivered to an OAR, should it 
receive the full prescribed dose of 36Gy. This facilitated comparison with doses 
permitted within a SABR regime. 
 
For each OAR, the maximum tolerated dose for the 55Gy in 5 fraction regimen 
was converted into the EQD2. In order to generate directly comparable values 
for SYSTEMS-2, the same maximum dose was then converted into the EQD2 for a 
6 fraction regime. An α/β ratio of 3 was assumed for late normal tissue 
complications for all organs except the spinal cord, where an α/β ratio of 2 was 
employed. For acute toxicity, an α/β ratio of 10 was used. Analysis of the 
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relative doses delivered within the SABR regime facilitated the generation of 
radiobiologically safe constraints for SYSTEMS-2. 
 
 2.1.2 PTV constraints 
In SYSTEMS-2 radiotherapy is delivered in accordance with International 
commission on radiation units 83 guidance, which recommends that dose volume 
specifications should be used to report a treatment plan. (Hodapp, 2012) 
Expected PTV coverage is therefore reported in terms of the absorbed dose (D) 
that covers a specified volume (v). Minimum absorbed dose will be represented 
by D98%, median dose by D50% and maximum dose by D2%.  
 
The protocol for SYSTEMS-2 states that PTV constraints should not be 
compromised to meet OAR constraints unless the treating clinician feels that 
proposed plan would result in an acute toxicity. (Ashton et al., 2018) There is no 
maximum PTV size specified within the protocol, reflecting the geographical 
distribution of this malignancy and the palliative nature of this study. If there 
are clinical concerns about delivering the dose escalated treatment due to the 
size of the PTV, or potential doses to OARs, the final fraction can be omitted, 
delivering a total dose of 30Gy in 5 fractions. (Ashton et al., 2018) 
 
 2.1.3 Radiotherapy feasibility planning studies 
Final dose constraints were submitted to the radiotherapy planning department 
at the Beatson West of Scotland Cancer Centre in March 2016. Five patients from 
the original SYSTEMS study, chosen on the basis of the close proximity of the PTV 
to critical radiosensitive organs were re-planned using VMAT-IMRT to assess 
whether the constraints were achievable. OARs for the re-planning study were 
contoured according to the Radiation Therapy Oncology Group (RTOG) 
Contouring Atlas. (Kong et al., 2011) Full details of the contouring requirements 
can be found in the radiotherapy planning guidelines (www.systems-2.co.uk). 
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In March 2019, the same radiotherapy plans were repeated by the same member 
of staff using the same planning technique, to assess the impact of increased 
experience on achievable dosimetry.  
 
2.2 Methods used for MCO analysis of SYSTEMS-2 radiotherapy plans 
 2.2.1 Dose escalated radiotherapy plans (Glasgow cohort) 
All SYSTEMS-2 patients have an initial radiotherapy plan generated for the dose 
escalated (36Gy in 6 fraction) arm of the study. Should a patient be randomised 
to 20Gy in 5 fractions then they are re-planned to this schedule and their 
original plan is de-activated. Since a record of the de-activated 36Gy plan is 
kept on the radiotherapy planning system, it was possible to locate a dose-
escalated plan for all study patients within Glasgow. Plans from 20 such patients 
were optimised using the multicriteria optimisation (MCO) software which has 
been available at the Beatson West of Scotland Cancer Centre since September 
2017. Patients whose original dose escalated plan was optimised using MCO were 
not included in this analysis.  
 
 2.2.2 Planning information 
Radiotherapy plans for all Glasgow patients were generated with IMRT/VMAT 
using Eclipse planning system version 15.5. The calculation model employed the 
anisotropic analytical algorithm (AAA), with either 6Mv or 10Mv flattening filter 
free photon beams, depending on the size of the target. In order to avoid 
contralateral structures, partial arcs were employed, although due to PTV size 
and location full arcs were occasionally required. Plans were optimised through 
an iterative process in which dose to one organ was manipulated in respect to 
that received by another, until all the dose constraints and the prescribed PTV 
coverage were met. 
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 2.2.3 MCO of the original 36Gy in 6 fraction plan  
The dose escalated plan was copied into a new folder within Eclipse. This 
ensured that all test plans were maintained separately from active clinical 
models. Opening the plan within the External Beam Planning interface allowed 
the achieved dose volume histogram (DVH) for each OAR and PTV constraint to 
be viewed. The MCO planning software could be launched from this platform 
(Planning> Optimize). 
 
 2.2.4 Setting optimisation objectives 
The optimisation objectives were set within the MCO platform. This detailed the 
required dose objectives for the PTV and OARs, in addition to a ‘prioritisation 
setting’ which could be set between 0 and 999 for each organ, reflecting the 
level of priority which should be attributed to that structure. PTV constraints 
were given the highest priority, followed by organs of particular clinical concern. 
It was possible to obtain increased flexibility between the generated plans by 
setting the dose objectives more stringently than required. As each plan was 
unique, the organs of primary clinical concern would depend on the size and 
position of the PTV. If an organ was particularly close to the PTV, then its 
objectives could be set more stringently and the prioritisation setting increased 
towards that of the PTV. Dosimetry from the original plan could be viewed in the 
MCO interface, allowing an appreciation of how much harder the system would 
need to work to achieve the set objective. Once the objectives were optimised 
for the structure set, trade-offs were generated and explored (>Explore trade-
offs). 
 
 2.2.5 Trade-off selection 
Structures were selected for trade-off, allowing the dose to one organ to be 
manipulated against that to another. Structures included the PTV plus one or a 
number of other OARs. Trade-offs were explored as ‘grouped’ or ‘ungrouped’, 
depending on the OAR. If the structure was required to conform to a Dmax (e.g. 
stomach) then selection of the ‘ungrouped’ option permitted visualisation of 
that particular dose point, but if multiple objectives needed to be met and the 
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dose was being evaluated across the whole OAR (e.g. contralateral lung) then a 
‘grouped’ objective was optimal. Plans were then be generated for each 
objective (>Generate plans). If the initial plan had been generated and 
optimised within VMAT, there was greater scope for trade off explorations. This 
is because an optimised plan is naturally closer to the Pareto surface and the 
final trade off will be more efficacious when generating OAR objectives in 
relation to the PTV. 
 
 2.2.6 Plan generation 
An optimised plan was generated from analysis of the collective PTV and OAR 
constraints, by calculating 3n+1 plans for every objective set.  
 
 2.2.7 Plan Trade-off 
A slider bar option was presented for each objective selected for trade-off. 
Moving the slider bar to the left allowed an improvement in the dose objective 
to the organ, whereas movement to the right incurred degradation. This is 
classed as Pareto surface navigation. Real time dosimetry updates illustrated the 
relative impact of manipulation on each OAR whereas expansion of the DVH view 
illustrated the effect on relative OAR doses and PTV coverage. Manipulation of 
the PTV was undertaken first to ensure this conformed to dose objectives. 
Subsequently setting the slider bar to ‘stop’ prevented the PTV coverage from 
changing and also incurred a reduction in the range available for other 
objectives. This is known as ‘pinning the plans’ to a restricted section of the 
Pareto surface that is of the most interest. Dose to the most clinically relevant 
organ was then manipulated accordingly. Once all of the available range for this 
structure had been utilised, the slider bar was locked down to prevent any 
degradation. Trade off opportunities could then be explored between other 
OARs until no further manipulation could be made amongst the plan collection. 
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 2.2.8 Generating a deliverable VMAT plan 
A deliverable VMAT plan could be generated using intermediate dose. This 
mathematically accounts for the differences between inverse optimisation and 
the final calculation and is particularly beneficial where there is electron density 
inhomogeneity within the PTV and surrounding tissue. The final plan was 
presented in the External Beam Planning interface and the dose was re-
calculated using an AAA calculation model.  
 
 2.2.9 Plan comparison 
The original and MCO plan could be compared in the Plan Evaluation interface, 
where DVHs illustrating the initial and new dose distribution for each OAR could 
be viewed. In the event that a plan failed to meet a PTV or OAR constraint, the 
plan collection and trade off parameters could be reviewed and re-manipulated 
by loading the new plan in External Beam planning and selecting ‘optimize’. 
Once a final optimised MCO plan was selected, it was important to inspect the 
new dosimetry to all the OARs, even if they were not included in the trade off, 
to ensure that dose had not been deposited in an organ which had previously 
met its constraint.  
 
 2.2.10 Statistical analysis 
Due to the limited number of radiotherapy plans generated, formal statistical 
analysis to look for a significant difference between OAR doses was not 
undertaken. Data are therefore presented using descriptive statistics, and 
clinically significant dose reductions are highlighted in the analysis. While these 
may be more open to interpretation than statistically significant findings, the 
clinical relevance of any change to the radiotherapy plan can be appreciated.  
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2.3 Methods used for 3D in vitro spheroid model 
 2.3.1 Cell culture 
All experiments were performed using 2 commercially available mesothelioma 
cell lines (NCI-H2052 and MSTO-211H). All cell culture work was conducted in a 
class II sterile laminar flow hood, using sterile plastic ware and solutions and 
employing aseptic technique. Cell lines were tested regularly for mycoplasma 
contamination. 
 
 2.3.1.1 Source of mesothelioma cell lines 
The cell lines NCI-H2052 (epithelioid MPM origin) and MSTO-211H (biphasic MPM 
origin) were a kind gift from Professor Sam Janes (University College, London). 
 
 2.3.1.2 Growth conditions 
Cells were cultured in 75cm2 cell culture flasks (Corning; reference 430641U) 
containing 10mls reduced serum medium (Gibco Advanced DMEM/F12 containing 
non-essential amino acids and 110mg/L sodium pyruvate; reference 12634-010) 
with 10% foetal bovine serum (Gibco; reference 10270-106), 0.5% 
penicillin/streptomycin (Gibco; reference 15140-122) and 0.5% L-Glutamine 
(Gibco; reference 25030-024). Media was stored at 4OC but warmed to 37OC in a 
water bath prior to use. Cells were incubated at 37OC; 5% CO2 in air gas 
concentration (Galaxy 170R incubator). 
 
 2.3.1.3 Serial passage of cells 
Cells were grown to a confluency of 85-90% from microscopic appearance, at 
which point the media was aspirated and 10mls of sterile phosphate buffered 
saline (PBS) (Oxoid; reference BR0014G) was added without disturbing the 
monolayer. Cells were washed by gently agitating the flask for 30 seconds. The 
PBS was then aspirated and 1ml pre-warmed Accutase (Gibco; reference A11105-
01) was pipetted directly onto the monolayer. The flask was gently agitated to 
ensure that the whole surface of the flask was in direct contact with the 
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Accutase. The flask was transferred to the incubator and left for 5 minutes, 
after which time the cells were viewed under the microscope to ensure that 
detachment from the surface of the flask was complete. A total of 9mls media 
was added to the flask and the cells were pipetted a number of times to 
encourage generation of a single cell suspension. A fraction of this cell 
suspension (usually 1ml to create a 1:10 split) was transferred into a fresh 75cm2 
culture flask containing 10mls media and replaced in the incubator. 
 
 2.3.1.4 Counting cells 
Cells were detached from the flask using the technique described in section 
2.3.1.3 and suspended in a total volume of 10mls media. A haemocytometer was 
cleaned with 70% ethanol and the coverslip placed over the counting surface 
prior to loading with 10µls of cell suspension using a Gilson P10 pipette. The 
loaded haemocytometer was placed on the stage of an inverted brightfield AXIO 
microscope and the counting grid brought into focus at its lowest power. The 
number of cells present in the 4 corner squares of the central grid were counted 
and only those cells touching the lines on 2 sides of the large squares were 
counted ‘in’ to avoid counting cells twice. The total cell count was divided by 4 
and multiplied by 10,000 to determine the number of cells per ml.  
 
 2.3.1.5 Cell storage and cryopreservation 
In order to prepare a cell line for cryopreservation and storage, cells were grown 
in bulk using Corning 150cm2 cell culture flasks containing 20mls media. At 90% 
confluency, cells were detached as detailed in section 2.3.1.3 and counted as 
outlined in section 2.3.1.4. The cell suspension was centrifuged using a Sigma 
benchtop centrifuge with a swing out rotor at 5000 RPM to pellet the cells. The 
supernatant was discarded and the cells re-suspended in reduced serum medium 
(Gibco Advanced DMEM/F12 containing non-essential amino acids and 110mg/L 
sodium pyruvate; reference 12634-010) with 10% DMSO at a concentration of 
106cells/ml and aliquoted into 1ml cryovials (Thermo Scientific; reference 
377224). Aliquots were immediately transferred to a cryo 1oC freezing container 
(Nalgene; reference 5100-0001), filled as directed with methoxyethane and 
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stored at -80OC overnight. After 24 hours at -80OC, aliquots were transferred to 
liquid nitrogen storage tanks.  
 
 2.3.1.6 Thawing cells from liquid nitrogen 
Media was prepared as per section 2.3.1.2 and pre-warmed to 37OC. Cells were 
retrieved from liquid nitrogen and placed immediately into dry ice for transfer 
to the laboratory. Aliquots were rapidly thawed in a 37OC water bath and cells 
were immediately transferred from the cryovial into a Corning 75cm2 cell culture 
flask containing 10mls of pre-warmed media, using a P1000 Gilson pipette. 
Flasks were incubated at 37OC, 5%CO2 overnight. The following day, the media 
was aspirated without disturbing the cell monolayer and replaced with 10mls 
fresh media. Cells were passaged a minimum of two times from frozen prior to 
being used in experiments. 
 
 2.3.2 Cell culture procedures for radiation only experiments 
 2.3.2.1 Preparation of in vitro 3D spheroid model using 96 well plates 
Polysystrene 96-well spheroid microplates with clear round bottom (Corning; 
reference 4515) were used to culture spheroids for all radiation experiments. An 
individual plate was prepared for each dose of radiation planned per 
experiment. Cells were counted and seeded in an initial volume of 100µls media 
per well. Any well not being used was filled with 200µls sterile PBS in order to 
mitigate against ‘edge effect’. Cells were seeded at day -4, following which they 
were incubated at 37OC to allow sufficient time for spheroids to develop. This 
technique is the pellet system of spheroid development. Spheroid generation 
was confirmed with microscopy at day -1. 
 
 2.3.2.2 Addition of media at day 0 
A further 100µls of media was added to each well using a P200 Gilson pipette, 
bringing the total volume per well to 200µls. 
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 2.3.2.3 Media change 
This was performed at least weekly throughout the experiment. A P1000 Gilson 
pipette was used to aspirate the contents of the well without disturbing the 
spheroid. If there was a suspicion that the spheroid had been aspirated, the 96 
well plate was removed from the tissue culture hood and the relevant well 
inspected under the microscope before the aspirate was discarded. The contents 
of the well were refreshed with 200µls of media as quickly as possible to prevent 
the spheroid drying out and plates were returned to the incubator. 
 
 2.3.3 Cell culture procedures for radiation and drug combination 
 experiments 
 2.3.3.1 Preparation of 96 well plates  
This was performed as outlined in section 2.3.2.1, but H2052 and 211H cells 
were seeded into separate 96 well plates, with 8 wells per drug concentration. 
For each cell line, an individual plate was prepared per radiation dose planned, 
to allow the effect of drug and radiotherapy dose titration to be assessed across 
both cell lines. Any wells not being used were filled with 200µls of PBS. 
 
 2.3.3.2 Source and preparation of radiosensitising drugs 
Stocks of NU7441 and A1331852 were obtained from SelleckChem (NU7441, 5mg, 
reference S2638; A1331852, 5mg, reference S7801). On arrival, both drugs were 
reconstituted into dimethyl sulphoxide (DMSO) (Thermo Scientific; reference 
20688) and aliquoted for long term storage at -80OC by Dr Mark Jackson. NU7441 
was prepared at a stock concentration of 5mM while A1331852 was prepared at a 
stock concentration of 10mM.  
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 2.3.3.3 Drug and DMSO preparation at day 0 
At day 0, stocks of NU7441 and A1331852 were retrieved from -80OC storage, 
thawed at room temperature and serial dilutions prepared in media using the 
following equation: 
 
2 x concentration required      x    total volume required 
   concentration of stock 
 
Once defrosted, aliquots of NU7441 and A1331852 were stored at -20OC for the 
duration of the experiment. A DMSO control was prepared in media, 
corresponding to the maximum volume of each drug stock utilised. 
 
 2.3.3.4 Addition of media/DMSO/drug at day 0 
A total of 100µls of drug (in media), DMSO (in media) or media alone was added 
to each well, bringing the total volume per well to 200µls. Plates were returned 
to the incubator for 6 hours prior to irradiation.  
 
 2.3.3.5 Drug and DMSO preparation after day 0 
The drug/DMSO/media was refreshed in each well 6 hours before each dose of IR 
and at each media change. In order to maintain consistency between the plates, 
the contents of each well was refreshed even if the plate was not due to receive 
IR. 
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Aliquots of NU7441 and A1331852 were retrieved from -20OC and serial dilutions 
prepared using the following equation:  
 
concentration required      x    total volume required 
   concentration of stock 
 
A relevant DMSO control was prepared corresponding to the maximum volume of 
each drug used.  
 
 2.3.3.6 Media change 
This was performed prior to each dose of IR and at least weekly thereafter. This 
was performed as detailed in section 2.3.2.3, with 200µls of drug (in media), 
DMSO (in media) or media alone being replaced into each well. 
 
 2.3.4 Irradiation of spheroids 
 2.3.4.1 Delivery of ionising radiation 
The spheroids were irradiated using an Xstrahl cabinet irradiator.  
The 96 well plates were removed from the incubator and placed individually into 
the irradiation cabinet. In instances where more than one plate required the 
same dose of irradiation, the distance of the shelf from the source could be 
increased to permit concurrent treatment and the irradiation time adjusted 
according to the dose rate (Gy per minute) to ensure accurate dose delivery. 
The relative dose rates at increasing distance from the source are shown in 
Table 2.1. Plates were returned to the incubator immediately after irradiation. 
In order to maintain consistency between the plates in terms of time out of the 
incubator, all plates were removed for the period of irradiation 
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 2.3.4.2 Timing of irradiation  
All radiation schedules commenced on day 0. Delivery of subsequent fractions 
took place at 24 hour intervals, until the intended total dose had been achieved. 
 
Table 2.1 Dose rate (in Gy/minute) delivered by the Xstrahl cabinet irradiator 
depending on the distance of the shelf from the source 
Shelf 
(mm) 
Dose rate 
(Gy/min) 
200 5.56 
300 2.47 
400 1.39 
500 0.9 
600 0.63 
700 0.48 
 
This information was used to calculate the time needed to deliver the required 
dose of radiation. 
 
 
 2.3.5 Spheroid imaging 
 2.3.5.1 GelCount 
Spheroids were imaged within the 96 well plates using the GelCountTM software 
(version 1.2.1.0; Oxford Optronix Ltd 2008-16). The 96 well plates were removed 
from the incubator in multiples of 4 and loaded into the GelCountTM cartridge. 
The software was programmed to photograph every well of each 96 well plate 
using an image resolution of 2400 dots per inch (dpi), corresponding to 
10.583µm/pixel. It took approximately 1 hour to complete the count for all 4 
plates, after which they were returned to the incubator and the next 4 loaded. 
In experiments where the total number of plates was not a multiple of 4, the 
final count was set to run for an hour to limit inaccuracies introduced by having 
plates out of the incubator for unequal amounts of time. 
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 2.3.5.2 Timing of imaging 
In each experiment, spheroids were imaged at day 0, day 1, day 2 and day 3. 
Following this, imaging took place at least twice per week to track growth at 
regular intervals following irradiation.  
 
 2.3.6 Image processing and spheroid quantification  
 2.3.6.1 Spyder 
Data sets generated from GelCountTM were processed using the Spyder software 
(Scientific PYthon Development EnviRonment, version 3.6). Scripts were 
generated by Dr Mark Jackson which programmed the software to retain only the 
images from wells containing spheroids, and organise these into relevant folders. 
Images were saved as black images on white backgrounds (Figure 2.1) 
 
 
Figure 2.1 Spheroid imaging using GelCountTM and Spyder software 
Spheroids were imaged at regular intervals throughout the experiment. Each 
well of the 96 well plates were photographed using GelCountTM software and 
relevant images saved using Spyder software, to facilitate further processing. 
 
 
 2.3.6.2 Image J 
To facilitate downstream image processing, data generated through Spyder was 
manipulated using the ImageJ software (National Institute of Health, USA; Java 
1.8.0_144). Scripts were used to program the software to invert and crop the 
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original images, producing an enlarged view of the spheroid, now represented as 
a white image on a black background. (Figure 2.2) 
 
 2.3.6.3 Cell profiler 
The area of each spheroid was quantified using the Cell Profiler programme 
(version 2.2.0). (Carpenter et al., 2006) This software was used to find the edge 
of each individual spheroid by detecting the change in pixel intensity across the 
image. A template pipeline was downloaded from the company website and 
optimised for use. The optimal settings for this analysis were: 
 
• Discard objects outside of the diameter range: yes 
• Discard objects touching the border of the image: yes 
• Threshold strategy: global 
• Thresholding method: RidlerCalvard 
• Smoothing method for thresholding: automatic 
• Threshold correction factor: 1.0 
 
As the spheroids grew larger and became less compact, it was often necessary to 
change the threshold detection limits for spheroid size and pixel intensity, to 
ensure that the optimal outline was found at each stage of the experiment. 
(Figure 2.2) 
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Figure 2.2 Analysis of 2D images using Cell Profiler determined the area of 
each spheroid 
Raw spheroid images were cropped and inverted using ImageJ software to 
facilitate further processing. An outline of the spheroid was generated using Cell 
profiler software, which detects pixel intensity across the image. The 
subsequent area was measured in pixel2. 
 
 
 2.3.6.4 Post processing of Cell Profiler data in Excel 
The data from Cell Profiler was directly exported into an Excel spreadsheet. This 
allowed the accuracy of the automated outline to be manual checked at each 
stage. Frequently, the software would detect erroneous objects in addition to 
the spheroid, which could then be deleted from the spreadsheet. The area for 
each spheroid was quoted in pixel2. The micrometre: pixel ratio = 10.583: 1 
(Gelcount software). Therefore, the area in pixel2 was multiplied by 10.5832 
(112) to convert into µm2. The average spheroid area for each time point under 
each experimental condition could then be calculated and plotted to show the 
relative growth over time. On occasions where the spheroid had been lost from 
the well (e.g. by accidental aspiration during media change), data from this well 
was negated so that it didn’t impact on the mean area calculated for each 
condition. Similarly, if the outlining of the spheroid was felt to be unsatisfactory 
despite optimisation of the settings, the spheroid was discounted and did not 
contribute to the data for that timepoint. On occasions where the spheroid 
became fragmented (e.g. following drug treatment), the largest fragment was 
used to represent the spheroid area. Where the spheroid was no longer 
measurable, but traces of cellular debris could be seen in the well (i.e. the 
spheroid had not been lost at media change), the area was recorded as ‘0’ and 
this figure did contribute to the calculated mean area for that experimental 
condition.  
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 2.3.6.5 Matlab 
In addition to generating quantitative data pertaining to spheroid area, Gel 
Count also produced a ‘mask’ for each delineated object within an image. These 
masks could be used to estimate the spheroid volume, which may be a more 
clinically relevant measurement, particularly within a 3D tumour model. The 
Matlab software (Version 2.0; R2014a, 8.3.0.532), available from the University 
of Glasgow, was used to interrogate the 2D masks which were subsequently 
converted into a 3D volume, using the Reconstruction and visualisation from a 
single projection (ReVISP) software, as shown in Figure 2.3. (Piccinini et al., 
2015) The resulting dataset was uploaded into an Excel spreadsheet and the 
values checked manually for accuracy. In instances where more than one object 
had been originally detected by Cell Profiler, the correct mask and 
corresponding value was identified by the position of the object in the image 
(i.e. increasing denominations left to right across the image). A similar approach 
was used as for the analysis of the ‘area’ data, in that if a spheroid had been 
accidentally removed or the outlining was sub-optimal, data was not counted 
towards the total mean volume for that time point and experimental condition. 
Where fragments of spheroids existed, the mask corresponding to the largest 
area was used to estimate volume and where the spheroid was unmeasurable the 
volume was recorded as ‘0’. 
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Figure 2.3 Generation of 3D volume data using 2D images 
Spheroid images generated from Cell Profiler were used to determine 3D volume 
data using Matlab in conjunction with the ‘reconstruction and visualisation from 
a single projection’ (ReVISP) software. Sequential imaging permitted an 
estimation of the change in spheroid volume over time. 
 
 
 2.3.7 Statistical analysis 
All statistical analyses were performed using IBM SPSS version 25 or R version 
3.5.0. 
 
 2.3.7.1 Data organisation 
Data for spheroid volume at day 21 was grouped in terms of radiation dose, drug 
dose and experiment number. Each experiment consisted of either 6 or 8 
replicates per condition and the full dataset was reported and subject to 
analysis. Where spheroid volumes were below the lower limit of detection (but 
where the spheroid hadn’t been lost from the well), the volume was reset to the 
lowest level of detection according to the limits of the equipment used to detect 
and quantify the spheroids. Methods for analysing data below the level of 
detection have been discussed extensively in other fields. (Antweiler, 2015) It is 
widely accepted that complex approaches are available that outperform naïve 
substitution methods when a high proportion of data are below level of 
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detection (i.e. censored). However, in cases where the censoring proportion is 
low (as is the case here), the performance of substitutions methods are 
comparable. The smallest diameter of detection in Cell Profiler is 1 pixel unit 
which can be converted to µm by the multiplier 10.583. Matlab quotes final 
spheroid volume in µm3, therefore the lowest level of spheroid detection was 
calculated to be 1185µm3. Data were then subjected to a number of simple 
graphical assessments, to investigate treatment effects as well as variability 
within and between experiments, prior to attempting to fit a statistical model. 
 
 2.3.7.2 The linear mixed effect model 
Data from each experiment were treated as independent, reflecting the distinct 
biological entity of a cell line cultured at a different point in time and at a 
different passage number. A repeated measures analysis of variance (ANOVA) 
model is often used to analyse data of this nature, however due to issues with 
missing data points (from spheroid loss) and variation in the number of 
replicates between experiments (i.e. an unbalanced design), this model could 
not be used to analyse the raw data set. Therefore, a linear mixed effect model 
was used. Radiotherapy dose and drug concentration were treated as fixed 
effects. Experiment and replicate (nested within experiment) were considered 
random effects, allowing the treatment inference to be generalised beyond this 
sample of experiments. Initially, individual replicates within each experiment 
were accounted for in the model; however this often created issues with model 
convergence, possibly due to the model being over-parameterised. An 
alternative method was to fit the mixed model ignoring any variability 
introduced by the individual replicates within experiments. This approach was 
justified given the minimal variability noted between the replicates (relative to, 
for example, between-treatment dose variability) and the well documented 
limitations of intra-experimental replicates in providing an independent test of 
the hypothesis. (Vaux et al., 2012)  
 
In addition to the untransformed volumes, a number of data transformations 
were considered in order to satisfy the statistical model assumptions. Firstly, 
due to the scale of the raw data, transformations were performed to express 
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these values in log, square root and cubed root format and a ‘rescaled’ volume 
was calculated in which the raw data was divided by 106. The mean and standard 
deviation of the entire dataset was also calculated and utilised to generate a 
‘standardised’ volume (standardised volume =individual volume - mean volume/ 
standard deviation). 
 
Once a model was fitted using the raw and transformed volume data, residuals 
were plotted to check for normal distribution and constant variance. 
Radiotherapy and drug dose effects were then investigated from the best fitting 
model, and inferences made about main and interaction effects. Optimal fit to 
the linear mixed effect model was seen with either the standardised or cubed 
root datasets. Pairwise comparisons were generated following Sidak adjustment 
for multiple comparisons and used to estimate the difference between 
treatment doses, in addition to confidence intervals and p values.   
 
 2.3.7.3 Normalisation of data to account for the effect of IR   
The linear effects model was used to analyse statistical differences between all 
the spheroid data. However, this approach has not been presented in the 
analysis of the drug/radiation spheroid volume data. In order to reveal any 
potentially radiosensitising effect of the selected drugs on spheroid volume, 
spheroid data was normalised for the effect of each IR regime. This allowed 
direct comparison of the therapeutic interaction between the drug and IR and 
data was expressed as the spheroid volume relative to the irradiated DMSO 
control within each fractionation regime. This normalised data was amenable to 
analysis using a one way ANOVA to assess differences between relative volumes. 
Pairwise comparisons were generated using a post hoc Tukey test. 
 
 2.3.8 Method used to estimate the α/β ratio of MPM spheroids 
The α/β ratio of MPM spheroids was explored using a technique adapted from 
Stewart et al (1984), which was introduced in section 1.5.4.2. (Stewart et al., 
1984) To investigate the α/β ratio of MPM cell lines, fractionation schedules 
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were selected on the basis of previous in vitro 3D spheroid response data to 
single dose IR. Doses of 4Gy to 16Gy were delivered in 1 to 4 fractions, with 
individual fraction sizes of between 1Gy and 10Gy. The overall treatment time 
was 4 days and radiation doses of multi-fraction regimes were delivered 24 hours 
apart, to allow sufficient time for SLD repair. The selected endpoint of spheroid 
damage was assessed at multiple timepoints throughout the study, from day 10 
until day 21 (in the 211H cell line) or day 28 (in the H2052 cell line). The 
variation in follow up time between the cell lines was a reflection of their 
relative ability to generate reliable data over time. 
 
Data was plotted as volume size (mm3) against time (days). The effect of a 
particular radiation regime was calculated as ‘spheroid volume reduction’ and 
was determined by subtracting the irradiated spheroid volume from that of the 
un-irradiated control at a chosen time point (e.g. day 21). Combining this data 
by fraction number allowed a response curve to be generated of total dose 
versus effect, for each IR regime delivered using an equal fraction number. 
Isoeffective dose could then be established across fractionation regimes by 
determining the total dose required to produce a fixed level of volume 
reduction. The equation of the straight line joining the data points incorporating 
the selected isoeffect was used to calculate the dose per fraction. 
 
Within any multi-dose radiation schedule, each successive fraction is 
radiobiologically equally effective. This principal was applied by Douglas and 
Fowler, when investigating the effect of multiple small doses of X rays on skin 
reactions in mice. (Douglas and Fowler, 1976) This work identified that data 
conforming to the LQ model exhibits a linear relationship when plotted as the 
reciprocal of the total isoeffective dose (Fe) against the corresponding dose per 
fraction. The gradient of the line is proportional to the value of β and the y-
intercept corresponds to the value of α. Manipulation of the equation of the 
straight line of best fit between data points therefore permitted mathematical 
determination of the α/β ratio. 
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2.4 Methods used for immunohistochemical studies 
 2.4.1 Tissue Acquisition 
Diagnostic mesothelioma tissue samples from patients who had entered the 
SYSTEMS or SYSTEMS-2 study were obtained from Glasgow Biorepository. Prior to 
undertaking IHC analysis on these specimens, selected antibodies were 
optimised on mesothelioma tissue obtained from five mesothelioma patients who 
had not enrolled in any clinical trials. In addition to clinical samples, IHC 
analysis was also performed on H2052 and 211H spheroids. Cells were initially 
seeded at 102 cells per well, as described in section 2.3.2.1 and were allowed to 
grow for 3 weeks prior to being fixed in formalin and embedded in paraffin.  
 
 2.4.2 Sectioning and mounting of tissue 
Formalin fixed paraffin embedded (FFPE) blocks containing clinical tissue were 
reviewed by a pathologist at the University of Glasgow to determine tissue 
suitability for further processing. A microtome was used to cut 4µm sections 
from suitable blocks and tissue was mounted onto adherent slides. Spheroid FFPE 
blocks were processed in the same manner. 
 
 2.4.3 Antibody optimisation 
Four of the nine antibodies selected for evaluation were routinely used at the 
University of Glasgow IHC laboratory and were already optimised for use on 
human tissue. Analysis with these antibodies was performed in the University of 
Glasgow IHC laboratory using two autostainer platforms. Two of the five 
remaining antibodies (γH2Ax and DNA-PKcs) were frequently used within our 
laboratory on human tissue with established parameters, and three antibodies 
(Bcl-xL, Bcl-2 and Mcl-1) were optimised on the MPM tissue samples provided by 
the Biorepository. The parameters evaluated throughout the optimisation 
procedure are shown in Table 2.2. The final conditions chosen for antigen 
retrieval and optimal antibody dilutions are illustrated in Table 2.3. 
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Table 2.2 Parameters investigated in the process of antibody optimisation for Bcl-xL, Bcl-2 and Mcl-1 antibodies 
  pH6 pH9 
Bcl-XL anti rabbit  
(Abcam 32370) 
1:500 1:1000 1:2000 1:50 1:300 1:500 1:1000 1:2000 
Result - - - +++ ++ + - - 
Bcl-2 anti mouse 
(Dako M0887) 
1:50 1:100 1:200 1:50 1:100 1:200   
Result - - - +++ ++ -   
Bcl-2  
(Leica NCL-L-bCl-2) 
1:200 1:600  1:100 1:200 1:600 1:1200  
Result - -  +++ ++ + -  
Mcl-1 
(Abcam 32087) 
1:100 1:500  1:50 1:100 1:500 1:1000  
Result +  -  +++  +++  ++  -  
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Table 2.3 Final conditions selected for antigen retrieval and antibody dilution 
Antibody Company Code Species Antigen 
retrieval 
Dilution Positive 
control 
Visualisation Autostainer 
platform (if 
appropriate) 
BCl-XL 
 
Abcam 32370 Rabbit pH9 1:300 Tonsil DAB  
BCl-2 Leica NCL-L-
bcl-2 
Mouse pH9 1:200 Tonsil DAB  
MCl-1 Abcam 32087 Rabbit pH9 1:500 Tonsil DAB 
 
 
γH2Ax Cell 
signalling 
9718 Rabbit pH6 1:500 MPM 
tissue 
DAB  
DNAPKcs Abcam GR2613
79-2 
Mouse pH6 1:500 MPM 
tissue 
DAB  
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Antibody Company Code Species Antigen 
retrieval 
Dilution Positive 
control 
Visualisation Autostainer 
platform (if 
appropriate) 
p21 
(WAF1/CIP1) 
Dako 
 
M7202 
 
Mouse pH9 
 
1:50 MPM 
tissue 
DAB Dako Autostainer 
Link48 
Ki67 (MIB-1) Dako M7240 Mouse pH8 1:100 MPM 
tissue 
DAB Dako Autostainer 
Link48 
Hif1α BD 
Biosciences 
610959 
 
Mouse pH6 
 
1:50 
 
MPM 
tissue 
DAB Dako Autostainer 
Link48 
Caspase 3 (Asp-
175) 
Cell 
Signalling 
9661 
 
Rabbit ER2 
 
1:500 MPM 
tissue 
DAB Leica Bond Rx 
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 2.4.4 Manual immunohistochemical procedures 
 2.4.4.1 De-waxing slides 
Paraffin wax was removed from the slides using a series of xylene and ethanol 
solutions, to which slides were exposed for five minutes. Completely de-waxed 
slides were submerged in water prior to antigen retrieval. 
 
 2.4.4.2 Antigen retrieval 
Dako antigen retrieval solution (Reference S2369- pH6; Reference S2367- pH9) 
was diluted in water and heated in an uncovered pressure cooker for 10 minutes. 
Slides were transferred into the warmed solution and the covered pressure 
cooker was heated at full power for a further 10 minutes. Slides were left to 
cool for 20-30 minutes in retrieval solution. 
 
 2.4.4.3 Immunohistochemistry staining 
Sections were washed twice in 10mM tris-buffered saline with tween (TBS-T) 
solution (pH 7.5). An endogenous peroxidase block solution (Dako Reference 
K4011) was applied and the slides were covered in parafilm for 10 minutes, 
before being washed a further two times in 10mM TBS-T solution (pH 7.5). 
Primary antibodies were diluted in DakoREAL diluent (Reference S2022) and 
100µls of diluted antibody was added to each slide. Parafilm was applied and the 
slides were incubated overnight at 4⁰C in a humidified chamber.  
 
Sections were washed twice in 10mM TBS-T solution (pH 7.5) prior to application 
of the horseradish peroxidase (HRP) labelled secondary antibody (Dako 
Reference K4003- anti rabbit; Dako Reference K4001- anti mouse). Slides were 
covered with parafilm and incubated for 40 minutes at room temperature.  
 
Sections were washed twice in 10mM TBS-T solution (pH 7.5). A solution of 3,3’-
diaminobenzidine tetrahydrochloride (DAB) was prepared using Dako Liquid DAB 
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and substrate chromogen solutions (Reference K3468) and one drop was applied 
to each slide. Parafilm was used to cover each slide and the sections were 
transferred to water following the development of colour. Nuclear 
counterstaining with Mayer’s Hematoxylin was performed using the Auto-stainer 
in the University of Glasgow IHC laboratory and slides were mounted with 
coverslips. 
 
 2.4.5 Automated immunohistochemical procedures 
De-waxing and antigen retrieval was performed as part of the Leica Bond Rx 
platform. For the Dako platform, these processes were carried out manually 
before the slides were placed in the autostainer.  
 
 2.4.6 Data interpretation 
Prior to embarking on data analysis, time was spent with a consultant 
pathologist to determine typical features of malignant invasion on H+E slides. 
Following this training, all data analysis and interpretation was done without 
pathology support. 
 
2.4.6.1 Scanning of stained slides 
Following IHC staining, slides were transferred to the Glasgow Biorepository 
where they were scanned and loaded onto the ‘Slidepath’ database. Files were 
subsequently transferred to an external hard drive and uploaded to the ‘HALO’ 
analysis programme, supplied by the University of Glasgow. 
 
  2.4.6.2 Slide analysis 
The HALO programme permitted the individual visualisation and analysis of each 
slide. H+E slides were studied in combination with the original pathology report 
to identify areas of tumour invasion and HALO was subsequently ‘trained’ to 
identify tumour cells through the manipulation of parameters of nuclear size and 
shape. Once optimised for an individual patient, these parameters were applied 
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to all relevant slides. For individual antibody, settings were then adjusted to 
allow the appropriate identification of weakly (1+), moderately (2+) and strongly 
(3+) stained tumour cells. Areas suitable for analysis were selected and a report 
was generated detailing the number of tumour cells detected within the fixed 
field, in addition to the relative strength of staining within each cell. Whilst 
tumour cell settings were individualised for each patient, settings for the 
intensity of staining were kept consistent between patient samples, to permit 
meaningful comparisons. The relative expression of each protein was determined 
through the calculation of the Histology-score (‘H’ Score). Using this method, 
the percentage of cells at each staining intensity level is calculated and an H 
Score is assigned using the following formula: 
 
(1 x (% cells 1+) + 2 x (% cells 2+) + 3 x (% cells 3+)) 
 
The final score ranges from 0-300 and gives more relative weight to higher-
intensity staining in a tumour sample. The sample can then be considered 
positive or negative on the basis of a specific threshold. 
 
  2.4.6.3 Positive and negative controls 
To determine consistency between batches of antibody staining and to ensure 
the specificity and sensitivity of antibody binding, positive and negative controls 
were included with all IHC. Tonsil tissue was primarily used as a positive control, 
although if this did not express the protein of interest, samples of MPM tissue 
which had previously demonstrated robust expression of the protein were 
utilised. Negative controls comprised tonsillar or MPM tissue, without addition of 
the primary antibody. 
 
  2.4.6.4 Statistical analysis 
A number of clinical parameters were chosen to correlate with the expression 
levels of each protein. For biopsy specimens obtained from patients who had 
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taken part in SYSTEMS-2, these parameters consisted of baseline clinical trial 
data only, whereas those that were obtained from SYSTEMS patients could be 
correlated with clinical trial outcome data in addition to baseline parameters.  
 
All statistical analysis was performed using the IBM SPSS Statistics 25 
programme. Data was initially analysed through the generation of basic plots and 
non-parametric summary statistics, to determine whether any association could 
be detected between baseline clinical data and expression scores. For 
continuous data, (e.g. pain scores and CRP values) this comprised scatterplots 
with Spearman’s rank correlation coefficient analysis, to determine any 
associated p-values. For categorical data, summary statistics were used to 
generate boxplots demonstrating the spread of expression data within each 
category. Where only two categories existed, the Mann Whitney U test was used 
to assess the significance of any relationship, but when data incorporated 
multiple categories, the Kruskal-Wallis test was employed. Data was adjusted for 
multiple testing using the FDR and Berferroni corrections. 
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Chapter 3: SYSTEMS-2 
 
Chapter aim 
This chapter will outline the design, set up and delivery of the SYSTEMS-2 
study. Some of the encountered challenges will be highlighted and the 
strategies used to overcome them discussed.  
 
3.1 Introduction 
The concept of SYSTEMS-2 was developed following the publication of the results 
of the SYSTEMS study in 2015.(MacLeod et al., 2015a) This multicentre, single 
arm, phase II trial recruited 40 patients from 3 centres over 18 months and was 
the first prospective study to use validated outcome measures to assess pain 
responses to radiotherapy in MPM. Parallel opposed radiotherapy beams were 
used to deliver a standard dose of 20Gy in 5 fractions over one week to sites of 
pain and the study reported clinically significant pain responses 5 weeks after 
radiotherapy in one third of patients, with minimal toxicity.  
 
SYSTEMS-2 is a randomised dose escalation study comparing two 
hypofractionated radiotherapy regimes for pain control in MPM: 20Gy in 5 
fractions over 1 week versus 36Gy in 6 fractions over 2 weeks. (Ashton et al., 
2018) The study is underpinned by the hypothesis that a higher dose of radiation 
may achieve clinically meaningful pain responses in a greater proportion of 
patients and could extend the duration of analgesia. Furthermore, although 
there is very little data available on which to determine the α/β ratio of 
mesothelioma, the clinical suspicion is that this cancer may exhibit a low α/β 
ratio and therefore may respond more favourably to hypofractionated 
radiotherapy. (MacLeod et al., 2015a) This hypothesis is supported by a number 
of other studies which have observed improved radiological or clinical responses 
to hypofractionated radiotherapy in MPM. (Jenkins et al., 2011, van der Zee et 
al., 2004) Nevertheless, the dose escalation aspect of SYSTEMS-2 may make data 
interpretation more complex, since the impact of dose escalation may not be 
distinct from that of hypofractionation.  
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Advanced radiotherapy techniques, principally IMRT, are being used in SYSTEMS-
2 to facilitate safe dose escalation to the tumour whilst maintaining acceptable 
doses to normal tissues. 
 
SYSTEMS-2 was developed through multidisciplinary collaboration between the 
Beatson West of Scotland Cancer Centre, Edinburgh Cancer Research Centre and 
the Cancer Research UK Clinical Trials Unit Glasgow. (Ashton et al., 2018) Joint 
funding was secured for the study in 2015 from the June Hancock Mesothelioma 
Research Fund and the Beatson Cancer Charity.  
 
I was recruited into the role of Clinical Research Fellow in December 2015. My 
primary responsibility within this remit has been to develop and implement the 
SYSTEMS-2 study, initially within Glasgow, and subsequently at multiple sites 
across the UK. To this end I have been responsible for the production of a 
number of trial-specific documents, including the case report forms, laboratory 
manual and the radiotherapy guidelines, for which I also developed the dose 
constraints. I was involved in the ethics approval process and although the trial 
protocol was written prior to my taking the role of Clinical Research Fellow, I 
have contributed to all protocol amendments through the duration of the trial. I 
approached a number of potential sites throughout the UK with regard to joining 
the study and have kept in close contact with sites in set up to ensure that any 
problems are overcome as swiftly as possible. I liaise with regulatory bodies, 
such as the radiotherapy trials quality assurance team (RTTQA) and participate 
in the monthly trial management group (TMG) meeting. I am responsible for the 
clinical aspects of SYSTEMS-2 in Glasgow. This includes screening potential 
patients and optimising their analgesia prior to recruitment. I am responsible for 
planning patient radiotherapy and conducting follow up visits. Furthermore, I 
coordinate the central radiology review in which baseline and week 9 CT scans 
from all sites are assessed for radiological response to radiotherapy. Through 
poster and oral presentations, I have ensured that SYSTEMS-2 is well publicised, 
both locally, nationally and internationally. I have set up a trial specific website 
to ensure information is readily available to patients and clinicians and I 
contribute to the regular SYSTEMS-2 newsletter. I secured funding for the sample 
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collection associated with SYSTEMS-2 and have been involved in setting up 
collaborations with other research centres who wish to utilise this collection for 
mesothelioma research. 
 
3.2 Methods 
 3.2.1 Regulatory processes 
 3.2.1.1 Ethical approval process 
In order to obtain ethical approval for SYSTEMS-2, an integrated research 
application system document was submitted to the research ethics committee 
(REC) on 17th November 2015. The study protocol and patient information sheet 
(PIS) was presented at the REC review meeting on 7th December 2015 and ethical 
approval was granted on 19th January 2016 (REC number 15/SS/0225). 
 
 3.2.1.2 Local approval processes 
Prior to SYSTEMS-2 being opened in Glasgow, the study needed to be approved 
by a number of local regulatory committees, including the clinical trials 
executive committee and radiotherapy management group. These boards 
reviewed the local capacity, funding and clinical demand for the study and 
approval from both was obtained in March 2016. Local research and development 
(R&D) and overall sponsor approval was granted on 12th July 2016 and SYSTEMS-2 
opened to recruitment at the Beatson West of Scotland Cancer Centre on 16th 
August 2016. 
 
 3.2.1.3 Radiotherapy quality assurance 
To ensure consistent radiotherapy plan quality across sites, quality assurance is 
undertaken by the RTTQA. To ensure that dose constraints can be achieved and 
that contouring is consistent with the protocol, centres are asked to perform a 
planning exercise on a ‘dummy patient’ (an anonymised image from a Glasgow 
SYSTEMS-2 patient). If sites have participated in other thoracic clinical trials 
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utilising IMRT, many of the QA processes can be streamlined with previous 
assessments. 
 
 3.2.2 Study design  
SYSTEMS-2 is a multicentre, phase II randomised dose escalation study, 
comparing two hypofractionated schedules of radiotherapy for pain control in 
MPM. The study complies with Research Governance Framework for Health and 
Community Care, the British Good Clinical Practice regulations and the 
Declaration of Helsinki. SYSTEMS-2 is registered on the publically available 
ISRCTN database and is badged by the National Institute for Health Research. 
(Ashton et al., 2018) The study is sponsored by NHS Greater Glasgow and Clyde 
and the University of Glasgow (GN13ON388). 
 
 3.2.3 Study population 
Patients with a histological or multidisciplinary team (MDT) diagnosis of MPM, in 
whom radiotherapy is clinically indicated for pain control, are being recruited. 
Potential patients are primarily identified through lung cancer or mesothelioma 
MDT meetings, although direct referrals from oncology or respiratory colleagues 
are common. The recruitment target for SYSTEMS-2 is 112 patients. 
 
 3.2.4 Inclusion criteria 
• Histological and/or MDT diagnosis of MPM 
• Performance status 0-2 
• Predicted life expectancy of ≥12 weeks 
• Contrast enhanced CT scan of chest and abdomen performed within 8 
weeks prior to starting radiotherapy 
• Worst Pain ≥4/10 (0-10 numerical rating scale) after analgesia 
optimisation 
• Ability to provide written informed consent prior to participating in the 
trial and any trial related procedures being performed 
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• Willingness to comply with scheduled visits, treatment plans and 
laboratory tests and other study procedures 
• Patients must have a radiotherapy plan compatible with the treatment 
arm (30-36 Gy in 5-6 fractions) prior to randomisation 
 
 3.2.5 Exclusion criteria 
• Patients who have received anti-cancer therapy within the 4 weeks of 
study entry that is likely to alter pain at the index site during the duration 
of the study 
• Patients who are planned to have further anti-cancer therapy within 6 
weeks of the radiotherapy treatment 
• Patients who have previously received palliative radiotherapy and where 
there is concern that the proposed treatment volume would overlap with 
a previously irradiated area. This does not include patients who have 
received superficial photon or electron therapy to drain sites 
• Psychotic disorders or cognitive impairment 
• Co-existing lung tumours at the time of study entry 
• Patients who are pregnant or breastfeeding 
• Patients of child-bearing potential, who are unwilling to use 2 effective 
methods of contraception 
 
 3.2.6 Schedule of assessment 
There are six planned visits within the SYSTEMS-2 study: screening, baseline, 
final day of radiotherapy, week 5, week 9 and week 26. A flowchart outlining 
the study visits is shown in Figure 3.1 and a detailed outline of the schedule of 
assessments is illustrated in Table 3.1. 
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Figure 3.1 Outline of the study visits for SYSTEMS-2 
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 Screening 
Visit 1 
Baseline 
Visit 2 
Final Day of RT 
Visit 3 
Week 5 
Visit 4 
Week 9 
Visit 5 
Week 26 
Visit 6 
Day -28 to -3 days -7 to 1 days 
(Day 1 = RT 
Start) 
Standard Arm: 8 +/- 3 days 
Treatment Arm: 15 +/- 3 
days 
35 +/- 5 days 63 +/- 7 
days 
182 +/- 14 
days 
Informed consent X      
Registration X      
Inclusion/exclusion X      
Vital signs X      
Medical history X      
Medication history X X X X X  
Mesothelioma treatment 
history 
X      
Physical examination  X  X X  
ECOG Performance 
status 
 X X X X  
Table 3.1 Schedule of assessment for SYSTEMS-2 
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 Screening 
Visit 1 
Baseline 
Visit 2 
Final Day of RT 
Visit 3 
Week 5 
Visit 4 
Week 9 
Visit 5 
Week 26 
Visit 6 
CT chest & abdomen X    X  
Research blood tests 
(optional) 
 X  X X  
Routine blood tests  X  X X  
Pregnancy Test X      
Toxicity Assessment  X X X X  
Randomisation  X     
QUESTIONNAIRES:       
Brief Pain Inventory  X X X X X 
EORTC QLQ C-30 & LC13  X  X X  
EQ5D  X  X X X 
ICECAP-SCM  X  X X X 
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 3.2.7 Study procedures 
 3.2.7.1 Patient consent processes 
Following the identification of a potentially eligible patient, a PIS is provided by 
a health care professional already known to the patient. Interested patients are 
given at least 24 hours to consider this document before being invited to attend 
for screening by the research team. Consent to obtain and use tissue and blood 
samples for research purposes are optional components of SYSTEMS-2 and as 
such, separate consent is required. 
 
 3.2.7.2 Patient registration process 
Following consent, patients are registered to the study and are allocated a 3-
digit sequential patient ID number.  
 
 3.2.7.3 Patient randomisation process 
Patients are randomised 1:1 to dose escalated, or standard radiotherapy and are 
stratified according to the following factors: 
1. Centre 
2. Gender (male/female) 
3. PS (0, 1, 2) 
4. White cell count (≥8.3, <8.3) 
5. Histological subtype (epithelioid, sarcomatoid, biphasic, histology 
unavailable) 
6. Planned dose escalated treatment (30Gy or 36Gy) 
7. Worst pain score (4-10) 
 
At randomisation, each patient is issued with a unique sequential randomisation 
number. 
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 3.2.7.4 Analgesia optimisation prior to randomisation 
Central to the validity of SYSTEMS-2 is the step of analgesia optimisation prior to 
randomisation. Pain should be stabilised as much as possible to allow the effects 
of radiotherapy to be determined accurately. Stable pain is defined as an 
average pain score at the planned site of radiotherapy of between 4 and 8 for a 
minimum of 72 hours prior to randomisation. Whilst this is recommended, it is 
not absolute inclusion criteria, however, any patients whose pain score is less 
than 4 at the baseline visit is no longer eligible. (Ashton et al., 2018) 
 
It is recommended that patients are reviewed by the local palliative care team 
at this stage. Since Glasgow was anticipated to be the primary recruiter, trial 
staff underwent a period of palliative care training, provided by Dr Barry Laird, 
Consultant in Palliative Medicine at St Columba’s Hospice, Edinburgh. Any 
particularly challenging cases were discussed directly with Dr Laird.  
 
To standardise prescribing practise across UK trial centres, a guideline was 
issued, outlining the anticipated analgesic regime for any patient being 
considered for SYSTEMS-2. The suggested regime adheres to the WHO pain 
ladder (Walker et al., 1988) and reflects the multifactorial pathophysiology of 
MPM associated pain, which frequently necessitates a combination of analgesics 
with different mechanisms of action. (MacLeod et al., 2015b) It includes regular 
paracetamol, preparations of sustained and immediate release morphine, an 
adjuvant such as pregabalin or gabapentin and a topical preparation such as a 
lidocaine patch.  
 
 3.2.7.5 Radiotherapy planning prior to randomisation 
To avoid bias in the radiotherapy planning and target volume delineation 
process, all patients must have a radiotherapy plan which satisfies the planning 
constraints of the dose escalated arm prior to randomisation. Patients 
subsequently randomised to the control arm have a second plan generated to 
comply with the standard radiotherapy regime.  
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For the purposes of the trial, radiotherapy is specifically targeted at sites of 
pain. In order to facilitate accurate dose delivery, painful areas are demarcated 
by adhesive radio-opaque markers at the time of CT acquisition. CTV delineation 
is subsequently guided by baseline imaging information and marker position, 
which frequently corresponds with areas of bulky disease, sites of previous 
pleural intervention, rib involvement or chest wall invasion. The use of IMRT for 
planning is encouraged, but not mandated. If IMRT is not available, 3DCRT must 
be utilised. If the anatomical location of the tumour precludes delivery of 36Gy 
in 6 fractions, it is acceptable to omit the final fraction and treat to 30Gy in 5 
fractions for the dose escalated arm. 
 
 3.2.8 Trial endpoints and objectives 
 3.2.8.1 Primary objective 
The primary objective of the SYSTEMS-2 study is to determine whether dose 
escalated, hypofractionated radiotherapy increases the proportion of patients 
experiencing a clinically significant reduction in pain at the radiotherapy site at 
week five, compared to standard radiotherapy. The primary endpoint is 
therefore pain control at week 5. Pain is evaluated using the brief pain 
inventory, which was successfully implemented in the SYSTEMS study. A 
clinically significant response is regarded as a reduction of ≥2 points in the 
‘worse pain score’ component of the brief pain inventory between the visit at 
baseline and week 5.  
 
 3.2.8.2 Secondary objective 
The secondary objectives are to determine the relative effects of dose escalated 
and standard radiotherapy on acute toxicity, pain and radiological responses, 
overall survival and quality of life after radiotherapy.  
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 3.2.8.3 Exploratory objectives 
These include change in strong opioid use, health related QOL at week 9 and 
translational biomarker studies. 
 
 3.2.9 Protocol development 
The initial SYSTEMS-2 protocol was written in 2015 by Dr Nick Macleod, Dr Barry 
Laird and Professor Anthony Chalmers. Ethical approval for the study was 
granted on version 2.0 and the study opened in Glasgow employing version 3.0. 
 
 3.2.9.1 Protocol amendments 
A number of substantial and non-substantial amendments have been made to the 
original protocol since ethical approval was granted in January 2016. The 
majority of the substantial changes reflect clinical and logistical decisions which 
have been implemented to help the study run more efficiently. These are 
summarised below: 
 
I. Radiotherapy planning 
The original protocol stated that patients were required to have a radiotherapy 
plan for each treatment arm generated prior to randomisation. This was 
contested by the physics department at the Beatson West of Scotland Cancer 
Centre, who felt that this would waste time and resources. A compromise was 
reached whereby all patients would be planned to the dose escalated arm and 
subsequently re-planned to the standard arm using the same OAR and PTV 
delineations should they be randomised to this lower dose.  
 
II. Baseline CT scans 
The protocol states that patients should have a diagnostic CT scan of chest and 
abdomen with contrast within 8 weeks of the radiotherapy start date. Whilst this 
was usually achievable, no funding was available for these scans and it could be 
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difficult to ensure that they were carried out in a timely manner. Delaying the 
start of the radiotherapy for this reason was felt to be unethical in a cohort of 
patients for whom pain is a primary symptom. The decision was made to allow 
the radiotherapy planning scan (which specifies coverage from the apex of the 
chest to the iliac crest) to be carried out with intravenous contrast and using the 
narrowest slice width attainable. These images could then be used as baseline 
images for study purposes.  
 
III. Previous chest wall radiotherapy 
The initial protocol specified that patients were ineligible for SYSTEMS-2 if they 
had received previous palliative radiotherapy and there was concern about 
overlapping treatment fields at the site of pain. This created confusion at 
centres which continued to give prophylactic irradiation to drain sites using 
electrons and necessitated a protocol amendment to clarify the safety of 
proceeding with SYSTEMS-2 in these circumstances. 
 
IV. Clarification of start date of RT 
The initial protocol was not clear in terms of how soon after the baseline visit 
the radiotherapy should begin. This was clarified as being seven days and a 
statement was added surrounding the necessity of repeating baseline 
assessments should this not be achievable. 
 
V. Assessment of renal function prior to CT scan with contrast at week 9 
The protocol states that routine bloods, including renal function, should be 
checked at baseline, week 5 and week 9. In order to assess for any radiological 
response to the radiotherapy, a CT scan with contrast is required at week 9. This 
is often arranged at the week 5 visit, using the parameters obtained at that 
point to assess safety for contrast. This recommendation was updated in the 
light of a case where a patient attended for a CT scan two days prior to their 
week 9 visit and was subsequently found to have developed acute renal 
impairment, requiring hospitalisation. The patient had demonstrated very mild 
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renal impairment at week 5, but had clinically deteriorated in the intervening 
month, with decreased appetite and poor fluid intake. This event was reported 
as a serious adverse event (SAE) and was subsequently discussed at the TMG 
meeting and reported to the REC. The protocol was updated to suggest that if 
there are any concerns regarding renal function at week 5 then bloods should be 
repeated locally prior to the CT scan at week 9. 
 
VI. Pain flare 
Pain flares at the radiotherapy site were initially noted in a small minority of 
patients receiving dose escalated radiotherapy. Episodes of sharp, pleuritic pain 
were reported, usually occurring after the second or third fraction of 
radiotherapy. The symptoms are believed to be a consequence of pleural 
irritation and inflammation and are almost exclusively seen in the dose 
escalated cohort. Short courses of steroids have been used to help alleviate the 
pain and this advice was formalised within the protocol to ensure that practice 
was standardised across trial sites.  
 
 3.2.10 Site selection and opening process 
The recruitment target of 112 patients is acknowledged to be ambitious, 
particularly for a relatively rare disease such as MPM. In order to achieve this, 
SYSTEMS-2 is being conducted as a multicentre study. A number of UK sites were 
approached by the study team, selected primarily on the basis of geographical 
location and MPM prevalence. The process of study set up involved the 
attainment of local ethical and R&D approval, in addition to liaison with the 
RTTQA regarding radiotherapy planning processes.  
 
3.2.11 Central radiology review process 
Radiological response is a secondary endpoint of SYSTEMS-2. The data obtained 
from the SYSTEMS study had been disappointing in this regard, since only 18/40 
patients had been well enough to attend for their CT scan at week 12 and only 
one partial response was recorded. In order to increase the uptake of patients 
- 131 - 
attending for their CT scan, the date of this assessment has been brought 
forward to week 9. To ensure consistency within the trial, all patient images are 
transferred to the Beatson West of Scotland Cancer Centre via the RTTQA team 
for central radiology review. The week 9 and baseline CT scans are assessed by 
Dr Simon Sheridan (Consultant Radiologist, Queen Elizabeth University Hospital), 
who is blinded to the dose of radiation the patient received. Any differences 
between the scans are graded using the Modified RECIST criteria. (Byrne and 
Nowak, 2004b) The radiotherapy plans are also studied at the time of review, to 
ensure that the irradiated area is accurately identified.  
 
 3.2.12 Safety reporting 
 3.2.12.1 Adverse event reporting  
Adverse events (AE), documented and graded according to the CTCAE version 4, 
are collected at baseline and at subsequent visits (end of radiotherapy, week 5 
and week 9). The start and stop dates, severity and causality with regard to 
radiotherapy or disease are recorded. The exacerbation of any previous 
condition is classed as an AE. AEs are followed until resolution or for at least 30 
days after the final fraction of radiotherapy, or until they are considered to be 
irreversible. Perceived lack of efficacy of the radiotherapy for pain control is not 
an AE. 
 
 3.2.12.2 Serious adverse event reporting  
Since the safety profile of radiotherapy is well known, only events that are 
directly related to the administration of radiotherapy and are unexpected should 
be reported as a serious adverse event (SAE). A list of expected adverse events 
related to the administration of radiotherapy is given in the protocol (which can 
be found at www.systems-2.co.uk) and include nausea, fatigue and radiation 
dermatitis.  
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 3.2.13 Statistical analysis 
The primary endpoint of SYSTEMS-2 is to detect the difference in the proportion 
of patients on dose escalated radiotherapy compared to standard radiotherapy 
who experience a clinically significant reduction in pain at the treatment site, 5 
weeks after the radiotherapy. To determine this, SYSTEMS-2 has been designed 
to detect an absolute increase of 20% in the proportion of responders at week 5 
on dose escalated radiotherapy compared to standard radiotherapy, from 40% 
(the response rate reported in the SYSTEMS study (MacLeod et al., 2015a)) to 
60%. This detection requires 112 patients, 56 per arm, (comparison of 
proportions, 90% power, 20% 1-sided level of statistical significance; equivalent 
to 80% power, 10% level of statistical significance). The 3-outcome design (Hong 
and Wang, 2007) will determine whether a phase III study is warranted. 
 
 3.2.14 Translational research 
 3.2.14.1 Sample collection 
The SYSTEMS-2 study presents a unique opportunity to collect clinical samples 
from patients before and after radiotherapy which could subsequently be 
analysed in the context of high-quality clinical outcome data to potentially 
advance the treatment and monitoring of this disease. Blood samples are 
collected at baseline, week 5 and week 9. These are processed and stored as 
plasma, serum and whole blood. Samples are initially stored locally but are 
subsequently transferred to the Glasgow Biorepository for longer term storage. 
In addition to blood samples, diagnostic tumour samples are also being retrieved 
and stored for use in future research. The SYSTEMS-2 sample collection is 
summarised in Table 3.2. 
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Table 3.2 Summary of the SYSTEMS-2 sample collection 
 Archival 
Material 
Baseline  Week 5  Week 9  
Plasma 
 
 X X X 
Serum   X X X 
Whole blood  
 
 X X X 
Tumour Sample 
(FFPE) 
X    
 
 3.2.14.2 Lab manual  
A SYSTEMS-2 laboratory manual was generated, detailing instructions for sample 
collection, processing and storage. Information was also required regarding the 
handling and transport of processed blood samples and of formalin fixed paraffin 
embedded tumour samples. This manual was completed with input from Dr Fiona 
Thomson at the Wolfson Wohl Cancer Research Centre and Dr Jane Hair at the 
Glasgow Biorepository. 
 
 3.2.14.3 Grant applications 
Funding for the SYSTEMS-2 sample collection was not provided in the initial 
study budget. In order to secure financial backing for this and to allow 
provisional laboratory work on samples to commence, an application was 
submitted to Cancer Research UK in June 2016 for a prospective sample 
collection award. This application was shortlisted for consideration by the 
Clinical Research Committee, but was not recommended for funding.  
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In December 2016, a further grant application was submitted to Slater and 
Gordon’s ‘health projects and research fund’. This application was accepted in 
May 2017 and a proportion of the anticipated costs were secured. An additional 
application was submitted to the Beatson Cancer Charity in March 2017 who 
agreed to co-fund the outstanding costs of the sample collection and laboratory 
work.  
 
 3.2.15 No-cost extension  
It was originally anticipated that the target sample size of 112 patients could be 
recruited from 5-8 study sites over a 24-month period. Due to a number of issues 
with site set up and patient recruitment, it became apparent in early 2018 that 
this target was unachievable and the possibility of a no cost extension was 
discussed with members of the TMG. At that time, the recruitment rate was 4.11 
patients per month and a number of additional centres were due to open. An 
extension period of 18 months (to February 2020) was proposed, based on the 
anticipated recruitment numbers and opening dates collected from each site. It 
was predicted that if sites opened on schedule, it would be possible to reach the 
target sample size of 112 patients by October 2019, however a recruitment 
extension until February 2020 would allow some flexibility in the event of 
further unanticipated delays. At the end of the recruitment period, there would 
be a 6-month follow-up period and a further 3 months for data cleaning and 
analysis. This would result in study completion in November 2020. 
 
An application for a no cost extension was submitted to the Clinical Trials Unit, 
the June Hancock Mesothelioma Research Fund and Beatson Cancer Charity in 
May 2018. This proposal was accepted by these regulatory bodies and sites have 
subsequently been informed of the updated recruitment timelines. 
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3.3 Results 
 3.3.1 Site set up and recruitment  
Between December 2015 and July 2018, thirty nine sites across the UK were 
invited to take part in SYSTEMS-2. Of the sites approached, fifteen have opened 
the study and six are in the process of set-up at the time of writing. (Table 3.3) 
Time to study opening from initial confirmation of interest has varied, with 53% 
of sites opening within one year, 40% opening within two years and 7% taking 
more than two years to open the study. The delays to set up and opening have 
primarily been caused by capacity issues affecting clinical trial units, 
radiotherapy planning and delivery departments, R&D divisions and medical 
units. These issues affected at least four sites which are already open and have 
presented a significant problem for all of the sites currently in set up. Nine sites 
have been unable to participate in SYSTEMS-2 due to capacity problems, 
including five which initially expressed an interest in the study. (Table 3.3) Four 
of the sites did not respond to the invitation to join the study and, despite 
perseverance from the SYSTEMS-2 team, communication has been lost with five 
sites who initially expressed an interest. 
 
Recruitment to SYSTEMS-2 has been slower than anticipated. Six sites have yet 
to recruit a patient, including three which have been open for more than three 
months and two which have been open for more than a year. (Table 3.3)  
Revised projected recruitment timelines are shown in Figure 3.2.  
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Figure 3.2 Predicted recruitment to the SYSTEMS-2 study 
Anticipated recruitment to an extended time point of February 2020. Total 
recruitment required is represented by the light blue dotted line, target 
recruitment is represented by the dark blue dotted line and the current number 
of randomised patients is represented by the dotted red line.
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Table 3.3 Outcome data for sites invited to enter SYSTEMS-2 
Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
1 
 
Beatson West of 
Scotland Cancer 
Centre, Glasgow 
N/A N/A N/A 24 per year 
August 
2016 
32   
2 
University Hospital 
Southampton 
Dec 2015 June 2016 Not stated 3-4 per year Dec 2016 3   
3 
Forth Valley Royal 
Hospital 
July 
2016 
Aug 2016 
Data 
unavailable 
Data 
unavailable 
Jan 2017 0   
4 
Weston Park 
Hospital Sheffield 
Dec 2015 April 2016 2-3 months 3-5 per year Feb 2017 6   
5 
Royal Marsden, 
Sutton 
Dec 2015 Oct 2016 4-6 weeks 4 per year 
April 
2017 
12   
6 
Norfolk and 
Norwich Hospital 
April 
2017 
June 2017 70 days 5+ per year Feb 2018 0   
- 138 - 
Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
7 
New Cross 
Hospital, 
Wolverhampton 
Jan 2017 March 2017 40 days 2 per year Feb 2018 1   
8 
Guys and St 
Thomas, London 
Dec 2016 June 2017 3 months 4 per year 
March 
2018 
6   
9 
Western General, 
Edinburgh 
Aug 2016 Oct 2016 3 months 2 per year 
April 
2018 
1   
10 
Belfast City 
Hospital 
Dec 2015 Aug 2016 3-6 months 2-4 per year May 2018 2   
11 
Southend 
University 
Hospital, Essex 
Oct 2017 Oct 2017 
Data 
unavailable 
8 per year 
June 
2018 
2   
12 
Royal Shrewsbury 
Hospital 
April 
2017 
Nov 2017 40 days 2-3 per year 
Sept 
2018 
0   
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Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
13 
Basildon and 
Thurrock 
University 
Hospitals 
June 
2017 
July 2017 
Data 
unavailable 
Data 
unavailable 
Nov 2018 0   
14 
Aberdeen Royal 
Infirmary 
April 
2017 
April 2017 
Data 
unavailable 
Data 
unavailable 
Dec 2018 0   
15 
St James 
University 
Hospital, Leeds 
Dec 2015 April 2016 2-3 months 
2-4 per year 
 
Jan 2019 1   
16 
Churchill Hospital, 
Oxford 
May 2017 Aug 2017 60 days 5-10 per year 
March 
2019 
0   
17 The Christie, 
Manchester 
Dec 2015 Dec 2015 6-8 weeks 10-20 per year 
Site in 
set-up 
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Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
18 
Northern Centre 
for Cancer Care, 
Newcastle 
July 
2016 
July 2016 
Data 
unavailable 
Data 
unavailable 
Site in 
set-up 
   
19 
Castlehill Hospital, 
Hull 
Sept 
2016 
March 2016 
Data 
unavailable 
Data 
unavailable 
Site in 
set-up 
   
20 
Leicester Royal 
Infirmary 
June 
2016 
June 2016 
Data 
unavailable 
Data 
unavailable 
Site in 
set-up 
   
21 
Kent Oncology 
Centre 
June 
2017 
June 2017 8-10 weeks 2 per year 
Site in 
set-up 
   
22 
Royal Derby 
Hospital 
May 2017 May 2017 Not stated 3 per year 
Site in 
set-up 
   
23 
Nottingham 
University Hospital 
Dec 2015 N/A 3 months 5 per year  
 
 
 
June 2016 
Capacity issues 
(RT planning) 
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Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
24 
Velindre Hospital, 
Cardiff 
Dec 2015 April 2016 Not stated 6-10 per year   
Not 
confirmed 
Poor response 
25 
Royal Preston 
Hospital 
Dec 2015 July 2017 3 months 2 per year   
Not 
confirmed 
Communication 
lost 
26 
Royal Stoke 
University Hospital 
July 
2018 
Sept 2018 40 days 3-5 per year   
Not 
confirmed 
Communication 
lost 
27 
Cheltenham & 
Gloucester 
Hospitals 
Sept 
2016 
December 
2016 
2 weeks 3-4 per year   Oct 2017 
Capacity issues 
(clinical trials) 
28 
Addenbrookes 
Hospital, 
Cambridge 
Dec 2015 N/A    
 
 
 
 
Jan 2016 
Capacity issues 
(RT planning) 
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Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
29 
Derriford Hospital, 
Plymouth 
Dec 2015 N/A     Sept 2016 
Capacity issues 
(RT planning); 
Lack of 
requirement 
30 
James Cook 
University 
Hospital, 
Middlesbrough 
March 
2017 
June 2017     Jan 2018 
Capacity issues 
(RT planning and 
clinical trials) 
31 
Bristol 
Haematology & 
Oncology Centre 
March 
2017 
April 2017     Aug 2017 
Capacity issues 
(RT planning & 
clinical trials) 
32 
Brighton and 
Sussex University 
Hospital 
April 
2017 
N/A    
 
 
 
May 2017 
Capacity issues 
(clinical trials) 
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Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
33 
The Royal Devon 
and Exeter 
Hospital 
Oct 2016 Feb 2017     Dec 2017 
Capacity issues 
(RT planning) 
34 
Treliske Hospital, 
Cornwall 
April 
2017 
April 2017     Aug 2017 
Capacity issues 
(RT planning & 
clinical trials) 
35 
North Wales 
Cancer Treatment 
Centre 
July 
2017 
July 2017     
Not 
confirmed 
Communication 
lost 
36 
Royal Surrey 
Hospital 
Jan 2017 Jan 2017     
Not 
confirmed 
Communication 
lost 
37 
Ninewells Hospital, 
Dundee 
April 
2017 
N/A 
 
   
 
 
 
N/A 
Communication 
lost 
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Nb Site 
Date of 
first 
contact 
Date 
interest 
confirmed 
Anticipated 
set-up time 
Anticipated 
recruitment 
Date 
opened 
Recruitment 
to date (April 
2019) 
Date 
inability to 
participate 
confirmed 
Reason for not 
participating 
38 
Kings Mill Hospital, 
Nottinghamshire 
April 
2017 
N/A     N/A 
Communication 
lost 
39 
Singleton Hospital, 
Swansea 
Sept 
2016 
N/A     N/A 
Communication 
lost 
40 
Clatterbridge 
Hospital, Liverpool 
Feb 2017 N/A     N/A 
Communication 
lost 
 
A total of thirty nine sites were invited to enter SYSTEMS-2 between December 2015 and July 2018. Current recruitment figures are 
shown for open sites and sites in set up are indicated. Sites which have declined to enter the study are listed, with the stated reason. 
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 3.3.2 Radiotherapy delivery technique 
Of the sixteen sites which are currently recruiting to SYSTEMS-2, nine are using 
IMRT/VMAT for radiotherapy planning, two are utilising 3DCRT and four are 
employing a combination of both. Data was unavailable for one site. Of the fifty 
nine patients currently randomised, 10 have been stratified to a 30Gy/5 fraction 
dose escalated regime. One patient has so far been ineligible for the study due 
to the inability to generate a safe dose escalated plan (Table 3.4). 
 
Table 3.4 Planning methods employed by current SYSTEMS-2 sites. 
Site 
Planning 
Technique 
Nb of patients 
treated with 
30Gy/5# 
Nb of patients ineligible 
for SYSTEMS-2 due to 
inability to generate safe 
dose escalated plan 
Beatson West of 
Scotland Cancer 
Centre, Glasgow 
VMAT 1 0 
University Hospital 
Southampton 
3DCRT 0 0 
Forth Valley Royal 
Hospital 
VMAT 0 0 
Weston Park 
Hospital Sheffield 
VMAT 1 0 
Royal Marsden, 
Sutton 
 
IMRT 5 0 
Norfolk and 
Norwich Hospital 
3DCRT/ 
IMRT 
0 0 
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Site 
Planning 
Technique 
Nb of patients 
treated with 
30Gy/5# 
Nb of patients ineligible 
for SYSTEMS-2 due to 
inability to generate safe 
dose escalated plan 
New Cross 
Hospital, 
Wolverhampton 
3DCRT/ 
IMRT 
0 1 
Guys and St 
Thomas, London 
VMAT 1 0 
Western General, 
Edinburgh 
3DCRT 0 0 
Belfast City 
Hospital 
 
VMAT 1 0 
Southend 
University 
Hospital, Essex 
VMAT 1 0 
Royal Shrewsbury 
Hospital 
3DCRT/ 
IMRT/ 
VMAT 
0 0 
Basildon and 
Thurrock 
University 
Hospitals 
Data 
unavailable 
0 0 
Aberdeen Royal 
Infirmary 
 
VMAT 0 0 
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Site 
Planning 
Technique 
Nb of patients 
treated with 
30Gy/5# 
Nb of patients ineligible 
for SYSTEMS-2 due to 
inability to generate safe 
dose escalated plan 
St James 
University 
Hospital, Leeds 
VMAT 0 0 
Churchill Hospital, 
Oxford 
3DCRT/ 
IMRT/ 
VMAT 
0 0 
 
 
 3.3.3 Glasgow Screening Cohort  
Within Glasgow, a total of sixty patients were screened for SYSTEMS-2 between 
August 2016 and April 2019. Of these, twenty nine patients passed screening and 
proceeded directly to study registration, twenty two failed screening, two died 
during the period of analgesia optimisation and seven passed screening, but 
were not registered for the trial. Data for the patients who failed screening, or 
who passed but did not enter the study, is shown in Table 3.5.  
 
Of the seven patients who passed screening but were not registered to SYSTEMS-
2, four chose not to participate, two were entered into an alternative clinical 
trial and one suffered a deterioration in their PS prior to registration. (Table 3.5) 
Of the twenty two patients who failed screening, eight were PS≥ 3, two had 
undergone previous standard dose radiotherapy at the site of pain and twelve 
had an inadequate pain score, either at first assessment or after the 
optimisation of their analgesia. (Table 3.5) The reasons for not entering patients 
into SYSTEMS-2 following initial screening are summarised in Figure 3.3. 
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The typical analgesic regimes required to reduce MPM associated pain to a score 
of ≤3/10 are presented in Table 3.5. Morphine was prescribed in 83% of these 
patients and three or more different types of painkiller were required in 67% of 
the cohort, reflecting the poly-pharmaceutical approach required in this disease. 
Close follow up of this group suggested that pain control deteriorated in a 
substantial proportion (66.7%) of patients, within weeks or months of the initial 
control. Of the eight Glasgow patients who experienced a worsening pain score, 
only three were of adequate PS to be considered for SYSTEMS-2, reflecting the 
association between pain, disease progression and clinical deterioration. In 
total, thirty two patients have been registered for SYSTEMS-2 in Glasgow to 
date, including three patients who initially failed screening. 
 
 
Figure 3.3 Summary of screening outcomes in patients who were not 
registered for SYSTEMS-2 
Data is taken from thirty one patients screened in Glasgow between August 2016 
and April 2019. Patients with an inadequate pain score may be re-screened for 
SYSTEMS-2 should their pain control deteriorate. 
 
 
 
 
 
39%
29%
13%
7%
6%
6%
Inadequate pain score
Poor PS
Patient choice
Patient death prior to
registration
Previous radiotherapy
Alternative trial
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Table 3.5 Screening outcomes for patients who did not enter SYSTEMS-2 immediately 
 
Referral 
date 
Referral 
source 
Screening 
outcome 
Reason for 
failing screening 
Analgesia regime if 
pain score ≤4/10 
Pain outcome 
Reason for 
not 
participating 
Other 
information 
1 21/07/2016 Respiratory Failed Poor PS N/A N/A N/A SFRT 
2 22/09/2016 MDT Failed 
Previous RT at 
site of pain 
N/A N/A N/A  
3 14/10/2016 MDT 
Passed; 
not 
registered 
N/A N/A N/A 
Patient 
declined 
study 
 
4 01/11/2016 Oncology Failed Poor PS N/A N/A 
 
N/A 
 
5 12/12/2016 Respiratory Failed Poor PS N/A N/A N/A SFRT 
6 12/12/2016 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, Shortec 
Recurred after 2 
months- poor PS 
N/A  
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Referral 
date 
Referral 
source 
Screening 
outcome 
Reason for 
failing screening 
Analgesia regime if 
pain score ≤4/10 
Pain outcome 
Reason for 
not 
participating 
Other 
information 
7 12/12/2016 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, MST, 
Oramorph, Pregabalin, 
Lidocaine patch, 
Dexamethasone 
Recurred after 4 
months- 
entered 
SYSTEMS-2 
N/A  
8 22/12/2016 Respiratory 
Died prior 
to 
screening 
N/A N/A N/A N/A  
9 16/01/2017 Respiratory Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, MST No further pain N/A  
10 26/01/2017 Oncology Failed Poor PS N/A N/A N/A  
11 07/03/2017 Oncology Failed 
Pain score <4/10 
on initial visit 
Paracetamol No further pain N/A 
Systemic 
treatment 
12 17/03/2017 Respiratory Failed Previous RT N/A N/A N/A Cordotomy 
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Referral 
date 
Referral 
source 
Screening 
outcome 
Reason for 
failing screening 
Analgesia regime if 
pain score ≤4/10 
Pain outcome 
Reason for 
not 
participating 
Other 
information 
13 21/03/2017 Oncology Failed 
Pain score <4/10 
on initial visit 
Paracetamol No further pain N/A  
14 27/03/2017 Respiratory Failed Poor PS N/A N/A N/A  
15 10/05/2017 Oncology Failed Poor PS N/A N/A N/A SFRT 
 
16 17/05/2017 Oncology 
Passed; 
not 
registered 
N/A N/A N/A 
Decline in PS 
prior to 
registration 
SFRT 
17 26/05/2017 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, Longtec, 
Shortec,  Lidocaine 
patch 
Recurred after 1 
month- poor PS 
N/A  
18 05/06/2017 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, Longtec, 
Shortec, Gabapentin, 
Lidocaine patch 
Recurred after 2 
months- 
SYSTEMS-2 
 
 
N/A 
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Referral 
date 
Referral 
source 
Screening 
outcome 
Reason for 
failing screening 
Analgesia regime if 
pain score ≤4/10 
Pain outcome 
Reason for 
not 
participating 
Other 
information 
19 24/08/2017 Oncology 
Passed; 
not 
registered 
 
N/A 
N/A N/A 
Patient 
declined 
study 
 
20 07/11/2017 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, MST, 
Sevredol, 
Amitriptylline 
Recurred after 7 
months- poor PS 
N/A  
21 17/11/2017 Respiratory 
Died prior 
to 
screening 
N/A N/A N/A N/A  
22 27/11/2017 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, Longtec, 
Shortec, Pregabalin 
Recurred after 4 
months- poor PS 
N/A  
23 03/01/2018 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, MST, 
Lidocaine patch 
Recurred after 2 
months- 
SYSTEMS-2 
N/A  
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Referral 
date 
Referral 
source 
Screening 
outcome 
Reason for 
failing screening 
Analgesia regime if 
pain score ≤4/10 
Pain outcome 
Reason for 
not 
participating 
Other 
information 
24 02/02/2018 Respiratory 
Passed; 
not 
registered 
N/A 
 
N/A N/A 
Patient 
declined 
study 
Systemic 
treatment 
25 11/05/2018 MDT Failed Poor PS N/A N/A N/A  
26 17/05/2018 MDT Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, MST, 
Oramorph, Pregabalin, 
Lidocaine patch 
Recurred after 2 
months- poor PS 
N/A SFRT 
27 08/06/2018 Respiratory Failed Poor PS N/A N/A N/A  
28 28/08/2018 Oncology Failed 
Pain score <4/10 
after analgesia 
optimisation 
Paracetamol, 
Oramorph, Pregabalin 
No further pain N/A 
Systemic 
treatment 
29 07/01/2019 Oncology 
Passed; 
not 
registered 
N/A N/A N/A 
Alternative 
clinical trial 
Given RT 
off study 
for pain 
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Referral 
date 
Referral 
source 
Screening 
outcome 
Reason for 
failing screening 
Analgesia regime if 
pain score ≤4/10 
Pain outcome 
Reason for 
not 
participating 
Other 
information 
30 13/02/2019 Oncology 
Passed; 
not 
registered 
N/A N/A N/A 
Alternative 
clinical trial 
Given RT 
off study 
for pain 
31 12/04/2019 MDT 
Passed; 
not 
registered 
N/A N/A N/A 
Patient 
declined 
study 
Patient 
declined RT 
off study 
 
Data is taken from thirty one Glasgow patients who were screened for SYSTEMS-2, but did not enter the study immediately. Patients 
were referred between July 2016 and April 2019. The source and date of the referral is indicated, in addition to the screening 
outcome. Reason for screen failure is given and the analgesic regime of any patient whose pain score was <4/10 is shown. Patients who 
had controlled pain were closely monitored and patients who subsequently became eligible for SYSTEMS-2 are indicated. Eligible 
patients who did not enter the study are shown, in addition to the reason for not participating. Additional information is provided 
where relevant. SFRT (single fraction radiotherapy).
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 3.3.4 Collaborations 
The SYSTEMS-2 sample collection has attracted high quality collaborations. 
Professor Andrew Mellor’s translational immunology group in Newcastle are 
studying levels of Kynurenine and Tryptophan in blood samples to estimate the 
activity of the intercellular enzyme indoleamine 2,3-dioxygenase (IDO). IDO is 
believed to have a role in the immune checkpoint pathways and may have the 
potential to mediate anti-tumour immune activity. Previous studies have 
suggested that elevated IDO activity is correlated with poor clinical outcomes in 
several types of cancers. (Godin-Ethier et al., 2011) Furthermore, a recent study 
assessing fluctuating levels of this enzyme before and after radiotherapy in non-
small cell lung cancer suggested that radiotherapy appeared to influence 
systemic IDO activity and that it exerted a significant impact on metastatic risk 
and overall survival. (Wang et al., 2018) Following approval from the TMG and 
the successful provision of a Material Transfer Agreement from both local R&D 
departments, plasma and serum samples from the Glasgow patient cohort have 
been sent to Newcastle to allow investigation of the pre- and post- radiotherapy 
levels of IDO activity in this MPM population. Following the final reporting of 
SYSTEMS-2, this data could be used to determine whether IDO levels are 
predictive of clinical response in this disease. 
 
3.4 Discussion 
SYSTEMS-2 has been successfully opened at a total of sixteen sites throughout 
the UK, but set up has been difficult, with a number of sites experiencing similar 
issues and delays. Furthermore, recruitment to the study has been slow, 
reflecting the inherent challenges of recruiting to a palliative study in a 
relatively rare disease.  
 
The primary challenges to site set up and patient recruitment, in addition to the 
steps taken to overcome them, are outlined below.  
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 3.4.1 Challenges of site set up  
 3.4.1.1 Staff shortages and capacity issues 
Between December 2015 and July 2018, a total of 39 sites were invited to join 
the SYSTEMS-2 study. Despite very enthusiastic responses, only 38% of these sites 
have joined to date. (Table 3.3) The main reasons stated for inability to 
participate have been staff shortages (across medical, radiotherapy planning and 
clinical trial departments) and a lack of capacity to take on clinical trials within 
radiotherapy departments. Unfortunately, these issues affected many sites who 
had expressed an initial interest to participate, including some of the larger 
centres from areas with a high incidence of MPM, such as Leicester Royal 
Infirmary, Newcastle, Velindre Hospital (Cardiff), Addenbrookes (Cambridge) and 
Bristol.  
 
The Christie Hospital, who were expected to participate from study start in 
2016, were unable to commit to taking on SYSTEMS-2 due to capacity issues until 
January 2018. At the time of writing, the process of set-up is still ongoing at this 
site, working towards opening in summer 2019. The Christie is anticipated to be 
a significant addition to SYSTEMS-2, given their projected recruitment target of 
10-20 patients per year. Furthermore, Leicester Royal Infirmary, who see up to 
130 potentially eligible patients per year, have as yet been unable to participate 
due to lack of thoracic clinical oncology staff and radiotherapy capacity issues. A 
potential resolution to the problems at Leicester was to set up a formal referral 
service to Sheffield, which had already opened SYSTEMS-2. Although this initially 
seemed to be a good solution, no patients have been treated on the study using 
this pathway. Despite approaching various funding committees, hotel costs could 
not be secured for these patients who therefore would need to travel for 
treatment each day. The return distance of 148 miles may serve as a barrier to 
robust recruitment in this cohort of patients.  
 
The issues surrounding local staff shortages are a government matter and as such 
cannot readily be influenced for the purposes of this study. Nevertheless, the 
capacity issues within radiotherapy departments which have represented a 
- 157 - 
common barrier to the implementation of SYSTEMS-2, along with many other 
important radiotherapy studies throughout the UK, have been raised with the 
National Cancer Research Institute Clinical and Translational Radiotherapy 
Research Group to be addressed at a national level.  
 
 3.4.1.2 Perceived lack of requirement 
Surprisingly, in addition to staff shortages, an anticipated lack of need for this 
study was given as a reason for SYSTEMS-2 not to be implemented at Derriford 
Hospital, Plymouth. The PI confirmed that very few fractions of radiotherapy are 
given at this centre for pain control and stated that the lung cancer clinic is run 
alongside the palliative care clinic. As such, it was felt that patients receive 
excellent palliation and very seldom required irradiation. This statement 
suggests that good palliative care may be the key to pain control in this disease, 
further strengthening the approach of analgesia optimisation prior to 
randomisation. 
 
 3.4.1.3 Introduction of the health research authority system 
In addition to sites being affected by local issues, set-up at some of the English 
sites was further hindered by the introduction of the new Health Research 
Authority system, which was established as an executive non-departmental 
public body sponsored by the Department of Health on 1 January 2015. The aim 
of this system is to combine local R&D processes with REC approval. An 
application was made for SYSTEMS-2 to be added to the Health Research 
Authority trial portfolio, but the backlog caused by the transition to a new 
system resulted in a substantial delay. 
 
 3.4.1.4 Radiotherapy planning QA 
It is acknowledged that the radiotherapy planning for SYSTEMS-2 can be 
challenging and that it may be difficult to generate an acceptable plan in terms 
of OAR dosimetry without compromising PTV coverage. A number of sites have 
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struggled with the radiotherapy planning exercise during the RTTQA assessment 
process and this has occasionally impacted on trial opening times.  
 
Specific issues raised by sites included whether the OAR constraints needed to 
be reduced if fewer fractions were delivered and whether it was acceptable to 
modify the PTV around the organ which was breaching the constraint. 
Furthermore, some sites were unclear as to whether the PTV could be altered, 
depending on which treatment regimen the patient received. In terms of 
contouring, there were also questions raised surrounding margins that needed to 
be added to treatment volumes. The protocol states that the CTV should be 
outlined as the area believed to be causing pain and that a margin of 1-2cm 
should be added to this to create the PTV.  In most radiotherapy planning the 
gross tumour volume (GTV) is outlined for treatment and a margin added to 
create the CTV, onto which a further margin is added to form the PTV. Since 
within SYSTEMS-2 we are not aiming to treat the entire GTV this volume was not 
mentioned in the planning guidelines, which caused confusion. 
 
Throughout this process, queries were answered swiftly and engagement of the 
radiotherapy planning team at the Beatson West of Scotland Cancer Centre  
facilitated the sharing of planning solutions, helping to overcome many of these 
issues. The creation of a Rapidplan model, discussed in Chapter 4, will help to 
speed up the planning process and ensure that plans are able to meet the 
required dose constraints at VMAT centres. 
 
 3.4.2 Challenges of patient recruitment 
Recruitment to SYSTEMS-2 has been slow, even when sites have opened as 
planned. The collection of screening logs from sites indicates that a number of 
patients are considered for the study who do not subsequently take part, for a 
number of reasons. 
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 3.4.2.1 Inadequate performance status  
The onset of difficult pain tends to indicate disease progression and is often 
accompanied by a deterioration in general health and PS. It is not uncommon 
therefore for patients to fail screening due to an inadequate PS or because they 
are deemed unlikely to survive for 12 weeks. Analysis of Glasgow screening data 
indicates that 29% of screen failures are due to poor PS. (Figure 3.3) 
 
When SYSTEMS-2 was first opened in Glasgow, many of the initial consultations, 
particularly to optimise analgesia, were conducted as home visits. Although this 
was more convenient for the patient and seemed to be good for recruitment, it 
was more difficult to accurately determine PS in a patient’s home environment. 
Bringing the same patients to clinic for formal screening or randomisation often 
served to highlight this discrepancy and a number of these patients did not 
proceed on the study. 
 
 3.4.2.2 Inadequate pain score 
Resolution of the worst pain score to <4/10 following analgesia optimisation has 
been observed throughout all sites and is the most common cause of screen 
failure (39%) in Glasgow patients to date (Figure 3.3). In addition, some 
registered patients have failed to be randomised due to inadequate pain scores 
at their baseline visit. Close monitoring of this group of patients in Glasgow has 
indicated that pain often returns at a later date, at which point patients may be 
eligible for SYSTEMS-2. Nevertheless, an associated decline in PS often precludes 
study entry at this stage. 
 
 3.4.2.3 Patient decision not to participate 
In the screened Glasgow cohort, 10.3% of eligible patients decided not to 
participate in SYSTEMS-2. The catchment area of the Beatson West of Scotland 
Cancer Centre is vast and although patients can be admitted for the duration of 
their radiotherapy, follow up visits may necessitate travelling significant 
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distances. This may be an overwhelming prospect in this patient population and 
is a primary reason quoted for not wishing to participate in the study. 
 
 3.4.2.4 Competing trials 
In recent months, recruitment to SYSTEMS-2 has been marginally impacted by 
other studies. In particular, the ATOMIC-Meso study, which opened in Glasgow in 
August 2018, is the only existing UK trial to offer a specific systemic treatment 
for sarcomatoid MPM. This subtype of MPM is associated with rapid progression 
and a very poor prognosis and patients are understandably often very keen to 
receive treatment within this study. Should these patients also have pain they 
could receive radiotherapy within the SYSTEMS-2 trial, however the study 
protocol dictates that systemic treatment is precluded for six weeks after the 
radiotherapy has been given. At least two patients in Glasgow have recently 
opted to have standard radiotherapy ‘off study’ for their pain in order to 
proceed to systemic treatment more quickly. This issue was discussed at the 
TMG in January 2019, however the six week ‘washout period’ after radiation is 
critical in ensuring that pain responses at week 5 cannot be attributed to any 
other intervention and is therefore central to study validity. 
 
 3.4.3 Measures taken to enhance trial recruitment 
 3.4.3.1 Trial promotion 
Local recruitment to SYSTEMS-2 has been encouraged through the promotion of 
the study to respiratory, palliative care and oncology colleagues. Oral 
presentations, delivered at MDTs, lunchtime meetings and designated teaching 
sessions, have outlined the study aims, recruitment criteria and referral process, 
to teams at a number of hospitals and hospices throughout the west of Scotland. 
Furthermore, posters have been distributed to sites for display in clinical areas, 
to facilitate the advertisement of the trial amongst patient groups who may 
recognise themselves as being eligible. Given the rapid patient decline observed 
in the SYSTEMS study, it was also hoped that an enhanced awareness of the 
study amongst appropriate teams would facilitate the referral of patients at an 
earlier stage in their disease trajectory.  
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Promotion has also taken place on a national and international level, with study-
specific oral and poster presentations being delivered at a number of 
conferences, including the British Thoracic Oncology Group conference 
(2016/17), the European Society of Radiation Oncology conference 2018 and the 
International Mesothelioma Interest Group meeting (2016/18). 
 
In addition to promoting the study to healthcare professionals, time has also 
been invested in ensuring that the mesothelioma population and their families 
are aware of SYSTEMS-2. Annual participation in the June Hancock Mesothelioma 
Research Fund ‘meet the researchers’ event allows patients to ask questions 
about the study and understand more about the role of radiotherapy in the 
palliation of this disease. 
 
 3.4.3.2 Social media presence 
The SYSTEMS-2 study website (www.systems-2.co.uk) was set up in 2016. It is a 
valuable resource which has aided recruitment by ensuring that up to date, 
accurate trial information is easily accessible to both patients and health care 
professionals. The website contains useful information on MPM, links to study 
documentation and the study newsletters. Updates are also provided online 
about current recruitment status. Regular updates on trial recruitment and site 
status are also communicated through a SYSTEMS-2 Twitter account.  
 
 3.4.3.3 Newsletter 
A designated SYSTEMS-2 newsletter is published on a quarterly basis and 
distributed to all sites that are open or in set up. In addition to providing general 
updates on trial-specific matters and tips for maximising recruitment, the 
newsletter includes site-specific recruitment and screening numbers. 
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 3.4.3.4 Extended site number 
It was originally planned that SYSTEMS-2 would open at five to eight sites across 
the UK. Given the delays experienced in site set up and the slow recruitment 
seen, the number of sites potential sites has been extended to twenty.  
  
3.4.3.5 Protocol amendments 
A number of the protocol amendments (section 3.2.9.1) were specifically 
implemented to facilitate the ease of recruitment to SYSTEMS-2.  
 
 3.4.3.6 Study screening logs 
These are collected on a monthly basis to provide information on the screening 
activity at each site. 
 
 3.4.3.7 TMG oversight 
Recruitment from each site is continuously monitored and discussed within the 
TMG. Sites identified as being poor recruiters are contacted by the study team 
to discuss any local barriers to recruitment, and possible resolutions.  
 
 3.4.3.8 Webex-conferencing 
A webex conference to discuss trial recruitment is planned for summer 2019. All 
open sites have been invited to participate, in addition to sites in set up. It is 
hoped that this supportive and positive discussion will help to overcome any 
problems which are being experienced or any specific barriers to recruitment. 
 
 3.4.4 Issues of analgesia optimisation  
Whilst the analgesia optimisation step is crucial to the validity of SYSTEMS-2, 
this process can be associated with a number of challenges in this patient 
cohort.  
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 3.4.4.1 Polypharmacy 
The multifactorial pathophysiology of the pain experienced in MPM often 
requires the use of a number of different analgesics with alternative mechanisms 
of action, as illustrated in Table 3.5. Therefore, most SYSTEMS-2 patients are 
usually on a combination of at least four different regular medications for pain, 
in addition to medication to take on an ‘as required’ basis. This elderly 
population frequently have other comorbidities, for which other long terms 
medications are required and the issue of polypharmacy can result in problems 
with compliance, side effects and confusion about which medicines to take. This 
problem is particularly common in patients who live alone, without any support. 
In order to overcome some of these issues, Glasgow patients are encouraged to 
keep a clear list of their medications and when they should be taken. Once their 
analgesia has been fully optimised, a request is made for a ‘dosset box’ to be 
provided by their local pharmacy in order to lessen the chance of a patient-
related medication error. Patients are also encouraged to keep ‘pain diary’, in 
which pain scores and the use of breakthrough analgesia is recorded. In addition 
to creating an accurate picture of their analgesic requirements, this is also 
helpful when assessing pain responses. Laxatives are routinely co-prescribed 
with opioids and oxycodone is often preferentially prescribed over morphine to 
prevent toxicity, particularly if patients are frail.  
 
 3.4.4.2 Multiple healthcare providers 
This patient group are often under the care of multiple healthcare professionals, 
in addition to the research study team. These usually include respiratory, 
palliative care, oncology and general practitioners. Although one team in 
particular may take responsibility for optimising analgesia, changes can be made 
by any of these specialists which can be confusing for patients and makes 
accurate recording of analgesic requirements difficult for the study team. 
Furthermore, if analgesia is changed following radiotherapy, this can make the 
interpretation of pain scores at week 5 challenging and could invalidate results. 
Within Glasgow, this issue has been addressed by careful communication with all 
the teams involved in the patient’s care. Any changes made to analgesia in clinic 
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are communicated promptly to the GP and palliative care team by telephone 
and in writing, to allow accurate update of their online records.  
 
 3.4.4.3 Frequent hospital admissions 
The long latency period of MPM and its association with industrialised, polluted 
environments, means that this disease primarily affects an older patient 
demographic, who frequently have additional comorbidities. These factors, in 
combination with the aggressive nature of MPM, result in relatively frequent 
hospital admissions in this vulnerable patient population. During these 
admissions, analgesia prescriptions are reviewed as part of good medical 
practise and are sometimes altered on discharge. It is not always clear in these 
circumstances why changes have been made, which can make accurate recording 
for trial purposes problematic. 
 
 3.4.5 Challenges of pain assessments 
MPM is an insidious disease which affects the entire hemithorax and can often 
result in patients having large areas of pain or multiple sites of discomfort. In 
this situation, it can be difficult to ascertain the exact location of the ‘worst’ 
area of pain, since this is the area which will be scored on the brief pain 
inventory and targeted for treatment. Usually however, it is possible to treat 
even relatively large areas of the chest wall within a single PTV and encompass 
more than one site of pain. On occasion, patients have returned to clinic at 
week 5 with a new site of discomfort which may now represent their ‘worst’ 
area of pain. In this situation, it is paramount that the questions on the brief 
pain inventory are answered in relation to area which was originally treated and 
for this reason, patients are talked through this questionnaire carefully, rather 
than being left to complete it independently.  
 
3.5 Summary 
SYSTEMS-2 is the first randomised study of radiotherapy dose escalation to be 
attempted in MPM, a disease in which research has been chronically underfunded 
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and for which very few treatment options exist. This important trial recruited its 
first patient in Glasgow in August 2016 and has subsequently opened at a total of 
sixteen sites around the UK, recruiting a total of sixty six patients to April 2019. 
A number of challenges have been encountered, in both site set up and patient 
recruitment, but the study team have worked hard to address these problems, 
adopting novel and innovative strategies to overcome them where possible.  
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Chapter 4: Development of dose constraints for SYSTEMS-2 
 
Chapter aim 
This chapter will describe the process through which the OAR dose constraints 
for the SYSTEMS-2 study were generated and tested.  
 
4.1 Introduction  
 4.1.1 Selection of hypofractionated radiotherapy regime for SYSTEMS-2 
Within SYSTEMS-2, the analgesic properties of two hypofractionated 
radiotherapy regimes are being compared (20Gy in 5 fractions over 1 week and 
36Gy in 6 fractions over two weeks). The dose of 20Gy in 5 fractions is a 
standard palliative radiotherapy dose used in a number of tumour sites and was 
the regime used in the original SYSTEMS study. (MacLeod et al., 2015a) This 
modest dose is tolerable to most radiosensitive organs and was demonstrated in 
SYSTEMS to be associated with very little toxicity. Delivery is usually achieved 
with a simple set up of parallel opposed pairs, without the requirement for 
dosimetry analysis to specific OARs. This allows rapid plan generation and swift 
administration for symptomatic relief.  
 
The premise behind the selection of a 36Gy in 6 fraction regime for the dose 
escalated arm of SYSTEMS-2 lies in the assumption that MPM may have a low α/β 
ratio and therefore may respond more favourably to a larger dose per fraction. 
The regime of 36Gy in 6 fractions allows a significantly larger dose to be 
delivered per fraction and facilitates the completion of treatment in a timely 
fashion, without incurring an unacceptable number of hospital visits.  
 
Dose escalation is associated with an increased potential for normal tissue 
toxicity. While the poor prognosis of MPM means that most of the patients would 
not live long enough to develop the problematic late tissue toxicity frequently 
associated with hypofractionated regimes, the delivery of 6Gy per fraction could 
still overwhelm cellular repair mechanisms and cause acute toxicities if normal 
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tissue tolerances are not respected.  This may result in unacceptable side 
effects which could negate the palliative benefit of radiotherapy. The SYSTEMS-2 
protocol therefore mandates the use of more sophisticated radiotherapy delivery 
techniques, such as 3DCRT or IMRT, to facilitate safe dose escalation. While 
IMRT provides an effective way of shaping dose to the tumour site and allows 
sparing of OARs, the inverse planning process used with this technique means 
that unless radiosensitive structures are outlined and allocated an appropriate 
constraint, the planning system may allow dose to be deposited in these regions, 
giving rise to hotspots greater than the highest ‘prescribed’ dose of 36Gy. 
Consequentially, appropriate dose constraints for a number of OARs needed to 
be developed and validated for this hypofractionated regime, prior to opening 
the study.  
 
 4.1.2 Established dose constraints for lung radiotherapy 
A century of experience with conventionally fractionated radiotherapy has 
afforded the oncological community a robust appreciation of normal tissue 
tolerances for 2Gy per fraction regimes. These are outlined in the 2010 
QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic) guidelines 
on an organ by organ basis. (Bentzen et al., 2010) Conversely, there is far less 
data available to guide dose constraints for safe delivery of hypofractionated 
treatments. 
 
Moderately hypofractionated radiotherapy regimes (delivering 2.1 - 5Gy per 
fraction) have been utilised in the treatment of locally advanced non-small cell 
lung cancer (NSCLC) for a number of years (Thirion et al., 2004) and a regime of 
55Gy/20 fractions was approved in the UK by NICE in 2011, despite a lack of 
established constraints to guide doses to OARs. (Swanick et al., 2015) A 
comprehensive systematic review published in 2016 by Fleming et al. provides a 
summary of dose-volume constraints for moderately hypofractionated regimes 
within the lung. (Fleming et al.) Toxicity data from numerous ongoing clinical 
trials of hypofractionated radiotherapy in NSCLC will provide robust additional 
information to allow these doses to be further modified in the future.  
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Ablative radiotherapy regimes (>8Gy per fraction) generally cause cell death on 
the linear (exponential) portion of the cell survival curve, where tissues have 
very limited capacity for self-repair. These regimes therefore have a huge 
capacity to cause acute and late effects and doses delivered to OARs must be 
carefully considered. (Timmerman, 2008) Stereotactic radiosurgery and 
intraoperative data in humans and animals have generated toxicity profiles 
associated with large single doses of radiotherapy, although the applicability of 
such constraints to regimes which are delivered non-invasively and to 
undisturbed tissue is debatable. (Timmerman, 2008) More recently, the success 
of SABR has generated early normal tissue toxicity data which can be used as a 
starting point to guide practice. Some of the earliest dose constraints for SABR 
were published by Timmerman in 2008 (Timmerman, 2008), but relative 
inexperience with the technique at the time and limited long-term follow-up 
meant that few of these recommendations were validated. Increasing 
experience with SABR, including within several clinical trials where robust 
toxicity data can be generated, has permitted the refinement and modification 
of these constraints. Many studies have reported toxicity data following SABR at 
various sites which have been summarised in a variety of documents, 
(Timmerman, 2008, Benedict et al., 2010, Lo et al., 2013) the most 
comprehensive of which is the AAPM-101 report, published in 2010. (Benedict et 
al., 2010) In 2017, these recommendations were revised in light of more recent 
data and published as a UK consensus on normal tissue constraints for SABR. 
(Hanna et al., 2018) These constraints will undoubtedly be adjusted again in the 
future as further prospective toxicity data is collected and our understanding of 
local normal tissue responses to such extreme hypofractionation is developed. 
 
 4.1.3 Developing dose constraints for SYSTEMS-2 
The dose constraints for SYSTEMS-2 have been generated using local thoracic 
SABR dose constraints as a guide. The local constraints originated primarily from 
the Timmerman paper (Timmerman, 2008), but have been adjusted over time, 
according to local experience. It should be noted however that there are large 
discrepancies between this palliative study and a SABR approach, particularly in 
terms of treatment intent, fraction size, total delivered dose and PTV size. 
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These differences mean that SABR dose constraints could not be directly applied 
to SYSTEMS-2 and needed modification, to establish radiobiological equivalence. 
 
4.2 Results 
 4.2.1 Typical PTV sizes for SYSTEMS-2 are an order of magnitude 
 greater than those for SABR 
To demonstrate the difference between SABR and SYSTEMS-2 in terms of 
planning target volume, dosimetric data from the last five patients treated with 
thoracic SABR at the Beatson West of Scotland Cancer Centre were reviewed. 
PTV sizes from these plans were compared with the PTV sizes for the five 
SYSTEMS patients who were re-planned in this study. This data is presented in 
Table 4.1 and demonstrates that the typical PTV for SYSTEMS-2 is an order of 
magnitude greater than that seen in SABR. 
 
Table 4.1 Comparative values for planning target volumes in SABR and 
SYSTEMS-2  
Lung SABR 
 
SYSTEMS-2 
 
56.62 cm3 841.9 cm3 
17.27 cm3 636.1 cm3 
28.9 cm3 582 cm3 
12.12 cm3 1126.3 cm3 
65.5 cm3 693.6 cm3 
Mean         36.082 cm3 
 
775.98 cm3 
 
SD              23.81 cm3 
 
218.55 cm3 
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4.2.2 Radiobiological analysis of local SABR dose constraints has guided 
 the development of constraints for a 6 fraction regime within 
 SYSTEMS-2 
To conceptualise the radiobiological differences between a SABR regime of 55Gy 
in 5 fractions and the SYSTEMS-2 regime of 36Gy in 6 fractions, these regimes 
were expressed in terms of their BED and EQD2. Calculations were performed 
using an α/β ratio of 10Gy for acute tissue reactions and of 3Gy for late normal 
tissue toxicity. These values are illustrated in Table 4.2.  
 
Table 4.2 BED and EQD2 for a 55Gy/5 fraction thoracic SABR regime and 
36Gy/6 fraction SYSTEMS-2 regime 
Regime  α/β  
(Gy) 
BED EQD2 
 
 
55Gy/5 fractions 
 
 
3 
10 
 
256Gy3 
115.5Gy10 
 
154Gy 
96.25Gy 
 
 
36Gy/6 fractions 
 
 
3 
10 
 
108Gy3 
57.6Gy10 
 
64.8Gy 
48Gy 
 
 
Local thoracic SABR OAR dose constraints are shown in Table 4.3. To determine 
the comparative radiobiological impact of applying these constraints directly 
within SYSTEMS-2, parameters of BED and EQD2 were calculated for delivery of 
the maximum permitted dose to a structure, in either 5 fractions or 6 fractions. 
For the spinal cord, calculations were performed using an α/β ratio of 2Gy, 
while for all other organs, late complications were modelled using an α/β ratio 
of 3Gy and for acute toxicities, an α/β ratio of 10Gy was assumed. These 
parameters are illustrated in Table 4.3. 
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Table 4.3 Comparison of maximum SABR OAR dose constraints delivered in 5 
or 6 fractions, expressed as EQD2 and BED  
Organ SABR 
Constraint 
α/β  
 
(Gy) 
Maximum 
SABR dose 
Radiobiological 
values for SABR 
constraint in 5 
fractions 
Radiobiological 
values for SABR 
constraint in 6 
fractions 
Spinal cord Dmax 1cc 2 28Gy 
 
EQD2 = 53.2Gy 
BED = 106.4Gy2 
 
EQD2 = 46.69Gy 
BED = 93.38Gy2 
Oesophagus Dmax 1cc 
3 28.5Gy 
 
EQD2 = 49.59Gy 
BED = 82.65Gy3 
 
EQD2 = 44.18Gy 
BED = 73.62Gy3 
10 28.5Gy 
 
EQD2 = 37.29Gy 
BED = 44.75Gy10 
 
EQD2 = 35.03Gy 
BED = 42.04Gy10 
Ipsilateral 
brachial 
plexus 
Dmax 1cc 
3 29Gy 
 
EQD2 = 51.04Gy 
BED = 85.07Gy3 
 
EQD2 = 45.41Gy 
BED = 75.7Gy3 
 
10 
 
29Gy 
 
EQD2 = 38.18Gy 
BED = 45.82Gy10 
 
EQD2 = 35.84Gy 
BED = 43.01Gy10 
Heart Dmax 1cc 
3 29Gy 
 
EQD2 = 51.04Gy 
BED = 85.07Gy3 
 
EQD2 = 45.41Gy 
BED = 75.7Gy3 
10 29Gy 
 
EQD2 = 38.18Gy 
BED = 45.82Gy10 
 
EQD2 = 35.84Gy 
BED = 43.01Gy10 
Trachea and 
bronchus 
Dmax 1cc 
3 35Gy 
 
EQD2 = 70Gy 
BED = 116.67Gy3 
 
EQD2 = 61.81Gy 
BED = 103.02Gy3 
10 35Gy 
 
EQD2 = 49.58Gy 
BED = 59.5Gy10 
 
EQD2 = 46.17Gy 
BED = 55.4Gy10 
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Organ SABR 
Constraint 
α/β  
 
(Gy) 
Maximum 
SABR dose 
Radiobiological 
values for SABR 
constraint in 5 
fractions 
Radiobiological 
values for SABR 
constraint in 6 
fractions 
 
Great 
vessels 
 
Dmax 
0.5cc 
 
3 
 
53Gy 
 
EQD2 =144.16Gy 
BED = 240.27Gy3 
 
EQD2 = 125.4Gy 
BED = 209Gy3 
 
10 
 
53Gy 
 
EQD2 = 90.98Gy 
BED = 109.2Gy10 
 
EQD2 = 83.17Gy 
BED = 99.8Gy10 
Liver 
Mean liver 
dose 
3 15.2Gy 
 
EQD2 = 18.36Gy 
BED = 30.6Gy3 
 
EQD2 = 16.81Gy 
BED = 28.02Gy3 
10 15.2Gy 
 
EQD2 = 16.52Gy 
BED = 19.82Gy10 
 
EQD2 = 15.87Gy 
BED = 19.05Gy10 
Kidneys 
Mean 
kidney 
dose 
3 10Gy 
 
EQD2 = 10Gy 
BED = 16.67Gy3 
 
EQD2 = 9.34Gy 
BED = 15.57Gy3 
10 10Gy 
 
EQD2 = 10Gy 
BED = 12.0Gy10 
 
EQD2 = 9.73Gy 
BED = 11.67Gy10 
Stomach 
Dmax 
0.5cc 
3 35Gy 
 
EQD2 = 70Gy 
BED = 116.67Gy3 
 
EQD2 = 61.81Gy 
BED = 103.02Gy3 
10 35Gy 
 
EQD2 = 49.58Gy 
BED = 59.5Gy10 
 
EQD2 = 46.17Gy 
BED = 55.4Gy10 
Small bowel 
Dmax 
0.5cc 
3 35Gy 
 
EQD2 = 70Gy 
BED = 116.67Gy3 
 
EQD2 = 61.81Gy 
BED = 103.02Gy3 
10 35Gy 
 
EQD2 = 49.58Gy 
BED = 59.5Gy10 
 
EQD2 = 46.17Gy 
BED = 55.4Gy10 
(Dmax: maximum dose; cc: cubic centimetres) 
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Initial dose constraints were generated based on the relative concern of inducing 
acute radiation toxicity within structures and are shown in Table 4.4. For organs 
where acute toxicity was a particular concern, (oesophagus, stomach, small 
bowel, liver) the SYSTEMS-2 constraint was kept in line with the EQD2 of the 
SABR 5 fraction dose limit. Analysis of data for the stomach and small bowel 
suggested that delivery of the full dose proposed in SYSTEMS-2 (36Gy in 6 
fractions, EQD2 = 48Gy; α/β ratio = 10) would not exceed the SABR constraint in 
these tissues (35Gy in 5 fractions, EQD2 = 49.58Gy; α/β ratio = 10) and therefore 
the initial constraint on these organs was 36Gy. The SABR constraint to the 
oesophagus was slightly tighter (28.5Gy in 5 fractions). This was reflected in the 
SYSTEMS-2 dose constraint of 30Gy, which was radiobiologically similar to that 
delivered in a SABR regime, assuming an α/β ratio of 10Gy (EQD2 of 30Gy/6 = 
37.5Gy; EQD2 of 28.5Gy/5 = 37.3Gy). 
 
A more cautious approach was taken with the dose to the spinal cord, given the 
serial nature of this organ. Direct application of the SABR constraint of 28Gy 
affords the radiobiological advantage of dose delivery across a greater number 
of fractions and reflects the guarded approach that needs to be taken with such 
tissue. 
 
For organs in which radiation effects were felt to be less likely to result in acute 
clinical symptoms (e.g. trachea, brachial plexus), the maximum recommended 
dose was 36Gy. Although for some organs this exceeded the EQD2 of the SABR 
regime, clinically this was felt to be within safe limits, since the purpose of this 
exercise was to prevent excessive doses being deposited in these tissues during 
the inverse planning process. In the case of the contralateral lung constraint, 
the V5 was increased from <1% to <5%, reflecting the palliative nature of this 
study.  
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Table 4.4 Initial dose constraints for SYSTEMS-2 presented as EQD2 and BED 
(SABR constraints presented for radiobiological comparison) 
Organ Constraint 
α/β 
(Gy) 
SYSTEMS- 2 dose 
constraints and 
radiobiological 
values 
SABR dose 
constraints and 
radiobiological 
values 
Spinal cord Dmax 1cc 2 
 
28Gy 
EQD2 = 46.67Gy 
BED = 93.38Gy2 
 
28Gy 
EQD2 = 53.2Gy 
BED = 106.4Gy2 
Oesophagus Dmax 1cc 
3 
 
30Gy 
EQD2 = 48Gy 
BED = 80Gy3 
 
28.5Gy 
EQD2 = 49.6Gy 
BED = 82.65Gy3 
10 
 
30Gy 
EQD2 = 37.5Gy 
BED = 45Gy10 
 
28.5Gy 
EQD2 = 37.29Gy 
BED = 44.75Gy10 
Ipsilateral 
brachial 
plexus 
Dmax 1cc 3 
 
36Gy 
EQD2 = 64.8Gy 
BED = 108Gy3 
 
29Gy 
EQD2 = 51.04Gy 
BED = 85.07Gy3 
Heart Dmax 1cc 3 
 
36Gy 
EQD2 = 64.8Gy 
BED = 108Gy3 
 
29Gy 
EQD2 = 51.04Gy 
BED = 85.07Gy3 
Trachea and 
bronchus 
Dmax 1cc 
 
 
3 
 
36Gy 
EQD2 = 64.8Gy 
BED = 108Gy3 
 
35Gy 
EQD2 = 70Gy 
BED = 116.67Gy3 
Great vessels 
Dmax 
0.5cc 
 
3 
 
36Gy 
EQD2 = 64.8Gy 
BED = 108Gy3 
 
53Gy 
EQD2 = 144.16Gy 
BED = 240.27Gy3 
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Organ Constraint 
α/β 
(Gy) 
SYSTEMS- 2 dose 
constraints and 
radiobiological 
values 
SABR dose 
constraints and 
radiobiological 
values 
Contralateral 
lung 
V5  <5% 
 
<1% 
 
Liver 
Mean liver 
dose 
 
3 
 
16Gy 
EQD2 = 18.14Gy 
BED = 30.24Gy3 
 
15.2Gy 
EQD2 = 18.36Gy 
BED = 30.6Gy3 
 
10 
 
16Gy 
EQD2 = 16.89Gy 
BED = 20.27Gy10 
 
15.2Gy 
EQD2 = 16.52Gy 
BED = 19.82 Gy10 
Kidneys 
Mean 
kidney 
dose 
3 
 
10Gy 
EQD2 = 9.34Gy 
BED = 15.57Gy3 
 
10Gy 
EQD2 = 10Gy 
BED = 16.67Gy3 
Stomach 
Dmax 
0.5cc 
 
3 
 
36Gy 
EQD2 = 64.8Gy 
BED = 108Gy3 
 
35Gy 
EQD2 = 70Gy 
BED = 116.67Gy3 
10 
 
36Gy 
EQD2 = 48Gy 
BED = 57.6Gy10 
 
35Gy 
EQD2 = 49.58Gy 
BED = 59.5Gy10 
 
Small bowel 
 
Dmax 
0.5cc 
 
3 
 
36Gy 
EQD2 = 64.8Gy 
BED = 108Gy3 
 
35Gy 
EQD2 = 70Gy 
BED = 116.67Gy3 
 
10 
 
36Gy 
EQD2 = 48Gy 
BED = 57.6Gy10 
 
35Gy 
EQD2 = 49.58Gy 
BED = 59.5Gy10 
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Further adjustments were made to the constraints in Table 4.4 following review 
by leading thoracic radiotherapy clinicians at the Beatson West of Scotland 
Cancer Centre and at the Leeds Cancer Centre (also due to participate in 
SYSTEMS-2). It was suggested that a contralateral lung V5 of <5% would be 
unachievable with rotational radiotherapy techniques and the volumetric 
parameters for contralateral lung dose were therefore adjusted to V20 <10% 
(and ideally <5%), V10 <50% and V5 <70%. Mean lung dose would be collected 
from centres for analysis purposes, but no specific constraint was allocated. 
Dmax constraint for all organs was reduced to 0.5cc to align with current 
practise. A more cautious approach to the spinal cord was suggested to reflect 
uncertainties in the precise α/β ratio for this organ. The maximum dose was 
reduced to 27Gy, allowing for an EQD2 of <50Gy where α/β= 1 and of <44Gy 
where α/β= 2. Finally, the stomach and small bowel constraints were reduced to 
30Gy to correspond with the maximal oesophagus dose.  
 
The final dose constraints put forward for planning feasibility studies are shown 
in Table 4.5. 
 
Table 4.5 Dose constraints submitted to Beatson West of Scotland Cancer 
Centre radiotherapy department for planning feasibility studies 
Organ Constraint SYSTEMS- 2 dose 
 
Spinal cord 
 
Dmax 0.5cc 
 
27Gy 
 
Oesophagus 
 
Dmax 0.5cc 
 
30Gy 
 
Ipsilateral brachial plexus 
 
Dmax 0.5cc 
 
36Gy 
 
Heart 
 
Dmax 0.5cc 
 
36Gy 
 
Trachea and bronchus 
 
Dmax 0.5cc 
 
36Gy 
- 177 - 
Organ Constraint SYSTEMS- 2 dose 
Contralateral lung 
V5 
 
V10 
 
V20 
70% 
 
50% 
 
10% 
 
Liver 
 
Mean liver dose 
 
16Gy 
 
Great vessels 
 
Dmax 0.5cc 
 
36Gy 
 
Kidneys 
 
Mean kidney dose 
 
10Gy 
 
Stomach 
 
Dmax 0.5cc 
 
30Gy 
 
Small bowel 
 
Dmax 0.5cc 
 
30Gy 
 
The anticipated PTV coverage for SYSTEMS-2 plans is shown in Table 4.6. 
 
Table 4.6 Expected PTV coverage 
 Constraint Prescribed dose 
PTV minimum 
 
D98% 
 
95% 
 
PTV median 
 
 
D50% 
 
 
100% 
 
PTV maximum D2% 
 
107% 
 
 
  
- 178 - 
4.2.3 VMAT planning studies highlight the challenge of achieving 
 adequate PTV coverage without breaching OAR dose constraints  
To test the deliverability of the proposed SYSTEMS-2 dose constraints, a planning 
feasibility study was conducted at the Beatson West of Scotland Cancer Centre 
prior to study opening. Five patients who had taken part in the original SYSTEMS 
study were selected on the basis of the close proximity of critical OARs to the 
PTV. Organs were contoured according to the radiotherapy planning guidelines 
and VMAT planning was conducted using Eclipse planning system version 15.5. 
The doses achieved in this exercise are shown in Table 4.7. 
 
Adequate PTV coverage was achieved in 2/5 patients (Patient 3 and Patient 5), 
however, this was associated with OAR breaches in both. In Patient 3, the 
contralateral lung V5 was 73.6% (constraint: V5< 70%) and in Patient 5, the 
oesophageal dose exceeded the constraint of 30Gy to 0.5cc by 4.7Gy. In Patients 
2 and 4, all OAR constraints were met, but the D98% of >95% was not achieved 
(94.6% and 94% in Patients 2 and 4 respectively). In Patient 1, PTV coverage was 
suboptimal (D98%= 92.8%) and dose to 0.5cc of oesophagus (32.2Gy) breached 
the objective. 
 
Table 4.7 Dosimetry data from VMAT planning studies undertaken on 5 
patients from the original SYSTEMS trial 
Organ Constraint 
 Maximum 
Dose Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 
 
Spinal cord 
Dmax 
0.5cc 
27Gy 26.3 6.6 21.9 14.2 26.9 
 
Oesophagus 
Dmax 
0.5cc 
30Gy 32.2 14 15.8 19.5 34.7 
 
Ipsilateral 
brachial plexus 
Dmax 
0.5cc 
36Gy 33.7 0.2 3.8 2.4 0.4 
 
Heart 
Dmax 
0.5cc 
36 Gy 16.4 24.8 25.4 34.9 29.5 
- 179 - 
Organ Constraint 
 Maximum 
Dose Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 
 
Trachea 
Dmax 
0.5cc 
36Gy 25.8 0.8 17.4 14 10.3 
 
Bronchus 
Dmax 
0.5cc 
36Gy 20.5 15.6 18.8 31.1 33.4 
 
Great vessels 
Dmax 
0.5cc 
36Gy 22.3 12.7 19.9 35.4 22.8 
Contralateral 
lung 
 
<70% 
V5Gy 57 13.4 73.6 67.1 21.5 
 
<50% 
V10Gy 7 0 2.8 7.4 0.1 
 
<10% 
V20Gy <0.1 <0.1 <0.1 <0.1 <0.1 
 
Liver 
Mean Liver 
Dose 
16Gy 0.2 2.5 0.4 1.4 5.3 
Kidneys 
(individual and 
combined) 
Mean 
Kidney 
Dose 
10Gy 0.2 0.5 
0.3/0.
2 
0.3/0.
2 
0.9/1.
3 
 
Stomach 
 
Dmax 
0.5cc 
30Gy 0.4 14 2 15.7 10.1 
 
Small bowel 
 
Dmax 
0.5cc 
30Gy 0.3 6.4 0.9 0.7 1.5 
 
PTV 
 
 
D98% 
 
>95 92.8 94.6 98 94 95.8 
 
D50% 
 
100 101.5 100.9 102 100 100.8 
 
D2% 
 
<107 106.7 104.8 106.1 105 106.7 
(Instances where the dose constraint could not be met are highlighted in red) 
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4.2.4 Planner experience impacts on the quality of a SYSTEMS-2 
 radiotherapy plan  
To determine the impact of planner experience on the quality of radiotherapy 
plans which could be generated, further VMAT planning was undertaken for the 
same five patients in March 2019, when SYSTEMS-2 had been open in Glasgow for 
over 2.5 years. This work was conducted by the same planner who undertook the 
original VMAT planning work and who has been responsible for planning most of 
the Glasgow SYSTEMS-2 cohort to date. The plans met all of the prescribed PTV 
constraints without breeching any OAR constraints. The dosimetry achieved is 
shown in Table 4.8.  
 
Table 4.8 Dosimetry data from VMAT planning studies undertaken in March 
2019  
 
Organ 
 
Constraint 
Maximum 
Dose 
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 
 
Spinal cord 
Dmax 
0.5cc 
27Gy 26.8 6.8 18 14.6 26.1 
 
Oesophagus 
Dmax 
0.5cc 
30Gy 26.7 14.3 18.2 20.2 27.7 
Ipsilateral 
brachial 
plexus 
Dmax 
0.5cc 
36Gy 35.5 0.3 3.3 2.6 0.4 
 
Heart 
 
Dmax 
0.5cc 
  36Gy 15 19.5 27.2 34.8 19.4 
 
Trachea 
 
Dmax 
0.5cc 
36Gy 25.1 0.8 18.3 14.6 8.9 
Bronchus 
 
Dmax 
0.5cc 
36Gy 22.0 18.1 25.8 32.8 33.1 
 
Great vessels 
 
Dmax 
0.5cc 
36Gy 26 12.3 22.1 35.3 25.1 
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Organ 
 
Constraint 
Maximum 
Dose 
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 
 
Liver 
 
Mean Liver 
Dose 
16Gy 0.2 2.5 0.3 8.4 4.8 
 
Stomach 
 
Dmax 
0.5cc 
30Gy 0.3 14.2 1.7 2.2 9.6 
 
Small bowel 
 
Dmax 
0.5cc 
30Gy 0.2 6.4 0.7 0.2 1.1 
 
 
Contralateral 
lung 
 
 
 
<70% 
V5Gy 66.3 2.5 60 67.2 46.9 
 
<50% 
V10Gy 13.4 3.3 7.5 7.7 6.6 
 
<10% 
V20Gy <0.1 5.5 <0.1 <0.1 <0.1 
 
Kidneys 
Mean 
Kidney 
Dose 
10Gy 0.1 0.5 0.3 0.2 0.7 
 
 
D98% 
 
>95 
 
95.3 
 
95.1 
 
95.6 
 
98 
 
96 
 
PTV 
 
 
D50% 
 
100 
 
100.7 
 
101.4 
 
101 
 
101.3 
 
101.1 
 
D2% 
 
<107 
 
104 
 
105.3 
 
106.1 
 
106 
 
106.2 
(Improvements in OAR dose or PTV coverage (compared to Table 4.7) are shown 
in green. Increases in the OAR dose from the original plan are shown in blue. All 
OAR dose constraints were met.) 
 
Improved PTV coverage was associated with an increase in D98% in 4/5 patients 
and a reduction in D2% for 2/5 patients. (Table 4.8) The DVH shown in Figure 4.1 
illustrates the improvement in PTV coverage achieved for Patient 1, where D98% 
was increased from 92.8% to 95.3% and D2% was reduced from 106.7% to 104%.      
           
- 182 - 
 
Figure 4.1 DVH illustrating the improvement in PTV coverage achieved for 
Patient 1  
Original plan (triangles); March 2019 plan (squares) 
 
Reductions were seen in dose deposition within a number of structures in the 
VMAT re-plans. For example, in Patient 5, dose to 0.5cc of oesophagus was 
reduced from 34.7Gy in the original VMAT plan to 27.7Gy in the March 2019 plan 
(Figure 4.2), while dose to 0.5cc of heart was reduced from 29.5Gy to 19.4Gy in 
the same patient. These improvements were marginally offset by an increase in 
contralateral lung dose (V5 increased from 21.5% to 46.9% and V10 from 0.1% to 
6.6% in the original and March 2019 plans respectively). Nevertheless, these 
doses were still well within the trial specific constraints and the improvement in 
the oesophageal dose to <30Gy to 0.5cc meant that this plan satisfied all 
objectives. In Patient 3, the contralateral lung V5 was reduced from 73.6% to 
60%, (Figure 4.3) which allowed this plan to meet the objective of V5 <70%. The 
V10 was increased from 2.8% to 7.5%, but this was still well below the trial 
objective of V10 <50%.  
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Figure 4.2 DVH showing improvements in oesophageal dose for Patient 5 
Original plan (squares); March 2019 plan (triangles) 
 
 
 
      36Gy/6 plan (Original)    36Gy/6 plan (March 2019) 
                 
Figure 4.3 Plan showing distribution of dose to 5Gy 
 Contralateral lung V5 is reduced from 73.6% in original plan to 60% in March 
2019. 
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4.3 Discussion 
 4.3.1 Clinical considerations of the SYSTEMS-2 dose constraints  
There are little data to support precise dose constraints to OARs for 
hypofractionated radiotherapy regimes, particularly in the palliative setting. 
Nevertheless, clinically relevant data has been generated from increasing 
experience with SABR. Whilst SYSTEMS-2 is not directly comparable to SABR, the 
radiobiological analysis of doses tolerated within a locally delivered 5 fraction 
SABR regime has permitted a conversion to acceptable doses for a 6 fraction 
regime. Particular attention has been paid to organs in which acute toxicity 
could cause symptoms and caution has been applied to the dose delivered to the 
radio-intolerant spinal cord.  
 
The majority of the dose constraints listed in the local SABR guidelines are 
quoted as the maximum volume of an organ which can receive a threshold dose 
or higher (Dmax to ‘x’cc). Direct conversion of this dose using the EQD2 principle 
allowed the generation of applicable dose constraints for SYSTEMS-2, using the 
same volumetric parameters. Dmax 0.5cc represents a volume which is both 
clinically realistic and comparable when calculated across different planning 
systems and is therefore appropriate to apply to a multicentre clinical trial. In 
the case of parallel organs, such as the lungs, percentage volumetric constraints 
are often more appropriate to guide the maximum percentage of an OAR that 
can receive a threshold dose or higher. Published toxicity data on IMRT in 
mesothelioma (Allen et al., 2006, Miles et al., 2008, Rice et al., 2007a), in 
addition to local clinical experience with SABR and moderately hypofractionated 
thoracic radiotherapy regimes, has permitted development of clinically 
appropriate contralateral lung constraints for SYSTEMS-2. Given the anticipated 
PTV sizes associated with SYSTEMS-2 and the potential for a greater volume of 
any OARs to be irradiated, percentage dose volume metrics may be a more 
appropriate guide for some parallel organs. The challenge of adopting clinically 
appropriate percentage volumetric dose constraints in novel hypofractionation 
regimes has been acknowledged in the QUANTEC guidelines, (Bentzen et al., 
2010) but SYSTEMS-2 will provide a robust mechanism through which such data 
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can be generated, by allowing correlation of toxicity outcomes with achieved 
volumetric parameters.  
 
It could be argued that the SYSTEMS-2 doses are overly cautious, particularly for 
the spinal cord and oesophagus, especially if interpreted in the context of the 
recently published UK consensus document. (Hanna et al., 2018) Constraints 
quoted for these organs within a 5 fraction regime are more generous than in our 
local guidance (30Gy for spinal cord and 34Gy for oesophagus compared to 28Gy 
and 28.5Gy respectively within the local protocol). Radiobiologically, this would 
equate to EQD2 of 60Gy for spinal cord (α/β ratio= 2) and 47.6Gy for oesophagus 
(α/β ratio= 10). Nevertheless, as illustrated in Table 4.1, PTV size in SYSTEMS-2 
will be far greater than that accepted for a SABR regime and therefore it is 
appropriate to remain cautious.  
 
Of the four organs permitted to receive the full dose of 36Gy in 6 fractions 
(EQD2 64.8Gy where α/β= 3; 48Gy where α/β= 10), the trachea/proximal 
bronchus and great vessels are within the EQD2 dose of the SABR regime (70Gy 
and 144Gy respectively where α/β=3; 49.6Gy and 91Gy where α/β=10). In 
contrast, the ipsilateral brachial plexus and heart exceed the EQD2 dose of a 
SABR regime (51.04Gy in both organs where α/β=3; 38.18Gy where α/β=10).  
 
In standard lung radiotherapy, planned and delivered locally by VMAT, the 
brachial plexus is not classified as an OAR. Radiobiologically, this standard lung 
regime of 55Gy in 20 fractions is similar to that delivered in SYSTEMS-2 (EQD2 = 
63.25Gy and 64.8Gy respectively where α/β=3) and therefore it was felt this 
organ could tolerate full dose to a constraint of 0.5cc.  
 
Radiation induced heart disease (RIHD) can have devastating consequences 
following the administration of radical doses of radiotherapy, particularly in lung 
and breast cancers. (Madan et al., 2015) The dose constraints of a SABR regime 
in particular, would be modelled around the prevention of this complication, 
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given the curative intent of treatment. Analysis of the recently published UK 
SABR consensus guidelines suggests that an 8 fraction regime should have a 
maximum heart dose of <50Gy (optimal) and <60Gy (mandatory). 
Radiobiologically, this equates to an EQD2 of 92.5Gy and 126Gy respectively, 
using an α/β ratio of 3. For comparison, the SYSTEMS-2 dose constraint has an 
EQD2 of 64.8Gy (α/β= 3). The latency period associated with RIHD is in the 
region of 10-15 years (Madan et al., 2015) and therefore patients participating in 
SYSTEMS-2 are unlikely to live long enough to develop these long term 
complications. 
 
More recently published data, however, has suggested that radiation to the 
heart may be associated with more acute toxicity than previously appreciated. A 
paper published by Atkins et al in 2019 suggests that in lung cancer patients, 
treated with radical thoracic radiotherapy, mean heart dose was associated with 
a statistically significant increased risk of major adverse cardiac events. (Atkins 
et al., 2019) Within the median follow up period of 20.4 months, 10.3% of 
patients had developed an acute cardiac event, including myocardial infarct, 
heart failure, requirement for re-vascularisation and cardiac-specific death. In 
patients with pre-existing cardiac risk factors, the risk of adverse cardiac events 
was increased and critically, no threshold dose was identified below which there 
was no risk. Advances in systemic therapy has led to improved outcomes in 
locally advanced NSCLC, with median survival times of more than 2 years. 
(Bradley et al., 2015, Senan et al., 2016) The identification of clinically 
significant post-radiotherapy cardiac events in a more condensed time-frame 
than tends to be seen following the treatment of other cancers, such as breast 
or lymphoma, (van Nimwegen et al., 2015, Darby et al., 2013) has prompted the 
requirement for early recognition and treatment of cardiac-related events and 
stricter planning criteria to lower heart doses in thoracic radiotherapy for 
NSCLC. Whilst the SYSTEMS-2 cardiac dose constraint of 36Gy in 6 fractions to 
0.5cc was felt to be clinically acceptable in this palliative study of mesothelioma 
patients, future radiotherapy studies in this cohort would likely need to adopt 
similar strategies in cardiac risk assessment and dose modification. 
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No dose constraint has been applied to the ipsilateral (treated) lung for several 
reasons. Firstly, the pleural thickening associated with MPM reduces the capacity 
for lung expansion on the affected side. This, in combination with other features 
of this disease including pleural fluid collections and areas of collapse mean that 
the baseline functional reserve in the ipsilateral lung is often poor. Secondly, 
areas of chest wall pain can be extensive and the size of the PTV often reflects 
this. It was felt that implementation of a dose constraint on the affected side 
would therefore be futile. Since the ipsilateral lung is not required to be 
outlined for planning purposes, dosimetric data (e.g. mean lung dose, V20) is not 
being collected. In contrast, dose constraints to the contralateral lung have been 
carefully selected and whilst there is no constraint denoted for contralateral 
mean lung dose, this is being collected from sites to permit retrospective 
analysis. Although dose escalated, hypofractionated radiotherapy has never been 
attempted in MPM, IMRT has been used to deliver radical doses of conventionally 
fractionated radiotherapy to the pleural surface following surgical resection for 
a number of years, particularly in the United States. Publication of toxicity data 
from 3 large institutions utilising this technique reported unacceptably high 
rates of fatal pneumonitis. (Miles et al., 2008, Rice et al., 2007a, Allen et al., 
2006) As a result, contralateral lung dose is now carefully considered, in 
particular V20, which has a statistically significant predictive association with 
pneumonitis. (Rice et al., 2007a) 
 
Whilst the contralateral lung constraints are slightly more lenient than suggested 
for V5 and V20 in a SABR regime, this reflects the palliative nature of SYSTEMS-
2. Nevertheless, the ability to generate a largely unilateral plan despite a 
rotational delivery technique, means that the V20 is often negligible and this is 
clearly illustrated in Table 4.7. 
 
Since SYSTEMS-2 opened to recruitment, dose constraints for two 
hypofractionated radiotherapy regimes in MPM have been published. (Gomez et 
al., 2019, Parisi et al., 2017) These regimes, both of which deliver radiotherapy 
to the entire hemithorax, are more closely aligned to SYSTEMS-2 in terms of dose 
per fraction, than a SABR protocol. Constraints used by Marc de Perrot’s team to 
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deliver accelerated hemithoracic radiotherapy (25Gy in 5 fractions with an 
optional 5Gy integrated boost to GTV and tract sites) to 62 patients in the 
‘SMART’ study (Cho et al., 2014, de Perrot et al., 2016) were recently published 
by Gomez et al. (Gomez et al., 2019) These constraints are generally more 
conservative than those employed in SYSTEMS-2, particularly in terms of the 
dose to the contralateral lung (V7 <20%) and spinal cord (Dmax <22Gy). 
Furthermore, doses to heart and liver are individualised depending on disease 
location and constraints are determined for maximum structure dose, rather 
than maximum dose to 0.5cc of structure. This cautious approach reflects the 
radical nature of this study, in which patients are required to undergo extensive 
surgery within a week of completing radiotherapy, and potentially 
chemotherapy, depending on post-operative nodal staging. Furthermore, the life 
expectancy of this patient cohort is likely to be longer than that anticipated in 
SYSTEMS-2 and therefore late normal tissue toxicity has to be considered. 
 
In 2017, Parisi et al published constraints employed to deliver 25Gy in 5 
fractions, with an inhomogeneous boost to the GTV of 37.5Gy to 36 patients 
after PD or biopsy for MPM. (Parisi et al., 2017) These dose constraints, which 
are quoted in terms of EQD2, are more closely aligned to those employed in 
SYSTEMS-2. The doses to the contralateral lung (V5<5%) and spinal cord (EQD2 
25Gy, α/β ratio= 3) are more conservative, but greater doses are permitted to 
the oesophagus, kidney and liver than are acceptable for SYSTEMS-2.  
 
The discrepancies between these published constraints reflect not only 
differences in treatment volumes and intent, but also the lack of established 
data on which to base them. The rigorous setting of a clinical trial, where 
toxicity data is collected at regular intervals, is the optimal setting in which to 
test the safety of the SYSTEMS-2 dose constraints, and to generate comparative 
data to the regimes employed by de Perrot and Parisi.  
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4.3.2 A planning study of five cases suggests that the SYSTEMS-2 PTV 
constraints are challenging to meet without breaching OAR constraints 
The protocol for SYSTEMS-2 states that OAR dose constraints should be used as a 
guide for radiotherapy planning, but that the dose to the PTV should not be 
compromised to meet them. This approach could be criticised in a study of 
palliative intent and results in a more complex radiotherapy planning process. 
Nevertheless, ensuring that the PTV received the intended fixed total dose 
across all dose escalated plans was felt to be an important factor in aiding 
accurate data interpretation and maintaining study validity in this randomised 
controlled trial. The use of alternative dose escalation approaches, such as 
isotoxic radiotherapy planning, would result in different dose escalated regimes 
being delivered to the PTV and may not generate sufficiently robust data to 
answer the relatively simple research question posed in SYSTEMS-2.  
 
Within this planning study, the SYSTEMS-2 dose constraints were tested on five 
patients who took part in the initial SYSTEMS study. Capacity within the 
radiotherapy planning unit at the Beatson West of Scotland Cancer Centre, 
combined with time constraints, meant that re-planning more patients was not 
feasible. Cases were specifically selected as being challenging from a 
radiotherapy planning perspective, in terms of PTV size and location. Therefore, 
while the limited number of cases in this planning study could be criticised, they 
permitted robust initial testing of the dose constraints.  
 
Not all of the proposed dose constraints could be met for every patient who was 
planned with VMAT and there was difficulty meeting a D98% of 95% in 3/5 
patients. In Patients 1 and 5, the oesophageal dose breached the constraint of 
30Gy to 0.5cc. Both of these patients had bulky tumours which abutted the 
oesophagus for several centimetres. In the case of Patient 5, the oesophagus was 
within the PTV for 2 centimetres. In Patient 3 the V5 was slightly in excess of 
the V5 constraint of 70%. Nevertheless, the favourable dosimetry achieved for 
V10 and V20 means that this plan may have been clinically acceptable. 
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The difficulty in achieving the required PTV coverage in this planning study was 
concerning, nevertheless, in a clinical situation these plans would have been 
formally reviewed by clinical staff in conjunction with the radiotherapy planner 
and compromises could have been made to OAR constraints in an attempt to 
ensure adequate PTV coverage. The final decision to accept the plan lies with 
the treating clinician and if there are concerns about doses to OARs then the 
final dose can be omitted, treating to 30Gy in 5 fractions in the dose escalated 
arm. It was accepted that for some plans it may be difficult to achieve all the 
OAR constraints and a clinical decision would need to be made at that point as 
to whether to treat to a total dose of 36Gy or 30Gy. The results from this initial 
planning study were therefore felt to be representative of the likely real-life 
scenario and the proposed constraints were accepted and taken forward to be 
used in SYSTEMS-2. 
 
 4.3.3 The quality of the radiotherapy plan is influenced by the 
 familiarity of the planner with SYSTEMS-2 planning 
Since SYSTEMS-2 opened in Glasgow in August 2016, thirty two patients have 
been treated locally and at the time of writing, there have been no patients for 
whom concerns about PTV size or dose delivery to OARs have prevented 
randomisation or necessitated a dose reduction to 30Gy/5 fractions. This 
perhaps reflects the dosimetry advantages gained from familiarity with a 
planning technique. The observation that clinically superior plans can be 
produced if a planner is familiar with the planning technique has been noted in 
other studies utilising IMRT in MPM and has been linked with a reduction in 
toxicity. (Patel et al., 2012) Data from the planning studies conducted in March 
2019 supports the suggestion. All five VMAT plans, generated from patients who 
had participated in the original SYSTEMS study, had originally failed to meet trial 
constraints. This was due to inadequate PTV coverage, excessive OAR doses, or 
both. When the same five patients were re-planned using the same treatment 
planning system, to the same dose and fractionation, by the same planner with 
the benefit of over two years experience with SYSTEMS-2 radiotherapy planning, 
all plans met the specified PTV prescription and OAR constraints.  
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The challenge presented by the complexity of the SYSTEMS-2 radiotherapy plans 
was felt to be a potential barrier to site engagement with the study and 
subsequently to patient recruitment. In order to help other centres overcome 
any difficulties with the radiotherapy planning, the physics department at the 
Beatson West of Scotland Cancer Centre have been able to share their planning 
solutions and are currently developing a RapidPlan model which can be shared 
with any site running SYSTEMS-2 with VMAT or IMRT. It is anticipated that this 
will facilitate the rapid generation of high quality, robust plans, enabling 
patients to be treated quickly within the study. 
 
4.4 Summary 
Novel dose constraints for the delivery of hypofractionated, dose escalated 
radiotherapy within a UK-wide clinical trial have been generated. The robust 
nature of a randomised clinical trial will provide the perfect setting in which the 
safety of these selected doses can be adequately tested. 
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Chapter 5: Assessing the impact of MCO on SYSTEMS-2 dose escalated VMAT 
plans 
 
Chapter aim 
This chapter aims to determine whether MCO can be used to improve the 
quality of dose escalated clinical VMAT plans generated for the Glasgow cohort 
of SYSTEMS-2. 
 
5.1 Introduction 
Within the SYSTEMS-2 study, radiotherapy is targeted specifically at sites of 
pain. In some patients, painful areas coincide with specific areas of bulky 
disease, rib infiltration or chest wall involvement, which can be encompassed 
within a relatively modest treatment volume. In many cases however, the 
pathophysiology of pain is multifactorial, arising from a combination of nerve 
involvement, disseminated pleural disease and the infiltration of local 
structures. This gives rise to a more diffuse pattern of pain, frequently involving 
large regions of the chest wall and necessitates a more extensive treatment 
volume. Furthermore, nerve root involvement can often give rise to neuropathic 
pain and adequate treatment of this necessitates close proximity of the CTV to 
critical radiosensitive structures.  
 
The selection of the OAR dose constraints for SYSTEMS-2 has been discussed in 
Chapter 4. They are particularly cautious, due to concerns about the induction 
of acute toxicities with this novel dose/fractionation regime, which could negate 
any palliative benefit of the treatment. The use of IMRT/VMAT also introduces 
the issue of dose bathing and therefore all organs are allocated a constraint to 
prevent excessive dose being deposited within them during the inverse planning 
process. These multiple constraints, in addition to a large PTV in close proximity 
to OARs, makes the radiotherapy planning difficult and time consuming and the 
inability to generate a clinically acceptable dose escalated plan has been 
recorded as a reason for patient ineligibility.  
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MCO has been demonstrated in a number of studies to lower radiation doses to 
OARs without compromising PTV coverage and has improved on both IMRT and 
VMAT plans within a number of tumour types, including prostate, pancreatic, 
glioblastoma and non-small cell lung cancer. (Teichert et al., 2019, Wala et al., 
2013, Kamran et al., 2016, Muller et al., 2017) Time taken to produce a 
clinically acceptable plan is also reported to be reduced with this planning 
solution. (Teichert et al., 2019, Muller et al., 2017, Craft et al., 2012b) MCO 
software was introduced at the Beatson West of Scotland Cancer Centre in 
September 2017, but is not routinely used for planning SYSTEMS-2 patients. All 
of the SYSTEMS-2 Glasgow cohort have been planned with VMAT and would be 
candidates for re-optimisation with MCO. Furthermore, regardless of the dose 
which was actually delivered, all trial patients have a clinically acceptable dose 
escalated plan generated prior to randomisation. A planning study was therefore 
undertaken using dose escalated clinical plans to determine whether MCO could 
achieve any further reductions in OAR dose without compromising PTV coverage.  
 
5.2 Results 
 5.2.1. MCO generated clinically superior radiotherapy plans for the 
 majority of SYSTEMS-2 patients 
To determine the value of MCO in reducing doses to OARs, the dose escalated 
VMAT radiotherapy plans of 20 patients from the Glasgow cohort of the SYSTEMS-
2 study were identified and analysed with MCO. Plans which improved OAR 
sparing without breaching any trial specific dose constraints or compromising 
PTV coverage were deemed to be acceptable. Plans which were identified as 
‘failing’ (i.e. those breaching any OAR constraint or failing to comply with the 
prescribed PTV coverage) were re-analysed through MCO a number of times to 
investigate whether dose distribution could be improved. Following this process, 
thirteen MCO plans were generated that improved OAR sparing compared to the 
clinical plans, whilst maintaining the PTV coverage. Seven plans were deemed to 
be unacceptable.  
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The dose reductions achieved by MCO in those plans which passed this planning 
study are shown in Tables 5.1 and 5.2 and Figures 5.1 and 5.2. Due to the 
limited number of acceptable plans, formal statistical analyses were not 
performed and descriptive statistics are used to describe this data. Clinically 
significant reductions in mean dose to OARs were observed in a number of cases. 
For example, a dose reduction of 599cGy was achieved in the mean dose to liver 
(patient 11) and of 670cGy in mean dose to stomach (patient 5). Furthermore, 
notable dose reductions to contralateral lung were achieved, including a 34% 
reduction in V5 (patient 7) and a 23% reduction in V10 (patient 3). The maximum 
point dose and maximum dose to 0.5cc of the OAR were also dramatically 
reduced in a number of cases and to a number of structures. This improvement 
is particularly relevant for serial organs, such as the spinal cord which can lose 
their complete functionality if even a small volume receives a dose above the 
tolerance limit. In the case of patient 11, for example, a maximal point dose 
reduction of 613cGy and 0.5cc dose reduction of 569cGy to the spinal cord was 
achieved. Clinically relevant reductions in cord dose were also seen in patients 
1, 2, 6 and 13. 
 
 5.2.2 No predictive pattern was identified between PTV location and 
 MCO dose sparing  
To determine whether MCO is more effective at sparing structures contralateral 
or ipsilateral to the PTV, data were analysed according to the hemithorax which 
required radiotherapy. Similar levels of sparing were observed in a number of 
bilateral structures regardless of the side of the PTV. For example, in patients 
requiring radiotherapy to the left hemithorax, mean bronchial dose was reduced 
by an average of 191cGy±281cGy (left) and 198cGy±222cGy (right) (Table 5.1 and 
Figure 5.1A) and in patients with right sided disease, this reduction was 
149cGy±186cGy and 145cGy±145cGy (left and right main bronchi respectively). 
(Table 5.2 and Figure 5.2A)  
 
Analysis of the sparing achieved for unilateral structures revealed variable 
results. The average reduction in mean stomach dose was similar regardless of 
the side of the PTV: 298cGy± 272cGy in patients with left sided MPM, (Table 5.1 
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and Figure 5.1A) and 279cGy± 178cGy for those with right sided disease. (Table 
5.2 and Figure 5.2A) For some structures, more effective ipsilateral dose sparing 
was observed. For example, in patients with right sided MPM, mean liver dose 
was reduced by an average of 267cGy± 239cGy, (Table 5.2 and Figure 5.2A) 
compared to 136cGy± 107cGy in left sided disease. (Table 5.1 and Figure 5.1A) 
For other structures, contralateral dose sparing was predominant: mean heart 
dose was reduced by an average of 171cGy± 94cGy in left sided disease, (Table 
5.1 and Figure 5.1A) compared to 300cGy ±189cGy on the right. (Table 5.2 and 
Figure 5.2A) 
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Organ/constraint 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
Mean 
Standard 
Deviation 
PTV 
        
D98 (%) 0.6 1 0.2 2.3 0.1 -0.1 0.68 0.88 
D50 (%) -1.6 0.6 1.7 0.9 0.8 0.2 0.43 1.11 
D2 (%) -0.9 0.4 0 0.7 2 -2 0.03 1.38 
Spinal cord  
        
Min (cGy) 0 -0.8 0 -1.1 0 0 -0.32 0.50 
Max (cGy) -300 -418 108 -237 -295 -452 -265.67 200.21 
Mean (cGy) -46 -71 -90 -39 -47 -82 -62.50 21.32 
0.5cc (cGy) -239 -417 -131 -232 -299 -433 -291.83 116.52 
Stomach 
        
Min (cGy) -236 -40 -30 -234 -738 -1 -213.17 277.47 
Max (cGy) -59 -684 -26 -930 127 0 -262.00 433.86 
Mean (cGy) -168 -370 -43 -534 -670 -1 -297.67 271.81 
0.5cc (cGy) 41 -712 -30 -978 -53 -1 -288.83 440.06 
Liver 
        
Min (cGy) -12 -13 -2 -12.3 -57 -1 -16.22 20.69 
Max (cGy) -216 -134 -80 -536 -421 -13 -233.33 204.48 
Mean (cGy) -172 -286 -22 -134 -197 -6 -136.17 107.16 
0.5cc (cGy) -290 -379 -74 -531 -499 -13 -297.67 215.74 
         
Patient  
Table 5.1 Changes to OAR doses achieved with MCO in left sided MPM 
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Organ/constraint 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
Mean 
Standard 
Deviation 
Oesophagus 
        
Min (cGy) -3 -4 -6 -5.4 -2 -6 -4.40 1.67 
Max (cGy) -156 -816 -332 -677 -568 -1028 -596.17 318.01 
Mean (cGy) -120 -347 -188 -253 -172 -345 -237.50 94.16 
0.5cc (cGy) -134 -872 -328 -628 -678 -1002 -607.00 326.59 
L Kidney 
        
Min (cGy) -1 -2 -2 -1.9 -18 0 -4.15 6.83 
Max (cGy) -28 -10 -31 -9 -123 0 -33.50 45.43 
Mean (cGy) -2 -4 -5 -4 128 -1 18.67 53.58 
0.5cc (cGy) -25 -11 -27 -3 -160 0 -37.67 60.94 
R Kidney 
        
Min (cGy) -2 -8 -1 -4.9 -11 0 -4.48 4.32 
Max (cGy) -93 -46 -14 -10.9 -189 -9 -60.32 70.79 
Mean (cGy) -10 -18 -5 -12 -61 -4 -18.33 21.51 
0.5cc (cGy) -42 -119 -12 -18 -159 -9 -59.83 63.68 
Heart 
        
Min (cGy) -299 -203 -133 -18 -25 -5 -113.83 119.60 
Max (cGy) -46 -66 -317 -243 69 -48 -108.50 143.14 
Mean (cGy) -263 -220 -242 -180 -106 -16 -171.17 94.06 
0.5cc (cGy) -89 -47 -336 -344 23 -49 -140.33 158.83 
Patient  
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Organ/constraint 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
Mean 
Standard 
Deviation 
Gt vessels 
        
Min (cGy) -2 -5 0 -0.9 -4 -5 -2.82 2.15 
Max (cGy) -49 -100 -151 -152 -775 -746 -328.83 336.65 
Mean (cGy) -78 -96 -184 -64 -133 -303 -143.00 89.51 
0.5cc (cGy) -58 -222 -232 -160 -756 -809 -372.83 323.75 
L Main Bronchus 
Min (cGy) -22 -22 -588 -9 -11 -109 -126.83 229.03 
Max (cGy) 259 219 -311 -163 -16 -1103 -185.83 499.60 
Mean (cGy) -14 -35 -379 -18.4 -14 -685 -190.90 281.48 
0.5cc (cGy) 77 -1 -457 -62 -17 -1033 -248.83 427.67 
R Main Bronchus 
        
Min (cGy) -24 -27 -510 
 
-12 -63 -127.20 214.84 
Max (cGy) -526 -66 -534 -129 -20 -674 -324.83 284.40 
Mean (cGy) -128 -39 -513 -50 -15 -444 -198.17 221.50 
0.5cc (cGy) -409 -70 -537 -114 -18 -644 -298.67 265.86 
Small Bowel 
        
Min (cGy) 0 -5 -4 -0.5 -17 
 
-5.30 6.89 
Max (cGy) -240 -50 -40 -378 172 
 
-107.20 210.18 
Mean (cGy) -11 -9 -7 -14 -387 
 
-85.60 168.51 
0.5cc (cGy) -263 -48 -39 -392 -91 
 
-166.60 155.05 
Patient  
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Organ/constraint 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
Mean 
Standard 
Deviation 
Large Bowel 
        
Min (cGy) 0 0 -1 -0.4 
  
-0.35 0.47 
Max (cGy) 20 -15 -54 -138 
  
-46.75 67.93 
Mean (cGy) -30 -11 -8 -21 
  
-17.50 10.02 
0.5cc (cGy) -8 -14 -47 -151 
  
-55.00 66.26 
Ipsilateral BP 
        
Min (cGy) -1 -2 -3 -1.8 0 -28 -5.97 10.84 
Max (cGy) -4 -2 -42 12.3 -2 -59 -16.12 27.79 
Mean (cGy) -2 -2 -14 -1.1 -2 -46 -11.18 17.75 
0.5cc (cGy) -4 -3 -34 5 -2 -10 -8.00 13.61 
Trachea 
        
Min (cGy) -3 -3 -5 -4.3 -3 -38 
  
Max (cGy) -17 -20 -348 -5 -8 -848 -207.67 341.24 
Mean (cGy) -8 -8 -95 -6.3 -4 -583 -117.38 230.84 
0.5cc (cGy) -19 -20 -421 -8 -9 -843 -220.00 345.95 
CL lung 
        
V5 (%) -21.2 -19.9 -12.4 -13.2 -6.4 -20.1 -15.53 5.84 
V10 (%) -5.9 -2.5 -22.94 0 -0.7 -1.5 -6.71 9.29 
V20 (%) -0.2 0 -0.3 0 0 0 -0.08 0.13 
Patient  
- 200 - 
Organ/constraint 
 
7 8 
 
9 
 
10 
 
11 
 
12 
 
13 Mean 
Standard 
Deviation 
PTV 
         
D98 (%) 0.9 -0.6 -0.2 0 -1.5 0.8 -1.6 -0.31 1.00 
D50 (%) 0.4 1.2 1.5 2.1 -2 0.8 -1 0.43 1.45 
D2 (%) 0.3 1.8 1 1.3 -0.6 1.3 -1.3 0.54 1.13 
Spinal cord 
         
Min (cGy) -3 -1.4 -0.4 -0.1 -2 -1 -1 -1.27 0.98 
Max (cGy) -164 -394 -395 -89 -613 217 -370 -258.29 270.45 
Mean (cGy) -112 -96 -47 -38 -214 -86 -117 -101.43 58.14 
0.5cc (cGy) -162 -436 -382 54 -569 -5 -459 -279.86 242.01 
Stomach 
         
Min (cGy) -146 -32 -25 -128 -151 -43 -6 -75.86 62.92 
Max (cGy) -731 -417 -352 -573 -847 -958 -55 -561.86 313.29 
Mean (cGy) -372 -201 -93 -365 -495 -413 -18 -279.57 177.70 
0.5cc (cGy) -662 -399 -317 -557 -846 -909 -47 -533.86 304.79 
Liver 
         
Min (cGy) -2 -4 -3 -3 -10 -1 0 -3.29 3.25 
Max (cGy) -134 -392 -176 30 -64 123 -12 -89.29 166.86 
Mean (cGy) -192 -530 -170 -372 -599 0 -6 -267.00 239.74 
0.5cc (cGy) -128 -661 -196 -3 -75 -126 -13 -171.71 226.20 
Patient  
Table 5.2 Changes to OAR doses achieved with MCO in right sided MPM 
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Organ/constraint 
 
7 8 
 
9 
 
10 
 
11 
 
12 
 
13 Mean 
Standard 
Deviation 
Oesophagus 
Min (cGy) -9 -4 -9 -3 -2.8 -2 -18 -6.83 5.72 
Max (cGy) -755 -570 -724 -573 -1084 225 -428 -558.43 402.78 
Mean (cGy) -378 -223 -352 -153 -286 -152 -215 -251.29 90.41 
0.5cc (cGy) -680 -581 -699 -539 -1041 30 -506 -573.71 320.33 
L Kidney 
         
Min (cGy) -20 -7 -5 -2 -31 -13 -2 -11.43 10.78 
Max (cGy) -397 -51 -27 3 -389 -237 -20 -159.71 178.08 
Mean (cGy) -91 -18 -12 -5 -205 -53 -5 -55.57 73.05 
0.5cc (cGy) -373 -47 -21 -51 -351 -198 -18 -151.29 156.47 
R Kidney 
         
Min (cGy) -6 -3 -4 -2 -6 -2 0 -3.29 2.21 
Max (cGy) 16 -52 -27 -24 -1053 -21 -9 -167.14 391.16 
Mean (cGy) -37 -16 -9 -9 -117 -24 -2 -30.57 39.82 
0.5cc (cGy) 19 -50 -18 -23 -1140 -29 0 -177.29 425.08 
Heart 
         
Min (cGy) -361 -41 -189 -32 -25 -56 -16 -102.86 128.26 
Max (cGy) 39 -1211 -197 -377 -408 91 -272 -333.57 431.82 
Mean (cGy) -565 -295 -550 -265 -113 -116 -195 -299.86 188.78 
0.5cc (cGy) -2 -935 -342 -424 -461 68 -254 -335.71 332.59 
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Organ/constraint 
 
7 8 
 
9 
 
10 
 
11 
 
12 
 
13 Mean 
Standard 
Deviation 
Gt vessels 
Min (cGy) -4 -4 -2 -2 -5 -1 0 -2.57 1.81 
Max (cGy) -250 -590 68 -233 -984 294 -180 -267.86 419.20 
Mean (cGy) -296 -107 -141 -77 -180 -96 -303 -171.43 93.62 
0.5cc (cGy)  -440 -619 -118 -309 -908 481 -175 -298.29 437.76 
L Main Bronchus 
         
Min (cGy) 
 
-37 -60 -10 -27 -40 -330 -84.00 121.62 
Max (cGy) 
 
-120 -350 -19 -49 -49 -548 -189.17 213.38 
Mean (cGy) 
 
-47 -296 -16 -32 -43 -462 -149.33 185.79 
0.5cc (cGy) 
 
-86 -379 -24 -42 -46 -574 -191.83 229.86 
R Main Bronchus 
         
Min (cGy) 
 
-26 -58 -10 -21 -55 -324 -82.33 119.92 
Max (cGy) 
 
-678 -683 -26 -36 -52 -283 -293.00 314.91 
Mean (cGy) 
 
-136 -339 -17 -22 -49 -307 -145.00 144.70 
0.5cc (cGy) 
 
-545 -683 -24 -29 -48 -274 -267.17 287.76 
Small Bowel 
         
Min (cGy) -10 -1 -3 0 -4 0 -1 -2.71 3.55 
Max (cGy) -258 -48 -244 -600 -267 -351 -11 -254.14 196.17 
Mean (cGy) -51 -11 -12 -44 -57 -23 -4 -28.86 21.47 
0.5cc (cGy) -242 -48 -253 -566 -224 -339 -10 -240.29 185.41 
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Organ/constraint 
 
7 8 
 
9 
 
10 
 
11 
 
12 
 
13 Mean 
Standard 
Deviation 
Large Bowel 
Min (cGy) -1 0 -3 -1 
 
-1 0 -1.00 1.10 
Max (cGy) -56 -103 -2 -472 
 
-3 -10 -107.67 182.81 
Mean (cGy) -10 -33 -2 -68 
 
-2 -3 -19.67 26.49 
0.5cc (cGy) -45 -98 -4 -423 
 
-3 -10 -97.17 163.73 
Ipsilateral BP 
         
Min (cGy) -7 -4 -7 1 -2 -4 -6 -4.14 2.91 
Max (cGy) -12 -7 -6 -7 -1 -5 -16 -7.71 4.89 
Mean (cGy) -7 -5 -5 -4 -2 -3 -15 -5.86 4.34 
0.5cc (cGy) -11 -7 -8 -6 -2 -4 -16 -7.71 4.64 
Trachea 
         
Min (cGy) -9 -4 -8 -4 -3 -1 -11 -5.71 3.64 
Max (cGy) -200 -27 -39 -11 -14 -55 -484 -118.57 173.89 
Mean (cGy) -50 -7 -27 -4 -6 -13 -206 -44.71 72.96 
0.5cc (cGy) -184 -21 1 -11 -14 -53 -398 -97.14 147.07 
CL lung 
         
V5 (%) -34 -0.59 -9.4 -7.1 -4.3 -4.4 -15 -10.68 11.25 
V10 (%) -1.35 0 0 -13.2 0 -13.2 -29 -8.11 11.04 
V20 (%) 0 0 0 0 0 0 -0.4 -0.06 0.15 
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Figure 5.1 Changes in dosimetry achieved with MCO compared to clinical 
VMAT plans in patients with left sided MPM  
The dose escalated VMAT plans of six SYSTEMS-2 patients with left sided MPM 
were replanned using MCO. Data are expressed as MCO-associated changes in the 
radiation dose received by OARs (A), changes in contralateral lung dosimetry (B) 
and changes in PTV coverage (C). Data are presented as box and whisker plots, 
plotted according to the Tukey method.  
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Figure 5.2 Changes in dosimetry achieved with MCO compared to clinical 
VMAT plans in patients with right sided MPM 
The dose escalated VMAT plans of seven SYSTEMS-2 patients with right sided 
MPM were replanned using MCO. Data are expressed as MCO-associated changes 
in the radiation dose received by OARs (A), changes in contralateral lung 
dosimetry (B) and changes in PTV coverage (C). Data are presented as box and 
whisker plots, plotted according to the Tukey method.  
 
 
 
 
 
Right sided disease 
A 
B C 
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 5.2.3 MCO achieved clinically significant reductions in multiple OAR 
 doses  without compromising PTV coverage 
Analysis of individual MCO plans revealed that dramatic dose reductions could be 
achieved in critical OARs without incurring unacceptable dose escalation to 
other structures. For all plans which passed the planning study, MCO reduced the 
mean organ dose for every structure, with the exception of Patient 5, in whom 
the dose to the left kidney was increased by 128cGy, from 892cGy to 1020cGy 
(V10: 44%). This rise was associated with a consequential reduction in mean 
stomach dose of 670cGy (from 2054cGy to 1384cGy) and a reduction in the mean 
small bowel dose of 387cGy (from 658cGy to 271cGy). Spinal cord was better 
spared (Dmax 0.5cc: 745cGy, compared to 1044cGy in the clinical plan), as was 
oesophagus (Dmax 0.5cc reduction of 678cGy, from 2014cGy to 1336cGy) and 
liver (Dmax 0.5cc reduced by 499cGy, from 2174cGy to 1675cGy). (Figures 5.3 
and 5.5) Furthermore, the contralateral lung was better spared, with a 
reduction in V5 of 6.4% (from 11% to 4.6%). These improvements in dose delivery 
to OARs were achieved in the context of acceptable PTV coverage, illustrated in 
Figure 5.4) with the MCO plan achieving D98 of 95.1%, D50 of 101% and D2 of 
105% (compared to 95%, 100.2% and 103% respectively in the clinical plan).  
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Figure 5.3 Dose volume histogram comparing OARs doses from the clinical 
VMAT plan (triangle markers) with the MCO generated plan (square markers) 
for patient 5  
Represented OARs are liver (blue), kidney (yellow), stomach (green) and small 
bowel (orange). Data are presented as dose delivered to total structure volume 
(%) 
 
 
 
Figure 5.4 Dose volume histogram showing PTV coverage in the clinical VMAT 
plan (triangle markers) and MCO plan (square markers) for patient 5 
Data are presented as dose delivered to total structure volume (%) 
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Figure 5.5 Comparison of the 30% isodose distribution between the clinical 
VMAT plan (A) and the MCO plan (B) for patient 5 
 
The MCO plan for patient 7 achieved a reduction in the contralateral lung V5 of 
34% (from 36% to 2%), illustrated in Figure 5.8. This improvement was associated 
with reductions in mean heart dose (565cGy), mean oesophageal dose (378cGy) 
and mean stomach dose (372cGy). (Figure 5.6) The PTV coverage remained 
satisfactory (D98 of 96.4%, D50 of 101% and D2 of 104.6%) and is shown in Figure 
5.7. 
 
 
Figure 5.6 Dose volume histograms comparing OARs doses from the clinical 
VMAT plan (triangle markers) with the MCO generated plan (square markers) 
for patient 7 
Represented OARs are heart (red), stomach (green) and oesophagus (purple). 
Data are presented as dose delivered to total structure volume (%). 
 
A B 
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Figure 5.7 Dose volume histogram showing PTV coverage in the clinical VMAT 
plan (triangle markers) and MCO plan (square markers) for patient 7  
Data are presented as dose delivered to total structure volume (%) 
 
 
      
Figure 5.8 Comparison of the 500cGy isodose distribution between the 
clinical VMAT plan (A) and the MCO plan (B) for patient 7 
 
Analysis of the MCO plan for patient 11 reveals dramatic reductions in dose 
delivered to critical OARs without any compensatory rise in dose delivered to 
other organs. Mean doses to stomach, oesophagus and liver were reduced by 
495cGy (from 660cGy to 165cGy), 286cGy (from 598cGy to 312cGy) and 599cGy 
(from 1539cGy to 940cGy) respectively. Dmax to 0.5cc spinal cord was reduced 
by 569cGy (from 1221cGy to 652cGy) and to great vessels by 908cGy (from 
1894cGy to 986cGy). These changes are illustrated in Figures 5.9 and 5.11. The 
MCO plan reduced contralateral lung V5 by 4.3% (from 5% to 0.3%). Both V10 and 
A B 
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V20 were <0.1% in the clinical and MCO plan. The PTV coverage in the MCO plan 
was within the trial stipulated limits, achieving a D98 of 95.2%, D50 of 101% and 
D2 of 105.4%. This compares to 96.7%, 103% and 106% respectively in the original 
clinical VMAT plan. (Figure 5.10) 
 
 
 
Figure 5.9 Dose volume histograms comparing OARs doses from the clinical 
VMAT plan (triangle markers) with the MCO generated plan (square markers) 
for patient 11 
 Represented OARs are great vessels (red), spinal cord (turquoise), oesophagus 
(purple), liver (blue) and stomach (yellow). Data are presented as dose delivered 
to total structure volume (%). 
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Figure 5.10 Dose volume histogram showing PTV coverage in the clinical 
VMAT plan (triangle markers) and MCO plan (square markers) for patient 11 
Data are presented as dose delivered to total structure volume (%). 
 
 
       
Figure 5.11 Comparison of the 50% isodose distribution between the clinical 
VMAT plan (A) and the MCO plan (B) for patient 11 
 
5.2.4 Plans which failed this planning study were predominantly left 
sided, but were not associated with significantly larger PTV sizes 
A comparison of the plans which passed this planning study and those which did 
not, are presented in Table 5.3. Plans were analysed with regard to their PTV 
size and location, the number of OARs directly within the PTV and the number of 
treatment volumes encompassed within a single plan.  
A B 
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Of the seven plans which failed (patient numbers 14-20), six had disease within 
the left hemithorax and two had more than one PTV, representing multiple sites 
of pain, which were combined to form one treatment volume. In contrast, all of 
the plans which passed the planning study had only one PTV.  
 
The inclusion of OARs within the PTV was seen in a number of plans, often for 
several centimetres. For example, in patient number 11, which passed the MCO 
planning study, the heart was in the PTV for 3.5cm, the oesophagus for 2.8cm 
and the liver for 4cm.  
 
Comparison between the two groups suggests that there was no significant 
difference in the size of the treatment volumes. The average PTV size in the 
plans which passed this planning study was 1163.2cm3 ±318.5 cm3, whereas in 
the plans which failed the average size was 1156 cm3 ±556 cm3, (p = 0.97). 
 
Table 5.3 Comparison of plan parameters 
Patient 
number 
PTV 
number 
PTV 
location OARs in PTV 
PTV 
size 
(cm3) 
Outcome of 
MCO plan 
 
1 1 
Left upper 
lobe None 
 
648 
 
Passed 
 
2 1 
Left lower 
lobe Great vessels (6cm) 
 
1268 
 
Passed 
 
3 1 
Left lower 
lobe Heart (2.2cm) 1700 
 
Passed 
 
4 1 
Left lower 
lobe Heart (3cm) 978 
 
Passed 
5 1 
Left lower 
lobe 
Great vessels (3cm), 
Spinal canal (2cm) 1322 
 
Passed 
 
6 1 
Left lower 
lobe None 1132 
 
Passed 
 
7 1 
Right 
lower lobe None 871 
 
Passed 
 
8 1 
Right 
lower lobe Liver (6cm) 1094 
 
Passed 
 
9 1 
Right 
lower lobe Liver (10.2cm) 869 
 
Passed 
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Patient 
number 
PTV 
number 
PTV 
location OARs in PTV 
PTV 
size 
(cm3) 
Outcome of 
MCO plan 
 
10 1 
Right 
lower lobe 
Heart (3cm),  
Liver (6cm) 1623 
 
Passed 
11 1 
Right 
lower lobe 
Heart (3.5cm), 
Oesophagus (2.8cm), 
Liver (4cm) 1186 
 
 
Passed 
 
12 1 
Right 
middle 
lobe Great vessels (1cm) 1530 
 
Passed 
 
 
13 1 
Right 
lower lobe Liver (1cm) 900 
 
Passed 
14 1 
Left upper 
lobe 
Brachial plexus 
(2.2cm),  
Great vessels 
(8.5cm) 415 
 
 
Failed 
15 1 
Left lower 
lobe 
Heart (5.8cm), 
Great vessels 
(7.4cm) 1043 
 
Failed 
16 2 
Left upper 
lobe and 
left lower 
chest wall 
Small bowel (1cm) 
1136 
 
 
Failed 
17 2 
Left upper 
and left 
lower lobe 
Stomach (3.5cm) 
2051 
 
Failed 
 
18 1 
Right 
middle 
lobe 
Spinal cord (1.75cm) 
1452 
 
Failed 
19 1 
Left upper 
lobe 
Great vessels 
(7.2cm),  
Heart (0.8cm) 579 
 
 
Failed 
 
20 1 
Left lower 
lobe 
Great vessels (6cm) 
1419 
 
Failed 
 
 
An analysis of the doses achieved to the OARs and PTV within the plans which 
failed is presented in Table 5.4. This data highlights that MCO was associated 
with clinically significant dose reductions to OARs in plans which subsequently 
failed this planning study. For example, in patient 14, significant dose reductions 
were seen to the spinal cord (4.6Gy to 0.5cc) and trachea (3.3Gy to 0.5cc), but 
this was offset by an increase in dose to the great vessels which was in excess of 
the dose constraint of 36Gy to 0.5cc. Furthermore, the PTV coverage was 
inadequate in this plan, not meeting the prescription of D98% >95%. Similarly, in 
patient 16, the small bowel constraint of 30Gy to 0.5cc could not be met, but 
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doses to 0.5cc of the oesophagus and stomach were reduced by 1.84Gy and 
4.6Gy respectively. The PTV coverage was also improved from a D98% of 95.9% in 
the original plan to 96.2% in the MCO plan. These gains were offset by an 
increase in the dose to the spinal cord, from 15.18Gy to 0.5cc in the original 
plan, to 19.7Gy in the MCO plan. This dose is within the constraint of 27Gy to 
0.5cc, as set out in the SYSTEMS-2 protocol.  
 
In some patients, MCO offered very few improvements to OAR dose or PTV 
coverage from the original VMAT plan and was associated with excessive doses to 
a number of organs. For example, in patient 20, the MCO plan increased dose to 
the great vessels, stomach and small bowel, breaching trial dose constraints. 
Dose to the heart was also increased from the original plan, from 33.5Gy to 
35.3Gy to 0.5cc, although this remained within the trial specified constraint of 
36Gy to 0.5cc. These compromises were not compensated for by improved PTV 
coverage: D98% = 95.4% in the original plan compared to 95.5% in the MCO plan 
and the D2 was greater with the MCO, indicating a hot spot.  
 
Table 5.4 PTV and OAR parameters achieved in plans which failed the 
planning study 
Patient 
number 
OARs Dose to 0.5cc 
(Gy) 
 
PTV coverage 
Original 
plan 
MCO 
plan 
Original plan MCO plan 
14 Spinal cord 
Oesophagus 
Trachea 
Brachial plexus 
Great vessels 
 
25.5 
28.5 
33.8 
36 
35.8 
20.9 
28 
30.5 
35.4 
36.7 
D98% = 95.6% 
D2% = 105.5% 
D98% = 94.9% 
D2% = 106% 
15 Spinal cord 
Stomach 
Oesophagus 
Great vessels 
25.6 
27.2 
27.3 
35.9 
23.7 
25.7 
25.4 
36.5 
D98% = 96.4% 
D2% = 106.9% 
D98% = 95.2% 
D2% = 106% 
16 Cord 
Small bowel 
Oesophagus 
Stomach 
 
15.18 
29.89 
26.34 
22.4 
19.77 
31.77 
24.5 
17.81 
D98% = 95.9% 
D2% = 105% 
D98% = 96.2% 
D2 = 106.1% 
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Patient 
number 
OARs Dose to 0.5cc 
(Gy) 
 
PTV coverage 
Original 
plan 
MCO 
plan 
Original plan MCO plan 
17 Brachial plexus 
Oesophagus 
Spinal cord 
Stomach 
Trachea 
35.31 
28.3 
26.66 
29.10 
25.23 
32.32 
29 
24.73 
32.54 
24.3 
 
D98% =9 5.3% 
D2 = 106.9% 
D98% = 94.9% 
D2% = 106.9% 
18 Spinal cord 
Oesophagus 
Trachea 
25.34 
27.64 
24.1 
28.84 
28.65 
22.8 
 
D98% = 95.4% 
D2 = 104.3% 
D98% = 97.4% 
D2% = 105.8% 
19 Great vessels 
Heart 
Oesophagus 
Spinal cord 
35.65 
35.74 
16.41 
7.6 
36.31 
37.2 
14.45 
6.3 
 
D98% = 95.1% 
D2% = 104.2% 
D98% = 95.2% 
D2% = 104.1% 
20 Great vessels 
Stomach 
Spinal cord 
Heart 
Small bowel 
35 
28.4 
26.8 
33.5 
29.54 
37.3 
30.29 
24.3 
35.3 
30.54 
 
D98% = 95.4% 
D2% = 105.2% 
D98% = 95.5% 
D2% = 106.2% 
(Improvements in OAR dose are shown in green. Increases in the OAR dose from 
the original plan are shown in blue where the constraint is still met and in red 
where it is breached.) 
 
5.3 Discussion 
The data presented in this chapter shows that MCO can be used to produce 
clinically superior radiotherapy plans for the majority of patients with MPM, 
without compromising PTV coverage or exceeding OAR constraints. Radiotherapy 
planning can be difficult in this patient cohort, due to the large target volumes 
which are often in close proximity to radiosensitive structures. This data is 
amongst the first to assess the role of MCO in the radiotherapy planning in this 
patient population and may impact on future planning, in both the palliative and 
radical settings.  
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5.3.1 MCO can significantly reduce dose to organs which are associated 
 with problematic acute toxicities 
MCO was able to improve on the clinical VMAT dose escalated plans of 13/20 
SYSTEMS-2 patients. Clinically significant dose reductions were observed in a 
number of organs, with some of the greatest gains observed in structures 
particularly vulnerable to acute radiation toxicity, such as liver and stomach. 
Furthermore, the increased conformity achieved with MCO enabled dose to be 
sculpted away from an OAR, even when the PTV was bordering this structure, as 
illustrated by the liver dosimetry in Figure 5.11. The reductions in dose were 
sometimes associated with a consequential dose increase to an alternative 
structure, but the trial constraints were not exceeded. The dosimetric changes 
were achieved with minimal effect on PTV coverage, with plans continuing to 
adhere to the trial PTV prescription. 
 
The VMAT planning for SYSTEMS-2 employs partial arcs to reduce dose to 
contralateral structures, particularly the contralateral lung. However, in many 
cases, the size and location of the PTV precludes this and full arcs are required 
to deliver the treatment. In spite of this, relatively unilateral plans were 
generated, usually achieving a contralateral lung V20 of <0.1%. Re-planning with 
MCO demonstrated the ability to further improve the contralateral lung dose, 
achieving reductions in both V5 and V10 of 15.5%± 5.8% and 6.7%± 9.3% 
respectively in left sided disease and of 10.7%± 11.3% and 8.1%± 11% respectively 
when the disease was on the right. These improvements are clinically 
significant, since V5 has been linked with the development of pneumonitis. (Rice 
et al., 2007a)  
 
The variety of sparing observed in this planning study for structures contralateral 
and ipsilateral to the PTV is likely due to a combination of factors, including the 
size and location of the PTV, the use of full versus partial arcs and the quality of 
the initial treatment plan. 
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 5.3.2 Plans generated by MCO may be clinically acceptable despite 
 breaching dose constraints 
All patients included in this planning study had an acceptable clinical dose 
escalated clinical plan and had taken part in SYSTEMS-2. It was observed that 
7/20 of these plans could not be improved upon with MCO, without breaching 
trial specific dose constraints. Details of these plans, including PTV size and 
location are shown in Tables 5.3 and 5.4.  
 
Only one of the plans which failed incorporated right sided disease, possibly 
suggesting that the benefit of MCO may be influenced by disease laterality. The 
principle right sided OAR is the liver, whereas there are numerous left sided 
OARs (heart, stomach, bowel loops). Arguably, this makes the planning of left 
sided MPM more difficult and it could be that the MCO trade off between OARs in 
this setting is more challenging. However, it is difficult to draw any firm 
conclusions from such a limited dataset, in which the initial distribution of 
disease was unequal (12 left sided cases and 8 right sided).  
 
Two of the plans which were rejected had more than one PTV: patients 16 and 
17 both had two areas of pain and both areas were treated. The total PTV in 
each case was a combination of the two individual treatment volumes. In 
contrast, all of the accepted plans contained single PTVs, suggesting that this 
may be a contributing factor to plan failure.  
 
The direct inclusion of OARs within the PTV did not necessarily seem to 
predispose to plan failure, suggesting that this can be tolerated within the 
planning constraints.  
 
Failure of MCO to improve on the clinical plan may be because the original plan 
was sufficiently close to the Pareto surface, with MCO offering little scope for 
further optimisation. This is demonstrated clearly in patients 18, 19 and 20. In 
other plans, however, clinically significant reductions were achieved in a 
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number of OARs, but this was at the expense of a dose breach in an alternative 
organ. Due to the strict terms of this re-planning study, these plans were not 
deemed to be satisfactory, but many of them may have been clinically 
acceptable. Dose breaches were often minimal and were usually offset by 
significant dose reductions in OARs where early normal tissue effects are 
problematic (e.g. liver, stomach, oesophagus). The protocol of SYSTEMS-2 states 
that the dose constraints are not mandated and should be used as a guide to 
planning only; the final decision of whether or not to accept a plan lies with the 
treating clinician. (Ashton et al., 2018) A pragmatic view should be taken in this 
palliative setting to ensure that quality of life is preserved and therefore many 
of the MCO plans which were rejected in this study may have been clinically 
acceptable. 
 
 5.3.3 The future role of MCO in SYSTEMS-2 radiotherapy planning 
The dose reductions achieved with MCO within this planning study are impressive 
and would likely reduce treatment related toxicity, which is already being 
carefully monitored, within this palliative clinical trial cohort. The deliverability 
of these plans is implied by the ‘aperture shape controller’ function within the 
MCO software, which does not allow an undeliverable plan to be calculated. 
Nevertheless, further ‘in house’ quality assurance processes are underway to 
ensure that the presented plans are clinically achievable. Assuming that these 
processes confirm deliverability, it is likely that MCO will be used to further 
enhance the radiotherapy planning process for the remainder of the Glasgow 
SYSTEMS-2 cohort. This, in conjunction with the findings presented in Chapter 4 
which demonstrated a link between plan quality and planner experience, 
suggests that the highest quality plans should be achieved for patients recruited 
to this study. 
 
Furthermore, this cohort of MCO optimised plans could serve as a useful resource 
in the building of an effective RapidPlan model for SYSTEMS-2. A study by Miguel 
et al, investigating the role of MCO in head and neck radiotherapy, reported that 
the optimal plan was created by performing MCO on a plan generated through a 
RapidPlan model which had been built using a training cohort of plans previously 
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optimised with MCO. (Miguel-Chumacero et al., 2018) Creating such a resource 
for SYSTEMS-2, which could be shared amongst sites, would facilitate the 
creation of high quality radiotherapy plans for trial patients and may encourage 
other sites to join the study. Furthermore, it could promote consistency 
between plans generated at different hospitals, in addition to reducing planning 
time.  
 
 5.3.4 The potential for further dose escalation with MCO 
The data presented in this chapter was generated using plans created for a dose 
of 36Gy in 6 fractions and suggests that further dose escalation may be safely 
achievable in MPM using MCO. This introduces the possibility of using 
radiotherapy for MPM in a more radical setting than is currently practised in the 
UK. It is already accepted that in other types of cancer (e.g. NSCLC), local 
control cannot be reliable achieved using conventional radiotherapy dosing 
schedules and techniques. (Nguyen et al., 2010) This, in combination with the 
demonstration of a clear radiotherapy dose-response relationship in NSCLC 
(Martel et al., 1999) has led to strategies aiming to escalate the dose of 
radiation delivered to the tumour. Nevertheless, results of the RTOG 0617 study 
suggest that conventionally fractionated dose escalated regimes, which increase 
overall treatment time, are not the optimal strategy in NSCLC. (Bradley et al., 
2015) Novel radiotherapy approaches are now being used, which permit the 
radiation dose to the tumour to be escalated, depending on the normal tissue 
constraints. (van Baardwijk et al., 2008, van Baardwijk et al., 2010) ‘Isotoxic 
radiotherapy’, delivered using IMRT and a hyperfractionated accelerated regime, 
is currently being assessed in a UK feasibility study in patients with stage III 
NSCLC. (Haslett et al., 2016) Future MCO planning studies within the SYSTEMS-2 
cohort will aim to investigate delivery of a dose escalated radiotherapy regime 
to the whole pleura, incorporating isotoxically prescribed boosts to areas of 
bulky disease and/or pain, depending on the results of the SYSTEMS-2 study.  
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 5.3.5 Physician led radiotherapy planning using MCO 
In addition to generating clinically superior radiotherapy plans, MCO allows the 
treatment planning to be distributed amongst clinical staff. A study by Kierkels 
et al demonstrated that novice treatment planners were able to produce head 
and neck radiotherapy plans which were almost indistinguishable from those 
generated conventionally and took less time to create (on average 43 minutes 
with MCO versus 205 minutes with conventional planning). (Kierkels et al., 2015) 
A further study by Muller et al which investigated the role of physician led MCO 
radiotherapy planning in brain and prostate tumours concluded that this is a 
feasible approach which could improve departmental efficiencies. (Muller et al., 
2017) Within the current study, all MCO plans were generated by a physician 
with no prior experience of radiotherapy planning. Physician-led MCO 
radiotherapy planning may potentially bring many benefits, the most important 
of which is the background clinical knowledge of the case and the ability to 
manipulate the dose to various structures, according to the clinical situation.  
 
5.4 Summary 
This data demonstrates that physician led MCO planning can achieve clinically 
significant improvements in the dose escalated radiotherapy plans of SYSTEMS-2 
patients, sparing OARs without compromising PTV coverage. This technique is 
likely to influence future radiotherapy planning in this disease, in both the 
palliative and radical settings. Furthermore, these MCO plans will contribute to a 
‘training cohort’ in the generation of a Rapidplan model which can be shared 
amongst sites to facilitate high quality radiotherapy planning in the SYSTEMS-2 
study. 
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Chapter 6: Characterising the radiosensitivity of mesothelioma using an in 
vitro 3D model 
 
Chapter aim 
The aim of this chapter is to explore the radiosensitivity and radiobiology of 
MPM using a clinically relevant in vitro spheroid model. Spheroids generated 
from two distinct MPM cell lines will be exposed to varying doses of 
radiotherapy, delivered using different fractionation regimes. The same model 
will be used to identify an isoeffective dose of IR, which could be used to 
estimate the α/β ratio of MPM. This information would be extremely useful in 
the planning and development of future clinical trials of radiotherapy in this 
disease, by guiding optimal fraction size.  
 
 
6.1 Introduction 
 6.1.1 Clinical assessment of radiosensitivity in MPM  
MPM is generally regarded as an inherently radioresistant tumour, for which the 
role of radiotherapy is limited exclusively to palliation of pain, employing 
modest doses of radiation which can be tolerated by nearby OARs. (Ashton et 
al., 2017) This reputation may be underpinned more by the difficulties of 
delivering a tumouricidal dose to the pleural cavity using traditional RT 
techniques, than by direct evidence of radioresistance. Furthermore, since 
follow up cross sectional imaging is not routinely performed after palliative 
treatments, the radiological impact of even modest doses of IR are rarely 
determined, making the true radiosensitivity of MPM difficult to ascertain in a 
clinical setting.  
 
A limited number of studies have attempted to define the radiological response 
of MPM to IR in a clinical setting. (Jenkins et al., 2011, Linden et al., 1996) 
Linden et al observed just one radiological response out of 31 patients treated 
with an IR dose of 40Gy in 20 fractions, (Linden et al., 1996) however, a 
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retrospective study by Jenkins et al report more encouraging data with a regime 
employing 3Gy per fraction. (Jenkins et al., 2011) In this series of 54 patients, a 
dose of 36Gy in 12 fractions was delivered over 2.5 weeks to sites of pain and 
bulky disease. CT imaging was conducted in fit patients after 2 months and 
compared to baseline imaging using the Modified RECIST criteria. (Byrne and 
Nowak, 2004b) An overall radiological response rate of 43% was reported, with a 
median reduction from baseline measurements of 32% within the radiotherapy 
field and a median increase of 22% from baseline measurements outside of the 
field. Furthermore, patients who had responded to RT had a significantly longer 
overall survival than non-responders (7.2 months versus 2.8 months; p= 0.001), 
suggesting that hypofractionated radiotherapy may be more effective in MPM 
and could be linked to improved overall survival. (Jenkins et al., 2011)  A similar 
sensitivity to fraction size has been observed by van der Zee et al, who reported 
a 54% clinical response rate to 40Gy in 10 fractions in a cohort of MPM patients 
treated for intervention site recurrence. (van der Zee et al., 2004) Whilst these 
data suggest an encouraging role for hypofractionation in MPM, they should be 
interpreted cautiously given their single arm design and the use of different 
total doses. 
 
In the SYSTEMS study, in which 20Gy was delivered in 4Gy per fraction, (MacLeod 
et al., 2015a) radiological data was collected at week 12 from 18 patients out of 
40 and scored according to the Modified RECIST criteria.(Byrne and Nowak, 
2004b) Only one partial response was identified, suggesting that MPM was 
radioresistant at this dose, despite hypofractionation and that clinical response 
did not correlate with a notable reduction in tumour bulk. (MacLeod et al., 
2015a) The impact of dose escalated hypofractionated radiotherapy in 
comparison to this standard dose is currently being assessed in the SYSTEMS-2 
study, in which radiological data is collected at week 9. (Ashton et al., 2018) 
 
 6.1.2 In vivo studies of MPM radiosensitivity 
In vivo studies of radiosensitivity require the tumour under investigation to grow 
reliably in a xenograft model, such that any regression following IR treatment 
can be accurately determined. Experiences within our own laboratory with 
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regard to this have been unsuccessful. Three MPM cell lines (H2052, 211H and 
H226) were used to establish subcutaneous xenografts in nude mice, however, 
only 211H cells were able to form tumours, which spontaneously regressed (data 
not shown). Further attempts with subcutaneous deposition of this cell line in 
SCID mice demonstrated tumour growth, but these were prone to ulceration and 
necrosis and were therefore unreliable. For this reason, preclinical models 
utilising cell lines have been employed for the investigation of this malignancy.  
 
 6.1.3 In vitro studies of MPM radiosensitivity 
 6.1.3.1 2D models of MPM 
Despite the radioresistant reputation of MPM in the clinic, there is evidence to 
suggest that MPM cell lines grown in vitro may be relatively radiosensitive. 
(Carmichael et al., 1989, Hakkinen et al., 1996)  
 
The first study to investigate the in vitro radiation response of MPM was 
conducted by Carmichael et al. (Carmichael et al., 1989) A clonogenic assay was 
used to investigate the effect of single radiation doses of between 1 and 12Gy on 
seventeen human lung cancer cell lines, including two MPM cell lines. Cells were 
incubated for 2-4 weeks following IR and differences in radiosensitivity were 
distinguished by comparisons of the MID, SF2Gy and values of α and β. While the 
observed responses of small cell and non-small cell lung cancer (SCLC and 
NSCLC) were largely similar to what would be expected in clinical practice, 
mesothelioma was noted to be unexpectedly sensitive to radiation in vitro. The 
SF2Gy was reported to be 0.34 - 0.35 and almost no shoulder was observed in 
cell survival curves, suggestive of limited capacity for SLD repair. (Carmichael et 
al., 1989) The α/β ratios reported for these cell lines were 5Gy and 26Gy, 
suggesting that they may have different sensitivities to fractionation. 
 
Further work by Hakkinen et al in 1996 studied the radiosensitivity, cell growth 
kinetics, radiation-induced cell cycle delay and genomic integrity of six different 
mesothelioma cell lines. (Hakkinen et al., 1996) Cells were exposed to single 
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radiation doses ranging from 1 to 8Gy, following which they were allowed to 
grow for 7 to 8 days to allow enough time for any damage to manifest. An MTT 
assay was conducted and the LQ model was used to determine the SF2Gy and the 
α/β ratio for each cell line. A large difference in radiosensitivity was noted 
between the cell lines, with SF2Gy varying from 0.36 (±0.06) to 0.81 (±0.08). 
Aneuploid cell lines (M28K and M38K) were relatively radioresistant. M28K cells 
had a SF2Gy of 0.74 (±0.09), and reported α and β values of 0.083Gy-1 (±0.015 
Gy-1) and 0.019Gy-2 (±0.004 Gy-2) respectively. Similarly, the SF2Gy in M38K cells 
was 0.81 (±0.08), with α of 0.089 Gy-1 (±0.015 Gy-1) and β of 0.012 Gy-2 (±0.003 
Gy-2). Predicted α/β ratios of 4Gy and 7Gy were reported for M28K and M38K cell 
lines respectively, suggesting that they may be sensitive to changes in dose per 
fraction. Diploid cell lines were found to be more radiosensitive, with a poorly 
defined shoulder in their survival curve. M14 cells were the most radiosensitive, 
with a reported SF2Gy of 0.36 (±0.06) and values of α and β of 0.48Gy-1 
(±0.04Gy-1) and 0.005Gy-2 (±0.005Gy-2) respectively. The predicted α/β ratio of 
this cell line was 92Gy, suggesting that these cells would not respond to changes 
in dose per fraction. (Hakkinen et al., 1996) This study provides interesting 
insight into the radiosensitivity of MPM; however, such contradictory data limits 
the potential for general clinical applicability. 
 
 6.1.3.2 3D models of MPM 
Despite the popularity of 3D tumour models and their established role in 
radiobiological studies, (Santini et al., 1999) there is a paucity of radiation 
research utilising 3D spheroid models of MPM, even though this tumour exhibits 
characteristics which particularly favour its investigation in such a system.  
 
In vivo, MPM forms a 3D mass from a 2D pleural monolayer. The resistance to 
therapeutic strategies seen clinically with this disease may in part be due to this 
adopted morphology. (Barbone et al., 2008, Daubriac et al., 2009) A recent 
study identified a total of 209 genes which were differentially expressed 
between mesothelioma cells cultured in a monolayer or as a spheroid culture, 
(Barbone et al., 2016) suggesting that changes in gene expression may also 
contribute to the resistant phenotype. Furthermore, cytological preparations of 
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pleural fluid often reveal the presence of cellular aggregates, similar to 
spheroids, containing a collagen-based extracellular matrix core. (Delahaye et 
al., 1990) These cores are strongly suggestive of malignancy and in a study by 
Delahaye et al, were detected in the pleural effusions of 64% of patients with 
MPM versus 4% of patients with adenocarcinoma. (Delahaye et al., 1990) The 
source of the aggregates is unclear, but they are suspected to be derived from 
shearing of the primary tumour or from breakage of papillary structures. (Kim et 
al., 2005) Data suggest that these non-adherent tumour aggregates are able to 
resist loss of anchorage-induced apoptosis (anoikis) through de-regulation of cell 
signalling pathways (PI3/Akt, ERK and SAPK/JNK), and through the sequestration 
of the BH3-only pro-apoptotic protein Bim by anti-apoptotic proteins. (Daubriac 
et al., 2009) These aggregates have also been demonstrated to increase in size 
over time, displaying an ability to grow without anchorage to a substrate. 
(Daubriac et al., 2009) The ability to survive and grow in a non-adherent 
environment facilitates the development of new MPM foci and may explain the 
multifocal nature of this disease within the pleural cavity. (Daubriac et al., 
2009) These properties have been replicated in vitro by MPM tumour fragment 
spheroids grown in non-adherent conditions, which were observed to proliferate 
at a similar rate to the original tumour for up to four weeks. (Kim et al., 2005) 
The ability of mesothelioma to form structures similar to spheroids in vivo lends 
weight to the rationale for using a spheroid model to study this highly aggressive 
and resistant tumour. 
 
 6.1.4 Validation of a 3D in vitro model of MPM 
Given the suitability of MPM to be studied in a 3D spheroid model, early work 
from our laboratory, conducted by Dr Mark Jackson, assessed the relative 
performance of various cell survival assays to determine the radiosensitivity of 
three MPM cell lines (data not shown). These included clonogenic and cell 
viability assays as well as a 3D spheroid model. Each independent experimental 
technique confirmed the observation that MPM is resistant to small doses of IR 
(2Gy) but that larger doses of 10Gy, delivered as a single fraction, were 
associated with markedly decreased cell survival. This work also validated the 
3D in vitro spheroid model as a robust system in which to study the effects of 
fractionated IR in mesothelioma. 
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6.2 Results 
 6.2.1 MPM cells exhibit radiosensitivity to IR in a dose dependent 
 manner 
Prior to embarking on detailed studies of MPM radiosensitivity, pilot studies were 
conducted to establish the optimal conditions of the in vitro 3D spheroid model, 
specifically in terms of seeding density and radiation dose. Previous work from 
our lab suggested that delivery of a single 2Gy fraction of IR to MPM spheroids, 
seeded at a density 104 cells per well, did not have any significant impact on 
spheroid size at 3 weeks (data not shown). To determine the optimal radiation 
dose which caused maximum spheroid growth delay, MPM cells were seeded at 
densities of 102, 103 and 104 cells per well and left to form spheroids before 
being exposed to single IR doses of between 4Gy and 12Gy. Sham irradiated 
spheroids were included as a control. Spheroid size was monitored over 21 days 
and image reconstruction using ReVISP software was used to generate a 3D 
volume from a 2D image.  
 
At a seeding density of 102 cells per well, sham irradiated spheroids 
progressively increased in volume over 3 weeks. For example, in the H2052 
model, the mean spheroid volume was 0.005mm3 (±0.0007mm3) on day 0 and 
0.5mm3 (±0.02mm3) by day 21. (Figure 6.1) Similarly, sham irradiated 211H 
spheroids increased their mean volume from 0.004mm3 (± 0.001mm3) on day 0 to 
1.1mm3 (±0.2mm3) on day 21. (Figure 6.2) In contrast, irradiated spheroids 
increased their volume more slowly and in a manner which was dependent on 
radiation dose. After 21 days, spheroids exposed to 7Gy were markedly smaller 
than those treated with 4Gy (Figures 6.1 to 6.4). This trend was observed in both 
cell lines. To illustrate, at day 5, the mean volume of H2052 spheroids exposed 
to 4Gy and 7Gy were similar (0.01mm3 ±0.002mm3 and 0.009mm3 ±0.002mm3 
respectively), but by day 21, those treated with 4Gy had grown to a volume of 
0.24mm3 (±0.05mm3) whereas the 7Gy group had a mean volume of 0.07mm3 
(±0.02mm3) at the same time point (Figure 6.1). In the 211H model, the day 5 
volumes of 4Gy and 7Gy treated spheroids were 0.04mm3 (±0.01mm3) and 
0.02mm3 (±0.006mm3) respectively, but by day 21 the volume of spheroids 
- 227 - 
exposed to 4Gy had increased to 0.9mm3 (±0.4mm3) whereas those exposed to 
7Gy had increased only marginally to 0.12mm3 (±0.08mm3) (Figure 6.3).  
 
Whilst relative volumes of both H2052 and 211H spheroids were similarly 
affected by exposure to 5Gy, 6Gy and 7Gy, a differential effect on spheroid 
volume was noted between the two cell lines following exposure to 4Gy. In the 
211H model, the growth curve of spheroids treated with 4Gy was similar to that 
of the sham irradiated controls. For example the mean spheroid volume at day 
21 in the sham irradiated group was 1.09mm3 (±0.22mm3), compared to 0.87mm3 
(±0.38mm3) in the group which had been exposed to 4Gy. (Figure 6.3) In 
contrast, the growth trajectories of sham irradiated H2052 spheroids and those 
exposed to 4Gy IR were distinct. (Figure 6.1) At day 21, the mean spheroid 
volume in the sham irradiated group was 0.48mm3 (±0.02mm3), whereas in the 
group which had received 4Gy the mean volume was 0.24mm3 (±0.05mm3). 
 
In both cell lines, exposure to 6Gy and 7Gy effectively delayed spheroid growth. 
(Figures 6.1 and 6.3) For example, in the H2052 cell line, the mean day 21 
spheroid volume was 0.06mm3 (±0.02mm3) after exposure to 6Gy, compared to 
0.07mm3 (±0.02mm3) in the group receiving 7Gy. This observation suggests that 
6Gy may be sufficient to maximally delay MPM growth at this seeding density. At 
IR doses above 8Gy, no change in spheroid volume was observed in either cell 
line from day 0 (data not shown). Variability between replicates was observed to 
be much greater in the 211H cell line than in the H2052 model. This is illustrated 
by the greater standard deviation observed between Figure 6.1 and Figure 6.3. 
Furthermore, this variability became more pronounced towards the end of the 
experiment, as the spheroids increased in volume. For example, at day 0, sham 
irradiated 211H spheroids displayed a mean volume of 0.004mm3, associated 
with a standard deviation of ±0.001mm3. By day 21, the mean volume had 
increased to 1.09mm3 and the standard deviation was ± 0.22mm3. In contrast, 
the mean and standard deviation of H2052 spheroid volumes at day 0 and 21 
were 0.005mm3 ±0.0007mm3 and 0.48mm3 ±0.02mm3 respectively. Expressing 
this error data using the coefficient of variance (CV) parameter (standard 
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deviation/mean), the CV for the 211H cell line at day 21 is 20.2%, compared to 
4.2% in the H2052 cell line. 
 
Figure 6.1 H2052 spheroid volumes following exposure to single IR  fractions 
H2052 spheroids, seeded at a density of 102 cells per well, were exposed to 
single doses of IR between 4Gy and 7Gy and growth was monitored over 21 days. 
A sham irradiated control was included. Data are expressed as spheroid volume 
(mm3) against time (days). Data was generated from a single experiment, 
employing 6 replicate spheroids per condition and error bars represent the 
standard deviation of replicates within the experimental group. 
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Figure 6.2 Representative H2052 spheroids at day 0 and day 21 following 
irradiation with increasing doses of IR 
H2052 spheroids, seeded at a density of 102 cells per well, were irradiated with 
single fractions of IR between 4 and 7Gy. A sham irradiated group were included 
as a control. Spheroid growth was monitored for 21 days by regular brightfield 
imaging. 
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Figure 6.3 211H spheroid volumes following exposure to single fractions of IR 
211H spheroids, seeded at a density of 102 cells per well, were exposed to single 
doses of IR between 4Gy and 7Gy and subsequent growth was monitored over 21 
days. A sham irradiated control was included. Data are expressed as spheroid 
volume (mm3) against time (days). Data was generated from a single 
experiment, employing 6 replicate spheroids per condition and error bars 
represent the standard deviation of replicates within the experimental group. 
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Figure 6.4 Representative 211H spheroids sizes at day 0 and day 21 following 
irradiation with increasing doses of IR 
211H spheroids, seeded at a density of 102 cells per well, were irradiated with 
single fractions of IR between 4 and 7Gy. A sham irradiated group were included 
as a control. Spheroid growth was monitored for 21 days by regular brightfield 
imaging. 
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To determine the effect of initial cell number on radiosensitivity, spheroids were 
established at higher seeding densities and treated with IR as before. At a 
seeding density of 103 cells per well, H2052 spheroid growth was maximally 
delayed by an IR dose of 6Gy (0.18mm3 ±0.03mm3 at day 21 compared to 
0.05mm3 ±0.003mm3 at day 0). (Figure 6.5) In contrast, maximal growth delay 
was not seen until a dose of 11Gy was delivered to 211H spheroids seeded at a 
density of 103 cells per well (day 21 volume of 0.17mm3 ±0.06mm3 compared to 
0.08mm3 ±0.002mm3 at day 0). (Figure 6.6) 
 
 
Figure 6.5 H2052 spheroid volumes following exposure to single fractions of 
IR 
H2052 spheroids, seeded at a density of 103 cells per well, were exposed to 
single doses of IR between 4Gy and 7Gy and subsequent growth was monitored 
over 21 days. A sham irradiated control was included. Data are expressed as 
spheroid volume (mm3) against time (days). Data was generated from a single 
experiment, employing 6 replicate spheroids per condition and error bars 
represent the standard deviation of replicates within the experimental group. 
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Figure 6.6 211H spheroid volumes following exposure to single fractions of IR 
211H spheroids, seeded at a density of 103 cells per well, were exposed to single 
doses of IR between 8Gy and 12Gy and subsequent growth was monitored over 
21 days. A sham irradiated control was included. Data are expressed as spheroid 
volume (mm3) against time (days). Data was generated from a single 
experiment, employing 6 replicate spheroids per condition and error bars 
represent the standard deviation of replicates within the experimental group. 
 
 
When the seeding density was further escalated to 104 cells per well, an IR dose 
of 6Gy was still able to adequately delay spheroid growth in the H2052 model 
(0.3mm3 ±0.02mm3) at day 21 compared to 0.23mm3 (±0.009mm3) at day 0 
(Figure 6.7). In the 211H model, the maximum growth delay was achieved with 
an IR dose of 11Gy until day 19 (0.21mm3 ±0.04mm3 compared to 0.27mm3 
±0.02mm3 at day 0), however by day 21 the average spheroid volume observed 
with this dose had risen to 0.39mm3 (± 0.13mm3). (Figure 6.8) 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 5 10 15 20 25
Sp
h
er
o
id
 v
o
lu
m
e
 (
m
m
3
)
Time (days)
0Gy 8Gy 9Gy 10Gy 11Gy 12Gy
- 232 - 
 
Figure 6.7 H2052 spheroid volumes following exposure to single fractions of 
IR 
H2052 spheroids, seeded at a density of 104 cells per well, were exposed to 
single doses of IR between 4Gy and 7Gy and subsequent growth was monitored 
over 21 days. A sham irradiated control was included. Data are expressed as 
spheroid volume (mm3) against time (days). Data was generated from a single 
experiment, employing 6 replicate spheroids per condition and error bars 
represent the standard deviation of replicates within the experimental group. 
 
 
Figure 6.8 211H spheroid volumes following exposure to single fractions of IR 
211H spheroids, seeded at a density of 104 cells per well, were exposed to single 
doses of IR between 8Gy and 12Gy and subsequent growth was monitored over 
21 days. A sham irradiated control was included. Data are expressed as spheroid 
volume (mm3) against time (days). Data was generated from a single 
experiment, employing 6 replicate spheroids per condition and error bars 
represent the standard deviation of replicates within the experimental group. 
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Together, these data demonstrate that IR can delay the growth of MPM spheroids 
and that larger doses of IR are associated with more efficacious control. Greater 
doses of IR were required to adequately delay the growth of 211H spheroids, 
particularly at higher seeding densities. 
 
An optimal seeding density of 102 cells per well was selected for ongoing studies 
using this model, in combination with IR doses of 6Gy to 8Gy. These parameters 
were chosen to reduce the variability between 211H replicates at later 
experimental time points and to ensure that MPM spheroid growth could be 
adequately delayed by the selected doses of IR. 
 
 6.2.2 Hypofractionated radiotherapy regimens delay MPM spheroid 
 growth with improved efficacy 
Pilot studies have demonstrated that a single fraction of 6Gy IR optimally delays 
the growth of MPM spheroids, seeded at a density of 102 cells per well, over a 
period of 21 days. In the clinic, however, radiotherapy is typically delivered over 
a number of treatments (usually employing a dose of 2Gy per fraction), since 
this preferentially spares the late responding normal tissue owing to its typically 
low α/β ratio. As the α/β ratio of MPM remains largely unknown, studies were 
performed using the 3D in vitro spheroid model to determine whether MPM 
might be similarly spared by conventional fractionation. H2052 and 211H cells 
were seeded at a density of 102 cells per well and left to form spheroids before 
being irradiated with fractionated radiation schedules with total doses of either 
6Gy or 8Gy. (Table 6.1) Where required, multiple radiation doses were delivered 
with a 24-hour inter fraction interval. Sham irradiated spheroids were included 
as a control. Spheroid growth was monitored for 21 days and data are reported 
as mean spheroid volume at day 21, averaged from 3 to 7 individual 
experiments, each incorporating 6 to 8 replicates per condition.  
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Table 6.1 Fractionated radiotherapy regimes 
Total dose Conventionally 
fractionated 
regimes 
Moderately 
hypofractionated 
regimes 
Maximally 
hypofractionated 
regimes 
6Gy 3x2Gy 
 
2x3Gy 1x6Gy 
8Gy 4x2Gy 
 
2x4Gy 1x8Gy 
Spheroids were exposed to a total IR dose of 6Gy or 8Gy, delivered in regimes 
employing different doses per fraction. Fractionated treatments were delivered 
24 hours apart and spheroid growth was monitored for 21 days. 
 
Delivery of a total IR dose of 6Gy to MPM spheroids was associated with a 
significant reduction in volume compared to the sham irradiated controls, 
regardless of how it was delivered. For example, the mean volume of sham 
irradiated H2052 spheroids was 0.5mm3 (±0.04mm3) at day 21, compared to 
0.26mm3 (±0.05mm3) in the group exposed to 3x2Gy (p<0.0001), 0.23mm3 (± 
0.04mm3) in those treated with 2x3Gy (p<0.0001) and just 0.07mm3 (± 0.02mm3) 
in the 1x6Gy group (p<0.0001). (Figure 6.9A) A similar trend was observed in the 
211H spheroids. In this model, the sham irradiated spheroids displayed a mean 
volume of 0.93mm3 (±0.19mm3), compared to 0.45mm3 (±0.08mm3) in those 
treated with 3x2Gy (p<0.05), 0.43mm3 (±0.11mm3) in the group receiving 2x3Gy 
(p<0.05) and 0.15mm3 (±0.11mm3) in the spheroids exposed to 1x6Gy (p<0.0001). 
(Figure 6.9B) 
 
Although all IR regimes delivered a total dose of 6Gy and were associated with a 
reduction in spheroid volume, the delivery of the dose in a single 6Gy fraction 
produced significantly smaller spheroids at day 21 than regimes employing 2Gy 
or 3Gy per fraction. For example, in the 211H model, delivery of 1x6Gy was 
associated with a mean spheroid volume of 0.15mm3 (±0.11mm3) at day 21, 
compared to 0.45mm3 (±0.08mm3) in the group exposed to 3x2Gy (p<0.0001) and 
0.43mm3 (±0.11mm3) in those treated with 2x3Gy (p<0.0001). (Figure 6.9B) The 
same pattern was seen in the H2052 model. (Figure 6.9A) 
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Figure 6.9 The effect of 6Gy on H2052 (A) and 211H (B) spheroid volumes at 
day 21 
Spheroids were exposed to a total IR dose of 6Gy, delivered in different doses 
per fraction and growth was monitored over 21 days. Data is expressed as the 
mean spheroid volume at day 21, averaged from 3 to 7 individual experiments, 
each incorporating 6 to 8 replicates per condition (0Gy n=7; 3x2Gy n=3; 2x3Gy 
n=3; 1x6Gy n=3). Error bars reflect the standard deviation of the means. 
Statistical significance was determined with a linear mixed effect model, using 
the cubed root of the transformed data value. (*p<0.05; ****p<0.0001) 
 
 
Exposure of MPM spheroids to a total IR dose of 8Gy reduced spheroid volume in 
a manner similar to that observed with 6Gy. In both cell lines, exposure to 8Gy 
significantly reduced day 21 spheroid volume compared to the sham irraditated 
control, regardless of the delivery regime, and the greatest reduction in volume 
was seen with a single 8Gy fraction. (Figure 6.10 A and B) In contrast to the data 
generated for 6Gy regimes, significant differences in day 21 spheroid volumes 
were observed between groups treated with conventionally fractionated and 
moderately hypofractionated IR regimes. For example, in the H2052 model, 
exposure to 4x2Gy IR was associated with a mean spheroid volume of 0.22mm3 
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(±0.05mm3) at day 21, compared to 0.15mm3(± 0.04mm3) in spheroids exposed to 
2x4Gy (p<0.0001). (Figure 6.10A) Similarly, 211H spheroids exposed to 4x2Gy IR 
had a mean day 21 volume of 0.5mm3(±0.2mm3), compared to 
0.32mm3(±0.21mm3) in the 2x4Gy group (p<0.001). (Figure 6.10B) 
 
 
         A       B 
 
 
 
 
 
 
 
 
 
Figure 6.10 The effect of 8Gy on H2052 (A) and 211H (B) spheroid volumes 
day at 21 
Spheroids were exposed to a total IR dose of 8Gy, delivered in different doses 
per fraction and growth was monitored over 21 days. Data is expressed as the 
mean spheroid volume at day 21, averaged from 7 individual experiments, each 
incorporating 6-8 replicates per condition. Error bars reflect the standard 
deviation of the means. Statistical significance was determined with a linear 
mixed effect model, using the cubed root of the transformed data value. 
(***p=0.001; ****p<0.0001) 
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In summary, these data suggest that MPM is sensitive to changes in radiation 
dose per fraction and that the most efficacious delay of spheroid growth is 
achieved with hypofractionated radiation regimes. These observations have 
clinical relevance, since the decision to select hypofractionated radiation 
regimes for the SYSTEMS-2 study was underpinned by the assumption that MPM 
has a low α/β ratio and may respond more favourably to IR delivered in larger 
doses per fraction. 
 
 6.2.3 Estimation of isoeffective radiation doses suggest MPM spheroids 
 exhibit a low α/β ratio 
To further explore the assumptions made about the α/β ratio of MPM within the 
SYSTEMS-2 clinical trial, additional in vitro studies were conducted using the 3D 
spheroid model of MPM. Cells were seeded at a density of 102 cells per well and 
left to form spheroids before being irradiated with a selection of IR regimes that 
employed a variety of total doses, given over a number of different fractionation 
schedules. (Table 6.2) A sham irradiated group was included as a control and 
spheroid volume was monitored for 21 days in the 211H model and for 28 days in 
the H2052 model. Treatment effect was defined as volume reduction from the 
sham irradiated control and was used to generate a dose effect curve within 
radiation regimes utilising equal numbers of fractions. An isoeffective dose was 
then identified across radiation regimes and used to estimate the α/β ratio.  
 
For clarity, the process used to estimate treatment effect, the generation of 
dose effect curves and calculations of isoeffective dose are illustrated for H2052 
spheroids at day 14. (Table 6.3 and Figures 6.13-6.14) The remainder of the data 
for the H2052 and 211H cell lines are presented in Appendix 1. 
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Table 6.2 Radiation schedules delivered to MPM spheroids to investigate 
tumour α/β ratio 
Regime fraction number 
 
Total dose Dose per fraction 
1 6Gy 
 
6Gy 
8Gy 
 
8Gy 
10Gy 
 
10Gy 
2 4Gy 
 
2Gy 
6Gy 
 
3Gy 
8Gy 
 
4Gy 
10Gy 
 
5Gy 
3 6Gy 
 
2Gy 
9Gy 
 
3Gy 
12Gy 
 
4Gy 
15Gy 
 
5Gy 
4 4Gy 
 
1Gy 
8Gy 
 
2Gy 
12Gy 
 
3Gy 
16Gy 
 
4Gy 
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Exposure of MPM spheroids to IR reduced spheroid volume in a dose dependent 
manner, as had been observed in earlier work. This is illustrated in both the 
single fraction and fractionated regimes, with greater total doses delaying 
spheroid growth more effectively. For example, in the H2052 model, delivery of 
10Gy as a single fraction resulted in a mean day 28 spheroid volume of 0.05mm3 
(±0.04mm3) whereas a 6Gy single fraction produced a mean day 28 spheroid 
volume of 0.28mm3 (±0.1mm3). (Figure 6.11) In the 211H model, delivery of a 
total dose of 9Gy as a 3x3Gy regime produced a mean day 21 spheroid volume of 
0.27mm3 (±0.16mm3), as compared to delivery of 6Gy in a 3x2Gy regime which 
produced a mean day 21 spheroid volume of 0.55mm3 (±0.08mm3) (Figure 6.12). 
Furthermore, the influence of fractionation on spheroid growth was again 
observed in this data set, with more hypofractionated regimes delaying growth 
with greater efficacy. For example, in the H2052 model, delivery of 10Gy as a 
single fraction was associated with a mean day 28 spheroid volume of 0.05mm3 
(±0.04mm3), whereas delivery of the same dose as 2x5Gy allowed the spheroid 
volume to increase to 0.21mm3 (±0.07mm3) by day 28. (Figure 6.11) Similarly, 
delivery of 8Gy as 2x4Gy was associated with a reduced mean day 21 volume 
(0.47mm3 ±0.3mm3) compared to delivery of the same dose as 4x2Gy (0.64mm3 
±0.18mm3) in the 211H model. (Figure 6.12) 
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Figure 6.11 H2052 spheroid growth delay curves following exposure to IR 
H2052 cells were seeded at 102 cells per well and allowed to form spheroids 
before being exposed to different doses of IR. IR was delivered either as single 
fractions, two fractions, three fractions, or as a four fraction regime. For clarity, 
data are plotted according to total dose delivered rather than by fractionation 
regime. Spheroid growth was monitored for 28 days and 3D volume data was 
generated from 2D images. Data is expressed as spheroid volume (mm3) against 
time (days) and was generated from a single experiment, incorporating 6 
replicates per condition. Error bars represent the standard deviation between 
the replicates. 
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Figure 6.12 211H spheroid growth delay curves following exposure to IR 
211H cells were seeded at 102 cells per well and allowed to form spheroids 
before being exposed to IR of differing doses. IR was delivered either as single 
fractions, two fractions, three fractions, or as a four fraction regime. For clarity, 
data are plotted according to total dose delivered rather than by fractionation 
regime. Growth was monitored for 21 days and 3D volume data was generated 
from 2D images. Data is expressed as spheroid volume (mm3) against time (days) 
and was generated from a single experiment, incorporating 6 replicates per 
condition. Error bars represent the standard deviation between the replicates. 
 
 
Useful estimations of treatment effect were observed from both MPM models 
from day 10 onwards. Prior to this, levels of spheroid damage were so similar 
between fractionation regimes that dose response curves could not accurately 
distinguish between IR doses. Furthermore, at these early time points, the size 
of effect was so limited that it was often not possible to identify a common level 
between the regimes.  
 
The day 14 volumes of irradiated H2052 spheroids and sham irradiated controls 
are illustrated in Table 6.3. The reduction in spheroid volume compared to that 
of the sham irradiated control was calculated and dose effect curves generated 
to illustrate the impact of different doses of IR, delivered in an equal number of 
fractions (Figure 6.13). A common effect level was selected, for example, 
0.2mm3, and the required total dose of IR necessary to reduce growth by this 
amount was determined for each fraction number.  
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Table 6.3 H2052 spheroid volume reduction caused by each IR regime at day 
14 
     
  
 
 
Regime 
Total 
dose 
Volume (mm3) 
Volume reduction from 
control (mm3) 
 
Sham-
irradiated 
control 
0Gy 0Gy 0.2506 0 
Single 
fraction 
    
1x6Gy 6Gy 0.0556 0.1950 
1x8Gy 8Gy 0.0327 0.2179 
1x10Gy 10Gy 0.0314 0.2191 
Two 
fractions 
2x2Gy 4Gy 0.1760 0.0746 
2x3Gy 6Gy 0.1209 0.1297 
2x4Gy 8Gy 0.0632 0.1873 
2x5Gy 10Gy 0.0410 0.2095 
Three 
fractions 
3x2Gy 6Gy 0.1227 0.1279 
3x3Gy 9Gy 0.0780 0.1726 
3x4Gy 12Gy 0.0386 0.2120 
3x5Gy 15Gy 0.0340 0.2165 
Four 
fractions 
4x1Gy 4Gy 0.1921 0.0585 
4x2Gy 8Gy 0.1215 0.1291 
4x3Gy 12Gy 0.0407 0.2098 
4x4Gy 16Gy 0.0410 0.2095 
The mean volume of irradiated H2052 spheroids is subtracted from the mean 
volume of the sham irradiated controls to provide an estimate of the relative 
effect (damage) of each IR schedule on spheroid volume at day 14. 
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Figure 6.13 Dose effect curves illustrating the impact of different 
fractionation schedules on H2052 spheroid damage at day 14 
Spheroid volume reductions from the sham irradiated control were used to 
generate a dose response curve for IR schedules delivered as a single fraction, 
two fractions, three fractions or four fractions. A common level of effect 
amongst all response curves was selected and the total dose of IR required to 
generate this effect determined. 
 
 
Table 6.4 Dosimetry information on the IR regimes required to reduce H2052 
spheroid volume by 0.2mm3 from the sham irradiated control at day 14 
Number of 
fractions (n) 
Effect 
(mm3) 
Total 
dose 
(D) 
Dose per 
fraction (D/n) 
Reciprocal total 
dose (1/D) 
1  0.2 6.441 6.441 0.155 
2  0.2 9.141 4.571 0.109 
3  0.2 11.089 3.696 0.090 
4  0.2 11.513 2.878 0.087 
The relative total IR dose is established from the dose response curves. The 
dose per fraction and reciprocal of the total dose is calculated for each regime. 
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The reciprocal of the total dose required for a given isoeffect and the 
corresponding dose per fraction were calculated. (Table 6.4) Plotting these 
values gives a straight line, with gradient proportional to the value of β and y-
intercept corresponding to the value of α. At day 14, the estimated α/β ratio in 
H2052 cells was 1.1. (Figure 6.14 and Table 6.5) 
 
Figure 6.14 Estimate of the α/β ratio of H2052 spheroids 
Plotting the reciprocal of the total IR dose required to reduce spheroid volume 
by 0.2mm3 at day 14 from the sham irradiated control, against the corresponding 
dose per fraction gives a line, whose slope is proportional to β and whose 
intercept on the vertical axis corresponds to the value of α. The equation for the 
regression line was used to calculate the α/β ratio and the fit of the data points 
is indicated by R2. 
 
 
This procedure was used to identify isoeffective dose levels of IR on each day 
that the spheroids were imaged. These data were subsequently used to estimate 
the α/β ratio of the cell lines, using the equation derived from the line of best 
fit between the data points. Multiple results were generated over the course of 
the study, which allowed the reproducibility and reliability of the method to be 
assessed. 
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An element of variability was observed in the α/β ratio estimates generated 
from the H2052 model, but data suggest that this cell line exhibits a mean α/β 
ratio of 1.67 (95% CI 1.0 -2.3). (Table 6.5) 
 
Table 6.5 Estimated α/β ratios from H2052 spheroids 
Day 
Isoeffect level 
(mm3) 
Estimated α/β 
ratio (Gy) 
10 0.13 0.8 
14 0.2 1.1 
16 0.28 2.3 
21 0.3 1.2 
24 0.35 2.9 
28 0.3 1.7 
Mean 1.67 
 x ± 1.96 (δ/√n) 1.0 - 2.3 
 
Isoeffective data from four dose response curves were utilised to generate the 
estimate of α/β ratio on each day of imaging. The average α/β ratio is quoted 
with 95% confidence intervals. 
 
Analysis of the data from the 211H model highlighted a greater degree of 
variability amongst α/β ratio estimates. Whilst the estimate from day 10 
reflected that seen in the H2052 model, data generated from subsequent time 
points saw the estimate rise progressively. To illustrate, the α/β ratio estimate 
at day 14 was 2.5Gy (using an isoeffect level of 0.51mm3) whereas by day 21 it 
had risen to 3.8Gy (using an isoeffect level of 0.65mm3). This cell line displayed 
a mean α/β ratio of 2.63 (95% CI 1.3- 3.9). (Table 6.6) 
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Table 6.6 Estimated α/β ratios from 211H spheroids. 
Day Isoeffect level (mm3) 
Estimated α/β 
ratio (Gy) 
10 0.29 0.8 
14 0.51 2.5 
16 0.55 3.4 
21 0.65 3.8 
Mean 2.63 
 x ± 1.96 (δ/√n) 1.3 – 3.9 
 
 Isoeffective data from four dose response curves were utilised to generate the 
estimate of α/β ratio on each day of imaging. The average α/β ratio is quoted 
with 95% confidence intervals. 
 
Although it may not be possible to establish a definitive α/β ratio for MPM using 
these data, results suggest that the α/β ratio may be lower than that exhibited 
by many other cancers. Considered with the other data presented in this 
chapter, specifically the sensitivity of MPM cell lines to changes in IR dose per 
fraction and the superior effect of dose hypofractionation in the delay of 
spheroid growth, these data add further support to the hypothesis that MPM 
exhibits a low α/β ratio and so would be optimally treated with 
hypofractionated radiation regimes. 
 
6.3 Discussion 
The radiobiology and radiosensitivity of MPM have not been well characterised 
and the limited number of in vitro studies exploring this to date have focussed 
on the impact of single fractions of IR, using 2D experimental models to 
generate measures of cell survival. (Carmichael et al., 1989, Hakkinen et al., 
1996) Earlier studies in our own laboratory used 2D clonogenic survival assays to 
investigate the radiobiology of 211H and H2052 cell lines. (Jackson et al., 2020) 
Data from this work generated cell survival curves which fitted the LQ model 
and although parameters for α and β were calculated, the α/β ratio has not 
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been formally reported, due to a large degree of variability seen between the 3 
biological replicates in the experiment, resulting in wide confidence intervals 
around the mean.  
 
This study is the first to use a more clinically relevant 3D in vitro model to assess 
specifically the impact of dose fractionation on MPM spheroids and to use this 
data to provide an informed estimate of α/β ratio. The challenges of generating 
robust measures of radiosensitivity from 3D models have been discussed in 
section 1.5.4. Nevertheless, a 3D spheroid approach has several strengths within 
the setting of MPM, in particular the ability to replicate more closely the 
properties of an in vivo tumour and to mimic the cellular aggregates found in 
pleural effusions that correlate with disease aggression. (Delahaye et al., 1990) 
Furthermore, this model allows for an estimation of volume, which is the 
parameter used for assessment of tumour in the clinical setting. The ReVISP 
software, (Piccinini et al., 2015) used to assess volume, is specifically designed 
to take into account spheroid protuberances and irregularities, facilitating the 
generation a more realistic 3D representation than other systems, which assume 
a sphere or ellipsoid morphology. (Gaylord and Clowes, 1906, Woglom, 1925, 
Tomayko and Reynolds, 1989) This is a particularly important consideration for 
the 211H spheroids, which exhibited an irregular growth pattern. 
 
 6.3.1 Cell line considerations 
All experiments were conducted using two cell lines (H2052 and 211H), originally 
derived from patients with epithelioid and biphasic MPM respectively. Intrinsic 
differences between the behaviour of these cells lines cultured as spheroids 
were observed.  
 
The growth characteristics displayed by these two cell lines were markedly 
different. When grown in 3D, H2052 cells formed compact structures, forming 
regularly shaped spheroids with sharply circumscribed borders. While the rate of 
growth changed following treatment with IR, the regular growth pattern of the 
spheroids was preserved, rendering them easy to delineate. In contrast, 211H 
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cells displayed an irregular growth pattern, forming loosely packed spheroids 
with a hazy border. Frequently, cellular projections could be seen from one side 
of the spheroid and as the volume increased, the spheroid lost its structural 
integrity. Cells became detached from the main body of the spheroid and the 
structure became increasingly difficult to delineate accurately. For this reason, 
211H spheroid replicates displayed greater variability in their shape and volume 
than their H2052 counterparts, particularly at later experimental time points. 
Acknowledging these limitations, data from both cell lines are represented and 
discussed.  
 
 6.3.2 The radiation dose-dependent response of MPM to IR 
In keeping with the studies of Carmichael and Hakkinen, in which the 
radiosensitivity of two MPM cell lines were established using a clonogenic assay, 
data presented here suggest that MPM cell lines are radiosensitive, and that the 
degree of radiosensitivity can vary between them. (Carmichael et al., 1989, 
Hakkinen et al., 1996) Data show that the growth of MPM spheroids, seeded at a 
density of 102 cells per well, was impaired by doses of IR greater than 4Gy, 
delivered as single doses. Whilst doses of IR above 6Gy were found to optimally 
delay spheroid growth at this seeding density, some spheroid recovery was 
observed following exposure to 4Gy and 5Gy. This dose dependent nature of the 
spheroid response to IR is likely a reflection of the extent of DNA damage 
inflicted by the IR and the capacity of the cell to repair it. For example, 
exposure to a single fraction of 6Gy IR would cause extensive DNA damage, 
which is likely to overwhelm molecular pathways of repair and cause significant 
cellular senescence or death. This is reflected in poor growth and reduced day 
21 spheroid volumes in both MPM models exposed to this dose. Conversely, 
exposure to a single IR dose of 4Gy IR would be predicted to induce fewer DNA 
DS breaks. The ability of spheroids to recover from the insult and continue to 
grow, suggests that cellular repair pathways remain functional and so this dose 
of IR is insufficient to significantly impact on the growth of MPM spheroids. 
 
The variable response of the two cell lines to equal doses of IR suggests that 
211H spheroids may be more radioresistant than their H2052 counterparts, in 
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keeping with the aggressive and treatment resistant nature of non-epithelioid 
MPM. The exact control exerted on spheroid growth by a specific dose of IR 
cannot be accurately ascertained in a single study and the lack of experimental 
repeats performed here is a clear limitation. However, this was preliminary 
work, conducted with the aim of generating pilot data with which to 
demonstrate ‘proof of principle’ and inform the optimal cell seeding density and 
radiation doses for subsequent studies of dose fractionation.  
 
 6.3.3 The response of MPM to hypofractionated IR 
In vitro 3D spheroid models have previously been demonstrated as a robust 
system in which to investigate the effect of dose hypofractionation on cancer 
cell radioresponse. (Kaaijk et al., 1997) Data generated within this study 
suggests that MPM spheroids are sensitive to changes in IR dose per fraction and 
that their growth is most effectively delayed by hypofractionated regimes. This 
observation suggests that there is a capacity for SLD repair in these cells.  
 
Following exposure to a single dose of 6Gy, spheroid volumes were significantly 
lower than with a regime delivering the same total dose in a number of smaller 
fractions (i.e. 3x2Gy or 2x3Gy). Fractionated IR causes proportionately less DNA 
damage with each exposure and a treatment gap of 24 hours allows the cell time 
to repair any SLD. This allows recovery before the next dose of IR is given and 
facilitates tumour sparing in the same way that dose fractionation spares late 
tissue toxicity. Delivery of the same total dose in a hypofractionated manner 
appears to dramatically impact on the level of spheroid growth delay achieved. 
 
This finding was further supported by the observation that spheroid volumes 
were significantly different between the conventionally and moderately 
fractionated regimes when a total dose of 8Gy IR was employed. This was not 
seen in the 6Gy model, potentially due to the relatively small difference 
between 2Gy per fraction and 3Gy per fraction schedules, but exposure to a 
more hypofractionated regime utilising 4Gy per fraction resulted in significantly 
smaller spheroids at day 21 than in the 4x2Gy group. In keeping with previous 
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findings, the most efficacious growth delay was observed with the maximum 
dose per fraction of 1x8Gy. 
 
Despite this novel data in an MPM model, the discovery that tumour control can 
be more efficacious with hypofractionated radiotherapy is not new. In the case 
of prostate and breast cancer, recently generated radiobiological data have 
altered clinical practise, (Yarnold et al., 2011, Miralbell et al., 2012) but 
published values for α/β in a number of tumour sites suggest that many cancers 
will exhibit sparing with fractionated radiotherapy. (van Leeuwen et al., 2018) 
Crucially, it is the degree of sparing compared to normal tissue which will guide 
fractionation protocols between tumour types. A clear limitation of this study is 
the lack of control group from which the relative sparing displayed by MPM could 
be estimated. Future studies should include cell lines with known α/β ratios to 
provide an optimal comparator. 
 
 6.3.4 Estimating the α/β ratio of MPM 
 6.3.4.1 Technique selection 
The technique used to generate estimates of MPM α/β ratio was adapted from a 
paper by Stewart et al (1984). (Stewart et al., 1984) Reduction in spheroid 
volume was used as a measure of effect, facilitating the generation of dose 
effect curves. Isoeffective doses between the differing radiation schedules were 
determined and α/β ratio was estimated by plotting the dose per fraction 
against the reciprocal of the total dose required for the isoeffect. 
 
Analysis of the dose effect curves demonstrates a profound influence of 
fractionation in this model, signified by the observation that the total radiation 
dose required to reduce spheroid volume by a given level increased progressively 
with increasing fraction number. As reported by Stewart et al, capacity for SLD 
repair can be assessed from the dose effect curves, by comparing the total dose 
required in different fractionation regimes to produce the same effect level. In 
keeping with previous findings, this analysis confirmed our observation that MPM 
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spheroids are susceptible to changes in dose per fraction and that the most 
effective spheroid growth delay is achieved with hypofractionated treatments. 
 
By analysing data in this manner, the estimated mean α/β ratio of the H2052 
MPM cell line was 1.67Gy (95% CI 1.0Gy- 2.3Gy) and 2.63Gy (95% CI 1.3Gy- 
3.9Gy) in the 211H cell line. Both cell lines therefore demonstrate relatively low 
α/β ratios compared to other types of cancer (van Leeuwen et al., 2018) and 
support the values obtained for the JMN cell line by Carmichael (Carmichael et 
al., 1989) and the aneuploid MPM cell lines investigated by Hakkinen et al. 
(Hakkinen et al., 1996) 
 
Although values of α and β have been generated for MPM, this data cannot be 
used as a direct measure of cell line radiosensitivity. This is because the output 
measure in these experiments was ‘spheroid volume’ rather than classical 
radiobiological parameter of ‘cell survival’. Nevertheless, while the raw values 
may not be directly reflective of radiosensitivity, the ratio between them is a 
valid predictor of the response to dose per fraction. 
 
 6.3.4.2 Limitations of the selected technique 
Whilst this method has generated MPM α/β ratios which were similar to those 
reported by other groups, there were a number of problems encountered with 
the technique which may have influenced our results. 
 
Firstly, it was observed that the isoeffective data points did not always conform 
to a linear relationship and occasionally there were data points which appeared 
to deviate from the trend. For H2052 this was most frequently data representing 
the single fraction of IR, whereas in the 211H dataset this was less consistently 
problematic. The presence of data points not conforming to the fit increased 
uncertainty in this method and the cause and impact of this issue needs to be 
carefully considered. Whilst the dose and fractionation regimes for this work 
were selected on the basis of previous spheroid irradiation data, the effects 
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observed following exposure to single fractions of IR were much greater than 
those seen in the other fractionation regimes. Consequently, equivalent effects 
were often at the extreme of the single fraction data. It was observed by 
Stewart et al that whilst the choice of isoeffect does not affect the outcome of 
the analysis, data taken from extremes of curves may be less reliable. (Stewart 
et al., 1984) However, this problem was not exclusively seen when data was 
taken from an extreme of a data set. Therefore, it may be that single fraction 
data should be avoided for this type of experiment and that multi-fraction data 
alone should be used to calculate precise measures of radiosensitivity. In future 
experiments, this issue could be further explored by selecting single fractions of 
lower doses, whose effect levels would more reliably align with those seen in the 
other fractionation regimes. Alternatively, single fraction data could be omitted 
altogether and replaced with an increased number of multi-fraction radiation 
regimes. Despite this acknowledged limitation, values generated for the 
parameter R2 were above 0.9 for all of the H2052 data, with the exception of 
data from day 10 which had an R2 value of 0.89. This suggests that the data 
points are adequately close to the regression line for this data to be considered 
valid. For the 211H data, values for R2 ranged from 0.72 to 0.89, suggesting that 
conformity to the regression line was more limited.  
 
A further issue noted with this technique was the increasing α/β ratio over time 
observed in the 211H cell line. Clinical studies have shown that over the course 
of a radiotherapy regime, the α/β ratio of tissue can increase, potentially 
through upregulation of the HRR pathway. (Somaiah et al., 2012) Specific 
analysis of the DNA repair pathways employed by the spheroids was outwith the 
scope of this project, but alterations in DDR may provide an explanation for this 
observation, in addition to radiobiological factors, such as hypoxia or 
proliferation. An alternative explanation may lie in the irregular growth pattern 
of the 211H spheroids, leading to increased experimental variability. The 
accuracy of the chosen technique relies on consistent spheroid responses which 
can be accurately determined and robustly compared across fractionation 
regimes. The growth pattern of the 211H cell line may render it a suboptimal 
choice for such an experimental approach and future work may incorporate 
alternative cell lines, with more regular growth patterns. 
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Due to time constraints, this study was only performed once. Clearly it is 
difficult to draw definitive conclusions regarding tumour α/β ratio from data 
generated in a single dose response experiment, performed using only 2 cell 
lines.  Nevertheless, the α/β data generated from this 3D model compliments 
that generated earlier in our lab in which 2D clonogenic modelling was 
performed on the same 2 cell lines. (Jackson et al., 2020) The α/β values 
obtained from this work have not been published due to uncertainties in their 
accuracy, reflected in the wide confidence intervals around the mean. They 
were however, estimated to be lower than those classically estimated for 
cancer. The combination of these dataset does lend weight to the suggestion 
that MPM may be more fraction size dependent than previously thought, 
although clearly further confirmatory studies need to be conducted. Given the 
range of radiosensitivities and variations in α/β ratios observed in other studies 
using MPM cell lines, it would be useful to repeat this work on a panel of cell 
lines, using both clonogenic assays and tumour growth delay approaches to gain 
further insight.   
 
Finally, whilst the approach used in this study has been based on that published 
by Stewart et al, (Stewart et al., 1984) there are important differences between 
these studies which need to be considered when assessing data reliability. In the 
Stewart paper, a comprehensive fractionation schedule was employed, 
employing 1-64 fractions, delivering between 0.9Gy and 16Gy per fraction. 
Responses were measured over 48 weeks, using 3 robust functional endpoints 
which could be reliably measured and used in combination to determine 
radiobiological parameters. In contrast, the α/β ratio estimate in this study is 
generated from the assessment of a single endpoint over a maximum of 28 days 
after irradiation with 1-4 fractions employing 1Gy to 10Gy per fraction. The 
difficulty in obtaining accurate data at early timepoints has already been 
discussed, and the restrictions imposed by experimental size limited the number 
of data points which could be generated within each fractionation regime. 
Although the premise of the experiments are similar, data generated from this 
study will be inherently less robust than that generated by Stewart et al. 
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 6.3.4.3 Strengths of the selected technique 
Despite these limitations, the chosen technique was reliable and informative. 
Both previous studies of MPM radiosensitivity were performed on cells in 2D. 
(Carmichael et al., 1989, Hakkinen et al., 1996) The current model utilises a 3D 
in vitro system, which represents an intermediate level of complexity between 
cells in monolayers and in vivo tumours. Despite the inherent challenges of 
determining robust radiobiological parameters from 3D systems, the increased 
therapeutic resistance displayed by cells in 3D (Kobayashi et al., 1993, Desoize 
and Jardillier, 2000, Barbone et al., 2008) may permit a more accurate 
estimation of true tumour radiosensitivity than can be achieved in 2D models 
and therefore such data may reflect the clinical scenario more closely. The data 
generated in this work complements that generated in 2D in our laboratory using 
the same cell lines, in which the α/β ratio was estimated to be low. 
 
The decision to expose spheroids to IR every 24 hours in the multi-fractionated 
regimes was informed by clinical practise and based on an assumption, 
supported by the literature surrounding the kinetics of cellular DNA repair, 
(Mariotti et al., 2013, Kochan et al., 2017) that this would allow sufficient time 
for SLD repair between exposures. Although it cannot be completely assured that 
SLD repair is fully completed in this timeframe, the greater spheroid recovery 
seen in fractionated regimes suggests that this methodology is sound.  
 
In order to limit the impact of radiobiological factors, such as repopulation, on 
spheroid volume over time, treatment time was limited to four days and 
spheroid growth data was collected for a maximum of four weeks. Nevertheless, 
it cannot be guaranteed that the observed results are completely due to 
spheroid radiosensitivity, since factors such as re-oxygenation or proliferation, 
which could not be actively controlled, may have influenced outcomes. 
However, as such factors influence clinical outcome following radiotherapy, 
consideration in the model system may be advantageous from a translational 
perspective. 
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 6.3.4.4 Alternative methods to determine spheroid response to IR 
In contrast to 2D models of cell survival, established methods of determining 
radiobiological parameters from 3D models are scarce. The technique used by 
Stewart et al was adopted because of the similarities between the functional 
parameters assessed in their work and the measures of spheroid growth 
reduction generated in this model. An alternative method of assessing spheroid 
response to multi fraction irradiation has been proposed by Stuschke et al. 
(Stuschke et al., 1992, Stuschke et al., 1990, Stuschke et al., 1995) This method 
utilises a ‘spheroid control assay’ to determine the radiation dose necessary to 
control the growth of 50% of the spheroids from which parameters of 
radiosensitivity can be calculated. In this assay, spheroids are transferred to 24 
well plates 48 hours after irradiation and subsequently grown as monolayers over 
a 3 month period to determine the level of control exerted by the various 
radiation regimes. The timeframes necessary to generate such data and the 
deviation from methods of spheroid analysis which had already been established 
in our laboratory meant that this approach was not taken. Furthermore, allowing 
the spheroids to continue to grow as 3D structures rather than as monolayers, 
facilitates a more accurate representation of the tumour response to IR 
compared to the approach used by Stuschke et al, and suggests that our data 
may be more robust. 
 
 6.3.5 Clinical translation of data 
It was not feasible to directly employ clinically relevant doses of IR within this in 
vitro study, since preliminary data suggested that doses sufficient for achieving 
control of spheroid growth were less than 15Gy, much lower than the total doses 
of 20Gy or 36Gy delivered in the SYSTEMS-2 study (data not shown). Doses of IR 
which delivered similar fraction sizes to those being investigated in SYSTEMS-2 
were therefore selected (i.e. 4Gy or 6Gy per fraction). It could be argued that a 
requirement of between 6Gy to 8Gy to control the growth of spheroids initially 
seeded at 100 cells per well may not reflect a level of radiosensitivity which 
could be clinically applicable to the bulk of tumours often seen in this disease. 
Nevertheless, this pre-clinical model demonstrates proof of concept that MPM is 
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susceptible to radiation, sensitive to changes in dose per fraction and responds 
more effectively to hypofractionated radiotherapy regimes. 
 
6.4 Summary 
These data are the first to use a clinically relevant 3D in vitro model to 
investigate the radiobiological properties of MPM and challenges some of the 
most firmly held conceptions of this disease. Results suggest that following 
exposure to sufficient doses, growth of MPM in vitro can be effectively delayed 
by radiation. Furthermore, whilst a definitive α/β ratio has proved difficult to 
determine, data show that MPM is sensitive to changes in radiation dose per 
fraction and is most effectively controlled by hypofractionated regimes. These 
observations complement clonogenic data generated previously within our lab 
and taken together with data from fractionation studies, suggest that this 
tumour may have an α/β ratio lower than many other cancers and may exhibit 
sparing with fractionated regimes. This finding is clinically pertinent, given the 
choice of radiation dose and fractionation currently being investigated in the 
SYSTEMS-2 study. Outcome data from this clinical trial is awaited, but a more 
accurate understanding of the radiobiology of this disease will aid the selection 
of appropriate dose and fractionation regimes for future radiotherapy trials in 
MPM. 
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Chapter 7: Assessing the impact of novel radiosensitising drugs with 
fractionated radiotherapy on MPM spheroids 
 
Chapter aim 
This purpose of this chapter is to explore the activity of two commercially 
available compounds shown to radiosensitise MPM in 2D, using an in vitro 3D 
spheroid model. The compounds, which have different molecular targets, will 
be delivered with fractionated radiotherapy regimes, to determine whether 
they can radiosensitise MPM in 3D and whether their efficacy is affected by 
fractionation schedule.  
 
7.1 Introduction 
 7.1.1 The rationale for using radiosensitisers 
Radiotherapy is an effective method of killing tumour cells, but can also damage 
healthy tissue, leading to normal tissue toxicity. The delivery of a sufficiently 
tumouricidal dose is therefore often precluded by the close proximity of normal 
radiosensitive structures to tumour targets. Dose fractionation is used to 
facilitate safe dose escalation by preferentially sparing normal tissues from late 
side effects. As explained in section 1.4.4, late tissue effects usually exhibit a 
low α/β ratio and are sensitive to changes in radiation dose per fraction, 
whereas tumour clonogen killing and acute tissue reactions are characterised by 
high α/β ratios and are relatively insensitive to changes in dose per fraction. 
This discrepancy means that dose fractionation is selectively beneficial in 
sparing late tissue toxicity. To make tumours more sensitive to the effects of IR, 
drugs which selectively augment the effect of IR in tumour cells are delivered in 
combination with radiotherapy. 
 
The superior clinical outcomes achieved when radiotherapy is delivered with 
such radiosensitising agents has been demonstrated in a variety of tumour types 
(Herskovic et al., 1992, Sultana et al., 2007, Rose et al., 1999, Rowell and 
O'Rourke N, 2004, Tobias et al., 2010)and has led to a combined approach 
becoming the standard of care in a number of malignancies. (Herskovic et al., 
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1992, Sultana et al., 2007, Pignon et al., 2009, Curran et al., 2011) 
Traditionally, chemotherapeutic agents that cause DNA damage, such as 
platinum compounds or topoisomerase inhibitors, were used to enhance the 
cancer cell kill resulting from exposure to IR. More recently, however, as our 
understanding of the molecular pathways governing cancer cell survival has 
grown, an interest has developed in the production of novel radiosensitising 
agents which target the pathways of resistance to IR. Commonly targeted 
pathways include those responsible for DNA-damage repair, intercellular 
signalling and transduction pathways and apoptosis. Many small molecules that 
affect these processes are being taken forward in clinical trials. (Zaidi et al., 
2009) 
 
The advantage of combining IR with a selective radiosensitising agent is that 
improved tumour kill can be achieved without necessitating an increase in 
radiation dose and therefore without incurring any escalation in normal tissue 
toxicity. In MPM, where tumour encases the irregularly shaped pleural cavity and 
lies in close proximity to a number of normal radiosensitive structures, safe 
delivery of radical doses of IR is particularly challenging. The discovery of an 
efficacious radiosensitising agent would therefore likely be of marked clinical 
benefit in this disease. 
 
 7.1.2 Rationale for investigating the radiosensitising properties of DNA 
 damage repair proteins  
The fundamental role of DNA damage in the pathogenesis of MPM (Betti et al., 
2017) and the implication that genetic aberrations within the NHEJ pathway may 
contribute to treatment resistance in this disease (Kettunen et al., 2001, Roe et 
al., 2010) has led to an interest in DNA damage repair proteins as potential 
therapeutic targets in MPM. (Toumpanakis and Theocharis, 2011) The critical 
role of DNA-PKcs in the NHEJ DNA repair pathway and its association with repair-
mediated radioresistance has been described in section 1.7.4. This 
serine/threonine kinase is a member of the phosphatidylinositol 3-kinase (PI3K) 
family, for which a number of inhibitors have been developed. Broad spectrum 
PI3K inhibitors, such as wortmannin and LY294002, (Nakamura et al., 1997, 
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Arcaro and Wymann, 1993) and those which are progressively more specific for 
DNA-PKcs, such as NU7026 (Willmore et al., 2004) and NU7441 (Leahy et al., 
2004) (discussed in section 1.7.5) have been described. 
 
Manipulation of DNA-PKcs function with the selective inhibitor NU7441 has been 
investigated as a strategy to enhance tumour responses to radiotherapy (Yu et 
al., 2015, Shaheen et al., 2011, Ciszewski et al., 2014, Zhao et al., 2006)and 
chemotherapy (Yanai et al., 2017) in a number of malignancies, and whilst 
NU7441 has been demonstrated to promote extensive radiosensitisation in non-
small cell lung cancer cell lines, (Saha et al., 2014) there is a paucity of research 
surrounding the use of this inhibitor in MPM. Nevertheless, unpublished data 
from our own lab suggests that NU7441 may demonstrate therapeutic activity in 
this disease. Studies investigating the activity of NU7441 in a 2D in vitro model, 
using two different MPM cell lines, showed that this drug exhibited single agent 
activity, with an EC50 1.69µM in 211H cells and 2.35µM in H2052 cells. 
Furthermore, when delivered with IR, 1µM NU7441 radiosensitized MPM cells 
with a sensitizer enhancement ratio (SER) of 1.85 and 2.43 in 211H and H2052 
cells respectively. 
 
Given the potent radiosensitising activity seen with this drug in previous studies, 
NU7441 was selected for use within our 3D spheroid model, where it was 
anticipated to act as a positive control. Inhibition of DNA-PK is unlikely to result 
in tumour specific radiosensitisation because the adjacent normal tissues also 
use the NHEJ pathway to repair DNA damage. Therefore, even if a therapeutic 
interaction with IR is demonstrated in MPM spheroids, NU7441 would not be our 
first choice of drug in the clinic because of the likelihood of exacerbating normal 
tissue effects.  
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 7.1.3 Rationale for investigating the radiosensitising properties of BH-3 
 mimetics  
The critical role of the intrinsic apoptotic pathway in mediating cellular death 
following IR and the reliance of MPM on anti-apoptotic BCl-2 proteins to evade 
apoptosis, suggests that manipulation of this pathway with BH3 mimetics may 
provide a valuable therapeutic opportunity for radiosensitisation in this disease. 
Whilst IR can induce apoptosis in both tumour cells and normal tissue, 
concurrent exposure to a BH3 mimetic, that would increase cellular levels of 
free pro-apoptotic proteins, may preferentially promote apoptosis in MPM cells, 
which are naturally more susceptible to this process. Any therapeutic activity 
demonstrated with this approach may therefore be tumour specific 
 
The validity of utilising BH3 mimetics as a therapeutic approach in cells which 
are ‘primed for death’ has been demonstrated in other malignancies. Exposure 
of Bcl-xL dependent human acute T lymphoblastic leukaemia cell lines to the 
Bcl-xL inhibitor A1331852 as a single agent resulted in reduced cell survival and 
a reported EC50 of 6nM. (Leverson et al., 2015) Furthermore, the potential for 
BH3 mimetics to overcome MPM resistance to apoptosis has been demonstrated 
in vitro in 2D studies and in vivo, where dual blockade of Bcl-2 and Bcl-xL with 
2-methoxy antimycin A3 engendered apoptosis, both as a single agent and in 
combination with chemotherapy. (Cao et al., 2007) The role of BH3 mimetics as 
radiosensitisers has been assessed in other studies, where an ability to overcome 
acquired radioresistance of breast cancer cells and increase the radiosensitivity 
of cervical cancer HeLa cells, via an apoptotic-driven pathway, has been 
demonstrated. (Wu et al., 2014, Li et al., 2012, Wang et al., 2012) Nevertheless, 
the only available data surrounding the use of BH3 mimetics as a potential 
radiosensitiser in MPM has been generated in our own lab. (Jackson et al., 2020) 
Results suggest that inhibition of apoptosis may underpin the radioresistance 
observed in this disease and that this tumour characteristic may be mediated in 
2D culture by a dependence on Bcl-xL. When Bcl-xL activity was inhibited in 
211H and H2052 cell lines using A1331852, cell survival was reduced. In addition 
to displaying single agent activity (EC50 270nM in 211H cells and 133nM in H2052 
cells), A1331852 also sensitised these cells to IR, via an apoptosis driven 
pathway, with a SER of 1.55 in 211H cells (1µM A1331852) and 1.80 in H2052 
- 265 - 
cells (0.3µM A1331852). (Jackson et al., 2020) Having identified clinically-
relevant targets for radiosensitisation, this encouraging work can be taken 
forward to establish the impact of dose fractionation on BH3 mimetic activity in 
MPM cell lines cultured in 3D. 
 
 7.1.4 Selection of radiosensitisers for investigation in MPM 
Two novel radiosensitising agents have therefore been selected for investigation 
with fractionated IR in a 3D model of MPM. These agents are NU7441, a selective 
inhibitor of DNA-PKcs, and A1331852, a selective Bcl-xL inhibitor.  
 
 7.1.5 Selection of an appropriate platform to investigate 
 radiosensitisation of MPM 
The specific attributes of the in vitro 3D spheroid system that make it a robust 
platform on which to study MPM have been discussed in sections 1.5.3 and 
6.1.3.2. Nevertheless, the increased resistance to apoptosis observed when MPM 
is cultured in 3D (Barbone et al., 2008) and the ability of MPM to form structures 
similar to spheroids in vivo (Delahaye et al., 1990, Kim et al., 2005) makes this a 
particularly strong model on which to perform these investigations. 
 
The in vitro 3D spheroid model will therefore be used for this work. The single 
agent activities of the drug and IR alone will be explored before any therapeutic 
interactions between them are investigated.  
 
 7.1.6 Confirming target proteins in experimental and clinical samples 
To confirm that these target proteins are present in MPM spheroids, DNA-PKcs 
and Bcl-xL expression will be quantified by IHC staining of FFPE H2052 and 211H 
spheroids. Given the redundancy of function known to exist between the anti-
apoptotic Bcl-2 proteins, (Ozvaran et al., 2004, Han et al., 1996) and the 
differential relative expression of anti-apoptotic Bcl-2 proteins in mesothelioma 
cells observed in our own lab, levels of Mcl-1 and Bcl-2 will also be explored. 
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To determine the potential translational impact of this in vitro work to the 
clinic, IHC will be used to determine the expression profile of DNA-PKcs and 
anti-apoptotic Bcl-2 proteins in the clinical samples of mesothelioma patients 
who took part in the SYSTEMS and SYSTEMS-2 studies.  
 
7.2 Results 
 7.2.1 Fractionation determines efficacy of IR in delaying MPM 
 spheroid growth 
To determine the sensitivity of MPM cells to IR, spheroids were treated and 
allowed to grow for 21 days. The effect of fractionation on MPM growth was 
assessed by exposing the spheroids to different radiation regimes. To control for 
the total dose received, all irradiated spheroids were treated with a dose of 
8Gy, but this was delivered in schedules with different doses per fraction. 
Spheroid size was monitored by regular imaging and 3D volume was determined 
by reconstruction of 2D representations. For simplicity, data are presented as 
the mean spheroid volume at the end of the experiment.  
 
Exposure of MPM spheroids to a total dose of 8Gy IR reduced growth by day 21, 
regardless of the fractionation regime. In the H2052 model, for example, the 
sham irradiated spheroids grew to a volume of 0.52 ± 0.03mm3 by day 21, 
compared to those receiving a single 8Gy fraction of IR, which grew to only 0.1 ± 
0.03mm3 (p<0.0001) (Figure 7.1A). Similarly, in the 211H spheroids, exposure to 
a single dose of 8Gy resulted in a day 21 volume of 0.25 ± 0.11mm3, as compared 
to 1.03 ± 0.26mm3 in the sham irradiated controls (p<0.0001) (Figure 7.1B). In 
keeping with data shown in section 6.2.2, delivery of a total dose of 8Gy 
reduced the growth of both H2052 and 211H spheroids in a manner that was 
dependent on fractionation schedule, with hypofractionated regimes 
demonstrating the greatest efficacy. (Figure 7.1)  
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Figure 7.1 The effect of radiation alone on MPM spheroid volume at day 21 
Spheroids were exposed to a total IR dose of 8Gy, delivered in different doses 
per fraction and growth was monitored over 21 days. Data is expressed as the 
mean spheroid volume in mm3 at day 21, averaged from 4 individual 
experiments, each incorporating 6-8 replicates per condition. Error bars reflect 
the standard deviation of the means. Statistical significance was determined 
with a linear mixed effect model, using the cubed root of the transformed data 
value. (*p<0.05; ***p<0.001; ****p<0.0001) 
 
 
7.2.2 NU7441 did not exert any single agent activity in MPM cell lines 
To determine the single agent activity of NU7441, MPM spheroids were treated 
with increasing concentrations of the drug or a DMSO control and were allowed 
to grow for 21 days. Spheroid size was monitored and data are presented as the 
mean spheroid volumes at day 21. Exposure of MPM spheroids to NU7441 at 
concentrations of 0.03µM to 0.3µM had no impact on the spheroid volume 
observed at day 21 in either cell line model. For example, the mean volume of 
H2052 spheroids treated with 0.3µM NU7441 was 0.49 ± 0.07mm3 at day 21, 
compared to 0.52 ± 0.03 mm3 in those which had been treated with the DMSO 
control (Figure 7.2A). Similarly, in the 211H model, exposure to the DMSO 
control allowed spheroids to grow to a volume of 1.03 ± 0.3mm3 by day 21, 
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compared to 1.09 ± 0.2mm3 in spheroids treated with 0.3µM NU7441 (Figure 
7.2B). 
 
 
 
            
Figure 7.2 The effect of NU7441 alone on MPM spheroid volume at day 21  
 
Spheroids were exposed to increasing concentrations of NU7441 and growth was 
monitored over 21 days. Data is expressed as the mean spheroid volume in mm3 
at day 21, averaged from 3-4 individual experiments (0µM n=4; 0.03µM n=3; 
0.1µM n=3; 0.3µM n=4). Each experiment incorporated 6-8 replicates per 
condition. Error bars reflect the standard deviation of the means. Statistical 
significance was determined with a linear mixed effect model, using the cubed 
root of the transformed data value. 
 
 
 7.2.3 Combination of NU7441 with IR exhibits a therapeutic interaction  
To determine whether NU7441 was capable of sensitizing MPM spheroids to IR, 
spheroids were treated concomitantly with varying concentrations of the drug 
and a single IR dose of 8Gy. Spheroid size was monitored over 21 days and 3D 
volume was determined by reconstruction of 2D images. To reveal any potential 
radiosensitising activity, data are plotted as spheroid volume relative to the 
irradiated DMSO control, following correction for the effect of a single IR dose of 
8Gy. This analysis acts to reveal any therapeutic interaction, for example if co-
administration of IR with the drug reduces the spheroid volume more effectively 
than with IR alone.   
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Combination of NU7441 with a single 8Gy fraction of IR significantly reduced 
MPM spheroid volumes at day 21, compared to the irradiated DMSO control. For 
example, exposure to 8Gy IR and 0.03µM NU7441 reduced the relative H2052 
spheroid volume to 72% ±6% of the control (p<0.001) and the same radiation dose 
combined with 0.3µM NU7441 reduced it to 27% ±16% (p<0.0001). (Figure 7.3A) In 
addition to being significantly different from the irradiated DMSO control, these 
volumes were also significantly different from each other (p<0.01) (Figure 7.3A). 
A similar trend was observed in the 211H model with this drug, where for 
example, the relative spheroid volume reduction seen with 0.1µM NU7441 and 
8Gy IR (47% ±12% of the control) was significantly different than that induced by 
exposure to 0.3µM NU7441 and 8Gy IR (20% ± 6% of the control) (p<0.05). (Figure 
7.3B) These data indicate that the combination of NU7441 and IR is associated 
with a therapeutic interaction in MPM spheroids, the magnitude of which is 
dependent on the concentration of NU7441. This radiosensitising effect was also 
evident in the volume data, shown in Appendix 2. 
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Figure 7.3 The effect of combination therapy with NU7441 and IR on relative 
MPM spheroid volume at day 21 
Spheroids were exposed to increasing concentrations of NU7441 delivered with a 
single 8Gy fraction of IR and growth was monitored over 21 days. Data is 
expressed as the mean day 21 spheroid volume relative to the DMSO control, 
following correction for the effect of a single IR dose of 8Gy. Data were 
generated from 3-4 independent experiments (0µM n=4; 0.03µM n=3; 0.1µM n=3; 
0.3µM n=4), with each experiment incorporating 6-8 replicates per condition. 
Error bars represent the standard deviations of the normalised means. Statistical 
analysis was performed using one way ANOVA and pairwise comparisons were 
generated with a post hoc Tukey test. (*p<0.05, **p<0.01, ***p<0.001; 
****p<0.0001) 
 
 
 
 
 7.2.4 An enhanced radiosensitising effect of NU7441 was detected 
 with hypofractionated IR at low drug concentrations 
NU7441 has been observed to cause a radiosensitising effect in MPM spheroids 
when delivered with a single 8Gy fraction of IR, but clinically radiotherapy is 
delivered in a large number of small fractions, typically of 2Gy each. To assess 
the impact of fractionation on the radiosensitising effect of NU7441, MPM 
spheroids were treated with increasing concentrations of this drug in 
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combination with radiotherapy regimes delivering a total dose of 8Gy, over a 
different number of fractions. Data showing the day 21 spheroid volumes 
obtained under each condition can be found in Appendix 2, but for the purposes 
of highlighting therapeutic interaction, data are plotted as volume relative to 
DMSO control, following correction for the effect of each of the fractionation 
schedules alone (Figure 7.4 A-F). 
 
In the H2052 model, exposure to a combination of 0.03µM NU7441 and IR was 
only associated with a significant reduction in the relative day 21 spheroid 
volume when hypofractionated radiation regimes were employed (Figure 7.4A). 
For example, when 0.03µM NU7441 was delivered with 2Gy per fraction (4x2Gy), 
the relative spheroid volume was not significantly different to the irradiated 
DMSO control (96% ±2%), whereas delivery of the same concentration of NU7441 
with 2x4Gy and 1x8Gy IR reduced the relative spheroid volumes to 82% ±16% 
(p<0.05) and 72% ±6% (p<0.001) of each irradiated control respectively. The 
difference observed in relative volume reduction between the 4x2Gy spheroids 
and 1x8Gy spheroids was associated with a p value of <0.01, suggesting that the 
therapeutic interaction of NU7441 at this concentration is significantly greater 
when larger doses per fraction are employed. No therapeutic interaction was 
observed with 0.03µM NU7441 in the 211H model, regardless of fractionation 
regime (Figure 7.4B). When the NU7441 concentration was increased to 0.1µM, 
combination with IR in the H2052 model significantly reduced the day 21 
spheroid volumes relative to the irradiated DMSO control across all fractionation 
regimes and the magnitude of the reductions were similar, regardless of the 
dose per fraction. (Figure 7.4C) In the 211H model, combination of 0.1µM 
NU7441 with 1x8Gy IR significantly reduced the day 21 spheroid volume relative 
to the irradiated control (47% ±12%; p<0.05), but no significant reductions were 
observed in the 2x4Gy or 4x2Gy regimes (Figure 7.4D). Combination of IR with 
0.3µM NU7441 reduced the relative spheroid volume at day 21 in both cell lines, 
with no significant differences noted in the magnitude of therapeutic interaction 
between fractionation regimes (Figure 7.4E and F) Together, these data suggest 
that NU7441 exerts a potent radiosensitising effect on MPM cells in a 
concentration dependent manner. Where the concentration of the drug was 
reduced sufficiently to allow a differential response to be detected, the 
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therapeutic interaction of NU7441 was marginally more efficacious with 
hypofractionated radiotherapy regimes. 
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Figure 7.4 The effect of NU7441 on relative MPM spheroid volume at day 21, 
normalised for the effect of fractionation regime 
Spheroids were exposed to increasing concentrations of NU7441 in combination 
with fractionated radiotherapy and their growth was monitored for 21 days. Data 
is expressed as the mean day 21 spheroid volume relative to DMSO control, 
following correction for the effect of each fractionation regime. Data were 
generated from 3-4 independent experiments (0µM n=4; 0.03µM n=3; 0.1µM n=3; 
0.3µM n=4), with each experiment incorporating 6-8 replicates per condition. 
Error bars represent the standard deviations of the normalised means. Statistical 
analysis was performed using one way ANOVA and pairwise comparisons were 
generated with a post hoc Tukey test. (*p<0.05; **p<0.01;***p<0.001; 
****p<0.0001) 
 
 
7.2.5 A1331852 exhibits single agent activity in H2052 cells  
To determine the single agent activity of A1331852, MPM spheroids were treated 
with increasing concentrations of the drug or a DMSO control and were allowed 
to grow for 21 days. Spheroid size was monitored and data are presented as the 
mean spheroid volumes at day 21. 
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Exposing H2052 spheroids to concentrations of A1331852 above 0.1µM reduced 
their growth in a concentration-dependent manner (Figure 7.5A). Spheroids 
exposed to the DMSO control grew to a volume of 0.52 ± 0.03mm3 by day 21, 
whereas those exposed to A1331852 at a concentration of 0.3µM and 3µM grew 
to only 0.45 ± 0.03mm3 (p<0.0001) and 0.31 ± 0.01 mm3 (p<0.0001) respectively. 
In addition to being significantly different from the DMSO control, these volumes 
were also significantly different from each other (p<0.0001), a trend which was 
repeated across the different concentrations. This pattern of growth reduction 
indicates that A1331852 exerts concentration-dependent single agent activity 
against H2052 spheroids in vitro. In contrast, no A1331852-mediated single agent 
therapeutic activity was observed in the 211H cell line (Figure 7.5B).  
 
 
                                                                                      
 
                                                                   
Figure 7.5 The effect of A1331852 alone on MPM spheroid volume at day 21 
Spheroids were exposed to increasing concentrations of A1331852 and growth 
was monitored over 21 days. Data is expressed as the mean spheroid volume in 
mm3at day 21, averaged from 2-4 individual experiments (0µM n=4; 0.1µM n=3; 
0.3µM n=4; 1µM n=4; 3µM n=2). Each experiment incorporated 6-8 replicates per 
condition. Error bars reflect the standard deviation of the means. Statistical 
significance was determined with a linear mixed effect model, using either the 
standardised volume value or the cubed root of the transformed data value. 
(*p<0.05; ****p<0.0001) 
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7.2.6 The combination of A1331852 with IR exhibits a therapeutic 
 interaction 
To determine whether A1331852 was capable of sensitizing MPM spheroids to IR, 
spheroids were treated concomitantly with varying concentrations of the drug 
and a single IR dose of 8Gy. Spheroid size was monitored over 21 days and 3D 
volume was determined by reconstruction of 2D images. Data are plotted as 
spheroid volume relative to irradiated control following correction for the effect 
of a single IR dose of 8Gy.  
 
The combination of A1331852 and IR (delivered as a single 8Gy fraction), 
significantly reduced the day 21 MPM spheroid volumes, relative to the DMSO 
controls treated with the same IR regime (Figure 7.6). For example, exposure of 
H2052 spheroids to 3μM A1331852 with an 8Gy single fraction reduced the 
relative day 21 volume to 0.8% ± 0.02% of the irradiated DMSO control (p<0.0001) 
(Figure 7.6A). Similarly, in the 211H model, exposure to 8Gy IR with 3μM 
A1331852 reduced the relative day 21 spheroid volume to 7% ± 9% of the 
irradiated DMSO control (p<0.001) (Figure 7.6B). Together, these data suggest 
that the combination A1331852 with IR is associated with significant 
radiosensitisation in MPM spheroids. 
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Figure 7.6 The effect of combination therapy with A1331852 and IR on 
relative MPM spheroid volume at day 21 
Spheroids were exposed to increasing concentrations of A1331852 delivered with 
a single 8Gy fraction of IR and growth was monitored over 21 days. Data is 
expressed as the mean day 21 spheroid volume relative to DMSO control, 
following correction for the effect of a single IR dose of 8Gy. Data were 
generated from 2-4 independent experiments (0µM n=4; 0.1µM n=3; 0.3µM n=4; 
1µM n=4; 3µM n=2), with each experiment incorporating 6-8 replicates per 
condition. Error bars represent the standard deviations of the normalised means. 
Statistical analysis was performed using one way ANOVA and pairwise 
comparisons were generated with a post hoc Tukey test. (***p<0.001; 
****p<0.0001) 
 
 
 
 
 7.2.7 The radiosensiting effects of A1331852 is enhanced with 
 hypofractionated IR 
To assess the impact of fractionation on the radiosensitising effect of A1331852, 
MPM spheroids were treated with increasing concentrations of this drug in 
combination with radiotherapy regimes delivering a total dose of 8Gy, over a 
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different number of fractions. Data are plotted as volume relative to DMSO 
control, following correction for the effect of each of the fractionation 
schedules alone (Figure 7.7). Data showing the day 21 spheroid volumes obtained 
under each condition can be found in Appendix 2.  
 
Exposure of MPM spheroids to IR with A1331852 at a concentration of 0.1µM 
reduced the day 21 spheroid volume relative to the DMSO control, regardless of 
the fractionation regime (Figure 7.7A and B). Nevertheless, the reduction in 
relative spheroid volume was greater when A1331852 was combined with 
hypofractionated regimes than when it was administered with IR delivered in 
smaller doses per fraction. For example, in the H2052 model, administration of 
0.1µM A1331852 with 2x4Gy reduced the day 21 spheroid volume to 52% ±25% of 
the irradiated DMSO control (p<0.01), whereas the same drug concentration 
given in combination with 1x8Gy reduced the volume to 22% ±22% of its 
irradiated control (p<0.0001) (Figure 7.7A). Similarly, in the 211H spheroids, 
0.1µM A1331852 combined with 4x2Gy reduced the day 21 spheroid volume to 
56% ±26% of the irradiated DMSO control (p<0.05), while the same concentration 
administered with 1x8Gy reduced it to 9% ±10% (p<0.0001) (Figure 7.7B). In 
addition to being statistically different from their irradiated DMSO controls, 
these relative spheroid volumes are statistically different from each other 
(p<0.01). This data suggest that the magnitude of the therapeutic interaction 
between A1331852 and IR increases with progressively hypofractionated 
radiotherapy regimes. Similar effects were seen in both MPM cell lines when IR 
was delivered with increasing concentrations of A1331852. The magnitude of the 
therapeutic effect increased in a concentration-dependent manner, such that at 
the highest concentrations of A1331852 explored, there was no discernible 
difference in the relative spheroid volumes between the fractionation regimes. 
For example, combination of 3µM A1331852 with 4x2Gy IR reduced H2052 
relative spheroid volume to 2.3% ± 3% of the irradiated DMSO control and 
combination of the same concentration with 1x8Gy IR reduced the spheroid 
volume to 0.8% ±0.02% of the control (Figure 7.7G and H). 
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Figure 7.7 The effect of A1331852 on relative MPM spheroid volume at day 
21, normalised for the effect of fractionation regime 
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(Figure 7.7) Spheroids were exposed to increasing concentrations of A1331852 in 
combination with fractionated radiotherapy and their growth was monitored for 
21 days. Data is expressed as the mean day 21 spheroid volume relative to DMSO 
control, following correction for the effect of each fractionation regime. Data 
were generated from 2-4 independent experiments (0µM n=4; 0.1µM n=3; 0.3µM 
n=4; 1µM n=4; 3µM n=2), with each experiment incorporating 6-8 replicates per 
condition. Error bars represent the standard deviations of the normalised means. 
Statistical analysis was performed using one way ANOVA and pairwise 
comparisons were generated with a post hoc Tukey test. (*p<0.05; 
**p<0.01;***p<0.001; ****p<0.0001) 
 
In summary, these data suggest that both NU7441 and A1331852 are potent 
radiosensitisers of MPM spheroids. At concentrations which allowed the 
differential effect of the drugs within each fractionation regime to be 
determined, both NU7441 and A1331852 demonstrated increased efficacy with 
hypofractionated radiotherapy. This effect is more clearly demonstrated when 
radiotherapy was combined with A1331852 than with NU7441. 
 
 7.2.8 MPM spheroids strongly express Bcl-xL and DNA-PKcs, but Bcl-2 
 and Mcl-1 are differentially expressed between H2052 and 211H cell 
 lines 
To confirm that DNA-PKcs and Bcl-xL are expressed in MPM spheroids and to 
therefore elucidate the likely mechanism of the observed radiosensitising effect 
of NU7441 and A1131852, unirradiated MPM spheroids were stained for these 
target proteins using IHC. For completeness, levels of Bcl-2 and Mcl-1 were also 
explored, given the level of redundancy known to exist between the anti-
apoptotic Bcl-2 proteins. Cells were seeded at 102 cells per well, left to form 
spheroids and cultured for three weeks to ensure that they were a suitable size 
for further processing. At day 21, spheroids were fixed in formalin, sectioned 
and subjected to IHC, with appropriate positive and negative controls. 
Expression of DNA-PKcs and anti-apoptotic Bcl-2 proteins was analysed using the 
‘Halo’ software, in which thresholds were set to detect positively stained cells. 
The structure of H2052 spheroids was well maintained throughout this process, 
whereas the integrity of 211H spheroids was degraded through fixing, sectioning 
and IHC staining. Consequentially, the spatial expression of these proteins is less 
clear in the 211H group than in the H2052 spheroids. (Figure 7.8 and Figure 7.10) 
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A total of 95% of cells in the H2052 spheroids were scored positive for DNA-PKcs 
staining, compared to 83% of cells in 211H spheroids. (Figure 7.8 and Figure 7.9)  
 
 
Figure 7.8 Relative expression of DNA-PKcs in H2052 and 211H spheroids  
 
Cells were seeded at 102 cells per well and cultured for 3 weeks before being 
fixed, sectioned and stained for DNA-PKcs using IHC. Cell nuclei were 
counterstained with haematoxylin. Images were obtained by scanning slides into 
Halo software where analysis was also performed. 
 
 
 
Figure 7.9 Percentage of cellular expression of DNA-PKcs in H2052 and 211H 
cells 
The number of DNA-PKcs positively stained cells within each spheroid was 
determined using the Halo software. Data are expressed as the percentage of 
positive cells. 
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In H2052 spheroids, expression of Bcl-xL was dominant, with 98% of cells within 
the spheroids scoring positive for this stain. Much lower expression of Mcl-1 was 
observed (12.5% of cells scoring positive) and minimal Bcl-2 expression was seen, 
with only 0.003% of cells within the spheroids scoring positive for this protein. 
(Figure 7.10 and Figure 7.11) In contrast, within the 211H spheroids, relatively 
high expression of both Bcl-xl and Mcl-1 was observed (99% and 88% of cells 
scoring positive for these proteins respectively). Bcl-2 expression in 211H 
spheroids was much lower, with 15.6% of cells scoring positive for this protein. 
(Figure 7.10 and Figure 7.11) 
 
 
 
Figure 7.10 Relative expression of Bcl-xL, Bcl-2 and Mcl-1 in H2052 and 211H 
spheroids 
Cells were seeded at 102 cells per well and cultured for 3 weeks before being 
fixed, sectioned and stained for anti-apoptotic Bcl-2 proteins using IHC. Cell 
nuclei were counterstained with haematoxylin. Images were obtained by 
scanning slides into Halo software, where analysis was also performed. 
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Figure 7.11 MPM expression of anti-apoptotic Bcl-2 proteins 
The number of cells which stained positive for Bcl-xL, Bcl-2 and Mcl-1 within 
each spheroid was determined using the Halo software. Data are expressed as 
the percentage of positive cells for each protein. 
 
 
 7.2.9  DNA-PKcs is robustly expressed in MPM tissue 
Having established that DNA-PKcs and Bcl-xL are expressed in MPM cells in vitro, 
MPM tumour samples were analysed, to determine whether the selected drugs 
were likely to be useful radiosensitisers in the clinic. Diagnostic FFPE samples of 
18 patients who subsequently participated in the SYSTEMS and SYSTEMS-2 studies 
were sectioned and stained. Corresponding H+E samples were used to identify 
areas of malignant infiltration and tumour cell protein expression was scored as 
absent, weak, moderate or strong. These data were used to determine an H 
score for each tissue sample analysed. Antibody performance and technique 
consistency was assessed by including a positive and negative control (no 
primary antibody) with each analysis. Appropriate clinical biopsy samples, 
identified during the process of antibody optimisation, were used for this 
purpose. Typical expression levels in positive and negative controls and the 
expected staining pattern are shown in Figure 7.12. Representative images and 
corresponding expression data are also presented from 5 patients, incorporating 
examples from patients with epithelioid and sarcomatoid subtypes of MPM. 
(Figure 7.13) 
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Analysis of the positive control identified nuclear staining for DNA-PKcs. (Figure 
7.12) This is consistent with the expression of this protein in regions of DNA 
damage repair and, together with the lack of background staining in the 
negative control, supports the specificity of the antibody employed. The same 
pattern of staining was seen in all of the clinical samples analysed, with strong 
levels of expression being observed throughout the presented cohort. (Figure 
7.13) This correlated with high tumour DNA-PKcs H scores, shown in Table 7.1, 
which ranged from 225 to 278. Analysis of the tumour DNA-PKcs H scores for all 
18 patients suggested that these findings were representative of the full cohort, 
where a mean tumour H score of 244± 28 was calculated. (Data shown and 
further discussed in Chapter 8) 
 
 
Figure 7.12 Expression of DNA-PKcs in MPM tissue selected as positive and 
negative controls 
FFPE diagnostic tissue samples obtained from patients subsequently diagnosed 
with MPM were sectioned and stained for DNA-PKcs expression using IHC. Cell 
nuclei were counterstained with haematoxylin. A nuclear pattern of staining was 
demonstrated, consistent with the known distribution of this protein. Minimal 
background staining was observed in the negative control. Images were obtained 
by scanning slides into Halo software. 
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Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
 
Figure 7.13 Expression of DNA-PKcs in MPM tissue 
FFPE diagnostic tissue samples from patients who subsequently entered the 
SYSTEMS or SYSTEMS-2 study were sectioned before being stained for DNA-PKcs 
expression using IHC. Cell nuclei were counterstained with haematoxylin. Images 
were obtained by scanning slides into Halo software, where analysis was also 
performed. Representative images are displayed from five patients with either 
epithelioid or sarcomatoid disease.  
 
Table 7.1 Levels of DNA-PKcs expression in MPM cells 
Clinical 
sample 
Histology 
% 
Positive 
Cells 
% 1+ 
Cells 
% 2+ 
Cells 
% 3+ 
Cells 
H-Score 
1 Epithelioid 96.5 6.19 23.54 66.76 253.56 
2 Epithelioid 99.7 1.99 16.46 81.26 278.67 
3 Epithelioid 92.7 7.91 36.59 48.18 225.63 
4 Sarcomatoid 98.3 3.22 27.54 67.51 260.85 
5 Sarcomatoid 99.2 3.79 30.69 64.72 259.35 
Tumour cells were identified in the biopsy specimens shown in Figure 7.11 and 
the relative expression of DNA-PKcs was determined. The intensity of staining 
was graded as absent, weak, moderate or strong. H scores were calculated using 
the equation (1x (% cells 1+) + 2x (% cells 2+) + 3x (% cells 3+)).  
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 7.2.10 Anti-apoptotic Bcl-2 proteins are expressed with differential 
 intensities in MPM tissue 
To determine whether the Bcl-xL is present in clinical samples from patients 
with MPM, and therefore whether A1331852 may represent a clinically useful 
radiosensitiser in this disease, Bcl-xL, Bcl-2 and Mcl-1 expression in clinical 
tissue samples was assessed by IHC staining. Diagnostic FFPE samples of 18 
patients who subsequently participated in the SYSTEMS and SYSTEMS-2 studies 
were sectioned and stained. Corresponding H+E samples were used to identify 
areas of malignant infiltration and tumour cell protein expression was scored as 
absent, weak, moderate or strong, facilitating the calculation of an H score for 
each tissue sample. A positive (tonsil tissue) and negative (tonsil tissue or 
clinical sample) control was also included. Typical expression levels in positive 
and negative controls and the expected staining pattern are shown in Figure 
7.14. Representative images and corresponding expression data are presented 
from 5 patients, incorporating examples from patients with epithelioid, biphasic 
and sarcomatoid subtypes of MPM. (Figure 7.15 and Table 2)  
 
Strong expression of all three anti-apoptotic Bcl-2 proteins was consistently seen 
in the positive controls, although the geographical distribution varied. Bcl-xL and 
Mcl-1 expression was highest in the follicles whereas expression of Bcl-2 
dominated in the lymph cells. (Figure 7.14) Analysis at high magnification (x20) 
confirmed cytoplasmic staining in all three proteins, consistent with 
mitochondrial localization. A circular staining pattern resulted, which tended to 
exclude the nuclei and remained consistent with the pattern observed in clinical 
samples. Minimal background staining was detected in the negative control. 
(Figure 7.14) 
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Positive control Positive control 
(x20) 
Negative control Clinical sample 
(x20) 
 
Figure 7.14 Expression of Bcl-xL, Bcl-2 and Mcl-1 in positive and negative 
controls and in clinical samples 
FFPE tissue samples were sectioned and stained for Bcl-xL, Bcl-2 and Mcl-1 
expression using IHC. Cell nuclei were counterstained with haematoxylin. Images 
were obtained by scanning slides into Halo software. Cytoplasmic staining was 
demonstrated, consistent with the known distribution of these proteins. At a 
magnification of x20, the same staining pattern was observed in clinical samples 
from MPM patients. Minimal background staining was observed in the negative 
controls. 
 
 
Analysis of the clinical samples show that Bcl-xL, Bcl-2 and Mcl-1 were expressed 
in all of the biopsy specimens, but that the levels of expression differed. (Figure 
7.15) Both Bcl-xL and Mcl-1 were strongly expressed in the tissue specimens, and 
this correlated with high levels of tumour expression. Accordingly, H scores of 
between 138 and 211 were recorded for Bcl-xL, and of between 123 and 264 for 
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Mcl-1, in this representative cohort. (Table 7.2) Expression of Bcl-2 was visibly 
lower in all the biopsy samples (Figure 7.15) and H scores for tumour expression 
of this protein was also notably reduced (between 9 and 91). (Table 7.2) 
 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
 
Figure 7.15 Expression of Bcl-xL, Bcl-2 and Mcl-1 in MPM tissue 
FFPE diagnostic tissue samples from patients who subsequently entered the 
SYSTEMS or SYSTEMS-2 study were sectioned and stained for Bcl-xL, Bcl-2 and 
Mcl-1expression using IHC. Cell nuclei were counterstained with haematoxylin. 
Images were obtained by scanning slides into Halo software, where analysis was 
also performed. Representative images are displayed from five patients with 
epithelioid, sarcomatoid or biphasic disease. 
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Table 7.2 Expression of Bcl-xL, Bcl-2 and Mcl-1 in MPM cells 
Protein Patient Histology 
% +ve 
Cells 
% 1+ 
Cells 
% 2+ 
Cells 
% 3+ 
Cells 
H-
Score 
Bcl-xL 
1 Epithelioid 74.64 9.01 13.71 51.92 192.20 
2 Epithelioid 78.31 5.70 12.38 60.23 211.16 
3 Epithelioid 72.06 14.53 26.37 31.16 160.74 
4 Sarcomatoid 90.81 56.31 21.14 13.36 138.67 
5 Biphasic 81.83 44.49 9.02 28.32 147.49 
Bcl-2 
1 Epithelioid 32.33 19.06 8.20 5.07 50.66 
2 Epithelioid 34.31 13.71 7.90 12.70 67.61 
3 Epithelioid 9.01 8.43 0.46 0.11 9.69 
4 Sarcomatoid 70.40 56.24 6.80 7.36 91.91 
5 Biphasic 17.49 9.35 5.72 2.42 28.04 
Mcl-1 
1 Epithelioid 83.36 19.16 36.44 27.76 175.31 
2 Epithelioid 57.46 13.49 21.75 22.22 123.64 
3 Epithelioid 98.26 4.26 21.39 72.60 264.85 
4 Sarcomatoid 71.41 25.80 30.63 14.98 132.00 
5 Biphasic 80.09 19.46 30.17 30.47 171.19 
 
Tumour cells were identified in the biopsy specimens shown in Figure 7.15 and 
the expression of each protein of interest was determined. The intensity of 
staining was graded as absent, weak, moderate or strong. H scores were 
calculated using the equation (1x (% cells 1+) + 2x (% cells 2+) + 3x (% cells 3+). 
 
Combined analysis of data from all 18 patients samples revealed that the 
variation in protein expression identified in this representative cohort was 
consistent with that of the complete data set. Within the complete cohort, the 
mean tumour H score for Bcl-xL expression was 122 (±54), compared to 61 (±54) 
for Bcl-2 expression. Mean tumour H score for Mcl-1 expression was 164 (±68), 
which was significantly greater than that for Bcl-2 (p= 0.02) but not statistically 
different from Bcl-xL expression. (Figure 7.16)
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Figure 7.16 Expression of Bcl-xL, Bcl-2 and Mcl-1 in MPM tissue 
FFPE samples from 18 patients who subsequently entered the SYSTEMS or 
SYSTEMS-2 clinical trial were sectioned and stained for expression of Bcl-xL, Bcl-
2 and Mcl-1. Tumour cells were identified and their expression of each protein 
was graded as absent, weak, moderate or strong. H scores were calculated using 
the equation (1x (% cells 1+) + 2x (% cells 2+) + 3x (% cells 3+). Data are 
represented as box and whisker plots box. The median is indicated by the red 
horizontal line in the box and the whiskers were plotted according to the Tukey 
method. Statistical analysis was conducted using the Kruskal-Wallis test with 
false discovery rate (FDR) correction of the p values (*p<0.05) 
 
 
Taken together, this data suggests that both DNA-PKcs and Bcl-xL are expressed 
in MPM tissue and are therefore valid targets of radiosensitisation in this disease.  
 
 
 
 
* 
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7.3 Discussion 
 7.3.1 The growth of MPM spheroids is delayed by ionising radiation and 
 A1331852, but unaffected by NU7441 
The delivery of a total dose of 8Gy IR alone caused a significant reduction in 
MPM spheroid volume by day 21, compared to the sham irradiated controls, 
regardless of how it was delivered. In keeping with the findings of chapter 6, the 
fraction size significantly impacted on the growth of the spheroid by day 21, 
with progressively larger doses per fraction causing a greater reduction in 
spheroid volume than smaller fraction sizes.  
 
Significant A1331852-mediated single agent therapeutic activity was noted in the 
H2052 cell line at concentrations of 0.3µM and above. Quantification of this 
activity through the calculation of an EC50 value has not been possible, primarily 
because the experiment was not designed for this purpose, so the maximum 
therapeutic effect was not determined. Nevertheless, impressive levels of single 
agent activity have been observed in other studies when Bcl-xL dependent cell 
lines are exposed to this drug, with a reported EC50 of 6nM in human acute T 
lymphoblastic leukaemia cells. (Leverson et al., 2015) Furthermore, previous 
data generated in our lab using traditional 2D cell viability assays suggests that 
A1331852 exerts single agent activity in H2052 MPM cells with an EC50 of 
0.133µM. (Jackson et al., 2020) Whilst this data cannot be directly compared 
with that from our 3D model, the absence of significant single agent activity at 
A1331852 concentrations lower than 0.3µM suggests that H2052 MPM cells 
cultured in 3D are more resistant to the cytotoxic effects of this agent than 
previously seen in 2D models. This observation is in keeping with the 
multicellular resistance demonstrated by 3D spheroids in other studies.(Barbone 
et al., 2008, Desoize and Jardillier, 2000)  
 
No single agent activity was observed for any of the concentrations of A1331852 
investigated in the 211H model. Previous data shows that when exposed to 211H 
cells in 2D, A1331852 exhibited single agent activity with an EC50 of 0.27µM, 
suggesting that 211H cells are more resistant to this drug than H2052 cells. 
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(Jackson et al., 2020) The current data supports this finding, and further 
corroborates the theory that MPM cells in 3D demonstrate multicellular 
resistance. (Barbone et al., 2008) 
 
A potential explanation for the difference in sensitivity to A1331852 observed 
between H2052 and 211H cells may be provided by 2D in vitro data generated in 
our laboratory by Dr Mark Jackson. In this work, relative expression of anti-
apoptotic Bcl-2 proteins within three different MPM cell lines was determined by 
Western blot. This data suggested that H2052 cells preferentially express Bcl-xL, 
whereas 211H cells do not demonstrate ‘addiction’ to any particular Bcl-2 
protein, expressing approximately equal levels of all the anti-apoptotic proteins 
assessed. (Jackson et al., 2020) This data is further substantiated by IHC data 
presented in Figure 7.10, where relative expression of the anti-apoptotic Bcl-2 
proteins was determined in 211H and H2052 spheroids. Bcl-xL was robustly 
expressed in both H2052 and 211H spheroids, but expression levels of Mcl-1 and 
Bcl-2 were much lower in the H2052 cells. The dependency of H2052 cells on 
Bcl-xL for survival makes these cells particularly sensitive to A1331852. In 211H 
cells, the delicate balance of pro- and anti-apoptotic proteins would be less 
susceptible to disruption with Bcl-xL inhibition, since the other anti-apoptotic 
proteins could compensate for any changes in Bcl-xL activity and maintain cell 
survival in the presence of A1331852. Thus, an approach capable of 
simultaneously targeting multiple Bcl-2 proteins, using broader spectrum or 
combination BH3-mimetics, might be advantageous in MPM subtypes expressing 
multiple Bcl-2 proteins.  
 
Exposure of MPM spheroids to NU7441 alone did not reveal any single agent 
activity. This is in contrast to 2D data generated previously in our lab, where 
single agent activity was observed with NU7441 and EC50 values of 1.69µM and 
2.35µM were reported in 211H and H2052 cell lines respectively. In addition to 
the increased drug resistance demonstrated by cells grown in 3D, an explanation 
for this observation may be a low baseline burden of DNA damage within the 
spheroids and consequentially reduced NHEJ activity. Under these conditions, 
exposure to NU7441 would not be expected to exert an influence on spheroid 
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growth; the effect of the drug only becomes apparent when the level of DNA 
damage is increased by exposure to IR. This theory is supported by other studies, 
demonstrating a lack of single agent activity of NU7441 in human cancer cell 
lines, but subsequently revealing extensive radiosensitisation when the drug was 
delivered with IR. (Zhao et al., 2006, Shaheen et al., 2011) Supplementary IHC 
data, quantifying spheroid-associated DS-DNA breaks before and after exposure 
to 10Gy IR, also supports this suggestion. This data is presented in Appendix 3 
and shows that γH2Ax expression, which is a marker of DS-DNA damage, 
increases dramatically following exposure to IR in both cell lines.  
 
 7.3.2 Both NU7441 and A1331852 exert a radiosensitising effect on 
 MPM cells when delivered with a single fraction of IR 
Data shows that when spheroids are exposed to a combination of IR and either 
NU7441 or A1331852, a greater reduction in spheroid volume is observed than 
when they are exposed to either the drug or IR alone. This observation implies a 
therapeutic interaction and suggests that these drugs can exert a 
radiosensitisation effect on MPM cells in 3D. Robust expression of both DNA-PKcs 
and Bcl-xL in MPM spheroids observed with IHC, lends support to the proposed 
mechanism of radiosensitisation being due to the selective inhibition of these 
target proteins. 
 
 7.3.2.1 NU7441 
The combination of a single 8Gy dose of IR with increasing concentrations of 
NU7441 resulted in progressively smaller relative spheroid volumes at day 21. 
This suggests that radiosensitisation with NU7441 occurs in a concentration-
dependent manner, a hypothesis which is supported by data from a number of 
other studies. (Ciszewski et al., 2014, Shaheen et al., 2011, Saha et al., 2014) 
Mechanistically, this dose dependency makes sense when the function of NU7441 
is considered. IR causes DNA damage and if the cell is unable to repair this 
damage then it dies, or is left unable to replicate. NU7441 exerts its 
radiosensitising effect by preventing DNA damage repair via the NHEJ pathway. 
As discussed in section 1.7.2, the NHEJ pathway is one of the two crucial 
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pathways of DS-DNA repair. Inhibition of this process leads to persistent DNA 
damage, prolonged cell cycle delay and the promotion of cell death, by 
apoptosis or mitotic catastrophe. Therefore, the greater the drug concentration 
present during IR, the greater the impact on the NHEJ pathway; consequentially, 
fewer cells will survive the insult of IR and the radiosensitisation effect of the 
drug will be larger. In addition to its impact on the NHEJ pathway, NU7441 has 
been reported to inhibit the HRR pathway of DNA damage repair (Allen et al., 
2003) and to cause PARP-1 inhibition. (Veuger et al., 2003) One of the 
weaknesses of this study is that we have not definitively clarified the 
mechanistic pathway of the radiosensitising activity observed. 
 
NU7441 has been demonstrated to be a potent radiosensitiser in a number of 
other pre-clinical studies using a variety of different cell lines cultured in 2D. 
(Ciszewski et al., 2014, Yang et al., 2016, Dong et al., 2017, Shaheen et al., 
2011, Zhao et al., 2006) Cisewski et al reported a 4 to 12 fold increase in breast 
cancer cell line radiosensitivity when 1µM NU7441 was combined with doses of IR 
of between 2Gy and 8Gy. (Ciszewski et al., 2014) The same concentration of 
NU7441 sensitised human nasopharyngeal cancer cells to IR (2Gy- 8Gy) (Dong et 
al., 2017) and in a different study, hormone sensitive and insensitive prostate 
cancer cells, were radiosensitised by 1µM NU7441. (Shaheen et al., 2011) Potent 
radiosensitising activity, associated with persistent DNA-DS breaks and G2/M 
arrest was demonstrated by clonogenic assay, following the exposure of human 
colon cancer cells to 1µM NU7441. (Zhao et al., 2006) 
 
Direct correlation of our data with that generated in these 2D studies is difficult 
because of the differences in concentrations of NU7441 used, the variation in 
methods used to report effects and the inherent challenges of comparing 
outcome measures generated from a 3D spheroid model assessing volume and a 
2D cell viability assay measuring cell survival directly. It is usual in drug-
radiation studies to generate cell survival curves and normalise for the effect of 
the drug, since this makes separation between survival curves clear. However, in 
our 3D model, accurate survival curves could not be generated because the 
surviving fraction of cells corresponding to the observed change in spheroid 
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volume is unknown. Furthermore, since our study was primarily assessing the 
effect of hypofractionation on drug activity, data has been corrected to account 
for the effect of radiation alone, to allow any therapeutic interaction arising 
from the change in fraction size to be revealed. This necessary discrepancy in 
data analysis renders any direct comparisons of our data and that generated in 
these 2D studies very challenging. Nevertheless, in agreement with 2D 
radiosensitisation, a clear therapeutic interaction was observed in the MPM 
spheroid model.  
 
Whilst NU7441 induced radiosensitisation of both MPM cell lines, the efficacy of 
the drug seemed to be greater in the H2052 model, in which spheroid volume 
was reduced compared to the irradiated DMSO control at all concentrations of 
NU7441 explored. By contrast, in the 211H model, significant reductions from 
the irradiated DMSO control were only noted at concentrations of 0.1µM and 
0.3µM NU7441, suggesting that this cell line may be less susceptible to the 
radiosensitising effects of this agent. Previous radiosensitisation studies 
performed in our lab support these finding. In these 2D studies, exposure of 
211H cells to 1µM NU7441 in combination with IR radiosensitised the cells with a 
SER of 1.85, whereas a greater degree of radiosensitisation was observed using 
the same drug concentration and IR in H2052 cells (SER 2.43). Although direct 
correlation with this 2D data is not possible, the principal remains that 211H 
seems to be more resistant to radiosensitisation than H2052 cells.  
 
As discussed in chapter 6, the 211H cell line was derived from a patient with 
biphasic MPM. This histological subtype is known to be inherently more 
aggressive and resistant to treatment than the epithelioid MPM, from which the 
H2052 cell line was generated. There are no published studies detailing the 
genetic profile of these two cell lines, however, they are both represented 
within the catalogue of somatic mutations in cancer database 
(https://cancer.sanger.ac.uk/cosmic). Analysis of this resource did not reveal 
any known genetic mutations within the NHEJ pathway in either cell line. In 
contrast, a single missense heterozygous mutation was identified within the 
Rad54B gene in the H2052 cell line in. This gene has a functional role in the HRR 
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pathway of DDR, coding for the Rad54B protein which binds to double-stranded 
DNA and exerts ATPase activity in the presence of DNA. Mutations within this 
gene are known to be important in malignancies of the lung, breast and colon. 
(McAndrew et al., 2016) Within the 211H cell line, three genetic mutations were 
identified within genes encoding proteins of the HRR pathway: Eme1, Rad51B 
and Top3b. Only the mutation in Top3b has been validated and is reported as a 
missense heterozygous mutation. This gene codes for DNA topoisomerase 3-beta-
1, an enzyme which controls the transient breaking and re-joining of single 
strand DNA during transcription, impacting on the supercoiling and topology of 
DNA. It has an important role in maintaining genome stability. (Gene) Although it 
could be surmised that the differences in radiosensitivity observed between the 
H2052 and 211H cell lines may in part due to their ability to repair DNA damage 
following IR, the functional impact of these mutations is not reported, making it 
difficult to draw any firm conclusions. Further analysis of the catalogue of 
somatic mutations in cancer database did not identify these mutations being 
present in human pleural mesothelioma tissue, regardless of subtype.  
 
 7.3.2.2 A1331852 
The radiosensitising properties of BH3 mimetics have been investigated in a 
number of in vitro studies, where their effects have been studied on breast 
cancer cells and cervical cancer HeLa cells. (Wu et al., 2014, Li et al., 2012, 
Wang et al., 2012)  Li et al used a 2D clonogenic assay to examine the activity of 
ABT 737 (a BH3 mimetic which targets both Bcl-2 and Bcl-xL) in breast cancer 
cell lines with acquired radioresistance. Cells were exposed to 1µM of the drug 
for 24 hours before being exposed to IR doses of 4Gy, 8Gy and 12Gy. Results 
suggested that radiosensitivity could be restored in these cell lines by exposure 
to ABT 737. A reduction in survival fraction from approximately 0.8 to 0.08 was 
observed when 8Gy IR was employed in combination with the drug and the 
associated radiosensitivity appeared to be mediated though an increase in 
apoptosis. (Li et al., 2012) Breast cancer cells were also used to investigate ABT 
737 associated radiosensitisation in a study by Wu et al. (Wu et al., 2014) 
Clonogenic assays were used to determine the effect of 2.5µM ABT 737 given in 
combination with 4Gy IR. Data revealed a significant radiosensitising effect, with 
a reduction in the number of surviving clones to 11.2% in the combination group 
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compared to 39.7% in the group treated with ABT 737 alone and 65.2% in the 
group exposed to 4Gy IR alone. Simultaneous analysis of apoptosis markers 
suggested that this increase in cell death was apoptosis-dependent. (Wu et al., 
2014) Wang et al used ABT 737 at a concentration of 10µM to treat cervical 
cancer HeLa cell lines prior to exposure to IR doses of 2Gy, 4Gy, 6Gy and 8Gy. 
(Wang et al., 2012) Results of a clonogenic assay suggested that combination 
treatment was associated with significant radiosensitisation, via an apoptosis-
dependent pathway. 
 
Despite these encouraging findings, the potential to make direct comparisons 
with, or mechanistic inferences from, such data are limited, since all of these 
studies used 2-D assays to assess the impact of ABT-737, a far less selective BH3 
mimetic than the specific Bcl-xL inhibitor employed in our 3-D model. Previous 
data generated in our own lab studying A1331852 in MPM clonogenic assays 
provides a representation of the size of the radiosensitisation effect seen with 
this drug in 2D. Data suggested that H2052 cells were radiosensitised by 0.3µM 
A1331852 (SER 1.80) and that 211H cells underwent radiosensitisation following 
exposure to 1µM A1331852 (SER 1.55), via an apoptosis driven pathway. (Jackson 
et al., 2020) 
 
Of particular relevance to the selection of a 3D platform on which to investigate 
the activity of a Bcl-xL inhibitor in MPM, is data from Barbone et al, which shows 
that MPM cells express a different repertoire of Bcl-2 proteins when they are 
grown in 3D. (Barbone et al., 2011) Furthermore, gene expression profiling 
studies have reported that in 3D culture, MPM cells downregulate genes 
associated with apoptosis. (Kim et al., 2012) Therefore, despite encouraging 2D 
data, it was important to confirm that Bcl-xL inhibition is effective in 3D, since 
this is more closely representative of the clinical scenario. 
 
Consistent with the 2D radiosensitisation data, a clear therapeutic interaction 
was seen in our spheroid model between A1331852 and IR. No difference in the 
relative efficacy of A1331852 was identified between H2052 and 211H spheroids 
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at the concentrations investigated in this 3D model, suggesting that this drug 
may be efficacious in both histological subtypes of MPM represented. 
Furthermore, the ability of the drug to produce a radiosensitising effect where 
no single agent activity was observed, supports a combination approach.  
 
Whilst our data shows that A1331852 induces a potent radiosensitising effect 
compared to the irradiated DMSO control, no statistical differences were noted 
between the relative spheroid volumes at day 21 with increasing concentrations 
of the drug, in either cell line. This observation suggests that even the minimum 
concentration investigated was above the threshold at which a concentration-
dependent effect could be observed. Future experimentation would aim to 
determine the concentration-dependency of the effect by assaying at lower 
concentrations.  
 
 7.3.3 Optimal radiosensitisation with hypofractionated IR is more 
 consistently demonstrated with A1331852 than with NU7441 
The combination of NU7441 with differently fractionated IR regimes confirmed 
the previously noted concentration dependent radiosensitising effect of this drug 
and improved efficacy in the H2052 cell line. The impact of dose fractionation 
observed with NU7441 was much less dramatic than with A1331852 and although 
increased efficacy was observed with hypofractionation, this was only revealed 
at a concentration of 0.1µM in the 211H model and at 0.03µM in the H2052 
model.  
 
In the case of A1331852, the dependency of radiosensitisation on dose per 
fraction was clearly demonstrated, showing the influence of fractionation on this 
class of agent for the first time. The separation of relative spheroid volumes 
according to fractionation schedule is very clear in the H2052 model at all 
concentrations of A1331852 under 1µM. In the 211H model, while concentrations 
of 0.3µM or less caused a clear difference in relative spheroid volumes when 
delivered with 4x2Gy, the separation of spheroid volumes between 2x4Gy and 
1x8Gy was less distinct. This perhaps reflects the irregular growth pattern of this 
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cell line, (previously discussed in chapter 6.3.1), leading to an increase in 
variability between experimental replicates, and rendering subtle differences in 
spheroid size difficult to detect. 
 
The disparity observed between the interaction of these drugs with 
hypofractionated IR may be in part explained by the mechanistic properties of 
the drugs and the influence of competing pathways. 
 
An elegant explanation for the observed interaction of NU7441 with fractionated 
IR may be provided by the work of Somaiah et al., in which the influence of 
specific DNA repair pathways have been investigated in relation to cellular 
response to fractionated radiotherapy. (Somaiah et al., 2015, Somaiah et al., 
2013) In vitro studies using cell lines deficient in different DDR pathways have 
identified that loss of fraction size sensitivity is associated with the dominance 
of the HRR pathway, while cells proficient in NHEJ remain sensitive to dose 
fractionation. (Somaiah et al., 2013) Data presented in this study implies that 
sensitivity to dose fractionation in MPM spheroids may be primarily mediated by 
NHEJ. Loss of this pathway through exposure to NU7441 may promote a reliance 
on the HRR pathway for DDR, resulting in the observed loss of fraction size 
sensitivity. This observation suggests that the HRR pathway remains functional in 
these cell lines, despite the mutations in the Rad54B and Top3b genes discussed 
previously. 
 
The differential impact exerted by A1331852 across fractionation regimes may 
be explained by considering the impact of dose fractionation on pro-apoptotic 
pathways. Although all spheroids in this study received a total dose of 8Gy, the 
differential way in which the dose was delivered would have greatly influenced 
the cellular response. Exposure to a single dose of 8Gy is likely to cause 
significant DNA damage, providing a robust pro-death stimulus sufficient for 
activation of apoptosis. Conversely, dividing this dose into four fractions of 2Gy, 
delivered with a gap of 24 hours between each fraction would result in far more 
containable levels of cellular stress and more time to repair injuries between 
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fractions. Consequentially, cells exposed to smaller doses per fraction are far 
less likely to trigger pro-apoptotic pathways as a response to IR. Cells exposed to 
hypofractionated RT already have an excess of pro-apoptotic signals and the 
addition of a Bcl-xL inhibitor further disrupts the delicate balance exerted by 
the Bcl-2 family of proteins. These cells are therefore far more likely to die by 
apoptosis than cells exposed to more conventionally fractionated radiotherapy 
regimes.  
 
An additional factor in the differential response to fractionated IR observed 
between NU7441 and A1331852 may be a more direct link between Bcl-2 
inhibition and cell death compared to DNA-PKcs inhibition. It may be that cells 
continue to survive following genetic damage and that the anticipated volume of 
cell death does not correlate with the observed experimental output. In 
contrast, disturbing the delicate balance of Bcl-2 proteins with a BH3 mimetic 
may be more likely to result in commitment to cell death through the induction 
of MOMP. 
 
 7.3.4 DNA-PKcs and Bcl-xL are clinically relevant targets of 
 radiosensitisation 
IHC data provides confirmation that both DNA-PKcs and Bcl-xL are strongly 
expressed in the tissue samples of patients with epithelioid, biphasic and 
sarcomatoid MPM and suggests that these protein targets are clinically 
appropriate and could potentially serve as effective radiosensitisers in all 
histological subtypes of this disease. 
 
The finding that Bcl-2 and Mcl-1 are also expressed in clinical samples may be 
clinically relevant. The binding groove of Mcl-1 is substantially different from 
that of Bcl-xL or Bcl-2 (Czabotar et al., 2007) and most Bcl-xL or Bcl-2 inhibitors 
don’t bind to Mcl-1 with any considerable affinity. (Hennessy, 2016) This lack of 
target heterogeneity is demonstrated in studies investigating the effect of ABT-
737 as a single agent, which report that Mcl-1 confers resistance to this drug 
(Woo et al., 2009) and can be a major factor of resistance in lung cancer 
- 301 - 
spheroids. (Yang et al., 2009) Similar studies in MPM found that although Mcl-1 
didn’t block the spheroid response to ABT 737, reduction of these protein levels 
(e.g. by siRNA) enhanced the effect of the drug, suggesting that Mcl-1 may blunt 
the response. (Barbone et al., 2011) 
 
The expression of multiple Bcl-2 proteins in clinical samples introduces the 
possibility that MPM tissue may not display the same level of dependency on 
specific anti-apoptotic Bcl-2 proteins as immortalised cell lines and that 
increased resistance to A1331852 may be encountered. A broader spectrum BH3 
mimetic may be required to induce clinically relevant levels of radiosensitisation 
in patients and this possibility requires further investigation.  
 
 7.3.5 Clinical application of data 
This work is amongst the first to assess the impact of radiosensiting drugs on the 
therapeutic ratio of IR in MPM cell lines and is the first work conducted to date 
to assess the impact of radiotherapy dose fractionation on the efficacy of these 
drugs in a clinically relevant 3D spheroid model. Data suggest that the 
therapeutic efficacy of IR can be dramatically enhanced in MPM by the addition 
of both the DNA-PKcs inhibitor, NU7441 and by the specific Bcl-xL inhibitor 
A1331852. Furthermore, it appears that A1331852 in particular exerts its optimal 
radiosensitising effect when it is delivered with a hypofractionated radiation 
dose, an observation which may be of therapeutic potential, especially given the 
emerging evidence of a low α/β ratio in this disease.  
 
In order for any therapeutic interaction demonstrated in vitro to be translated 
into a viable clinical opportunity, the drug should be able to selectively sensitise 
tumour over normal tissue to radiation. While both drugs investigated in this 
study displayed clear radiosensitising activity in MPM, their clinical potential 
may differ in this regard. The radiosensitising activity of NU7441 is unlikely to be 
discriminatory, whereas A1331852 could potentially exert selective MPM activity 
in combination with IR because of the reliance of MPM cells on anti-apoptotic 
proteins for survival. Any therapeutic interaction demonstrated with this drug 
- 302 - 
may therefore represent a tumour specific effect which could be translated into 
a therapeutic option.  
 
Although BH-3 mimetics may selectively induce radiosensitivity in MPM cells, the 
normal tissue effects of this drug need to be considered if systemic 
administration is to be attempted. Bcl-xL is expressed at the RNA and protein 
level in a number of normal tissues, including brain, lung, GI tract, endocrine 
tissue and reproductive organs. 
(https://www.proteinatlas.org/ENSG00000171552-BCL2L1/tissue) Clinical 
studies using multitarget BH3 mimetics have previously reported ‘on target’ 
normal tissue toxicities to be dose limiting, leading to a reduced interest in 
these drugs. Nevertheless, the reported toxicities are primarily haematological, 
with Bcl-xL inhibition causing thrombocytopenia and neutropenia associated with 
Bcl-2 inhibition. (Zhang et al., 2007, Mason et al., 2007) Subsequently, in vivo 
studies using a range of solid tumours have suggested that single agent Bcl-xL 
inhibition in combination with docetaxel chemotherapy could produce robust 
clinical effects, without inducing dose limiting toxicities. (Leverson et al., 2015) 
The radiosensitising activity observed with Bcl-xL inhibitors in this study 
introduces the possibility of using them in combination with IR, rather than as 
single agents. In this situation, efficacy may be maintained with shorter 
treatment duration and lower drug concentrations, thereby reducing 
haematological effects. Furthermore, the combined use of Bcl-xL inhibition and 
chemotherapy probably exacerbates systemic toxicity, whereas the effects of 
Bcl-xL inhibition and IR should be localised to the treatment field, thereby 
minimising the effect on the bone marrow.  
 
7.4 Summary 
This study has demonstrated concentration-dependent single agent activity of 
A1131852 in H2052 MPM cells in 3D. Furthermore, it has confirmed that both 
NU7441 and A1331852 are potent radiosensitisers in two independent MPM cell 
lines, which robustly express the relevant target proteins, in a clinically relevant 
3D model. Radiosensitisation was found to be greater with hypofractionated 
radiation and the validity of the selected proteins as clinically relevant targets 
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has been confirmed through the IHC analysis of diagnostic tissue samples 
obtained from MPM patients. Although both radiosensitisers worked with optimal 
efficacy with hypofractionated radiotherapy, this trend was far more evident 
with the BH3 mimetic than with the DNA-PKcs inhibitor. These findings are 
clinically pertinent, since data presented in chapter 6 suggests that MPM may 
have a low α/β ratio and therefore would be likely to respond more favourably 
to a hypofractionated radiotherapy regime. The addition of a radiosensitiser 
which is potentially tumour selective, efficacious across histological subtypes 
and optimally effective when combined with hypofractionated radiotherapy 
therefore has great potential in this disease. 
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Chapter 8: Assessment of potential biomarkers of radiotherapy response in 
MPM 
 
Aim 
The aim of this chapter is to determine the expression of selected proteins, 
chosen for their potential to influence radiotherapy response, in diagnostic 
tissue samples collected from patients participating in the SYSTEMS and 
SYSTEMS-2 studies. Pilot data on the correlation of protein expression with 
radiation responses will be generated using tissue collected from SYSTEMS 
patients and clinical trial outcome data. Biopsy tissue collected from SYSTEMS-2 
patients will be used at this stage to determine whether protein expression can 
be linked to baseline clinical parameters. 
 
8.1 Introduction 
 8.1.1 Predictive biomarkers of radiotherapy response 
Radiotherapy is employed in the treatment of more than half of newly diagnosed 
malignancies. (Delaney et al., 2005) It is a key component in the curative 
management of many common cancers (Glimelius et al., 2013, Horwich et al., 
2013, Senkus et al., 2013) and is the cornerstone of symptom palliation. (Lutz et 
al., 2014) Whilst advances in radiotherapy delivery have allowed treatments to 
be personalised to patient anatomy, predictive biomarkers, which would allow 
radiotherapy to be tailored to tumour and normal tissue biology, are lacking. 
(Forker et al., 2015) Such biomarkers could inform decisions on radical 
treatment options, dosing strategies and optimal end of life care.  
 
The crucial role of predictive biomarkers in systemic therapies has been 
demonstrated in breast and lung cancer, where the ability to detect and target 
genetic mutations in HER2, EGFR and ALK have revolutionised cancer-related 
outcomes in select groups of patients. (Slamon et al., 2001, Verma et al., 2012, 
Mitsudomi et al., 2010, Shaw et al., 2011) Several studies have identified a 
number of encouraging candidates reported to predict a radiotherapy benefit at 
a number of different tumour sites. (Drukker et al., 2014, Soderlund et al., 
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2007, Eschrich et al., 2009, Eschrich et al., 2012, Choudhury et al., 2010, 
Noordermeer et al., 2012, Torres-Roca et al., 2005) These include genetic 
signatures, such as the radiosensitivity index, (Torres-Roca et al., 2005, Eschrich 
et al., 2012, Eschrich et al., 2009) as well as a number of DNA-damage repair 
markers (Soderlund et al., 2007, Choudhury et al., 2010, Noordermeer et al., 
2012). Nevertheless, none of these candidate biomarkers have been robustly 
assessed in a clinical trial randomising between radiotherapy and no 
radiotherapy, to allow a predictive value to be determined. (Forker et al., 2015) 
 
The SYSTEMS-2 clinical trial provides a unique opportunity to conduct MPM-
specific radiotherapy biomarker research. Within this study, original diagnostic 
tumour biopsies are obtained from a well characterised population in whom 
radiotherapy response will be documented at several time points using a 
validated pain scale and imaging. Correlation of clinical trial radiotherapy 
outcomes with immuno-histochemical data on selected protein expression could 
potentially help to identify a biomarker of radiotherapy response. Furthermore, 
the identification of proteins associated with radio-resistance could inform 
future targets for radiosensitisation in this disease.  
 
Since the SYSTEMS-2 trial is still recruiting, radiotherapy outcome data is 
currently unavailable. Nevertheless, protein expression in biopsy samples taken 
from the Glasgow patient cohort can be determined at this stage and correlated 
with baseline clinical trial data in an exploratory analysis. Furthermore, pilot 
data into the association of selected protein expression with radiotherapy 
response can be generated using biopsy samples obtained from patients who 
participated in SYSTEMS, from which full outcome data is available.  
 
 8.1.2 Selection of proteins for investigation 
A total of nine proteins have been selected for investigation. These have been 
chosen for their potential to impact on radiotherapy response and include 
proteins associated with DNA repair, proliferation, hypoxia and the control of 
apoptosis.  
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 8.1.2.1 Anti-apoptotic Bcl-2 proteins: Mcl-1, Bcl-2 and Bcl-xL 
A large body of evidence indicates that defects in apoptotic pathways are 
common in mesothelioma and may provide an important mechanism of radio-
resistance. (Fennell and Rudd, 2004, Narasimhan et al., 1998, Segers et al., 
1994, Soini et al., 1999) Furthermore, in vitro studies by our own group have 
confirmed the radio-resistant nature of a panel of human mesothelioma cells to 
low doses of radiation and showed that these cells are extremely refractory to 
induction of apoptosis. Small molecule inhibitors of Bcl-xL reduced cell survival 
as single-agents and, crucially, sensitized mesothelioma cells to IR. This 
reduction in survival was associated with increased levels of caspase-3/7 activity 
and apoptosis. (Manuscript submitted) As discussed in section 1.6.6, these 
proteins represent promising and novel targets for radiosensitisation, and 
preclinical data presented earlier in this thesis have confirmed that their 
selective inhibition radiosensitises MPM spheroids in a clinically relevant 3D in 
vitro model. Expression of these proteins in archival tissue specimens taken for 
diagnostic purposes might therefore have predictive value in determining which 
patients will benefit from radiotherapy. 
 
 8.1.2.2 Activated caspase 3 
The central role of executioner caspase 3 in the final common pathway of 
apoptosis has been discussed in section 1.6.4. Using an antibody which is specific 
to the activated form of caspase 3, baseline levels of activity will be determined 
in MPM patient samples and used to assess whether this information could be 
used to predict radioresponse.  
 
 8.1.2.3 P21  
The cyclin dependent kinase inhibitor, p21, is a principal mediator of cell cycle 
arrest. (Abbas and Dutta, 2009) It is able to inhibit all cyclin/CDK complexes, 
(Xiong et al., 1993) but primarily exerts its effect through the inhibition of 
CDK2, (Wade Harper et al., 1993, Abbas and Dutta, 2009) which operates in the 
G1/S phase of the cell cycle. In addition to mediating p53-dependent growth 
arrest in G1 phase, (Deng et al., 1995) p21 has been implicated in the promotion 
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of cell cycle arrest in response to a number of p53 independent stimuli, 
demonstrating an ability to act as an effective sensor and effector of many anti-
proliferative signals. (Abbas and Dutta, 2009) As well as mediating cell cycle 
arrest, p21 has a dominant role in promoting cellular senescence and 
differentiation, in addition to modulating DNA damage repair. (Abbas and Dutta, 
2009) 
 
P21 is also thought to have a role in the control of apoptosis, although the 
mechanism is not fully understood, with reports of both pro- and anti-apoptotic 
functions of the protein. (Roninson, 2002, Gartel, 2005) Furthermore, despite its 
robust cytoprotective properties, evidence suggests that under certain 
circumstances, p21 can drive cell proliferation and take on an oncogenic role, 
potentially mediated through the inhibition of apoptosis. (Roninson, 2002) 
 
 8.1.2.4 DNA-PKcs 
Ionising radiation mediates its cytotoxic effect through the generation of DS-DNA 
breaks and repair of these lesions represents a potential mechanism through 
which tumours develop resistance to radiotherapy. As discussed in section 1.7.2, 
the NHEJ pathway is a crucial pathway of DS-DNA damage repair, in which the 
protein DNA-PKcs is fundamental. (DeFazio et al., 2002, Chen et al., 2005, Chen 
et al., 2007, Cui et al., 2005, Douglas et al., 2007, Douglas et al., 2002, Ding et 
al., 2003) Mutations within the NHEJ pathway have been implicated in the 
resistance of MPM to treatment (Toumpanakis and Theocharis, 2011, Kettunen et 
al., 2001, Roe et al., 2010) and data presented earlier in this thesis 
demonstrated that specific disruption of NHEJ by inhibition of DNA-PKcs can 
radiosensitise MPM spheroids in vitro. Levels of DNA-PKcs expression within 
clinical samples may therefore not only be useful in determining response to IR, 
but also to potentially identify patients with tumours that may be amenable to 
radiosensitisation. 
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 8.1.2.5 Ki67 
Tumour proliferation rate can impact on radiation response through the 
processes of repopulation and re-assortment. Tumour initiating cells that survive 
IR and are capable of rapid proliferation can repopulate the tumour, reducing 
the efficiency of radiotherapy and mediate treatment resistance. Conversely, 
the rapid progression of proliferating cells through the cell cycle increases the 
chance of a cell which was in a radioresistance phase of the cycle redistributing 
to the radiosensitive late G2/M phase in a multi-fractionated regime. The Ki67 
protein is a marker of cellular proliferation, present during all active phases of 
the cell cycle but absent in quiescent (G0) cells. (Bruno and Darzynkiewicz, 
1992) Data suggests that tissue proliferation indices are inversely correlated with 
sensitivity to fraction size. (Thames et al., 1990, Hopewell et al., 2003) 
Correlation of the baseline tumour proliferation rate with responses to the 
hypofractionated radiotherapy delivered in SYSTEMS-2 would therefore be of 
radiobiological interest. 
 
 8.1.2.6 HIF1α 
The impact of tumour hypoxia on radiation response is dictated by the oxygen 
fixation hypothesis,(Gray et al., 1953) previously discussed in section 1.5.3. In 
addition to being resistant to radiotherapy, hypoxic tumours further prevent 
effective treatment, by favouring the enrichment of tumour cells with stem-like 
properties (Ghattass et al., 2013) and by promoting disease progression through 
the activity of the α and β subunits of hypoxia-inducible factor-1 (HIF-1) and HIF-
2. (Nabavi et al., 2016) Under hypoxic conditions, HIF1α becomes stable and 
accumulates, associating with the constitutively expressed HIF1 β to affect the 
transcription of target genes. (Kallio et al., 1997) Detection of HIF1α expression 
can therefore be associated with tissue hypoxia and will be used in this study as 
a surrogate marker of hypoxia in baseline biopsy specimens. The role of hypoxia 
in MPM pathogenesis, progression and resistance to treatment has not been well 
studied, (Nabavi et al., 2016) although evidence suggests that hypoxic cells can 
be found within MPM tissue (Ravenna et al., 2014) and studies using 
fluoromisonidazole PET-CT identified hypoxic areas in bulky tumour masses in 
MPM patients.(Francis et al., 2015)  
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 8.1.2.7 γH2Ax 
Double stranded DNA breaks can be detected by the focal localisation of the 
phosphorylated histone γH2Ax, with each focus representing an individual DSB. 
(Kuo and Yang, 2008) Phosphorylation of this protein by ATM and ATR occurs 
immediately after the formation of a DS-DNA break and is the first step in the 
recruitment of DDR proteins to the break. Foci of γH2Ax form rapidly after IR, 
with a maximal response 30 minutes after exposure, subsequently declining over 
a period of hours as the cells repair the damage. (Redon et al., 2009) 
Determining the expression of this protein in tissue samples taken from 
treatment naïve MPM patients will provide an indication of the baseline level of 
DNA damage within the tumour and may also provide some insight into the 
relative capability for repair.  
 
By analysing FFPE tissue taken from patients participating in SYSTEMS and 
SYSTEMS-2, the expression of these 9 proteins of interest will be determined. In 
addition to providing pilot data on prospective biomarkers of radiotherapy 
response, this information could represent a valuable resource in the future 
research of this disease, given the paucity of MPM IHC samples currently 
available within public datasets (e.g. ProteinAtlas and The Cancer Genome Atlas 
Project). 
 
8.2 Results 
 8.2.1 IHC validity in MPM samples is enhanced by the generation of 
 reliable positive controls 
To determine the expression of selected proteins within diagnostic MPM tissue, 
FFPE tissue blocks were obtained from patients who entered the SYSTEMS or 
SYSTEMS-2 study. The blocks were sectioned and subjected to IHC staining for 
the proteins of interest. One slide from each block was stained with H&E, to 
determine tissue architecture and distinguish areas of malignant infiltration. 
Areas of tumour invasion were identified and protein expression within tumour 
cells was determined by scoring for staining intensity. This allowed an H score to 
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be generated, which served as a comparator for relative protein expression 
between samples. 
 
In total, 21 blocks were obtained for this purpose from the Glasgow 
Biorepository over the course of two years. Of these samples, 8 originated from 
patients who took part in SYSTEMS and 13 were from SYSTEMS-2 patients. 
Following review of the H&E and the initial pathology report, 3 samples were 
discounted from the final analysis, because no tumour cells could be identified. 
This left 7 samples from SYSTEMS patients and 11 from SYSTEMS-2 for further 
analysis and correlation studies. These samples comprised 10 samples of 
epithelioid subtype, 7 samples of sarcomatoid subtype and 1 sample expressing a 
biphasic pattern of disease. 
 
A total of 9 proteins were selected for analysis. These included 6 which were 
expressed in the nucleus (DNA-PKcs, γH2Ax, P21, Activated caspase 3, Ki67 and 
HIF1α) and 3 which localised to the mitochondria, represented by cytoplasmic 
staining (Bcl-xL, Bcl-2 and Mcl-1).  
 
To determine consistency between batches of antibody staining and to ensure 
the specificity and sensitivity of antibody binding, positive and negative controls 
were included with all IHC. These comprised human tonsil tissue, or MPM tissue 
previously demonstrated to express sufficient levels of protein to act as a 
reliable control. Negative controls, comprised human tonsil or MPM tissue, with 
no primary antibody. Patterns of staining were consistent between different 
batches of IHC. (Figure 8.1) Robust positive control samples were identified for 
each protein, with the exception of ‘activated caspase 3’, in which only the 
germinal centre of tonsillar tissue could be reliably demonstrated to express this 
protein on a weak basis. (Figure 8.1) Representative images of protein 
expression in epithelioid and non-epithelioid MPM tissue, with corresponding 
H&E are shown in Figure 8.1, in addition to the typical levels of staining 
achieved in positive controls. Representative negative controls for IHC 
performed manually and on the autostainer are shown in Figure 8.2. 
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Figure 8.1 Representative expression profiles of selected proteins in MPM 
biopsy tissue and positive controls  
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(Figure 8.1) Tissue from FFPE samples obtained from MPM patients were stained 
for their expression of 9 selected proteins. Proteins demonstrated either a 
nuclear or a cytoplasmic staining pattern. Data validity was confirmed using 
positive controls of human tonsil tissue, or MPM tissue previously demonstrated 
to have high protein expression. Representative images are shown from two 
patients with epithelioid disease, one patient with sarcomatoid disease and one 
with biphasic histology. Nuclei were counterstained with haematoxylin and 
images were obtained by scanning slides into Halo software, where analysis was 
also carried out. 
 
 
 
 
Figure 8.2 Negative controls determining binding specificity of rabbit and 
mouse primary antibodies 
To determine that staining is dependent on the primary antibodies employed for 
IHC, tonsillar or MPM tissue was subjected to the IHC staining process, but 
without the addition of the primary antibody. Negative controls were run during 
both the manual and automated IHC. 
 
 
 
 
Manual IHC 
Autostainer 
IHC 
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 8.2.2 MPM tissue exhibits heterogeneity in protein expression  
Expression of all 9 proteins of interest was detected within the MPM tissue 
samples, but the level of expression differed between proteins and between 
patients. (Figure 8.1 and Figure 8.3) For example, strong expression of DNA-PKcs 
was noted throughout all 18 samples, with a mean H score of 242 ±28, whereas 
expression of activated caspase 3 and HIF1α were uniformly low, with mean H 
scores of 7 ±6 and 14 ±16 respectively. (Figure 8.3) Expression data for other 
proteins suggest a high level of variation in the expression of a single protein 
between different tissue samples. For example, the mean H score of Bcl-2 
expression was 61, with a standard deviation of 54, suggesting substantial 
variability within the dataset. Similar levels of variance around the mean were 
seen with Bcl-xL, Ki67, Mcl-1, γH2Ax and p21 expression. (Figure 8.3) 
 
 
Figure 8.3 Expression of selected proteins in MPM tissue samples 
Data were generated from IHC analysis of 18 diagnostic tissue samples 
comprising 10 epithelioid, 7 sarcomatoid and 1 biphasic subtype. Tumour cells 
were identified and their expression of each protein was graded as absent, 
weak, moderate or strong. H scores were calculated using the equation (1x (% 
cells 1+) + 2x (% cells 2+) + 3x (% cells 3+). Data are presented as box and 
whisker plots, plotted according to the Tukey method and the median is denoted 
by the horizontal red line. 
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 8.2.3 Protein expression is not significantly different between 
 histological subtypes of MPM 
To determine whether protein expression varied between epithelioid and non-
epithelioid MPM, data was dichotomised by histological subtype and analysed 
using the Mann Whitney U test, with false discovery rate (FDR) p value 
correction. This analysis revealed no significant differences in H-scores between 
tissue subtypes. 
 
 8.2.4 No correlation was found between baseline clinical parameters 
 and protein expression in MPM tissue 
To determine whether protein expression could be predictive of clinical 
parameters, tumour H scores generated from SYSTEMS and SYSTEMS-2 patients 
were correlated with clinical trial information. In cases where the biopsy 
specimens were obtained from patients who had taken part in SYSTEMS-2, these 
parameters consisted of baseline clinical trial data only, whereas those that 
were obtained from SYSTEMS patients could also be correlated with clinical trial 
outcome data, such as pain response to radiotherapy. 
 
No statistically significant interactions were found when H scores from SYSTEMS 
patients were correlated with pain response to radiotherapy, either at week 5 or 
at week 12. A pain response was defined as a ≥30% reduction in pain from the 
baseline, assessed using the brief pain inventory. This data is shown in Figure 8.4 
A-R. 
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   Week 5     Week 12 
 
   
Figure 8.4 A-R Correlation of protein H-scores in tissue samples taken from 
SYSTEMS patients with pain outcomes at week 5 and 12 after radiotherapy 
Data were generated from IHC analysis of 7 diagnostic tissue samples comprising 
3 epithelioid, 3 sarcomatoid and 1 biphasic subtype. Tumour cells were 
identified and their expression of each protein was graded as absent (0), weak 
(1+), moderate (2+) or strong (3+). H scores were calculated using the equation 
(1x (% cells 1+) + 2x (% cells 2+) + 3x (% cells 3+). Data are presented as box and 
whisker plots, plotted according to the Tukey method and the median is denoted 
by the horizontal line. Statistical analyses were performed using the Mann 
Whitney U Test. 
 
 
 
On initial analysis, statistically significant correlations were revealed between a 
number of baseline parameters and protein expression. These associations 
included Bcl-xL and DNA-PKcs expression with the requirement for pleurodesis, 
expression of activated caspase 3 with histological subtype, Ki67 expression with 
stage of disease at the time of requiring radiotherapy and a raised baseline CRP 
correlating with expression of Ki67 and γH2Ax. 
 
Following correction for multiple testing using both FDR and Berferroni 
corrections however, all of these significant findings were lost at the p>0.05 
level. The initial p values associated with each investigated interaction, in 
addition to those obtained following Bonferroni and FDR correction are shown in 
Table 8.1. Further graphical illustrations of this dataset can be found in 
Appendix 4. 
Q R 
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Table 8.1 Statistical significance of correlation analyses between protein 
expression in patient biopsy samples and clinical trial data 
 HIF1 P21 
Act 
casp 
3 
ƴH2A
x 
Ki67 
Bcl-
xL 
Bcl-2 
Mcl-
1 
DNA 
PKcs 
Worse pain 
score at 
baseline 
         
P value 0.895 0.856 0.765 0.792 0.437 0.921 0.62 0.083 0.869 
FDR 1 1 1 1 1 1 1 0.679 1 
Bonferroni 1 1 1 1 1 1 1 1 1 
Histology 
P value  
0.762 0.101 0.043 0.36 0.829 0.068 0.06 0.07 0.161 
FDR 1 0.758 0.63 1 1 0.63 0.63 0.63 0.966 
Bonferroni 1 1 1 1 1 1 1 1 1 
White cell 
count 
         
P value  0.798 0.277 0.676 0.645 0.878 0.442 0.16 0.624 0.35 
FDR 1 1 1 1 1 1 0.97 1 1 
Bonferroni 1 1 1 1 1 1 1 1 1 
Gender          
P value  0.654 0.824 0.953 0.738 0.25 0.203 0.57 0.3 0.51 
FDR 1 1 1 1 1 0.999 1 1 1 
Bonferroni 1 1 1 1 1 1 1 1 1 
Previous 
thoracic 
radiotherapy 
 
 
 
0.732 
 
 
 
0.327 
 
 
 
0.368 
 
 
 
0.941 
 
 
 
0.641 
 
 
 
0.118 
 
 
 
0.47 
 
 
 
0.06 
 
 
 
0.176 
P value 
FDR 
 
1 
 
1 
 
1 
 
1 
 
1 
 
0.817 
 
1 
 
0.63 
 
0.99 
Bonferroni 1 1 1 1 1 1 1 1 1 
Pleurodesis          
P value  0.211 1 0.315 0.375 0.246 0.027 0.54 0.364 0.025 
FDR 0.999 1 1 1 1 0.486 1 1 0.486 
Bonferroni 1 1 1 1 1 1 1 1 1 
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 HIF1 P21 
Act 
casp 
3 
ƴH2A
x 
Ki67 
Bcl-
xL 
Bcl-2 
Mcl-
1 
DNA 
PKcs 
Stage of 
disease  
         
P value  0.233 0.878 0.878 0.477 0.025 1 0.96 0.785 0.956 
FDR 1 1 1 1 0.486 1 1 1 1 
Bonferroni 1 1 1 1 1 1 1 1 1 
Pain 
response 
(week 5 )* 
         
P value  0.381 0.857 0.533 0.571 0.857 1 0.86 0.857 0.571 
FDR 1 1 1 1 1 1 1 1 1 
Bonferroni 1 1 1 1 1 1 1 1 1 
Pain 
response 
(week 12 )* 
         
P value  0.571 0.571 0.667 1 1 0.857 0.57 0.857 0.857 
FDR 1 1 1 1 1 1 1 1 1 
Bonferroni 1 1 1 1 1 1 1 1 1 
CRP*          
P value  0.872 0.957 0.505 0.005 0.005 0.957 0.21 0.266 0.704 
FDR 1 1 1 0.225 0.225 1 1 1 1 
Bonferroni 1 1 1 0.45 0.45 1 1 1 1 
 
 
8.3 Discussion 
 8.3.1 Proteins of interest were expressed in MPM tissue 
Data confirmed that all 9 proteins were expressed in the diagnostic biopsies of 
MPM patients, at differing levels of intensity. Expression of some proteins (e.g. 
DNA-PKcs and HIF1α) was relatively uniform in all biopsy specimens, whereas 
others displayed a large degree of variability between patients, indicated by the 
substantial standard deviations observed within some of the datasets. MPM is 
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known to be a highly heterogeneous tumour (Oehl et al., 2018) and random 
sampling during the biopsy process may in part explain the variation in protein 
levels observed.  
 
The validity of expression data was confirmed through the use of positive and 
negative controls. Where possible, MPM tissue was used for this purpose. This 
enhances confidence in our data, since control and target tissue were processed 
in the same way, reducing the potential for technical variation to influence 
results. Staining was found to correlate well with the anticipated subcellular 
distribution of each protein. 
 
Reliable positive controls were obtained for all proteins, with the exception of 
activated caspase 3. Despite use of this antibody with a variety of different 
tissues, staining could only be repeatedly seen in the germinal centres of human 
tonsil tissue, and this was of weak intensity. MPM cells in vitro are inherently 
resistant to apoptosis (Fennell and Rudd, 2004, Narasimhan et al., 1998) and the 
manipulation of apoptotic pathways to enhance radiosensitivity in MPM has been 
explored earlier in this thesis. The low expression of activated caspase 3 
observed in these tumour samples may be due to a baseline resistance to 
apoptosis in these treatment naïve patients. Nevertheless, without a positive 
control which robustly expresses this protein to act as a comparator, accurate 
interpretation of this data is difficult. Future IHC analysis on SYSTEMS and 
SYSTEMS-2 tissue samples should aim to use a different positive control tissue, 
for example, tissue treated with apoptosis-inducing drugs, or select an 
alternative antibody for detection of activated caspase 3 than the one used in 
this study.  
 
The variability seen in protein expression between biopsy specimens makes it 
difficult to make generalised comment on the relevance of these proteins in 
MPM. Nevertheless, DNA-PKcs was found to be robustly expressed in all tissue 
samples analysed, suggesting that the NHEJ pathway of DNA damage repair may 
be an important process in this tumour. Furthermore, this observation lends 
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weight to data presented in chapter 7, which highlighted the radiosensitising 
properties of the DNA-PKcs inhibitor NU7441 in MPM and the apparent 
importance of the NHEJ pathway in fractionation sensitivity in this tumour. 
Expression of HIF1α was found to be uniformly low across tissue samples. This is 
an interesting finding and suggests that hypoxia may not be a significant 
pathogenic driver in this tumour. Representative images shown in Figure 8.1 
demonstrate that areas of HIF1α expression were detected in some samples, but 
these were small pockets of HIF1α positive cells, indicating only limited areas of 
hypoxia. Data presented by Francis et al. suggest that areas of significant 
hypoxia in MPM are found in bulky tumour deposits. (Francis et al., 2015) An 
alternative explanation for our findings may therefore be that whilst bulky areas 
of disease are likely to have been targeted for biopsy, sufficient depth may not 
have been reached to allow central hypoxic areas of tumour to be sampled. 
 
 8.3.2 Protein expression in MPM tissue could not be correlated with 
 baseline clinical parameters in this limited dataset  
Although initial statistical analysis using the Mann Whitney U and Spearman Rank 
Correlation tests identified a number of statistically significant associations 
between baseline clinical characteristics and protein expression, the statistical 
significance all correlations was lost at the p>0.05 level, following correction for 
multiple comparisons. This is a clear limitation of the sample size utilised in this 
study and larger sample sizes will be required to thoroughly investigate 
correlations in future analyses. 
 
The lack of detected interaction between baseline clinical trial data and protein 
expression may not necessarily be surprising, given that the proteins were 
selected for their potential to impact on radiation response. Disappointingly, 
correlation of protein expression from SYSTEMS patients with clinical trial 
outcome data failed to identify any potential biomarker of radiotherapy 
response. Nevertheless, only 7 samples out of a potential 30 were obtained for 
this analysis, severely limiting the power of this dataset to reveal any significant 
association. Analysis of protein expression in SYSTEMS-2 biopsy specimens is 
ongoing and in addition to the current dataset, will provide a far more robust 
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cohort for correlation with pain and radiological response data when SYSTEMS-2 
completes recruitment and reports its outcomes.  
 
 8.3.3 Study limitations 
There are a number of weaknesses in this study, the most important of which 
was the limited number of patient samples obtained on which to carry out IHC 
and subsequent correlation analyses. Originally, it had been anticipated that 
tissue would be obtained from the majority of the Glasgow cohort of SYSTEMS-2 
patients and all of Glasgow’s SYSTEMS patients with histological diagnoses of 
MPM. Together, this totalled more than 60 FFPE blocks. Despite timely request 
for this tissue, capacity issues within Glasgow Biorepository meant that approval 
of the request was delayed by 13 months and a lack of on-site storage meant 
that subsequent retrieval of the blocks was slow. Furthermore, staffing issues 
resulted in a substantial delay in the review and sectioning of blocks by a 
consultant pathologist. To overcome this issue, the tissue blocks were released 
directly from the Biorepository in batches, to be reviewed and sectioned by 
histopathology staff at the University of Glasgow. Following this process, blocks 
were returned and a further batch collected. Despite these measures, only 21 
FFPE samples were obtained, 3 of which did not contain tumour cells and could 
not be included in subsequent analysis. This issue has limited the ability to draw 
robust conclusions from our dataset. 
 
In addition to the number of samples obtained, there were also problems with 
the quality of the samples received. These diagnostic biopsies were often 
obtained through medical thoracoscopy rather than through a video assisted 
thoracoscopic procedure. Consequentially, they were small and susceptible to 
non-specific staining at the edge of the sample. If not recognised, this ‘edge 
effect’ could falsely increase the H score, thereby invalidating our results. This 
problem was overcome through selection of the region of interest at digital 
analysis, to prevent cells at the edge contributing to the expression score. 
However, this further reduced the volume of tissue in which to locate tumour 
cells.  
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A further issue was that some of the tissue samples were degraded through the 
IHC process. This meant that they appeared histologically different from their 
respective H&E sample, rendering the process of tumour identification more 
difficult. In addition, some tissue samples became detached from the slide, 
making them blurred at microscopy and rendering analysis impossible.  
 
Areas of malignant invasion were identified through the inspection of H&E slides 
with the corresponding pathology report. This was often challenging because of 
the recognised diagnostic difficulties in MPM (Inai, 2008, Henderson et al., 2013) 
and also because malignant cells were often diffusely infiltrated within normal 
pleura, making them hard to identify. Subsequent IHC slide analysis was 
performed individually, with parameters of cell size and shape manipulated on 
the ‘Halo’ software to facilitate the identification of tumour cells within the 
specimen. Confirmation of the selected cells in a field of view as malignant was 
performed before the entire sample was analysed. Despite these measures, non-
malignant cells may still have been inadvertently included in the analysis. 
 
Finally, although a period of training was undertaken with a consultant 
pathologist prior to embarking on data analysis, the lack of formal pathology 
input with regard to the identification of areas of malignant invasion and the 
generation of subsequent H scores, is an acknowledged limitation of this work. 
 
8.4 Summary 
In summary, the data reported here demonstrate that the selected proteins of 
interest are expressed in MPM tissue at differing levels of intensity, with most 
displaying variable expression between biopsy samples. Exploratory analyses 
correlating clinical trial data with protein expression did not reveal any 
statistically significant interactions and disappointingly, no potential biomarkers 
of radiotherapy response were identified from analysis of the limited number of 
SYSTEMS samples. A more robust correlation analysis will be performed when 
SYSTEMS-2 has completed recruitment and reported its radiotherapy outcomes.  
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Chapter 9: Final discussion 
 
9.1 The changing landscape of MPM research 
Over the last few years, there has been a focused effort within the UK to fund 
research into cancers of unmet need. This policy has facilitated basic scientific 
research into malignancies such as MPM, which had been chronically 
underfunded. As a result, a gradual understanding of the biology of this 
malignancy is being established and methods to overcome its resistance to a 
variety of therapeutic strategies are being investigated. Efforts to standardise 
patient care across the UK have intensified, with British Thoracic Society 
guidance recommending that every patient should be discussed at a central MDT, 
where the most appropriate treatment options can be considered. (Woolhouse et 
al., 2018) 
 
The research drive in MPM has led to increasing clinical trial availability, 
particularly for systemic therapies, where early data, especially around 
immunotherapy has been encouraging. (Alley et al., 2017) Although to date, 
clinical trials have only demonstrated a role for radiotherapy in the palliation of 
MPM, (MacLeod et al., 2015a) a number of phase II studies have been conducted 
to assess radiotherapy in the multimodality setting, following chemotherapy and 
surgery. (Federico et al., 2013, Krug et al., 2009, Weder et al., 2007, Van Schil 
et al., 2010, Hasegawa et al., 2016) Despite the encouraging survival data 
reported, the lack of randomisation and inherent biases associated with surgical 
studies (typified by the exclusion of patients who were not fit enough for 
surgery), makes it difficult to draw firm conclusions from these data. 
 
SYSTEMS-2 is the first randomised study of radiotherapy dose escalation to be 
attempted in MPM. (Ashton et al., 2018) The challenges of conducting 
randomised clinical trials in relatively rare diseases have been discussed in the 
literature. (Lilford et al., 1995, Tan et al., 2003) The added difficulties of 
conducting such trials in a palliative context is also acknowledged, (McWhinney 
et al., 1994, Grande and Todd, 2000) and have been outlined within this thesis. 
Nevertheless, the importance of overcoming these issues to permit the 
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recruitment of adequate numbers of patients from which high quality data can 
be generated is evidenced by the fact that only two randomised clinical trials of 
radical treatment in MPM have been published to date (Stahel et al., 2015, 
Treasure et al., 2011) and both have generally been regarded as inconclusive, 
largely due to insufficient power. (Rimner et al., 2016a, Rusch et al., 2013)  
 
The future of MPM research is likely to be guided in part by a recently published 
landmark article detailing the molecular characterisation of 216 cases of MPM. 
This analysis, which was based on exome sequencing, identified only a small 
number of coding mutations (on average 24±11 per tumour), suggesting that the 
mutational burden of MPM is much lower than in most other cancers. (Bueno et 
al., 2016) Furthermore, this molecular analysis revealed that the dominant 
protein alterations in MPM are loss-of-function mutations in tumour suppressor 
genes. Very few oncogene driver mutations were identified, suggesting that 
patients with MPM are unlikely to respond to currently available small molecule 
inhibitors. (Bueno et al., 2016) The low mutational burden of MPM, in 
combination with the lack of obviously druggable targets suggests that a multi-
modal approach is likely to be required for the successful treatment of this 
disease, further substantiating the importance of radiotherapy research in MPM. 
(Blyth and Murphy, 2018)  
 
There is escalating evidence to suggest that hypofractionated RT may provide a 
specific anti-tumour activation of the immune system. (Bernstein et al., 2016) 
Demonstration of a cytotoxic T cell response to hypofractionated radiotherapy in 
MPM mouse models, (De La Maza et al., 2017, Wu et al., 2015) provides a 
compelling strategy for a combination approach with immunotherapy in the 
future treatment of this disease. 
 
9.2 Dose constraints 
The SYSTEMS-2 study necessitated generation of novel dose constraints for a 
hypofractionated thoracic radiotherapy regime. Local SABR thoracic protocols 
were used as a template on which these constraints were modelled and they 
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have also been interpreted in light of the more recently published UK consensus 
on normal tissue constraints for SABR. (Hanna et al., 2018) Nevertheless, 
substantial differences exist between the radiotherapy delivered in SABR and 
SYSTEMS-2, particularly in terms of PTV size, dose per fraction and treatment 
intent.  
 
The recent publications by Gomez et al and Parisi et al of normal tissue dose 
constraints for hypofractionated radiotherapy regimes in MPM, offer appropriate 
comparisons. These constraints were noted to be more conservative than those 
suggested for SYSTEMS-2, reflecting the more radical approach taken in these 
studies. Nevertheless, the rigorous setting of a clinical trial, where toxicity data 
is collected at regular intervals, is the optimal setting in which to test the safety 
of the SYSTEMS-2 dose constraints, and to generate robust comparative data to 
the regimes employed by de Perrot and Parisi. Future hypofractionated 
radiotherapy protocols are likely to be guided by toxicity data generated from 
SYSTEMS-2 and this data may also facilitate the development of macroscopic 
models of normal tissue volume effects, particularly for acute tissue 
complications following large doses per fraction. Hypofractionated radiotherapy 
regimes with radical intent however, would need to give greater consideration 
to the issue of late normal tissue complications, which were largely negated by 
the life expectancy of the SYSTEMS-2 cohort. 
 
9.3. Dose delivery 
Safe dose escalation in SYSTEMS-2 has been achieved through the use of 3D 
conformal radiotherapy or IMRT/VMAT, which facilitates sparing of normal tissue 
without compromising dose to the tumour. Large PTV volumes and close 
proximity of radiosensitive structures makes the radiotherapy planning for 
SYSTEMS-2 challenging. This is evidenced by the fact that none of the ‘test’ 
patients at the Beatson West of Scotland Cancer Centre met every dose 
constraint and at some recruiting centres, patients have not been randomised on 
the study due to the inability to generate a suitable dose escalated plan.  
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Radical radiotherapy planning for MPM is likely to be even more challenging, 
since doses to OARs will need to be maintained at an acceptable level, in the 
context of further dose escalation to a larger PTV. Recent procurement of MCO 
planning software by the Beatson West of Scotland Cancer Centre has permitted 
the re-planning study presented in this thesis, which suggests that clinically 
significant dose reductions can be achieved in a number of OARs without 
compromising the PTV coverage. These data suggest that further dose escalation 
to the PTV may be possible without breaching dose constraints. Ongoing planning 
studies at the Beatson West of Scotland Cancer Centre will determine whether 
the entire pleura could be treated to the dose escalated regime of 36Gy in 6 
fractions without compromising OAR constraints and isotoxic radiotherapy 
planning studies will investigate the maximal dose achievable in the pleura. 
Outcomes from this work will be crucial in guiding further dose escalation in 
MPM.  
 
The potential for radical radiotherapy in MPM is enhanced by ongoing advances 
in radiotherapy planning and delivery, which are likely to afford further 
protection to OARs by increasing dose conformity. These developments include 
4D CT planning, which facilitates an appreciation of intra-fraction motion of the 
target volume, and the advent of methods which reduce the impact of 
respiratory tumour motion on radiotherapy planning: ‘respiratory gated 
radiotherapy techniques’. (Giraud and Houle, 2013) In 2004 Ling et al described 
how these methods could be employed to facilitate dose escalation without 
increasing toxicity, (Ling et al., 2004) and subsequently they have been widely 
employed to improve geometric precision and dosimetry at a number of tumour 
sites affected by respiratory motion such as lung, breast and liver. (Underberg et 
al., 2005, Saito et al., 2014, Berg et al., 2018, Wagman et al., 2003) 
 
Other developments which are likely to impact on radiotherapy delivery in the 
future include the integration of radiobiological modelling into treatment 
planning systems (Mesbahi et al., 2019, D’Andrea et al., 2018) and functional 
imaging techniques. Modern functional imaging provides a surrogate for the 
visualisation of a variety of tumour characteristics, including metabolism, 
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hypoxia, perfusion and proliferation. (Thorwarth, 2015) Integration of this 
information with radiotherapy planning offers a powerful tool through which 
plans can be further personalised and dose can be tailored to overcome biology-
driven radiation resistance. (Nestle et al., 2009, van der Heide et al., 2012)  
 
The advance of MRI-guided radiotherapy offers further opportunities for dose 
escalation to the pleura. MRI is already used in the treatment planning of a 
number of different cancers, where the improved resolution of soft tissue allows 
more precise delineation of treatment volumes and OARs than can be achieved 
by CT. This imaging is currently used in the staging of MPM where surgery is 
being considered, since improved soft tissue visualisation facilitates the accurate 
assessment of diaphragmatic, chest wall and mediastinal involvement. (Stewart 
et al., 2003) 
 
Combining MRI with a linac in a single unit has been challenging, since the 
magnetic field impacts on dose distribution and the movement of the linac 
influences the magnetic field. (Chin et al., 2020) Nevertheless, overcoming 
these issues has permitted the development of a system from which online 
adaptive RT planning can be performed with greater accuracy than can currently 
be achieved with onboard CT scanners. (Lütgendorf-Caucig et al., 2011) MRI 
guided radiotherapy offers the ability to make accurate daily online corrections 
to account for positional and volume changes of OAR and target volumes, and 
the ability to continuously image while the beam is on permits live verification 
of tumour coverage and OAR dosimetry. This technology has great potential in 
tumour sites where inter and intrafraction motion causes doubt over treatment 
accuracy (e.g. thorax). (Chin et al., 2020) Furthermore, a number of dosimetric 
studies of adaptive radiotherapy planning have confirmed promising results, 
demonstrating less normal tissue irradiation in a number of tumour sites, 
including in lung cancer. (Møller et al., 2016, Nijkamp et al., 2008, Castelli et 
al., 2015) MRI-guided radiotherapy in MPM could facilitate the improved 
coverage of a radical PTV, permitting further dose escalation, while reducing 
toxicities in critical neighbouring normal tissue. Furthermore, combination of 
MRI with functional modalities (eg. MRI/PET, diffusion-weighted MRI) may 
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complement MR guided radiotherapy to allow synergies between the systems, 
facilitating the implementation of focal boosts to areas of hypoxia or increased 
cell proliferation. (Rosenkrantz et al., 2016) 
 
Finally, the growing availability of proton therapy throughout the UK is expected 
to offer further opportunities for dose escalation in MPM. While protons have 
been investigated extensively in locally advanced non-small cell lung cancer 
(NSCLC), (Remick et al., 2017, Higgins et al., 2017, Chang et al., 2017, Chao et 
al., 2017) their clinical application in MPM has been limited to date, to a small 
number of institutional series. (Pan et al., 2015, Badiyan et al., 2018, Lee et al., 
2017) A planning study by Krayenbuehl et al, comparing the dosimetry achieved 
with IMRT and protons in eight MPM patients post EPP, suggested that although 
protons could reduce dose to most OARs, they are more susceptible to changing 
air cavities and therefore adaptive radiotherapy planning may be required. 
(Krayenbuehl et al., 2010) 
 
9.4 Radiobiological considerations of MPM 
A fundamental consideration of any radiotherapy regime is the underlying 
radiosensitivity of the tumour and adjacent normal tissues, in addition to their 
relative sensitivity to changes in dose per fraction. There is a paucity of 
information surrounding the radiobiology of mesothelioma and the challenge of 
delivering tumouricidal doses using traditional radiotherapy techniques has 
afforded this tumour a reputation for radioresistance. Within this thesis, the 
radioresponse of mesothelioma cell lines has been examined using a clinically 
relevant 3D model. Data suggest that the growth of mesothelioma spheroids can 
be delayed with radiation, intimating that if a suitable radiation dose could be 
selectively achieved within the pleural cavity, radiotherapy may offer a valid 
therapeutic option for patients with MPM. Furthermore, the discovery that 
spheroid growth is sensitive to changes in dose per fraction and optimally 
delayed with hypofractionated radiotherapy, supports the hypothesis that MPM 
has a low α/β ratio, an assumption which underpinned the selection of dose and 
fractionation for the SYSTEMS-2 study. Although a definitive α/β ratio for MPM 
spheroids could not be established, data suggest that the two cell lines explored 
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have different α/β ratios, and that these values are low, consistent with their 
observed response to hypofractionation of dose. 
 
This novel data supporting a low tumour α/β ratio is clinically relevant and may 
be used to guide optimal dose and fractionation schedules for future clinical 
trials of radiotherapy in MPM. Of particular relevance is the fact that tumours 
with a low α/β ratio treated with hypofractionated regimes require a lower total 
dose of radiation to achieve tumour control than with conventionally 
fractionated treatment. This was demonstrated in the case of prostate cancer 
within the CHIIP study (Dearnaley et al., 2016) and is particularly important in 
MPM, where multiple dose limiting organs are in close proximity to the PTV. The 
development of hypofractionated radiotherapy regimes for the treatment of 
both breast and prostate cancer has been guided by a clinical suspicion that 
these tumours exhibit a low α/β ratio. Clinical data to support this proposal has 
been generated over time, but in vitro studies utilising tumour cell lines to 
determine the α/β ratio provided an important early step in establishing best 
practise in the treatment of these malignancies. (Algan et al., 1996, Chapman, 
2014, Leith et al., 1993, DeWeese et al., 1998, Babazadeh Toloti et al., 2018) 
 
9.5 The potential for radiosensitisation in MPM 
Even if the low α/β ratio of MPM suggests that a lower total dose could be 
employed without compromising tumour kill, the frailty of this patient 
population and the volume of the pleural cavity that would receive radiation in 
any radical approach, means that treatment related toxicity would remain a 
significant concern. For this reason, the potential role of two radiosensitising 
drugs has been explored in combination with fractionated radiotherapy, to 
determine efficacy in 3D models of MPM. The DNA-PK inhibitor, NU7441, which 
targets the NHEJ pathway of DDR, was selected as a positive control. Since both 
tumour and normal tissue utilise the NHEJ pathway, radiosensitisation mediated 
by this approach would not be tumour specific and concerns about associated 
exacerbation of normal tissue toxicity would be likely to limit clinical 
translation. In contrast, the selective Bcl-xL inhibitor, A1331852, which acts as a 
BH3 mimetic, is likely to be more active in tumour tissue, given the reliance of 
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MPM cells on anti-apoptotic Bcl-2 proteins. Therefore, radiosensitisation 
mediated by this approach would be likely to be tumour selective and have 
greater clinical potential. Both agents were found to be potent radiosensitisers 
in MPM, suggesting that apoptotic and DDR pathways are important in the MPM-
mediated resistance to radiotherapy. The tumour selectivity offered through an 
apoptosis-mediated approach and the observation that A1331852 displayed 
optimal therapeutic activity in combination with hypofractionated radiotherapy, 
highlights this drug as a promising candidate in future radiosensitising strategies 
in MPM.  
 
Tumour sensitivity to radiation may, in the future, be enhanced by selective 
drug delivery. An elegant approach to this, currently being investigated at the 
University of Greenwich, exploits the arginine dependency of MPM. In this work, 
funded by the University Alliance DTA Scheme (https://unialliance.ac.uk/dta/), 
an anticancer agent is tagged to an arginine molecule which is preferentially 
taken up by MPM tissue. Current strategies centre on the delivery of 
chemotherapeutic agents to the tumour, but if a radiosensitising agent could be 
tagged to arginine in the same way, then concurrent radiation would be 
selectively more toxic to the tumour than to the normal surrounding tissues.  
 
Alternative approaches of selective drug delivery to the tumour include the 
employment of gold nanoparticles targeted to MPM cells, the efficacy of which 
has recently been demonstrated in an in vitro system, using Pemetrexed-loaded 
nanoparticles targeted to CD146. (Cova et al., 2019) Furthermore, the 
anatomical distribution of MPM is such that in many cases, selective drug 
delivery may be simply achieved through direct treatment administration into 
the pleural space. 
 
9.6 Biomarkers of MPM radiosensitivity 
A radical treatment approach may not be suitable for all patients with MPM, not 
only because of patient-related factors, such as frailty and comorbidities, but 
also because of tumour specific considerations. It was noted in the SYSTEMS 
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study that one third of patients had a clinically significant pain response at week 
five. In contrast, approximately one third had a pain response which was not 
significant and one third had no improvement in their pain. (MacLeod et al., 
2015a) There is no clear explanation why some patients responded to radiation 
and others did not, although this is likely to reflect a combination of physical 
factors, including tumour bulk, position and infiltration of surrounding 
structures, in addition to psychological factors and underlying tumour biology. 
Although a predictive link has been reported between the EORTC prognostic 
index and radiation response, (Jenkins et al., 2011) this association has not been 
validated and there remains no predictive indicator for radiotherapy response in 
MPM. The identification of a biomarker that would distinguish a subset of 
patients with radio-responsive disease would bring with it enormous clinical 
implications, especially in the radical setting, where the trade-off between 
tumour control and normal tissue toxicity is paramount. Unfortunately, the data 
presented in this thesis is too preliminary to identify a potential biomarker of 
radiation response from the SYSTEMS study, although pilot data was obtained 
using the limited dataset available. The SYSTEMS-2 study continues to recruit 
and it is anticipated that this much larger trial will generate biomarker 
information that might establish an initial correlation between protein 
expression and radiotherapy outcomes in this well studied patient population. 
The work conducted to date, in which IHC conditions have been optimised for 
the selected proteins of interest will facilitate rapid analysis of FFPE samples 
from SYSTEMS-2. In addition to guiding patient selection for radiotherapy, 
biomarker research may identify proteins which confer radio-resistance, 
providing targets for future therapy in this disease. The impact of this for 
patients could be enormous and could change the landscape of this disease from 
one of palliation to prolonged disease control or cure within a short number of 
years. For this reason, biomarker research is an area of intense research in MPM. 
Of particular relevance is research into predictive biomarkers of tumour 
fractionation sensitivity, where markers of proliferation and checkpoint proteins 
may be implicated. (Somaiah et al., 2015) If, as suggested by other groups 
investigating the α/β ratio of MPM, (Hakkinen et al., 1996, Carmichael et al., 
1989) the range of fractionation sensitivities within this tumour type is broad, 
then a biomarker to identify those patients who may selectively benefit from 
hypofractionation of dose would be clinically invaluable. 
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9.7 Summary 
The research presented in this thesis has been conducted at a time when the 
role of radiotherapy in MPM is in transition. Traditionally regarded as having only 
a palliative role in the management of this disease, radiotherapy is starting to 
be used with the aim of disease control, in combination with other treatment 
modalities, with encouraging data reported from a number of non-randomised, 
phase I/II studies conducted outside of the UK. (Cho et al., 2014, Minatel et al., 
2014, Rice et al., 2007b, Krug et al., 2009, Van Schil et al., 2010) 
 
SYSTEMS-2 will provide the first randomised controlled data of patient outcomes 
following dose escalated, hypofractionated radiotherapy in MPM. Despite the 
palliative intent of this study, it represents an important step towards a more 
radical approach to the management of this disease, at a time when the 
boundaries of modern radiotherapy planning are being pushed to investigate the 
limits of radical treatment in a number of cancers.  
 
Within this thesis, important radiobiological parameters of MPM have been 
investigated. Data suggests that MPM is more radiosensitive than traditionally 
assumed and considerable evidence has been generated to support the 
hypothesis that MPM exhibits a low α/β ratio. These radiobiological observations 
could have important implications for the design of future clinical trials of 
radiotherapy in MPM and are presented in this thesis in combination with data 
pertaining to a number of strategies which may safely facilitate further dose 
escalation in MPM, beyond that being investigated in SYSTEMS-2. It is hoped that 
this body of work will be used to inform future radiotherapy practise in MPM and 
will advance the possibility of using radiotherapy with radical intent in the 
treatment of patients with this cancer of unmet need. 
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Appendix 1: Isoeffective data  
 
H2052 Data: Day 10 
            
 
         
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.13 6.105 6.105 0.164 
2 0.13 7.923 3.961 0.126 
3 0.13 10.950 3.650 0.091 
4 0.13 11.269 2.817 0.089 
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H2052 Data: Day 14 
 
         
 
       
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.2 6.441 6.441 0.155 
2 0.2 9.141 4.571 0.109 
3 0.2 11.089 3.696 0.090 
4 0.2 11.513 2.878 0.087 
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H2052 Data: Day 16 
 
           
 
       
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.28 6.886 6.886 0.145 
2 0.28 9.489 4.744 0.105 
3 0.28 11.133 3.711 0.090 
4 0.28 11.648 2.912 0.086 
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H2052 Data: Day 21 
 
        
 
       
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.3 6.278 6.278 0.159 
2 0.3 9.299 4.649 0.108 
3 0.3 10.523 3.508 0.095 
4 0.3 11.309 2.827 0.088 
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H2052 Data: Day 24 
 
        
 
      
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.35 7.058 7.058 0.142 
2 0.35 9.685 4.842 0.103 
3 0.35 11.047 3.682 0.091 
4 0.35 11.719 2.930 0.085 
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H2052 Data: Day 28 
 
        
 
        
 
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.3 6.360709 6.360709 0.157215 
2 0.3 9.379644 4.689822 0.106614 
3 0.3 10.46214 3.49 0.095583 
4 0.3 11.06791 2.766978 0.090351 
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211H Data: Day 10 
 
       
 
      
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.29 6.392 6.392 0.156 
2 0.29 9.770 4.885 0.102 
3 0.29 10.981 3.660 0.091 
4 0.29 11.870 2.967 0.084 
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211H Data: Day 14 
 
        
 
         
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.51 6.501 6.501 0.154 
2 0.51 9.793 4.896 0.102 
3 0.51 10.394 3.465 0.096 
4 0.51 10.973 2.743 0.091 
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211H Data: Day 16 
 
         
 
       
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.55 6.360 6.360 0.157 
2 0.55 9.908 4.954 0.101 
3 0.55 9.726 3.242 0.103 
4 0.55 10.651 2.663 0.094 
 
 
 
 
0.50
0.55
0.60
0.65
0.70
6 7 8 9 10
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Single fraction effect 
0.30
0.40
0.50
0.60
4 6 8 10
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Two fraction effect 
0.30
0.40
0.50
0.60
0.70
6 7 8 9 10 11 12 13 14 15
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Three fraction effect 
0.20
0.30
0.40
0.50
0.60
0.70
4 5 6 7 8 9 10 11 12 13 14 15 16
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Four fraction effect 
y = 0.0148x + 0.0501
R² = 0.7212
0.00
0.04
0.08
0.12
0.16
0.20
0 1 2 3 4 5 6 7
R
e
ci
p
ro
ca
l o
f 
to
ta
l d
o
se
 (
G
y-
1 )
Radiation dose per fraction (Gy)
Isoeffective dose  for 0.55mm3
α/β= 3.385 
 
 
- 343 - 
211H Data: Day 21 
 
        
 
        
 
Fraction 
number 
Effect size 
(mm3) 
Total dose 
(Gy) 
Dose per 
fraction 
(Gy) 
Reciprocal 
total dose 
1 0.65 6.821 6.821 0.147 
2 0.65 9.703 4.852 0.103 
3 0.65 9.976 3.325 0.100 
4 0.65 11.215 2.804 0.089 
 
 
 
 
0.5
0.6
0.7
0.8
0.9
6 7 8 9 10
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Single fraction effect 
0.0
0.2
0.4
0.6
0.8
4 5 6 7 8 9 10
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Two fraction effect 
0.0
0.2
0.4
0.6
0.8
1.0
6 7 8 9 10 11 12 13 14 15
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Three fraction effect 
0.0
0.2
0.4
0.6
0.8
1.0
4 5 6 7 8 9 10 11 12 13 14 15 16
V
o
lu
m
e
 r
e
d
u
ct
io
n
 
fr
o
m
 c
o
n
tr
o
l (
m
m
3 )
Total radiation dose (Gy)
Four fraction effect 
y = 0.0133x + 0.0508
R² = 0.8933
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0 1 2 3 4 5 6 7 8R
e
ci
p
ro
ca
l o
f 
to
ta
l d
o
se
 (
G
y-
1
)
Radiation dose per fraction (Gy)
Isoeffective dose for 0.65mm3
α/β= 3.8195 
 
- 344 - 
Appendix 2: Volume data for radiosensitising drug experiments 
 
Effect of A1331852 & fractionated radiotherapy on H2052 spheroid volume at 
day 21 
 
 
 
 
Effect of NU7441 & fractionated radiotherapy on H2052 spheroid volume at day 
21 
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Effect of A1331852 & fractionated radiotherapy on 211H spheroid volume at day 
21 
 
 
 
 
 
Effect of NU7441 & fractionated radiotherapy on 211H spheroid volume at day 
21 
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Appendix 3: ƴH2Ax expression 
 
 
 
 
Condition 
Percentage ƴH2Ax 
positive cells 
211H 0Gy  40.5621 
211H 10Gy 95.7347 
H2052 0Gy 49.7587 
H2052 10Gy  80.6842 
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Appendix 4: IHC Correlation data 
Bcl-2 correlation data 
 
      Worst pain score at baseline            Histology    White cell count 
                                 
Spearman’s rank correlation p= 0.617                   Mann Whitney test p= 0.55       Mann Whitney test p= 0.158 
 
           Gender   Stage of disease     Previous radiotherapy 
               
 Mann Whitney test p= 0.574          Mann Whitney test p= 0.959                       Mann Whitney test p= 0.471 
 
 
 
        Pleurodesis          Week 5 pain response                       Week 12 pain response  
 
           
    Mann Whitney test p= 0.536   Mann Whitney test p= 0.857                Mann Whitney test p= 0.571 
  
 
 
            Baseline CRP 
                                                           
               Spearman’s rank correlation p= 0.208 
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Bcl-xL correlation data 
     Worst pain score at baseline             Histology      White cell count 
             
Spearman’s rank correlation p= 0.921   Mann Whitney test p= 0.068  Mann Whitney test p= 0.442 
  
 
            Gender          Stage of disease                    Previous radiotherapy 
           
 Mann Whitney test p= 0.203  Mann Whitney test p= 1.0  Mann Whitney test p= 0.118 
 
 
        Week 5 pain response               Week 12 pain response        Pleurodesis  
  
          
 Mann Whitney test p= 0.027  Mann Whitney test p= 1  Mann Whitney test p= 0.857  
     
       
              Baseline CRP 
 
 
         Spearman’s rank correlation p= 0.957 
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Activated caspase 3 correlation data 
 
   Worst pain score at baseline             White cell count         Gender 
       
 Spearman’s rank correlation p= 0.078  Mann Whitney test p= 0.676  Mann Whitney test p= 0.953 
 
 
 
 
 Stage        Previous radiotherapy   Pleurodesis 
       
 Mann Whitney test p= 0.878  Mann Whitney test p= 0.368  Mann Whitney test p= 0.315 
 
 
 
   
    Week 5 pain response   Week 12 pain response         Histology 
        
 Mann Whitney test p= 0.533  Mann Whitney test p= 0.667       Spearman’s rank correlation p= 0.50 
 
                 
 
     
 
        Baseline CRP 
                                                                         
     Mann Whitney test p= 0.043 
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DNA-PKcs correlation data           
 
        Worst pain score at baseline                           Histology   White cell count  
     
      Spearman’s rank correlation p= 0.869    Mann Whitney test p= 0.161    Mann Whitney test p= 0.35 
 
  Gender       Stage of disease   Previous radiotherapy  
    
 Mann Whitney test p= 0.51  Mann Whitney test p= 0.956  Mann Whitney test p= 0.176 
  
 
 Week 5 pain response      Week 12 pain response            Pleurodesis  
     
 Mann Whitney test p= 0.571  Mann Whitney test p= 0.857  Mann Whitney test p= 0.025 
 
          Baseline CRP 
 
        Spearman’s rank correlation p= 0.704 
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γH2Ax correlation data 
   Worst pain score at baseline        Histology                White cell count 
             
Spearman’s rank correlation p= 0.792  Mann Whitney test p= 0.360  Mann Whitney test p= 0.645 
 
 
  Gender   Stage of disease        Previous radiotherapy 
           
 Mann Whitney test p= 0.738  Mann Whitney test p= 0.477  Mann Whitney test p= 0.941 
 
 
  Pleurodesis    Week 5 pain response  Week 12 pain response 
        
 Mann Whitney test p= 0.375  Mann Whitney test p= 0.571  Mann Whitney test p= 1.0 
 
 
        Baseline CRP 
                                                                              
            Spearman’s rank correlation p= 0.005 
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HIF1α correlation data 
            Worst pain score at baseline  Histology  White cell count 
           
    Spearman’s rank correlation p= 0.895  Mann Whitney test p= 0.762  Mann Whitney test p= 0.798 
 
 
  Gender       Stage of disease  Previous radiotherapy 
           
 Mann Whitney test p= 0.654   Mann Whitney test p= 0.233  Mann Whitney test p= 0.732 
 
 
  Pleurodesis  Week 5 pain response  Week 12 pain response 
           
 Mann Whitney test p= 0.211  Mann Whitney test p= 0.381  Mann Whitney test p= 0.571 
  
                  Baseline CRP 
 
        Spearman’s rank correlation p= 0.872 
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Ki67 correlation data 
 Worst pain score at baseline  Histology                White cell count 
           
    Spearman’s rank correlation p= 0.437 Mann Whitney test p= 0.829  Mann Whitney test p= 0.878 
 
 
  Gender    Previous radiotherapy                               Pleurodesis 
           
         Mann Whitney test p= 0.250   Mann Whitney test p= 0.641  Mann Whitney test p= 0.246  
 
 
    Week 5 pain response               Week 12 pain response                    Stage of disease 
           
 Mann Whitney test p= 0.857  Mann Whitney test p= 1.0   Mann Whitney test p= 0.025 
 
          Baseline CRP 
 
        Spearman’s rank correlation p= 0.005 
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Mcl-1 correlation data 
    Worst pain score at baseline          Histology      White cell count 
          
Spearman’s rank correlation p= 0.083  Mann Whitney test p= 0.07  Mann Whitney test p= 0.624 
 
 
          Gender                  Stage of disease                          Previous radiotherapy 
           
 Mann Whitney test p= 0.3  Mann Whitney test p= 0.785  Mann Whitney test p= 0.06 
 
 
        Pleurodesis                   Week 5 pain response  Week 12 pain response 
           
 Mann Whitney test p= 0.364  Mann Whitney test p= 0.857  Mann Whitney test p= 0.857 
 
          Baseline CRP 
 
       Spearman’s rank correlation p= 0.266 
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P21 correlation data 
   Worst pain score   Histology         White cell count 
           
Spearman’s rank correlation p= 0.856  Mann Whitney test p= 0.101  Mann Whitney test p= 0.277 
 
 
  Gender   Stage of disease     Previous radiotherapy 
           
    Mann Whitney test p= 0.824  Mann Whitney test p= 0.878  Mann Whitney test p= 0.327 
 
 
      Pleurodesis   Week 5 pain response  Week 12 pain response 
          
 Mann Whitney test p= 1.0  Mann Whitney test p= 0.857  Mann Whitney test p= 0.571 
 
              Baseline CRP 
 
         Spearman’s rank correlation p= 0.957 
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